<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14D-1
TENDER OFFER STATEMENT PURSUANT TO SECTION 14(d)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
SIBIA NEUROSCIENCES, INC.
(Name of Subject Company)
MERCK & CO., INC.
MC SUBSIDIARY CORP.
(BIDDERS)
COMMON STOCK, $.001 PAR VALUE
(INCLUDING THE
ASSOCIATED RIGHTS)
(TITLE OF CLASS OF SECURITIES)
825732100
(CUSIP NUMBER OF COMMON STOCK)
CELIA A. COLBERT
MC SUBSIDIARY CORP.
C/O MERCK & CO., INC.
ONE MERCK DRIVE
WHITEHOUSE STATION, NEW JERSEY 08889
(908) 423-1000
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO
RECEIVE NOTICES AND COMMUNICATIONS ON BEHALF OF BIDDERS)
COPIES TO:
GARY P. COOPERSTEIN, ESQ.
FRIED, FRANK, HARRIS, SHRIVER & JACOBSON
ONE NEW YORK PLAZA
NEW YORK, NEW YORK 10004
(212) 859-8000
------------------------
CALCULATION OF FILING FEE
<TABLE>
<CAPTION>
==============================================================================
TRANSACTION VALUATION* AMOUNT OF FILING FEE
- ------------------------------------------------------------------------------
<S> <C>
$85,935,212 $17,187.04
==============================================================================
</TABLE>
* FOR PURPOSES OF CALCULATING FEE ONLY. THIS AMOUNT IS BASED ON A PER SHARE
OFFERING PRICE OF $8.50, FOR 9,703,769 SHARES OF COMMON STOCK OUTSTANDING
AS OF JULY 23, 1999, PLUS THE NUMBER OF SHARES ASSUMED ISSUABLE PURSUANT
TO THE SHARE OF OUTSTANDING CONVERTIBLE PREFERRED STOCK. THE AMOUNT OF THE
FILING FEE, CALCULATED IN ACCORDANCE WITH RULE 0-11 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED, EQUALS 1/50 OF ONE PERCENT OF THE
AGGREGATE OF THE CASH OFFERED BY THE BIDDER.
[ ] CHECK BOX IF ANY PART OF THE FEE IS OFFSET AS PROVIDED BY RULE 0-11(a)(2)
AND IDENTIFY THE FILING WITH WHICH THE OFFSETTING FEE WAS PREVIOUSLY PAID.
IDENTIFY THE PREVIOUS FILING BY REGISTRATION STATEMENT NUMBER, OR THE FORM
OR SCHEDULE AND THE DATE OF ITS FILING.
<PAGE> 2
AMOUNT PREVIOUSLY PAID: N/A
FORM OR REGISTRATION NO.: N/A
FILING PARTY: N/A
DATE FILED: N/A
-2-
<PAGE> 3
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
MERCK & CO., INC.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |_|
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
WC
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(e) or 2(f) |_|
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
NEW JERSEY
- -------------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,308,897
- -------------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES CERTAIN SHARES
(See Instructions) |_|
- -------------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)
44.9%(1)
- -------------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON (See Instructions)
CO
- -------------------------------------------------------------------------------
- --------
(1) Merck & Co., Inc. ("Merck"), MC Subsidiary Corp. ("Merger Sub") a direct
wholly owned subsidiary of Merck, and SIBIA Neurosciences, Inc. ("SIBIA")
entered into an Agreement and Plan of Merger (the "Merger Agreement") as of July
30, 1999 providing for, among other things, the merger of SIBIA with and into
Merger Sub. Simultaneously with the execution and delivery of the Merger
Agreement, Merger Sub entered into a Shareholders Agreement dated July 30, 1999
(the "Shareholders Agreement") with certain shareholders of SIBIA (the "Lock-up
Shareholders") as follows: (i) The Salk Institute for Biological Studies -
1,933,461 shares; (ii) Skandigen AB - 986,696 shares; and (iii) William T. Comer
- - 267,900 shares and 189,790 options exercisable within 60 days. Under the
Shareholders Agreement, the Lock-up Shareholders have agreed, subject to the
terms thereof, to tender all of their shares of SIBIA Common Stock to Merger Sub
pursuant to the tender offer described in the Merger Agreement, and to vote
their shares in favor of the merger described in the Merger Agreement. The
Lock-up Shareholders have also granted Merger Sub a proxy to vote their shares,
representing approximately 34.1% of the issued and outstanding shares of SIBIA
Common Stock as of July 23, 1999, in favor of the merger. Simultaneously with
the execution and delivery of the Merger Agreement, Merck also entered into an
Option Agreement (the "Company Option") pursuant to which SIBIA granted to Merck
an option to purchase 1,931,050 shares of Common Stock, subject to the terms
thereof. If this option were to be exercised and these shares were issued to
Merck and outstanding, such shares would, together with the shares subject to
the Shareholders Agreement, represent approximately 44.9% of the issued and
outstanding shares of SIBIA Common Stock as of July 23, 1999.
The foregoing summary of the Shareholders Agreement and Company Option is
qualified in its entirety by reference to such agreements, which have been filed
as exhibits to this Schedule 14D-1.
-3-
<PAGE> 4
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
MC SUBSIDIARY CORP.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) |_|
(b) |_|
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
AF
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(e) or 2(f) |_|
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,377,847
- -------------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES CERTAIN SHARES
(See Instructions) |_|
- -------------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7)
34.1%(2)
- -------------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON (See Instructions)
CO
- -------------------------------------------------------------------------------
- ---------------
(2) Merck & Co., Inc. ("Merck"), MC Subsidiary Corp. ("Merger Sub") a direct
wholly owned subsidiary of Merck, and SIBIA Neurosciences, Inc. ("SIBIA")
entered into an Agreement and Plan of Merger (the "Merger Agreement") as of July
30, 1999 providing for, among other things, the merger of SIBIA with and into
Merger Sub. Simultaneously with the execution and delivery of the Merger
Agreement, Merger Sub entered into a Shareholders Agreement dated July 30, 1999
(the "Shareholders Agreement") with certain shareholders of SIBIA (the "Lock-up
Shareholders") as follows: (i) The Salk Institute for Biological Studies -
1,933,461 shares; (ii) Skandigen AB - 986,696 shares; and (iii) William T. Comer
- - 267,900 shares and 189,790 options exercisable within 60 days. Under the
Shareholders Agreement, the Lock-up Shareholders have agreed, subject to the
terms thereof, to tender all of their shares of SIBIA Common Stock to Merger Sub
pursuant to the tender offer described in the Merger Agreement, and to vote
their shares in favor of the merger described in the Merger Agreement. The
Lock-up Shareholders have also granted Merger Sub a proxy to vote their shares,
representing approximately 34.1% of the issued and outstanding shares of SIBIA
Common Stock as of July 23, 1999, in favor of the merger. Simultaneously with
the execution and delivery of the Merger Agreement, Merck also entered into an
Option Agreement (the "Company Option") pursuant to which SIBIA has granted to
Merck an option to purchase 1,931,050 shares of Common Stock, subject to the
terms thereof. If this option were to be exercised and these shares were issued
to Merck and outstanding, such shares would, together with the shares subject to
the Shareholders Agreement, represent approximately 44.9% of the issued and
outstanding shares of SIBIA Common Stock as of July 23, 1999.
The foregoing summary of the Shareholders Agreement and Company Option is
qualified in its entirety by reference to such agreements, which have been filed
as exhibits to this Schedule 14D-1.
-4-
<PAGE> 5
This Tender Offer Statement on Schedule 14D-1 relates to a tender offer by
MC Subsidiary Corp., a Delaware corporation ("Offeror") and a direct wholly
owned subsidiary of Merck & Co., Inc., a New Jersey corporation ("Parent"), to
purchase all outstanding shares of Common Stock, par value $.001 per share (the
"Common Stock"), including the associated preferred stock purchase rights issued
pursuant to the Rights Agreement, dated as of March 17, 1997, and amended as of
July 30, 1999, between the Company and ChaseMellon Shareholder Services L.L.C.,
as Rights Agent (the "Rights" and, together with the Common Stock, the
"Shares"), of SIBIA Neurosciences, Inc., a Delaware corporation (the "Company"),
at a purchase price of $8.50 per Share, net to the seller in cash, without
interest, upon the terms and subject to the conditions set forth in the Offer to
Purchase, dated August 6, 1999 (the "Offer to Purchase"), and in the related
Letter of Transmittal (which, together with any amendments or supplements
thereto, collectively constitute the "Offer"), copies of which are filed as
Exhibits (a)(1) and (a)(2) hereto, respectively, and which are incorporated
herein by reference. Offeror has been formed by Parent in connection with the
Offer and the transactions contemplated thereby.
ITEM 1. SECURITY AND SUBJECT COMPANY.
(a) The name of the subject company is SIBIA Neurosciences, Inc. The
address of the principal executive offices of the Company is 505 Coast Boulevard
South, Suite 300, La Jolla, California 92037.
(b) The information set forth in the Introduction and Section 1 ("Terms of
the Offer; Expiration Date") of the Offer to Purchase is incorporated herein by
reference.
(c) The information set forth in Section 6 ("Price Range of Shares ") of
the Offer to Purchase is incorporated herein by reference.
ITEM 2. IDENTITY AND BACKGROUND.
(a) through (d), (g) This Schedule 14D-1 is filed by Parent and Offeror.
The information set forth in the Introduction and Section 9 ("Certain
Information Concerning Parent and Offeror") of the Offer to Purchase and in
Schedule I thereto is incorporated herein by reference.
(e) and (f) None of Offeror or Parent or, to the best of their knowledge,
any of the persons listed in Schedule I of the Offer to Purchase, has during the
last five years (i) been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) or (ii) been a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction and as a result
of such proceeding was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting activities subject to, federal or
state securities laws or finding any violation of such laws.
ITEM 3. PAST CONTACTS, TRANSACTIONS OR NEGOTIATIONS WITH THE SUBJECT COMPANY.
(a) and (b) The information set forth in the Introduction, Section 8
("Certain Information Concerning the Company"), Section 9 ("Certain Information
Concerning Parent and Offeror"), Section 11 ("Background of the Offer") and
Section 12 (Purpose of the Offer and the Merger; Plans for the Company; The
Transaction Documents) of the Offer to Purchase is incorporated herein by
reference.
ITEM 4. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
(a) The information set forth in Section 10 ("Source and Amount of Funds")
of the Offer to Purchase is incorporated herein by reference.
(b) and (c) Not applicable.
ITEM 5. PURPOSE OF THE TENDER OFFER AND PLANS OR PROPOSALS OF THE BIDDER.
(a) through (c), (e) The information set forth in the Introduction,
Section 12 ("Purpose of the Offer and the Merger; Plans for the Company; The
Transaction Documents") and Section 13 ("Dividends and Distribution") of the
Offer to Purchase is incorporated herein by reference.
(d) The information set forth in the Offer to Purchase is incorporated
herein by reference.
-5-
<PAGE> 6
(f) through (g) The information set forth in Section 7 ("Effect of the
Offer on the Market for Shares; Stock Quotation; Exchange Act Registration and
Margin Securities") of the Offer to Purchase is incorporated herein by
reference.
ITEM 6. INTEREST IN SECURITIES OF THE SUBJECT COMPANY.
(a) None.
(b) Not applicable.
ITEM 7. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
THE SUBJECT COMPANY'S SECURITIES.
The information set forth in the Introduction, Section 1 ("Terms of the
Offer"), Section 9 ("Certain Information Concerning Parent and Offeror"),
Section 10 ("Source and Amount of Funds"), Section 11 ("Background of the
Offer"), Section 12 ("Purpose of the Offer and the Merger; Plans for the
Company; The Transaction Documents"), Section 13 ("Dividends and Distributions")
and Section 14 ("Certain Conditions to the Offer") of the Offer to Purchase is
incorporated herein by reference.
ITEM 8. PERSONS RETAINED, EMPLOYED OR TO BE COMPENSATED.
The information set forth in the Introduction and Section 16 ("Fees and
Expenses") of the Offer to Purchase is incorporated herein by reference.
ITEM 9. FINANCIAL STATEMENTS OF CERTAIN BIDDERS.
The information set forth in Section 9 ("Certain Information Concerning
Parent and Offeror") of the Offer to Purchase is incorporated herein by
reference.
ITEM 10. ADDITIONAL INFORMATION.
(a) The information set forth in the Introduction, Section 9 ("Certain
Information Concerning Parent and Offeror") and Section 12 ("Purpose of the
Offer and the Merger; Plans for the Company; The Transaction Documents") of the
Offer to Purchase is incorporated herein by reference.
(b) and (c) The information set forth in Section 15 ("Certain Regulatory
and Legal Matters") of the Offer to Purchase is incorporated herein by
reference.
(d) The information set forth in Section 7 ("Effect of the Offer on the
Market for Shares, Stock Quotation, Exchange Act Registration and Margin
Securities") of the Offer to Purchase is incorporated herein by reference.
(e) None.
(f) The information set forth in the Offer to Purchase, a copy of which is
attached as Exhibit (a)(1), and the Letter of Transmittal, a copy of which is
attached as Exhibit (a)(2), is incorporated herein by reference in its entirety.
ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.
(a)(1) Offer to Purchase, dated August 6, 1999.
(a)(2) Letter of Transmittal.
(a)(3) Letter to Brokers, Dealers, Commercial Banks, Trust Companies
and Other Nominees.
(a)(4) Letter from Brokers, Dealers, Commercial Banks, Trust
Companies and Other Nominees to Clients.
(a)(5) Notice of Guaranteed Delivery.
(a)(6) Guidelines for Certification of Taxpayer Identification Number
on Substitute Form W-9.
(a)(7) Joint Press Release, dated August 2, 1999.
(a)(8) Press Release issued by Parent on August 6, 1999.
(b) Not applicable.
(c)(1) Agreement and Plan of Merger dated as of July 30, 1999, among
Parent, Offeror and the Company.
-6-
<PAGE> 7
(c)(2) Shareholders Agreement dated as of July 30, among the persons
listed on Schedule 1 thereto, Parent and Offeror.
(c)(3) Stock Option Agreement dated as of July 30, 1999, among Parent,
Offeror and the Company.
(c)(4) Confidentiality Agreement dated as of June 23, 1999, between
Company and Parent.
(d) None.
(e) Not applicable.
(f) None.
-7-
<PAGE> 8
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: August 6, 1999
MERCK & CO., INC.
By: /s/ Judy C. Lewent
--------------------------------------
Name: Judy C. Lewent
Title: Senior Vice President and
Chief Financial Officer
MC SUBSIDIARY CORP.
By: /s/ Judy C. Lewent
--------------------------------------
Name: Judy C. Lewent
Title: President
-8-
<PAGE> 9
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT DESCRIPTION NO. PAGE NO.
- ------- --------------- --------
<S> <C> <C>
(a)(l) -- Offer to Purchase, dated August 6, 1999.
(a)(2) -- Letter of Transmittal.
(a)(3) -- Letter to Brokers, Dealers, Commercial Banks, Trust
Companies and Other Nominees.
(a)(4) -- Letter from Brokers, Dealers, Commercial Banks, Trust
Companies and Other Nominees to Clients.
(a)(5) -- Notice of Guaranteed Delivery.
(a)(6) -- Guidelines for Certification of Taxpayer Identification
Number on Substitute Form W-9.
(a)(7) -- Joint Press Release, dated August 2, 1999.
(a)(8) -- Press Release issued by Parent on August 6, 1999.
(b) -- Not applicable.
(c)(1) -- Agreement and Plan of Merger dated as of July 30, 1999, -- among
Parent, Offeror and the Company.
(c)(2) -- Shareholders Agreement dated as of July 30, among the
persons listed on Schedule 1 thereto, Parent and Offeror.
(c)(3) -- Stock Option Agreement dated as of July 30, among the
Parent, Offeror and the Company.
(c)(4) -- Confidentiality Agreement dated as of June 23, 1999
between Company and Parent.
(d) -- None.
(e) -- Not applicable.
(f) -- None.
</TABLE>
-9-
<PAGE> 1
EXHIBIT (a)(1)
OFFER TO PURCHASE FOR CASH
ALL OUTSTANDING SHARES OF COMMON STOCK
(INCLUDING THE ASSOCIATED RIGHTS)
OF
SIBIA NEUROSCIENCES, INC.
AT
$8.50 NET PER SHARE
BY
MC SUBSIDIARY CORP.,
A DIRECT WHOLLY-OWNED SUBSIDIARY OF
MERCK & CO., INC.
-------------------------------------
THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK
CITY TIME, ON THURSDAY, SEPTEMBER 2, 1999, UNLESS THE OFFER IS EXTENDED.
THE OFFER IS CONDITIONED UPON, AMONG OTHER THINGS, THERE BEING VALIDLY
TENDERED AND NOT WITHDRAWN PRIOR TO THE EXPIRATION DATE (AS DEFINED BELOW) OF
THE OFFER AT LEAST THAT NUMBER OF SHARES EQUIVALENT TO A MAJORITY OF THE TOTAL
ISSUED AND OUTSTANDING SHARES ON A FULLY DILUTED BASIS. SEE SECTIONS 12 AND 14.
-------------------------------------
THE BOARD OF DIRECTORS OF SIBIA NEUROSCIENCES, INC. (THE "COMPANY") HAS
UNANIMOUSLY APPROVED THE OFFER, THE MERGER AND THE MERGER AGREEMENT REFERRED TO
HEREIN AND HAS DETERMINED THAT THE OFFER AND THE MERGER ARE FAIR TO AND IN THE
BEST INTERESTS OF THE STOCKHOLDERS OF THE COMPANY AND RECOMMENDS THAT THE
STOCKHOLDERS OF THE COMPANY ACCEPT THE OFFER AND TENDER ALL OF THEIR SHARES
PURSUANT THERETO.
-------------------------------------
IMPORTANT
ANY STOCKHOLDER DESIRING TO TENDER ALL OR ANY PORTION OF SUCH STOCKHOLDER'S
SHARES AND THE ASSOCIATED RIGHTS (EACH AS HEREINAFTER DEFINED) SHOULD EITHER (I)
COMPLETE AND SIGN THE LETTER OF TRANSMITTAL (OR A FACSIMILE THEREOF) IN
ACCORDANCE WITH THE INSTRUCTIONS IN THE LETTER OF TRANSMITTAL AND MAIL OR
DELIVER THE CERTIFICATE(S) REPRESENTING THE TENDERED SHARES, AND ALL OTHER
REQUIRED DOCUMENTS, TO THE DEPOSITARY OR TENDER SUCH SHARES PURSUANT TO THE
PROCEDURE FOR BOOK-ENTRY TRANSFER SET FORTH IN SECTION 3 OR (II) REQUEST HIS
BROKER, DEALER, COMMERCIAL BANK, TRUST COMPANY OR OTHER NOMINEE TO EFFECT THE
TRANSACTION FOR HIM. A STOCKHOLDER WHOSE SHARES ARE REGISTERED IN THE NAME OF A
BROKER, DEALER, COMMERCIAL BANK, TRUST COMPANY OR OTHER NOMINEE MUST CONTACT
SUCH PERSON IF HE DESIRES TO TENDER SUCH SHARES.
A STOCKHOLDER WHO DESIRES TO TENDER SHARES AND WHOSE CERTIFICATES
REPRESENTING SUCH SHARES ARE NOT IMMEDIATELY AVAILABLE OR WHO CANNOT COMPLY WITH
THE PROCEDURES FOR BOOK-ENTRY TRANSFER ON A TIMELY BASIS MAY TENDER SUCH SHARES
BY FOLLOWING THE PROCEDURE FOR GUARANTEED DELIVERY SET FORTH IN SECTION 3.
QUESTIONS AND REQUESTS FOR ASSISTANCE MAY BE DIRECTED TO THE INFORMATION
AGENT, AT ITS ADDRESS AND TELEPHONE NUMBER SET FORTH ON THE BACK COVER OF THIS
OFFER TO PURCHASE. ADDITIONAL COPIES OF THIS OFFER TO PURCHASE, THE LETTER OF
TRANSMITTAL, THE NOTICE OF GUARANTEED DELIVERY AND OTHER RELATED MATERIALS MAY
BE OBTAINED FROM THE INFORMATION AGENT OR FROM BROKERS, DEALERS, COMMERCIAL
BANKS AND TRUST COMPANIES.
-------------------------------------
THE INFORMATION AGENT FOR THE OFFER IS:
MORROW & CO., INC.
AUGUST 6, 1999
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<C> <S> <C>
Introduction..................................................... 1
1. Terms of the Offer; Expiration Date......................... 4
2. Acceptance for Payment and Payment for Shares............... 5
3. Procedure for Tendering Shares.............................. 6
4. Withdrawal Rights........................................... 8
5. Certain Federal Income Tax Consequences..................... 8
6. Price Range of Shares....................................... 10
7. Effect of the Offer on the Market for Shares; Stock
Quotation; Exchange Act Registration and Margin
Securities.................................................. 10
8. Certain Information Concerning the Company.................. 11
9. Certain Information Concerning Parent and Offeror........... 14
10. Source and Amount of Funds.................................. 15
11. Background of the Offer..................................... 15
12. Purpose of the Offer and the Merger; Plans for the Company;
The Transaction Documents................................... 16
13. Dividends and Distributions................................. 33
14. Certain Conditions to the Offer............................. 33
15. Certain Regulatory and Legal Matters........................ 34
16. Fees and Expenses........................................... 36
17. Miscellaneous............................................... 36
Schedule I -- CERTAIN INFORMATION CONCERNING THE DIRECTORS AND
EXECUTIVE OFFICERS OF PARENT AND OFFEROR........... I-1
</TABLE>
i
<PAGE> 3
To the Holders of Common Stock of
SIBIA NEUROSCIENCES, INC.:
INTRODUCTION
MC Subsidiary Corp., a Delaware corporation ("Offeror"), and a direct
wholly-owned subsidiary of Merck & Co., Inc., a New Jersey corporation
("Parent"), hereby offers to purchase all outstanding shares of Common Stock,
par value $.001 per share (the "Common Stock"), inclusive of their respective
associated preferred stock purchase rights (the "Rights" and, the shares of
Common Stock inclusive of their respective Rights, the "Shares"), of SIBIA
Neurosciences, Inc., a Delaware corporation (the "Company"), at a purchase price
of $8.50 per Share, net to the seller in cash, without interest (the "Offer
Price"), upon the terms and subject to the conditions set forth in this Offer to
Purchase and in the related Letter of Transmittal (which, together with any
amendments or supplements hereto or thereto, collectively constitute the
"Offer"). The Rights were issued pursuant to the Rights Agreement, dated as of
March 17, 1997 and as amended as of July 30, 1999 (the "Rights Agreement"),
between the Company and ChaseMellon Shareholder Services L.L.C., as Rights
Agent, and are currently evidenced by and trade with certificates evidencing the
Common Stock.
Offeror is a corporation newly formed by Parent in connection with the
Offer and the transactions contemplated thereby. For information concerning
Parent, see Section 9.
Tendering stockholders will not be obligated to pay brokerage fees or
commissions or, except as set forth in Instruction 6 of the Letter of
Transmittal, transfer taxes on the purchase of Shares pursuant to the Offer.
Offeror will pay all fees and expenses of Norwest Bank Minnesota, N.A., which is
acting as the Depositary (the "Depositary") and Morrow & Co., Inc., which is
acting as Information Agent (the "Information Agent"), incurred in connection
with the Offer. See Section 16.
THE BOARD OF DIRECTORS OF THE COMPANY HAS UNANIMOUSLY APPROVED THE OFFER,
THE MERGER AND THE MERGER AGREEMENT AND DETERMINED THAT THE OFFER AND THE MERGER
ARE FAIR TO AND IN THE BEST INTERESTS OF THE STOCKHOLDERS OF THE COMPANY AND
RECOMMENDS THAT THE STOCKHOLDERS OF THE COMPANY ACCEPT THE OFFER AND TENDER ALL
OF THEIR SHARES PURSUANT THERETO.
CIBC WORLD MARKETS CORP., THE COMPANY'S FINANCIAL ADVISOR (THE "FINANCIAL
ADVISOR"), HAS DELIVERED TO THE BOARD OF DIRECTORS OF THE COMPANY ITS WRITTEN
OPINION TO THE EFFECT THAT, AS OF JULY 30, 1999, THE CONSIDERATION TO BE
RECEIVED BY HOLDERS OF SHARES (OTHER THAN PARENT, OFFEROR AND ANY AFFILIATES
THEREOF) PURSUANT TO THE MERGER AGREEMENT IS FAIR TO SUCH HOLDERS FROM A
FINANCIAL POINT OF VIEW. SUCH OPINION IS SET FORTH IN FULL AS AN ANNEX TO THE
COMPANY'S SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 (THE "SCHEDULE
14D-9"), WHICH IS BEING MAILED TO STOCKHOLDERS OF THE COMPANY CONCURRENTLY
HEREWITH.
THE OFFER IS CONDITIONED UPON, AMONG OTHER THINGS, THERE BEING VALIDLY
TENDERED AND NOT WITHDRAWN PRIOR TO THE EXPIRATION DATE OF THE OFFER AT LEAST
THAT NUMBER OF SHARES EQUIVALENT TO A MAJORITY OF THE TOTAL ISSUED AND
OUTSTANDING SHARES ON A FULLY DILUTED BASIS (SUCH CONDITION, THE "MINIMUM
CONDITION", AND SUCH SHARES, THE "MINIMUM SHARES"). SEE SECTIONS 12 AND 14.
The Offer is being made pursuant to the Agreement and Plan of Merger, dated
as of July 30, 1999 (the "Merger Agreement"), among Parent, Offeror and the
Company, pursuant to which, following the later of the consummation of the Offer
and the satisfaction or waiver of certain conditions, Offeror will be merged
with and into the Company (the "Merger"). Following the consummation of the
Merger, the Company will be the surviving corporation (the "Surviving
Corporation"). Parent also has the right to assign Offeror's rights under
1
<PAGE> 4
the Merger Agreement to another wholly owned direct subsidiary of Parent. In the
Merger, each outstanding Share (other than Shares held by the Company or any
direct or indirect subsidiary of the Company or owned by Parent or Offeror or
any other direct or indirect subsidiary of Parent and other than Shares held by
stockholders, if any, who perfect their appraisal rights under Delaware law (the
"Excluded Shareholders")) will be converted into, and become exchangeable for,
the right to receive $8.50 per Share in cash (the "Merger Consideration") and
the Company will become a direct wholly owned subsidiary of Parent. See Section
12.
Subject to the terms of the Merger Agreement and the applicable rules and
regulations of the Securities and Exchange Commission (the "Commission"),
Offeror expressly reserves the right, in its sole discretion, at any time and
from time to time, and regardless of whether or not any of the events set forth
in Section 14 hereof shall have occurred or shall have been determined by
Offeror to have occurred, (i) to extend the period of time during which the
Offer is open, and thereby delay acceptance for payment of and the payment for
any Shares, by giving oral or written notice of such extension to the Depositary
and (ii) to amend the Offer in any other respect by giving oral or written
notice of such amendment to the Depositary.
If by 12:00 Midnight, New York City time, on Thursday, September 2, 1999
(or any other date or time then set as the Expiration Date), any or all
conditions to the Offer have not been satisfied or waived, Offeror reserves the
right (but shall not be obligated), subject to the terms and conditions
contained in the Merger Agreement and to the applicable rules and regulations of
the Commission, to (i) terminate the Offer and not accept for payment any Shares
and return all tendered Shares to tendering stockholders, (ii) waive all the
unsatisfied conditions and, subject to complying with the terms of the Merger
Agreement and the applicable rules and regulations of the Commission, accept for
payment and pay for all Shares validly tendered prior to the Expiration Date and
not theretofore withdrawn, (iii) extend the Offer and, subject to the right of
stockholders to withdraw Shares until the Expiration Date, retain the Shares
that have been tendered during the period or periods for which the Offer is
extended or (iv) amend the Offer.
There can be no assurance that Offeror will exercise its right to extend
the Offer. Any extension, waiver, amendment or termination will be followed as
promptly as practicable by public announcement thereof. In the case of an
extension, Rule 14e-1(d) under the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), requires that the announcement be issued no later than
9:00 am., Eastern time, on the next business day after the previously scheduled
Expiration Date in accordance with the public announcement requirements of Rule
14d-4(c) under the Exchange Act, subject to applicable law (including Rules
14d-4(c) and 14d-6(d) under the Exchange Act, which require that any material
change in the information published, sent or given to stockholders in connection
with the Offer be promptly disseminated to stockholders in a manner reasonably
designed to inform stockholders of such change). Without limiting the obligation
of Offeror under such rules or the manner in which Offeror may choose to make
any public announcement, Offeror will not have any obligation to publish,
advertise or otherwise communicate any such public announcement other than by
issuing a release to the Dow Jones News Service.
In the Merger Agreement, Offeror has agreed that it will not, without the
prior consent of the Company, extend the Offer if all of the conditions to the
Offer have been satisfied, except that Offeror may, without the consent of the
Company, extend the Offer (i) if on the scheduled Expiration Date of the Offer
any of the conditions to the Offer shall not have been satisfied or waived, for
one or more periods (none of which shall exceed ten business days) but in no
event past 90 days from the date of the Merger Agreement unless the waiting
period applicable to the transactions contemplated by the Merger Agreement under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR
Act") has not terminated or expired and then in any event not later than March
1, 2000, (ii) for such period as may be required by any rule, regulation,
interpretation or position of the Commission or its staff applicable to the
Offer, or (iii) if all conditions to the Offer are satisfied or waived but more
than 90% of the issued and outstanding Shares have not been tendered, for one or
more periods (each such period to be for not more than three business days and
such extensions to be for an aggregate period of not more than ten business days
beyond the latest expiration date that would be permitted under clause (i) or
(ii) of this sentence). In addition, Offeror has agreed that, without the prior
written consent of the Company, it will not (i) decrease the amount or change
the form of consideration payable in the Offer, (ii) decrease the number of
Shares sought in the Offer, (iii) impose
2
<PAGE> 5
additional conditions to the Offer, (iv) change any conditions to the Offer
(including the conditions described in Section 14) or amend any other term of
the Offer if any such change or amendment would be adverse in any respect to the
holders of Shares (other than Parent or Offeror) or (v) amend or waive the
Minimum Condition.
If Offeror makes a material change in the terms of the Offer or the
information concerning the Offer or waives a material condition of the Offer
(including, with the consent of the Company, the Minimum Condition), Offeror
will disseminate additional tender offer materials and extend the Offer to the
extent required by Rules 14d-4(c), 14d-6(d) and 14e-l under the Exchange Act.
The minimum period during which an offer must remain open following material
changes in the terms of the offer or information concerning the offer, other
than a change in price or a change in the percentage of securities sought, will
depend upon the facts and circumstances then existing, including the relative
materiality of the changed terms or information. With respect to a change in
price or a change in the percentage of securities sought, a minimum period of 10
business days is generally required to allow for adequate dissemination to
stockholders. As used in this Offer to Purchase, "business day" has the meaning
set forth in Rule 14d-1 under the Exchange Act.
Based on the representations and warranties of the Company contained in the
Merger Agreement, and information provided by the Company, as of July 23, 1999,
(i) 9,703,769 Shares were outstanding, (ii) one share of Series B Convertible
Preferred Stock, par value $0.001 (the "Series B Convertible Preferred Stock")
was outstanding, which as of July 23, 1999 was convertible into approximately
406,256 shares of Common Stock, (iii) 2,513,141 shares of Common Stock were
reserved for issuance under the Company's 1996 Equity Incentive Plan, as
amended, of which options to acquire 1,057,205 shares of Common Stock were
outstanding, (iv) 500,000 shares of Common Stock were reserved for issuance
under the Company's Employee Stock Purchase Plan, of which 9,934 shares of
Common Stock could be purchased, (v) 235,000 shares of Common Stock were
reserved for issuance under the Company's 1996 Non-Employee Directors' Stock
Option Plan, of which options to acquire 65,000 shares of Common Stock were
outstanding, (vi) 219,304 shares of Common Stock were reserved for issuance
under the Company's Amended and Restated 1992 Stock Option and Restricted Stock
Plan, of which options to acquire 219,304 shares of Common Stock were
outstanding, (vii) 205,487 shares of Common Stock were outstanding under the
Management Change of Control Plan and (viii) 1,410 shares of Common Stock were
outstanding under the 1981 Employee Stock Option Plan. In addition, 150,000
shares of Series A Junior Participating Preferred Stock of the Company are
subject to issuance upon the exercise of the Rights. Further, in connection with
the execution and delivery of the Merger Agreement, the Company has entered into
an agreement (the "Stock Option Agreement") with Parent granting Parent an
option to purchase Shares on certain terms and conditions.
Based on the foregoing, the Minimum Condition will be satisfied if
5,834,183 Shares are validly tendered and not withdrawn prior to the Expiration
Date (assuming the Series B Convertible Preferred Stock would be convertible
into 406,256 shares of Common Stock in connection with the Offer). The number of
Shares required to be validly tendered and not withdrawn in order to satisfy the
Minimum Condition will increase to the extent additional Shares are deemed to be
outstanding on a fully diluted basis. For purposes of the Offer to Purchase, any
reference to a majority of the total issued and outstanding shares or shares
outstanding on a fully diluted basis excludes any shares of Common Stock
issuable upon exercise of or subject to the Stock Option Agreement.
The consummation of the Merger is subject to the satisfaction or waiver of
a number of conditions, including, if required, the approval of the Merger by
the requisite vote or consent of the stockholders of the Company. Under the
General Corporation Law of the State of Delaware ("Delaware Law") and the
Company's certificate of incorporation, the stockholder vote necessary to
approve the Merger will be the affirmative vote of the holders of at least a
majority of the outstanding Shares, including Shares held by Offeror and its
affiliates. Accordingly, if Offeror acquires a majority of the outstanding
Shares, Offeror will have the voting power required to approve the Merger
without the affirmative vote of any other stockholders of the Company.
Furthermore, if Offeror acquires at least 90% of each class of outstanding
shares (which would include each of the outstanding shares of Common Stock as
well as the outstanding share of Series B Convertible Preferred Stock) pursuant
to the Offer or otherwise, Offeror would be able to effect the Merger pursuant
to the "short-form" merger provisions of Section 253 of the Delaware Law,
without prior notice to, or any action by, any other stockholder of the Company.
In such event, Offeror intends to effect the Merger as
3
<PAGE> 6
promptly as practicable following the purchase of Shares in the Offer. Parent
expects during the pendency of the Offer to seek to have discussions with the
holder of the Series B Convertible Preferred Stock regarding the sale by such
holder to Parent after consummation of the Offer. However, Parent cannot under
Rule 10b-13 under the Exchange Act, directly or indirectly, purchase, or make
any arrangement to purchase, the Series B Convertible Preferred Stock until
after consummation of the Offer. If the outstanding share of Series B
Convertible Preferred Stock is not converted and tendered in the Offer or Parent
does not purchase the Series B Convertible Preferred Stock following
consummation of the Offer, Parent will be unable to effect a "short-form"
merger. The Merger Agreement is more fully described in Section 12.
Concurrently with the execution and delivery of the Merger Agreement, the
Company granted to Parent an option purchase up to 1,931,050 Shares at a cash
price equal to $8.50 per share and on the other terms and subject to the
conditions set forth in the Stock Option Agreement dated July 30, 1999, among
the Company, Parent and Offeror (the "Stock Option Agreement"). See Section 12.
Concurrently with the execution and delivery of the Merger Agreement, The
Salk Institute for Biological Studies, Skandigen AB and Dr. William T. Comer
(collectively, the "Major Stockholders"), entered into a Shareholders Agreement,
dated as of July 30, 1999 (the "Shareholders Agreement"), with Parent and
Offeror. As of July 30, 1999, the Major Stockholders beneficially owned (as
defined pursuant to Rule 13d-3 of the Exchange Act) approximately 34.1% of the
Shares (approximately 29.0% of the Shares on a fully diluted basis). Pursuant to
the Shareholders Agreement, the Major Stockholders have, among other things,
entered into a voting agreement with Parent and Offeror, granted an irrevocable
proxy to Offeror's designees with respect to their Shares, agreed to tender
their Shares in the Offer and agreed to grant to Offeror an option to purchase
the Shares held by them at the Offer Price under specified circumstances. If the
Major Stockholders tender in the Offer, as they have agreed to do, the Minimum
Condition will be satisfied if 2,646,126 Shares (approximately 22.7% of the
Shares on a fully diluted basis) are tendered in the Offer by other
stockholders. For purposes of this Offer to Purchase, any reference to
beneficial ownership of Parent or Offeror of Shares or similar references shall
exclude Shares subject to the Shareholders Agreement.
The Company has distributed one Right for each outstanding share of Common
Stock pursuant to the Rights Agreement. Based on the information disclosed by
the Company in the Merger Agreement and in the Schedule 14D-9, in connection
with the Company's entering into the Merger Agreement, the Board of Directors
authorized an amendment to the Rights Agreement so that the Rights Agreement
shall not be applicable as a result of the execution, delivery or performance of
the Merger Agreement, the Shareholders Agreement or the Stock Option Agreement
or the consummation of the Offer and the Merger or the other transactions
contemplated by such agreements. If the Rights Agreement had not been so
amended, a distribution of Rights certificates separate from the Common Stock
might have resulted from the Offer, the Merger Agreement, the Shareholders
Agreement or the Stock Option Agreement or any of the respective transactions
contemplated thereby.
THIS OFFER TO PURCHASE AND THE RELATED LETTER OF TRANSMITTAL CONTAIN
IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE
WITH RESPECT TO THE OFFER. THIS OFFER TO PURCHASE CONTAINS FORWARD-LOOKING
STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING THE RISKS ASSOCIATED
WITH SATISFYING THE CONDITIONS TO THE OFFER. CERTAIN OF THESE RISK FACTORS, AS
WELL AS ADDITIONAL RISKS AND UNCERTAINTIES, ARE DETAILED IN THE COMPANY'S
PERIODIC FILINGS WITH THE COMMISSION.
1. TERMS OF THE OFFER; EXPIRATION DATE.
Upon the terms and subject to the conditions to the Offer (including, if
the Offer is extended or amended, the terms and conditions of any such extension
or amendment), Offeror will accept for payment and pay for all Shares validly
tendered prior to the Expiration Date and not withdrawn in accordance with
Section 4. The term "Expiration Date" means 12:00 Midnight, New York City time,
on Thursday, September 2, 1999, unless and until Offeror (subject to the terms
of the Merger Agreement) shall have extended the period of time during which the
Offer is open, in which event the term "Expiration Date" shall mean the latest
time and date at which the Offer, as so extended by Offeror, shall expire.
4
<PAGE> 7
Consummation of the Offer is conditioned upon satisfaction of the Minimum
Condition and the other conditions set forth in Section 14. Subject to the terms
and conditions contained in the Merger Agreement, Offeror reserves the right
(but shall not be obligated) to waive any or all such conditions.
The Company is providing Offeror with its list of stockholders and security
position listings for the purpose of disseminating the Offer to holders of
Shares. This Offer to Purchase and the related Letter of Transmittal and other
relevant materials will be mailed by Offeror to record holders of Shares and
will be furnished by Offeror to brokers, dealers, commercial banks, trust
companies and similar persons whose names, or the names of whose nominees,
appear on the stockholder lists or, if applicable, who are listed as
participants in a clearing agency's security position listing, for subsequent
transmittal to beneficial owners of Shares.
2. ACCEPTANCE FOR PAYMENT AND PAYMENT FOR SHARES.
Subject to and in accordance with the terms and subject to the conditions
of the Offer (including, if the Offer is extended or amended, the terms and
conditions of any such extension or amendment), Offeror will accept for payment
and will pay for all Shares validly tendered prior to the Expiration Date, and
not properly withdrawn in accordance with Section 4, as soon as practicable
after the Expiration Date. Any determination concerning the satisfaction or
waiver of such terms and conditions will be within the reasonable discretion of
Offeror, and such determination will be final and binding on all tendering
stockholders. See Sections 1 and 14. Offeror expressly reserves the right, in
its sole discretion, to delay acceptance for payment of, or payment for, Shares
in order to comply in whole or in part with any applicable law. Any such delays
will be effected in compliance with Rule 14e-1(c) under the Exchange Act
(relating to Offeror's obligation to pay for or return tendered Shares promptly
after the termination or withdrawal of the Offer).
In all cases, payment for Shares accepted for payment pursuant to the Offer
will be made only after timely receipt by the Depositary of (i) certificates for
such Shares or timely confirmation (a "Book-Entry Confirmation") of the
book-entry transfer of such Shares into the Depositary's account at The
Depository Trust Company (a "Book-Entry Transfer Facility") pursuant to the
procedures set forth in Section 3, (ii) a Letter of Transmittal (or facsimile
thereof) properly completed and duly executed, with any required signature
guarantees, or an Agent's Message (as hereinafter defined) in connection with a
book-entry transfer and (iii) any other documents required by the Letter of
Transmittal.
The per Share consideration paid to any stockholder pursuant to the Offer
will be the highest per Share consideration paid to any other stockholder
pursuant to the Offer.
The term "Agent's Message" means a message, transmitted by the Book-Entry
Transfer Facility to, and received by, the Depositary and forming a part of a
Book-Entry Confirmation, which states that the Book-Entry Transfer Facility has
received an express acknowledgment from the participant in the Book-Entry
Transfer Facility tendering the Shares which are the subject of such Book-Entry
Confirmation, that such participant has received and agrees to be bound by the
terms of the Letter of Transmittal and that Offeror may enforce such agreement
against such participant.
For purposes of the Offer, Offeror will be deemed to have accepted for
payment, and thereby purchased, Shares properly tendered to Offeror and not
withdrawn as, if and when Offeror gives oral or written notice to the Depositary
of Offeror's acceptance for payment of such Shares pursuant to the Offer. Upon
the terms and subject to the conditions to the Offer, payment for Shares
accepted for payment pursuant to the Offer will be made by deposit of the
purchase price therefor with the Depositary, which will act as agent for
tendering stockholders for the purpose of receiving payment from Offeror and
transmitting payment to tendering stockholders. If Offeror is delayed in its
acceptance for payment of, or payment for, Shares or is unable to accept for
payment or pay for Shares pursuant to the Offer for any reason, then, without
prejudice to Offeror's rights under the Offer (but subject to compliance with
Rule 14e-l(c) under the Exchange Act, which requires that a tender offeror pay
the consideration offered or return the tendered securities promptly after the
termination or withdrawal of a tender offer), the Depositary may, nevertheless,
on behalf of Offeror, retain tendered Shares, and any such Shares may not be
withdrawn except to the extent tendering stockholders are entitled to exercise,
and duly exercise, withdrawal rights as described in Section 4. UNDER NO
CIRCUMSTANCES
5
<PAGE> 8
WILL INTEREST BE PAID ON THE PURCHASE PRICE OF THE SHARES TO BE PAID BY OFFEROR,
REGARDLESS OF ANY EXTENSION OF THE OFFER OR ANY DELAY IN MAKING SUCH PAYMENT.
If any tendered Shares are not purchased pursuant to the Offer because of
an invalid tender or otherwise, certificates for any such Shares will be
returned, without expense to the tendering stockholder (or, in the case of
Shares delivered by book-entry transfer of such Shares into the Depositary's
account at the Book-Entry Transfer Facility pursuant to the procedures set forth
in Section 3, such Shares will be credited to an account maintained at the
Book-Entry Transfer Facility), as promptly as practicable after the expiration
or termination of the Offer.
3. PROCEDURE FOR TENDERING SHARES.
Valid Tender. For Shares to be validly tendered pursuant to the Offer, a
properly completed and duly executed Letter of Transmittal (or a manually signed
facsimile thereof), together with any required signature guarantees, or an
Agent's Message in connection with a book-entry transfer of Shares, and any
other documents required by the Letter of Transmittal, must be received by the
Depositary at one of its addresses set forth on the back cover of this Offer to
Purchase prior to the Expiration Date. In addition, either (i) certificates for
tendered Shares must be received by the Depositary along with the Letter of
Transmittal at one of such addresses or such Shares must be tendered pursuant to
the procedure for book-entry transfer set forth below (and a Book-Entry
Confirmation received by the Depositary), in each case prior to the Expiration
Date, or (ii) the tendering stockholder must comply with the guaranteed delivery
procedure set forth below.
THE METHOD OF DELIVERY OF SHARE CERTIFICATES, THE LETTER OF TRANSMITTAL AND
ALL OTHER REQUIRED DOCUMENTS, INCLUDING DELIVERY THROUGH ANY BOOK-ENTRY TRANSFER
FACILITY, IS AT THE ELECTION AND RISK OF THE TENDERING STOCKHOLDER. SHARES WILL
BE DEEMED DELIVERED ONLY WHEN ACTUALLY RECEIVED BY THE DEPOSITARY. IF DELIVERY
IS BY MAIL, REGISTERED MAIL WITH RETURN RECEIPT REQUESTED, PROPERLY INSURED, IS
RECOMMENDED. IN ALL CASES, SUFFICIENT TIME SHOULD BE ALLOWED TO ENSURE TIMELY
DELIVERY.
Book-Entry Transfer. The Depositary will establish an account with respect
to the Shares at the Book-Entry Transfer Facility for purposes of the Offer
within two business days after the date of this Offer to Purchase. Any financial
institution that is a participant in the Book-Entry Transfer Facility's systems
may make book-entry delivery of Shares by causing the Book-Entry Transfer
Facility to transfer such Shares into the Depositary's account at the Book-Entry
Transfer Facility in accordance with the Book-Entry Transfer Facility's
procedures for such transfer. However, although delivery of Shares may be
effected through book-entry at the Book-Entry Transfer Facility, a properly
completed and duly executed Letter of Transmittal (or manually signed facsimile
thereof) with any required signature guarantees or an Agent's Message in
connection with a book-entry delivery of Shares, and any other documents
required by the Letter of Transmittal, must, in any case, be transmitted to, and
received by, the Depositary at one of its addresses set forth on the back cover
of this Offer to Purchase prior to the Expiration Date, or the tendering
stockholder must comply with the guaranteed delivery procedure described below.
DELIVERY OF DOCUMENTS TO THE BOOK-ENTRY TRANSFER FACILITY IN ACCORDANCE WITH THE
BOOK-ENTRY TRANSFER FACILITY'S PROCEDURES DOES NOT CONSTITUTE DELIVERY TO THE
DEPOSITARY.
Signature Guarantees. No signature guarantee is required on the Letter of
Transmittal if (i) the Letter of Transmittal is signed by the registered holder
of Shares (which term, for purposes of this Section, includes any participant in
the Book-Entry Transfer Facility whose name appears on a security position
listing as the owner of the Shares) tendered therewith and such registered
holder has not completed either the box entitled "Special Delivery Instructions"
or the box entitled "Special Payment Instructions" on the Letter of Transmittal
or (ii) such Shares are tendered for the account of a bank, broker, dealer,
credit union, savings association or other entity that is a member in good
standing of a recognized Medallion Program approved by The Securities Transfer
Association, Inc. (an "Eligible Institution"). In all other cases, all
signatures on the Letter of Transmittal must be guaranteed by an Eligible
Institution. See Instructions 1 and 5 to the Letter of Transmittal. If the
certificates for Shares are registered in the name of a person other than the
signer of the Letter of Transmittal, or if payment is to be made or certificates
for Shares not tendered or not accepted for payment are to be issued to a person
other than the registered holder of the certificates surrendered, the
6
<PAGE> 9
tendered certificates must be endorsed or accompanied by appropriate stock
powers, in either case signed exactly as the name or names of the registered
holders or owners appear on the certificates, with the signatures on the
certificates or stock powers guaranteed as described above. See Instruction 5 to
the Letter of Transmittal.
Guaranteed Delivery. If a stockholder desires to tender Shares pursuant to
the Offer and such stockholder's certificates for Shares are not immediately
available or the procedure for book-entry transfer cannot be completed on a
timely basis or time will not permit all required documents to reach the
Depositary prior to the Expiration Date, such stockholder's tender may be
effected if all the following conditions are met:
(1) such tender is made by or through an Eligible Institution;
(2) a properly completed and duly executed Notice of Guaranteed
Delivery, substantially in the form provided by Offeror herewith, is
received by the Depositary as provided below, prior to the Expiration Date;
and
(3) the certificates for all tendered Shares, in proper form for
transfer (or a Book-Entry Confirmation with respect to such Shares),
together with a properly completed and duly executed Letter of Transmittal
(or a manually signed facsimile thereof), with any required signature
guarantees and any other documents required by the Letter of Transmittal,
are received by the Depositary within three NASDAQ National Market trading
days after the date of execution of such Notice of Guaranteed Delivery.
The Notice of Guaranteed Delivery may be delivered by hand to the
Depositary or transmitted by telegram, facsimile transmission or mail to the
Depositary and must include a signature guarantee by an Eligible Institution in
the form set forth in such Notice of Guaranteed Delivery.
Notwithstanding any other provision hereof, payment for Shares accepted for
payment pursuant to the Offer will in all cases be made only after timely
receipt by the Depositary of (i) certificates for the Shares or a Book-Entry
Confirmation with respect to such Shares, (ii) a properly completed and duly
executed Letter of Transmittal (or a manually signed facsimile thereof) with any
required signature guarantees or an Agent's Message in connection with a
book-entry delivery of Shares, and (iii) any other documents required by the
Letter of Transmittal. Accordingly, tendering stockholders may be paid at
different times depending upon when certificates for Shares or Book-Entry
Confirmations are actually received by the Depositary. UNDER NO CIRCUMSTANCES
WILL INTEREST BE PAID ON THE PURCHASE PRICE OF THE SHARES TO BE PAID BY OFFEROR,
REGARDLESS OF ANY EXTENSION OF THE OFFER OR ANY DELAY IN MAKING SUCH PAYMENT.
The valid tender of Shares pursuant to one of the procedures described
above will constitute a binding agreement between the tendering stockholder and
Offeror upon the terms and subject to the conditions to the Offer.
Backup Withholding. Under the United States federal income tax backup
withholding rules, payments in connection with the Offer or the Merger may be
subject to "backup withholding" as discussed in Section 5.
Appointment. By executing the Letter of Transmittal, the tendering
stockholder will irrevocably appoint designees of Offeror as such stockholder's
attorneys-in-fact and proxies in the manner set forth in the Letter of
Transmittal, each with full power of substitution, to the full extent of such
stockholder's rights with respect to the Shares tendered by such stockholder and
accepted for payment by Offeror and with respect to any and all other Shares or
other securities or rights issued or issuable in respect of such Shares on or
after August 6, 1999. All such proxies shall be considered coupled with an
interest in the tendered Shares. Such appointment will be effective when, and
only to the extent that, Offeror accepts for payment Shares tendered by such
stockholder as provided herein. Upon such acceptance for payment, all prior
powers of attorney and proxies given by such stockholder with respect to such
Shares or other securities or rights will, without further action, be revoked
and no subsequent powers of attorney and proxies may be given (and, if given,
will not be deemed effective). The designees of Offeror will thereby be
empowered to exercise all voting and other rights with respect to such Shares or
other securities or rights in respect of any annual, special or adjourned
meeting of the Company's stockholders, or otherwise, as they in their sole
discretion deem proper. Offeror reserves the right
7
<PAGE> 10
to require that, in order for Shares to be deemed validly tendered, immediately
upon Offeror's acceptance for payment of such Shares, Offeror must be able to
exercise full voting and other rights with respect to such Shares and other
securities or rights, including voting at any meeting of stockholders then
scheduled.
Determination of Validity. All questions as to the validity, form,
eligibility (including time of receipt) and acceptance for payment of any tender
of Shares will be determined by Offeror, in its sole discretion, which
determination will be final and binding. Offeror reserves the absolute right to
reject any or all tenders determined by it not to be in proper form or the
acceptance for payment of or payment for which may, in the opinion of Offeror's
counsel, be unlawful. Offeror also reserves the absolute right, in its sole
discretion, subject to the terms and conditions of the Merger Agreement, to
waive any of the conditions to the Offer or any defect or irregularity in any
tender with respect to any particular Shares, whether or not similar defects or
irregularities are waived in the case of other Shares. No tender of Shares will
be deemed to have been validly made until all defects or irregularities relating
thereto have been cured or waived. None of Parent, Offeror, the Depositary, the
Information Agent or any other person will be under any duty to give
notification of any defects or irregularities in tenders or incur any liability
for failure to give any such notification. Offeror's interpretation of the terms
and conditions of the Offer (including the Letter of Transmittal and the
instructions thereto) will be final and binding.
4. WITHDRAWAL RIGHTS.
Except as otherwise provided in this Section 4, tenders of Shares are
irrevocable. Shares tendered pursuant to the Offer may be withdrawn pursuant to
the procedures set forth below at any time prior to the Expiration Date and,
unless accepted for payment and paid for by Offeror pursuant to the Offer, may
also be withdrawn at any time after October 4, 1999.
For a withdrawal to be effective, a written, telegraphic or facsimile
transmission notice of withdrawal must be timely received by the Depositary at
one of its addresses set forth on the back cover of this Offer to Purchase and
must specify the name of the person having tendered the Shares to be withdrawn,
the number of Shares to be withdrawn and the name of the registered holder of
the Shares to be withdrawn, if different from the name of the person who
tendered the Shares. If certificates for Shares have been delivered or otherwise
identified to the Depositary, then, prior to the physical release of such
certificates, the serial numbers shown on such certificates must be submitted to
the Depositary and, unless such Shares have been tendered by an Eligible
Institution, the signatures on the notice of withdrawal must be guaranteed by an
Eligible Institution. If Shares have been tendered pursuant to the procedures
for book-entry transfer set forth in Section 3, the notice of withdrawal must
specify the name and number of the account at the Book-Entry Transfer Facility
to be credited with the withdrawn Shares. Withdrawals of tenders of Shares may
not be rescinded, and any Shares properly withdrawn will thereafter be deemed
not validly tendered for any purposes of the Offer. However, withdrawn Shares
may be retendered by again following one of the procedures described in Section
3 at any time prior to the Expiration Date.
All questions as to the form and validity (including time of receipt) of
notices of withdrawal will be determined by Offeror in its sole discretion,
which determination will be final and binding. None of Offeror, Parent, the
Depositary, the Information Agent or any other person will be under any duty to
give notification of any defects or irregularities in any notice of withdrawal
or incur any liability for failure to give any such notification.
5. CERTAIN FEDERAL INCOME TAX CONSEQUENCES.
THE FOLLOWING IS A SUMMARY OF CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF
THE OFFER AND THE MERGER TO HOLDERS WHOSE SHARES ARE PURCHASED PURSUANT TO THE
OFFER OR WHOSE SHARES ARE CONVERTED INTO THE RIGHT TO RECEIVE CASH IN THE
MERGER. THE SUMMARY IS BASED ON THE PROVISIONS OF THE INTERNAL REVENUE CODE OF
1986, AS AMENDED (THE "CODE"), APPLICABLE CURRENT AND PROPOSED UNITED STATES
TREASURY REGULATIONS ISSUED THEREUNDER, JUDICIAL AUTHORITY AND ADMINISTRATIVE
RULINGS AND PRACTICE, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH
RETROACTIVE EFFECT, AT ANY TIME AND, THEREFORE, THE FOLLOWING STATEMENTS AND
CONCLUSIONS COULD BE ALTERED OR MODIFIED. THE DISCUSSION DOES NOT ADDRESS
HOLDERS OF SHARES IN WHOSE HANDS SHARES ARE NOT CAPITAL
8
<PAGE> 11
ASSETS, NOR DOES IT ADDRESS HOLDERS WHO RECEIVED SHARES AS PART OF A HEDGING,
"STRADDLE," CONVERSION OR OTHER INTEGRATED TRANSACTION, UPON CONVERSION OF
SECURITIES OR EXERCISE OF WARRANTS OR OTHER RIGHTS TO ACQUIRE SHARES OR PURSUANT
TO THE EXERCISE OF EMPLOYEE STOCK OPTIONS OR OTHERWISE AS COMPENSATION, OR TO
HOLDERS OF SHARES WHO ARE IN SPECIAL TAX SITUATIONS (SUCH AS INSURANCE
COMPANIES, TAX-EXEMPT ORGANIZATIONS, FINANCIAL INSTITUTIONS, UNITED STATES
EXPATRIATES OR NON-U.S. PERSONS). FURTHERMORE, THE DISCUSSION DOES NOT ADDRESS
THE TAX TREATMENT OF HOLDERS WHO EXERCISE APPRAISAL RIGHTS IN THE MERGER, NOR
DOES IT ADDRESS ANY ASPECT OF FOREIGN, STATE OR LOCAL TAXATION OR ESTATE AND
GIFT TAXATION.
THE FEDERAL INCOME TAX CONSEQUENCES SET FORTH BELOW ARE INCLUDED FOR
GENERAL INFORMATIONAL PURPOSES ONLY. BECAUSE INDIVIDUAL CIRCUMSTANCES MAY
DIFFER, EACH HOLDER OF SHARES SHOULD CONSULT SUCH HOLDER'S OWN TAX ADVISOR TO
DETERMINE THE APPLICABILITY OF THE RULES DISCUSSED BELOW TO SUCH STOCKHOLDER AND
THE PARTICULAR TAX EFFECTS OF THE OFFER AND THE MERGER, INCLUDING THE
APPLICATION AND EFFECT OF STATE, LOCAL AND OTHER INCOME TAX LAWS.
The receipt of cash for Shares pursuant to the Offer or the Merger will be
a taxable transaction for federal income tax purposes under the Code (and also
may be a taxable transaction under applicable state, local, foreign and other
income tax laws). In general, for federal income tax purposes, a holder of
Shares will recognize gain or loss in an amount equal to the difference between
its adjusted tax basis in the Shares sold pursuant to the Offer or converted
into the right to receive cash in the Merger and the amount of cash received
therefor. Gain or loss must be determined separately for each block of Shares
(i.e., Shares acquired at the same cost in a single transaction) sold pursuant
to the Offer or converted to cash in the Merger. Such gain or loss will be
capital gain or loss and will be long-term gain or loss if, on the date of sale
(or, if applicable, the date of the Merger), the Shares were held for more than
one year.
Under the United States federal income tax backup withholding rules,
payments in connection with the Offer or the Merger may be subject to "backup
withholding" at a rate of 31%. In order to avoid backup withholding, each
tendering stockholder, unless an exemption applies, must provide the Depositary
with such stockholder's correct taxpayer identification number and certify that
such stockholder is not subject to such backup withholding by completing the
Substitute Form W-9 included in the Letter of Transmittal. Backup withholding is
not an additional tax but merely an advance payment, which may be refunded to
the extent it results in an overpayment of tax. Certain persons generally are
entitled to exemption from backup withholding, including corporations, financial
institutions and certain foreign individuals. Each stockholder should consult
with such holder's own tax advisor as to such holder's qualification for
exemption from backup withholding and the procedure for obtaining such
exemption.
All stockholders surrendering Shares pursuant to the Offer should complete
and sign the main signature form and the Substitute Form W-9 included as part of
the Letter of Transmittal to provide the information and certification necessary
to avoid backup withholding (unless an applicable exemption exists and is proved
in a manner satisfactory to Offeror and the Depositary). Noncorporate foreign
stockholders should complete and sign the main signature form and a Form W-8,
Certificate of Foreign Status, a copy of which may be obtained from the
Depositary, in order to avoid backup withholding. See Instruction 9 to the
Letter of Transmittal.
9
<PAGE> 12
6. PRICE RANGE OF SHARES.
The Shares are included for trading on the National Association of
Securities Dealers Automated Quotation National Market System ("NASDAQ/NMS")
under the trading symbol "SIBI". The Company has never paid cash dividends on
the Shares. The following table sets forth, for the periods indicated, the high
and low bid quotations per Share on the NASDAQ/NMS for the applicable periods.
<TABLE>
<CAPTION>
HIGH LOW
-------- --------
<S> <C> <C>
1997
First Quarter............................................. $9 1/2 $7 1/2
Second Quarter............................................ 9 5 1/4
Third Quarter............................................. 9 1/8 6
Fourth Quarter............................................ 9 5 5/8
1998
First Quarter............................................. $7 1/4 $5
Second Quarter............................................ 7 3/4 4 7/8
Third Quarter............................................. 5 1/4 2 1/2
Fourth Quarter............................................ 6 3/4 3
1999
First Quarter............................................. $6 3/8 $3 1/2
Second Quarter............................................ 5 3/4 3 11/16
Third Quarter (through August 5, 1999).................... 8 3/4 4 3/4
</TABLE>
On July 30, 1999, the last full trading day before the public announcement
of the execution of the Merger Agreement, the closing sales price per Share as
reported on the NASDAQ/NMS was $5 1/4. On August 5, 1999, the last full trading
day before the commencement of the Offer, the closing sales price per Share as
reported on the NASDAQ/NMS was $8 7/16 per Share. STOCKHOLDERS ARE URGED TO
OBTAIN CURRENT MARKET QUOTATIONS FOR THE SHARES.
7. EFFECT OF THE OFFER ON THE MARKET FOR SHARES; STOCK QUOTATION; EXCHANGE ACT
REGISTRATION AND MARGIN SECURITIES.
The purchase of Shares pursuant to the Offer will reduce the number of
holders of Shares and the number of Shares that might otherwise trade publicly
and could adversely affect the liquidity and market value of the remaining
Shares, if any, held by the public.
The Shares are currently listed and traded on the NASDAQ/NMS, which
constitutes the principal trading market for the Shares. Depending upon the
number of shares purchased pursuant to the Offer, the Shares may no longer meet
the requirements of the NASD for continued inclusion on the NASDAQ/NMS, which
requires that an issuer either (i) have at least 750,000 publicly held shares,
held by at least 400 round lot shareholders, with a market value of at least
$5.0 million, have at least 2 active market makers, have net tangible assets of
at least $4.0 million, and have a minimum bid price of $1 or (ii) have at least
1.1 million publicly held shares, held by at least 400 round lot shareholders,
with a market value of at least $15.0 million, have a minimum bid price of $5,
have at least 4 active market makers and have either (A) market capitalization
of at least $50.0 million or (B) total assets and total revenue of at least
$50.0 million each for the most recently completed fiscal year or two of the
last three most recently completed fiscal years. If the NASDAQ/NMS were to cease
to publish quotations for the Shares, it is possible that the Shares would
continue to trade in the over-the-counter market and that price or other
quotations would be reported by other sources. The extent of the public market
for such Shares and the availability of such quotations would depend, however,
upon such factors as the number of stockholders and/or the aggregate market
value of such securities remaining at such time, the interest in maintaining a
market in the Shares on the part of securities firms, the possible termination
of registration under the Exchange Act as described below, and other factors.
Parent cannot predict whether the reduction in the number of Shares that might
otherwise trade publicly would have an adverse or beneficial effect on the
market price for, or marketability of, the Shares or whether it would cause
future market prices to be greater or lesser than the Offer Price.
10
<PAGE> 13
The Shares are currently registered under the Exchange Act. Registration of
the Shares under the Exchange Act may be terminated upon application of the
Company to the Commission if the Shares are neither listed on a national
securities exchange nor held by 300 or more holders of record. Termination of
registration of the Shares under the Exchange Act would substantially reduce the
information required to be furnished by the Company to its stockholders and to
the Commission and would make certain provisions of the Exchange Act no longer
applicable to the Company, such as the short-swing profit recovery provisions of
Section 16(b) of the Exchange Act, the requirement of furnishing a proxy
statement pursuant to Section 14(a) of the Exchange Act in connection with
stockholders' meetings and the related requirement of furnishing an annual
report to stockholders, and the requirements of Rule 13e-3 under the Exchange
Act with respect to "going private" transactions. Furthermore, the ability of
"affiliates" of the Company and persons holding "restricted securities" of the
Company to dispose of such securities pursuant to Rule 144 or 144A promulgated
under the Securities Act of 1933, as amended (the "Securities Act"), may be
impaired or eliminated.
Parent intends to seek delisting of the Shares from the NASDAQ/NMS and to
cause the Company to apply for termination of registration of the Shares under
the Exchange Act as soon after the completion of the Offer as the requirements
for such delisting and termination are met. If registration of the Shares is not
terminated prior to the Merger, then the Shares will cease to be reported on the
NASDAQ/NMS and the registration of the Shares under the Exchange Act will be
terminated following the consummation of the Merger.
The Shares are currently "margin securities" under the regulations of the
Board of Governors of the Federal Reserve System (the "Federal Reserve Board"),
which has the effect, among other things, of allowing brokers to extend credit
on the collateral of the Shares. Depending upon factors similar to those
described above regarding listing and market quotations, it is possible that
following the Offer the Shares would no longer constitute "margin securities"
for the purposes of the margin regulations of the Federal Reserve Board and
therefore could no longer be used as collateral for loans made by brokers.
8. CERTAIN INFORMATION CONCERNING THE COMPANY.
Except as specifically set forth herein, the historical information
concerning the Company contained in this Offer to Purchase, including financial
information, has been taken from or based upon publicly available documents and
records on file with the Commission and other public sources. None of Parent,
Offeror, the Information Agent or the Depositary assumes any responsibility for
the accuracy or completeness of the information concerning the Company contained
in such documents and records or for any failure by the Company to disclose
events which may have occurred or may affect the significance or accuracy of any
such information to Parent or Offeror.
The Company is a Delaware corporation with its principal place of business
located at 505 Coast Boulevard South, Suite 300, La Jolla, California 92037.
According to the Company Form 10-K for the period ending December 31, 1998, the
Company is engaged in the discovery and development of novel small molecule
therapeutics for the treatment of neurodegenerative, neuropsychiatric and
neurological disorders. The Company is a leader in the development of
proprietary drug discovery platforms that combine key tools necessary for modern
drug discovery, including genomics, high throughput screening, advanced
combinatorial chemistry techniques and pharmacology.
Set forth below is certain selected historical consolidated financial
information with respect to the Company and its subsidiaries excerpted or
derived from the audited consolidated financial statements included in the
Company Form 10-K and from the unaudited consolidated financial statements
included in the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 1999. More comprehensive financial information is included in such
reports and other documents filed by the Company with the Commission, and the
following summary is qualified in its entirety by reference to such reports and
such other documents and all the financial information (including any related
notes) contained therein. The reports and other documents filed with the
Commission should be available for inspection and copies thereof should be
obtainable in the manner set forth below under "Available Information".
11
<PAGE> 14
SIBIA NEUROSCIENCES, INC.
SELECTED HISTORICAL FINANCIAL DATA
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------------------------------
1998 1997 1996 1995 1994
-------- -------- -------- -------- --------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Total revenue....................... $ 7,043 $ 11,197 $ 8,481 $ 10,448 $ 4,852
Research and development expenses... $ 18,247 $ 15,819 $ 12,268 $ 8,949 $ 8,663
Net income (loss)................... $(15,807) $ (7,593) $ (5,564) $ 2,926 $ (27)
Basic net income (loss) per common
share............................. $ (1.68) $ (0.82) $ (0.73) $ 0.60
Diluted net income (loss) per common
share............................. $ (1.68) $ (0.82) $ (0.73) $ 0.47
Shares used in computing basic net
income (loss) per common share.... 9,421 9,248 7,596 4,893
Shares used in computing diluted net
income (loss) per common share.... 9,421 9,248 7,596 6,164
</TABLE>
<TABLE>
<CAPTION>
AT DECEMBER 31,
--------------------------------------------------------
1998 1997 1996 1995 1994
-------- -------- -------- -------- --------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<S> <C> <C> <C> <C> <C>
BALANCE SHEET DATA:
Cash, cash equivalents and
investment securities............. $ 17,187 $ 33,347 $ 37,464 $ 16,488 $ 5,944
Working capital..................... $ 13,662 $ 31,214 $ 35,324 $ 14,338 $ 4,523
Total assets........................ $ 21,199 $ 36,180 $ 39,983 $ 18,251 $ 8,005
Long-term debt, less current
portion........................... $ 1,350 $ 695 $ 519 $ 721 $ 860
Accumulated deficit................. $(45,093) $(29,286) $(21,693) $(16,129) $(19,055)
Total stockholders' equity.......... $ 15,140 $ 32,214 $ 36,572 $ 15,107 $ 5,166
</TABLE>
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
--------------------------
1999 1998
---------- ----------
(IN THOUSANDS, EXCEPT PER
SHARE AMOUNTS)
<S> <C> <C>
STATEMENT OF OPERATIONS DATA (UNAUDITED):
Total revenue(A)............................................ $ 2,515 $ 1,534
Research and development expenses........................... $ 4,502 $ 4,796
Net loss.................................................... $ (2,840) $ (4,052)
Basic and diluted net loss per common share................. $ (0.30) $ (0.43)
Shares used in computing basic and diluted net loss per
common share.............................................. 9,523 9,365
</TABLE>
12
<PAGE> 15
<TABLE>
<CAPTION>
AT MARCH 31,
----------------------
1999 1998
-------- --------
(IN THOUSANDS)
<S> <C> <C>
BALANCE SHEET DATA (UNAUDITED):
Cash and cash equivalents................................... $ 8,899 $ 3,537
Investment securities....................................... $ 5,444 $ 26,386
Total assets................................................ $ 19,175 $ 33,360
Long-term debt, less current portion........................ $ 1,280 N/A
Accumulated deficit......................................... $(47,933) $(33,338)
Total stockholders' equity........................ $ 12,277 $ 27,810
</TABLE>
- ---------------
(A) Total revenue for the quarter ended March 31, 1999 included no amounts from
collaborative partners that are related parties. For the corresponding
period in 1998, the total revenue included $713,000 from a collaborative
partner that is a related party.
Certain Company Projections
To the knowledge of Parent and Offeror, the Company does not as a matter of
course make public forecasts as to its future financial performance. However, in
connection with the preliminary discussions concerning the feasibility of the
Offer and the Merger, the Company furnished Parent with certain financial
projections.
The projections set forth below (the "Projections") are derived or
excerpted from information provided by the Company and are based on numerous
assumptions concerning future events. The Projections have not been adjusted to
reflect the effects of the Offer or the Merger. The Projections should be read
together with the other information contained in this Section 8.
The Projections included operating projections for the Company for the
years 1999 through 2004 (the Company reports its financial results based on a
December 31 year end) developed by the Company's senior management predicated on
their then preliminary assumptions for revenue resulting from existing and
projected new technology licensing and research collaboration arrangements and
operating expenses. The Projections estimated total revenue of $21.4 million,
total expenses of $20.9 million and net income of $1.5 million for the year
ending December 31, 1999; total revenue of $29.7 million, total expenses of
$22.5 million and net income of $9.0 million for the year ending December 31,
2000; total revenue of $44.5 million, total expenses of $24.6 million and net
income of $22.7 million for the year ending December 31, 2001; total revenue of
$53.5 million, total expenses of $26.3 million and net income of $23.4 million
for the year ending December 31, 2002; total revenue of $79.0 million, total
expenses of $28.3 million and net income of $33.7 million for the year ending
December 31, 2003; and total revenue of $83.7 million, total expenses of $30.1
million and net income of $36.4 million for the year ending December 31, 2004.
THE PROJECTIONS WERE NOT PREPARED WITH A VIEW TO PUBLIC DISCLOSURE OR
COMPLIANCE WITH PUBLISHED GUIDELINES OF THE COMMISSION OR THE GUIDELINES
ESTABLISHED BY THE AMERICAN INSTITUTE OF CERTIFIED PUBLIC ACCOUNTANTS REGARDING
PROJECTIONS OR FORECASTS AND ARE INCLUDED HEREIN ONLY BECAUSE SUCH INFORMATION
WAS PROVIDED TO PARENT. THESE FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN
RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY
FROM THE PROJECTIONS. THE PROJECTIONS REFLECT NUMEROUS ASSUMPTIONS (NOT ALL OF
WHICH WERE STATED IN THE PROJECTIONS AND NOT ALL OF WHICH WERE PROVIDED TO
PARENT), ALL MADE BY MANAGEMENT OF THE COMPANY, WITH RESPECT TO INDUSTRY
PERFORMANCE, GENERAL BUSINESS, ECONOMIC, MARKET AND FINANCIAL CONDITIONS AND
OTHER MATTERS, ALL OF WHICH ARE DIFFICULT TO PREDICT, MANY OF WHICH ARE BEYOND
THE COMPANY'S CONTROL AND NONE OF WHICH WERE SUBJECT TO APPROVAL BY PARENT OR
OFFEROR. ACCORDINGLY, THERE CAN BE NO ASSURANCE THAT THE ASSUMPTIONS MADE IN
PREPARING THE PROJECTIONS WILL PROVE ACCURATE, AND ACTUAL RESULTS MAY BE
MATERIALLY GREATER OR LESS THAN THOSE CONTAINED IN THE PROJECTIONS. THE
INCLUSION OF THE PROJECTIONS HEREIN SHOULD NOT BE REGARDED AS AN INDICATION THAT
ANY OF PARENT OR OFFEROR OR THEIR RESPECTIVE REPRESENTATIVES CONSIDERED OR
CONSIDER THE PROJECTIONS TO BE A RELIABLE PREDICTION OF FUTURE EVENTS, AND THE
PROJECTIONS SHOULD NOT BE RELIED UPON AS SUCH. NONE OF PARENT OR OFFEROR AND
THEIR RESPECTIVE REPRESENTATIVES
13
<PAGE> 16
ASSUMES ANY RESPONSIBILITY FOR THE VALIDITY, REASONABLENESS, ACCURACY OR
COMPLETENESS OF THE PROJECTIONS. NONE OF PARENT OR OFFEROR AND ANY OF THEIR
REPRESENTATIVES HAS MADE, OR MAKES, ANY REPRESENTATION TO ANY PERSON REGARDING
THE INFORMATION CONTAINED IN THE PROJECTIONS AND NONE OF THEM INTENDS TO UPDATE
OR OTHERWISE REVISE THE PROJECTIONS TO REFLECT CIRCUMSTANCES EXISTING AFTER THE
DATE WHEN MADE OR TO REFLECT THE OCCURRENCE OF FUTURE EVENTS EVEN IN THE EVENT
THAT ANY OR ALL OF THE ASSUMPTIONS UNDERLYING THE PROJECTIONS ARE SHOWN TO BE IN
ERROR.
Available Information
The Company is subject to the reporting requirements of the Exchange Act
and, in accordance therewith, is required to file reports and other information
with the Commission relating to its business, financial condition and other
matters. Information as of particular dates concerning the Company's directors
and officers, their remuneration, options granted to them, the principal holders
of the Company's securities and any material interests of such persons in
transactions with the Company is required to be disclosed in proxy statements
distributed to the Company's stockholders and filed with the Commission. Such
reports, proxy statements and other information should be available for
inspection at the public reference facilities of the Commission located at 450
Fifth Street, N.W., Washington, D.C. 20549, and at the regional offices of the
Commission located in the Northwestern Atrium Center, 500 West Madison Street
(Suite 1400), Chicago, Illinois 60661 and Seven World Trade Center, 13th Floor,
New York, New York 10048. Copies should be obtainable, by mail, upon payment of
the Commission's customary charges, by writing to the Commission's principal
office at 450 Fifth Street, N.W., Washington, D.C. 20549. The Commission also
maintains a World Wide Web site on the Internet at http://www.sec.gov that
contains reports, proxy statements and other information regarding registrants
that file electronically with the Commission.
9. CERTAIN INFORMATION CONCERNING PARENT AND OFFEROR.
Parent is a global research-driven pharmaceutical company that discovers,
develops, manufactures and markets a broad range of human and animal health
products, directly and through its joint ventures, and provides pharmaceutical
benefit services.
Parent's operations are principally managed on a products and services
basis. At the end of 1998, Parent had 57,300 employees worldwide. For the year
ended December 31, 1998, Parent had sales of approximately $26.9 billion, and
net income of approximately $5.2 billion. Parent's stockholders' equity at
December 31, 1998 was approximately $12.8 billion. Parent's principal executive
offices are located at One Merck Drive, Whitehouse Station, New Jersey
08889-0100. Parent is subject to the reporting requirements of the Exchange Act
and, in accordance therewith, is required to file reports and other information
with the Commission relating to its business, financial condition and other
matters. Information as of particular dates concerning Parent's directors and
officers, their remuneration, options granted to them, the principal holders of
Parent's securities and any material interests of such persons in transactions
with Parent is required to be disclosed in proxy statements distributed to
Parent's stockholders and filed with the Commission. Such reports and other
documents should be available for inspection and copies should be attainable
from the offices of the Commission in the same manner as set forth under
"Available Information" in Section 8 above.
Offeror is a Delaware corporation, newly formed by Parent in connection
with the Offer and the transactions contemplated thereby. The offices of Offeror
are located at One Merck Drive, Whitehouse Station, New Jersey 08889-0100.
Parent directly owns all the outstanding capital stock of Offeror. It is not
anticipated that, prior to the consummation of the Offer and the Merger, Offeror
will have any significant assets or liabilities or will engage in any activities
other than those incident to the Offer and the Merger.
For certain information concerning the directors and executive officers of
the Parent and Offeror, see Schedule I to this Offer to Purchase.
Except as set forth in this Offer to Purchase: (i) none of Parent nor
Offeror nor, to the best knowledge of any of the foregoing, any of the persons
listed in Schedule I to this Offer to Purchase or any associate or majority
owned subsidiary of any of the foregoing, beneficially owns or has a right to
acquire any Shares or any other equity securities of the Company; (ii) none of
Parent nor Offeror nor, to the best knowledge of any of
14
<PAGE> 17
the foregoing, any of the persons or entities referred to in clause (i) above or
any of their executive officers, directors, or subsidiaries has effected any
transaction in the Shares or any other equity securities of the Company during
the past 60 days; (iii) none of Parent nor Offeror nor, to the best knowledge of
any of the foregoing, any of the persons listed in Schedule I to this Offer to
Purchase has any contract, arrangement, understanding or relationship with any
other person with respect to any securities of the Company, including but not
limited to, contracts, arrangements, understandings or relationships concerning
the transfer or voting thereof, joint ventures, loan or option arrangements,
puts or calls, guaranties of loans, guaranties against loss or the giving or
withholding of proxies, consents or authorizations; (iv) since January 1, 1996,
there have been no transactions or business relationships which would be
required to be disclosed under the rules and regulations of the Commission
between any of Parent, Offeror or any of their respective subsidiaries or, to
the best knowledge of any of Parent or Offeror, any of the persons listed in
Schedule I to this Offer to Purchase, on the one hand, and the Company or any of
its executive officers, directors or affiliates, on the other hand; and (v)
since January 1, 1996, there have been no contacts, negotiations or transactions
between any of Parent, Offeror or any of their respective subsidiaries or, to
the best knowledge of any of Parent, Offeror or any of the persons listed in
Schedule I to this Offer to Purchase, on the one hand, and the Company or its
subsidiaries or affiliates, on the other hand, concerning a merger,
consolidation or acquisition, tender offer or other acquisition of securities,
an election of directors or a sale or other transfer of a material amount of
assets of the Company or any of its subsidiaries.
Except for discussions with respect to certain possible licensing
arrangements between Parent and the Company, none of Parent or Offeror had any
relationship with the Company prior to the commencement of the discussions which
led to the execution of the Merger Agreement. See Section 11. Each of Parent and
Offeror disclaims that it is an "affiliate" of the Company within the meaning of
Rule 13e-3 under the Exchange Act.
10. SOURCE AND AMOUNT OF FUNDS.
The total amount of funds required by Offeror to purchase all of the Shares
and to pay related fees and expenses is expected to be approximately $88.0
million. Offeror intends to obtain all of such funds from Parent which in turn
would obtain such funds from Parent's existing working capital.
11. BACKGROUND OF THE OFFER.
On June 18, 1999, Richard N. Kender, Vice President, Financial Evaluation
and Analysis and Business Development, of Parent contacted Stephen F. Keane,
Vice President, Corporate Development of the Company, concerning a possible
transaction with the Company by Parent. The parties executed a confidentiality
agreement on June 23, 1999.
On June 30, 1999, William T. Comer, Jeffrey F. McKelvy, Carla M. Suto, Ian
A. McDonald and Stephen F. Keane, representatives of the Company, delivered a
presentation reviewing the Company's technology and intellectual property.
Thereafter, representatives of Parent expressed their continued interest in
exploring a transaction and were authorized to conduct a due diligence
investigation of the Company.
On July 21, 1999, after substantially completing its due diligence review
of the Company, Parent submitted a proposal to purchase all of the outstanding
shares of the Company at a price of $7.50 per share in cash, subject to certain
other terms and conditions. On July 21, 1999, Parent provided a draft Merger
Agreement to the Company and representatives of the Company and Parent, and
thereafter their respective legal and financial advisors began to negotiate the
Merger Agreement and related documentation.
During the following week, representatives of Parent and the Company
continued to discuss and negotiate the proposed transaction and possible terms
and conditions relating thereto. On July 30, 1999, the parties agreed on the per
share price of $8.50, subject to certain terms and conditions, including
negotiation and execution of a satisfactory Merger Agreement. The Merger
Agreement and related documents were executed as of July 30, 1999.
15
<PAGE> 18
12. PURPOSE OF THE OFFER AND THE MERGER; PLANS FOR THE COMPANY; THE TRANSACTION
DOCUMENTS.
Purpose of the Offer and the Merger
The purpose of the Offer is to enable Parent to acquire control of, and the
entire equity interest in, the Company. The purpose of the Merger is to acquire
all outstanding Shares not purchased pursuant to the Offer. The purchase of
Shares pursuant to the Offer will increase the likelihood that the Merger will
be effected. Following the completion of the Offer, Parent intends to acquire
any remaining Shares not then owned by it by consummating the Merger. In the
Merger, each outstanding Share (other than Shares held by the Excluded
Shareholders), will be converted into the right to receive the Merger
Consideration, without interest, and the Company will become a wholly owned
subsidiary of Parent.
The acquisition of the entire interest in the Company is structured as a
cash tender offer followed by a merger in order to expedite the opportunity for
Parent to obtain a controlling interest in the Company. Under the Delaware Law
and the Company's certificate of incorporation, the affirmative vote of the
holders of a majority of the outstanding Shares is required to approve the
Merger. If the Minimum Condition is satisfied, Parent would have sufficient
voting power to approve the Merger without the affirmative vote of any other
stockholder of the Company.
Plans for the Company
Following the Offer and the Merger, Parent intends to operate the Company
on a basis generally consistent with the Company's existing plans and programs.
If and to the extent that the Parent acquires control of the Company, Parent
intends to conduct a detailed review of the Company and its assets, corporate
structure, capitalization, operations, properties, policies, management and
personnel and consider and determine what, if any, changes would be desirable in
light of the circumstances which then exist. Such strategies could include,
among other things and subject to the terms of the Merger Agreement, changes in
the Company's business, corporate structure, certificate of incorporation,
bylaws, capitalization, management or dividend policy.
Except as noted in this Offer to Purchase, Parent and Offeror have no
present plans or proposals that would result in an extraordinary corporate
transaction, such as a merger, reorganization, liquidation, or sale or transfer
of a material amount of assets, involving the Company or any subsidiary of the
Company or any other material changes in the Company's capitalization, dividend
policy, corporate structure, business or composition of its management or Board
of Directors.
The Merger Agreement
The following is a summary of the material terms of the Merger Agreement.
This summary is not a complete description of the terms and conditions thereof
and is qualified in its entirety by reference to the full text thereof, which is
incorporated herein by reference and a copy of which has been filed with the
Commission as an exhibit to the Schedule 14D-1. The Merger Agreement may be
examined, and copies thereof may be obtained, as set forth in Section 8.
The Offer. The Merger Agreement provides for the commencement of the
Offer, in connection with which Parent and Offeror have expressly reserved the
right to waive certain conditions to the Offer, but without the prior written
consent of the Company, Offeror has agreed not to (i) decrease the amount or
change the form of consideration payable in the Offer, (ii) decrease the number
of Shares sought in the Offer, (iii) impose additional conditions to the Offer,
(iv) change any conditions to the Offer or amend any other term of the Offer if
any such change or amendment would be adverse in any respect to the holders of
Shares (other than Parent or Offeror), (v) except as provided below, extend the
Offer if all of the conditions to the Offer have been satisfied or (vi) amend or
waive the Minimum Condition. Notwithstanding the foregoing, Offeror may, without
the consent of the Board of Directors of the Company, (A) extend the Offer, if
on the scheduled Expiration Date of the Offer any of the conditions to the Offer
shall not have been satisfied or waived, for one or more periods (none of which
shall exceed ten business days) but in no event past 90 days from the date of
the Merger Agreement unless the waiting period applicable to the transactions
contemplated
16
<PAGE> 19
by the Merger Agreement under the HSR Act has not terminated or expired, and
then in any event not later than March 1, 2000, (B) extend the Offer for such
period as may be required by any rule, regulation, interpretation or position of
the Commission or its staff applicable to the Offer or (C) extend the Offer for
one or more periods (each such period to be for not more than three business
days and such extensions to be for an aggregate period of not more than ten
business days beyond the latest expiration date that would otherwise be
permitted under clause (A) or (B) of this sentence) if on such expiration date
the conditions to the Offer shall have been satisfied or waived but there shall
not have been tendered that number of Shares which would equal more than 90% of
the issued and outstanding Shares. So long as the Merger Agreement is in effect
and the conditions to the Offer have not been satisfied on any scheduled
Expiration Date of the Offer, then, provided that all such conditions are and
continue to be reasonably probable of being satisfied by the date that is 60
business days after the commencement of the Offer, Offeror shall extend the
Offer for one or more periods of not more than 10 business days each if
requested to do so by the Company; provided that Offeror shall not be required
to extend the Offer beyond 60 business days after commencement of the Offer or,
if earlier, the date of termination of the Merger Agreement in accordance with
the terms thereof.
Consideration to be Paid in the Merger. The Merger Agreement provides that
subject to the terms and conditions set forth in the Merger Agreement and the
applicable provisions of the Delaware Law, Offeror shall be merged with and into
the Company and the separate existence of Offeror will cease, and the Company
shall be the Surviving Corporation and shall be a wholly owned subsidiary of
Parent. In the Merger, each share of common stock, $.01 par value per share, of
Offeror issued and outstanding immediately prior to the time of filing of a
certificate of merger relating to the Merger with the Secretary of State of the
State of Delaware, or such later time as is set forth therein (the "Effective
Time"), shall continue to remain outstanding and shall constitute one share of
common stock of the Surviving Corporation. At the Effective Time, each
outstanding Share (other than Shares owned by Parent or any direct or indirect
subsidiary of Parent or the Excluded Shareholders or shares owned by the Company
or any direct or indirect subsidiary of the Company), shall, by virtue of the
Merger and without any action on the part of the holder thereof, be converted
into the right to receive the Merger Consideration, without interest. The Merger
Agreement provides that (subject to the provisions of the Merger Agreement and
the applicable provisions of the Delaware Law) the closing of the Merger shall
occur on the latest to occur of (i) the business day on which the condition set
forth in Section 8.1(a) of the Merger Agreement is satisfied or waived in
accordance with the Merger Agreement and (ii) the first business day following
the date on which the last to be satisfied or waived of the other conditions set
forth in Article VIII of the Merger Agreement (other than those conditions that
by their nature are to be satisfied at the closing of the Merger, but subject to
the satisfaction or waiver of those conditions) are satisfied or waived in
accordance with the Merger Agreement.
Treatment of Stock Options and Purchase Rights. The Merger Agreement
provides that at the Effective Time, each outstanding option to purchase Shares
under the Company stock plans (the "Company Options"), whether vested or
unvested, shall be deemed to constitute an option to acquire (a "New Parent
Option"), on the same terms and conditions as were applicable under such Company
Option, the number of shares of common stock of Parent (rounded to the nearest
whole number) equal to the product of (A) the number of Shares issuable upon
exercise of such Company Option and (B) Offer Price divided by the average of
the closing sales prices of common stock of Parent on the New York Stock
Exchange for the 10 consecutive days immediately prior to and including the day
preceding the Effective Time, at an exercise price per share (rounded to the
nearest whole cent) equal to (x) the aggregate exercise price for the Shares
otherwise purchasable pursuant to such Company Option divided by (y) the
aggregate number of shares of Common Stock of Parent purchasable pursuant to the
New Parent Option (as calculated immediately above); provided, however, that in
the case of any Company Option to which Section 422 of the Code applies, the
option price, the number of shares purchasable pursuant to such option and the
terms and conditions of exercise of such option shall be determined in
accordance with the foregoing, subject to such adjustments as are necessary in
order to satisfy the requirements of Section 424(a) of the Code. At or prior to
the Effective Time, the Company has agreed to take all necessary actions to
permit the assumption of the unexercised Company Options by Parent pursuant to
this paragraph and shall take all action necessary to cause the funds held in
the Company's Employee Stock Purchase Plan to be used to purchase outstanding
Shares through open market
17
<PAGE> 20
transactions so that such Shares will be converted into the right to receive
cash in the Merger; provided that thereafter the Company shall terminate the
Company's Employee Stock Purchase Plan.
The Merger Agreement further provides that effective at the Effective Time,
Parent shall assume, as a New Parent Option, each outstanding Company Option in
accordance with the prior paragraph and with the terms of the Company stock plan
under which it was issued and the stock option agreement by which it is
evidenced. Parent has further agreed that not later than thirty calendar days
after the closing date of the Merger, Parent shall file a registration statement
under the Securities Act on Form S-8, or other appropriate form, covering shares
of Parent common stock subject to such New Parent Options.
Board Representation. The Merger Agreement provides that, promptly upon
the acceptance for payment of, and payment by Offeror in accordance with the
Offer for, not less than that number of Shares equal to the Minimum Shares,
Offeror shall be entitled to designate such number of directors, rounded up to
the next whole number, as will give Offeror representation on the Board of
Directors of the Company equal to the product of (i) the total number of
directors on the Board of Directors of the Company (giving effect to the
directors elected pursuant to this sentence) and (ii) the percentage that such
number of Shares owned in the aggregate by Offeror or Parent, upon such
acceptance for payment, bears to the number of Shares outstanding. Upon the
written request of Offeror, the Company shall, on the date of such request, (x)
either increase the size of the Board of Directors or use its reasonable efforts
to secure the resignations of such number of its incumbent directors as is
necessary to enable Parent's designees to be so elected to the Board of
Directors of the Company and (y) cause Parent's designees to be so elected. The
Company's obligations to appoint designees to the Board of Directors are subject
to Section 14(f) of the Exchange Act.
The Merger Agreement also provides that from and after the time that
Parent's designees constitute at least a majority of the Board of Directors of
the Company and until the Effective Time, the Board of Directors shall always
have at least two members (the "Independent Directors") who are neither officers
of Parent nor designees, shareholders or affiliates of Parent or Parent's
affiliates. During such period, any (i) amendment or termination of the Merger
Agreement, (ii) extension of time for the performance or waiver of the
obligations or other acts of Parent or Offeror or waiver of the Company's rights
under the Merger Agreement or (iii) action by the Company with respect to the
Merger Agreement and the transactions contemplated hereby which adversely
affects the interests of the stockholders of the Company, shall require the
approval of a majority of the Independent Directors in addition to any required
approval thereof by the full Board of Directors of the Company.
Stockholder Meeting. The Merger Agreement provides that, if approval or
action in respect of the Merger by the stockholders of the Company is required
by applicable law, the Company, acting through the Board of Directors, shall (i)
call as promptly as practicable following consummation of the Offer, a meeting
of its stockholders (the "Stockholder Meeting") for the purpose of voting upon
the Merger, (ii) hold the Stockholder Meeting as soon as practicable following
the purchase of Shares pursuant to the Offer, and (iii) recommend to its
stockholders the approval of the Merger. At the Stockholders Meeting, Parent and
Offeror shall cause all Shares then owned by them to be voted in favor of
approval and adoption of the Merger. The Merger Agreement provides that,
notwithstanding the foregoing, if Parent, Offeror or any other subsidiary of
Parent shall acquire at least 90% of the outstanding Shares and preferred stock,
the parties thereto shall take all necessary and appropriate action to cause the
Merger to become effective as soon as practicable after the expiration of the
Offer without a stockholders meeting in accordance with Section 253 of the
Delaware Law. Parent expects during the pendency of the Offer to seek to have
discussions with the holder of the Series B Convertible Preferred Stock
regarding the sale by such holder to Parent after consummation of the Offer.
However, Parent cannot under Rule 10b-13 under the Exchange Act, directly or
indirectly, purchase, or make any arrangement to purchase, the Series B
Convertible Preferred Stock until after consummation of the Offer. If the
outstanding share of Series B Convertible Preferred Stock is not converted and
tendered in the Offer or Parent does not purchase the Series B Convertible
Preferred Stock following consummation of the Offer, Parent will be unable to
effect a "short-form" merger.
Representations and Warranties. The Merger Agreement contains various
representations and warranties of the parties thereto. These include
representations and warranties by the Company with respect to
18
<PAGE> 21
(i) the due organization, existence, qualification, good standing, corporate
power and authority of the Company and its subsidiaries; (ii) the capital
structure of the Company; (iii) the due authorization, execution, delivery and
performance of the Merger Agreement and the Stock Option Agreement and the
consummation of transactions contemplated thereby, and the validity and
enforceability thereof; (iv) required filings, consents and approvals and the
absence of any violations, breaches or defaults which would result from
performance by the Company of the Merger Agreement and the Stock Option
Agreement; (v) the accuracy of reports filed by the Company with the Commission
(including financial statements) since January 1, 1998; (vi) the absence of
certain changes or events; (vii) the absence of any material litigation; (viii)
the absence of any undisclosed material liabilities; (ix) certain employee
benefit matters; (x) compliance with applicable laws, licenses and permits and
the absence of any default or violation with respect to material contracts; (xi)
antitakeover statutes; (xii) environmental matters relating to the Company and
its subsidiaries; (xii) the opinion of the Financial Advisor; (xiii) certain tax
matters; (xiv) certain regulatory matters, including Food and Drug
Administration warning letters, problem reports, product recalls and material
regulatory communications and regulatory filings; (xv) certain intellectual
property matters; (xvi) matters relating to product registration files; (xvi)
year 2000 compliance; (xvii) labor matters; (xviii) the Rights Agreement; (xix)
the absence of brokers or finders other than the Financial Advisor; (xx) supply
arrangements; (xxi) investigational compounds; (xxii) the validity and
enforceability of material contracts; (xxiii) the documents supplied by the
Company relating to the Offer; and (xxiv) stockholder approvals.
Parent and Offeror have also made certain representations and warranties,
including with respect to (i) the capital structure of the Offeror; (ii) the due
organization, existence, good standing and corporate power and authority of
Parent and its subsidiaries; (iii) the due authorization, execution, delivery
and performance of the Merger Agreement and the Stock Option Agreement and the
consummation of transactions contemplated thereby, and the validity and
enforceability thereof; (iv) required filings, consents and approvals and the
absence of any violations, breaches or defaults which would result from
performance by Parent or Offeror with the Merger Agreement and the Stock Option
Agreement; (v) the absence of any material litigation; (vi) compliance with
applicable laws and the absence of any default or violation with respect to
material contracts; (vii) the absence of brokers or finders; (viii) the
sufficiency of funds available to Parent and Offeror for the consummation of the
Offer and the Merger; and (ix) documents related to the Offer and the Merger.
Conduct of Interim Operations. The Company has agreed that from the date
of the Merger Agreement to the Effective Time, with certain exceptions, unless
Parent has consented in writing thereto (such consent not to be unreasonably
withheld or delayed), the Company shall, and shall cause each of its
subsidiaries to: (i) conduct its business, in all material respects, in the
ordinary and usual course, and use its commercially reasonable best efforts to
preserve its business organization substantially intact and substantially
maintain its existing relations and goodwill with customers, suppliers,
distributors, creditors, lessors, employees and business associates; (ii) not
issue, sell, pledge, dispose of or encumber any capital stock owned by it in any
of its subsidiaries; (iii) not amend its certificate or bylaws or amend, modify
or terminate the Rights Agreement; (iv) not split, combine or reclassify its
outstanding shares of capital stock; (v) not declare, set aside or pay any
dividend payable in cash, stock or other property in respect of any capital
stock; (vi) not repurchase, redeem or otherwise acquire, except in connection
with its stock option and stock purchase plans, any shares of its capital stock
or any securities convertible into or exchangeable or exercisable for any shares
of its capital stock; (vii) not issue, sell, pledge, dispose of or encumber any
shares of, or securities convertible into or exchangeable or exercisable for, or
options, warrants, calls, commitments or rights of any kind to acquire, any
shares of its capital stock of any class or any voting debt or any other
property or assets, with certain exceptions; (viii) not transfer, lease,
license, guarantee, sell, mortgage, pledge, dispose of or encumber any other
property or assets (including capital stock of any of its subsidiaries) or incur
or modify any material indebtedness or other liability; (ix) not make any
commitments for, make or authorize any capital expenditures or, by any means,
make any acquisition of, or investment in, assets or stock of any other person
or entity in each case, involving amounts in excess of $100,000 in the aggregate
other than in the ordinary and usual course; (x) not, except as may be required
by existing contractual commitments or as required by applicable law, enter into
any new agreements or commitments for any severance or termination pay to, or
enter into an employment or severance agreement with, any of its directors,
officers or employees, including
19
<PAGE> 22
adding new participants to the Company's Management Change of Control Plan, or
terminate, establish, adopt, enter into, make any new grants or awards under,
amend or otherwise modify, any compensation and benefit plans or increase or
accelerate the salary, wage, bonus or other compensation of any employees,
officers or directors (except for increases in salaries, wages and cash bonuses
of nonexecutive employees made in the ordinary course of business consistent
with past practice) or pay or agree to pay any pension, retirement allowance or
other employee benefit not required by any existing compensation and benefit
plan; (xi) not settle or compromise any material claims or litigation or modify,
amend or terminate any of its material contracts or waive, release or assign any
material rights or claims; (xii) not make any tax election or permit any
insurance policy naming it as a beneficiary or loss-payable payee to be canceled
or terminated except in the ordinary and usual course of business; (xiii) not,
except as may be required as a result of a change in law or in generally
accepted accounting principles, change any of the accounting practices or
principles used by it or its subsidiaries; (xiv) not adopt a plan of complete or
partial liquidation, dissolution, merger, consolidation, restructuring,
recapitalization, or other reorganization of the Company or any of its
subsidiaries not constituting an inactive subsidiary (other than the Merger);
(xv) not suffer or permit capital expenditures made or incurred by the Company
and its subsidiaries for any period to exceed $100,000 except for expenses
incurred in connection with the transactions contemplated by the Merger
Agreement; and (xvi) not offer to, or enter into an agreement to, do any of the
foregoing.
Access to Information. Under the Merger Agreement, from the date of the
Merger Agreement to the Effective Time or the termination of the Merger
Agreement, the Company has agreed to afford to the officers, employees,
accountants, counsel, financial advisors and other representatives of Parent
reasonable access to all of its and its subsidiaries properties, books,
contracts, commitments and records (including security position listings or
other information concerning beneficial and record owners of the Company's
securities) and its officers, management employees and representatives and,
during such period, the Company has agreed to furnish promptly to Parent,
consistent with its legal obligations, all information concerning its business,
properties and personnel as the other party may reasonably request. Such
information shall be held in confidence to the extent required by, and in
accordance with, the provisions of the Confidentiality Agreement, dated as of
June 21, 1999, between the Company and Parent (the "Confidentiality Agreement"),
which shall remain in full force and effect.
No Solicitation. The Company has agreed in the Merger Agreement that the
Company shall, and shall use its best efforts to cause its nonstockholder
affiliates and the officers, directors and employees of the Company and its
subsidiaries to, and shall instruct its stockholder affiliates and the
representatives and agents of the Company and its subsidiaries (including,
without limitation, any investment banker, attorney or accountant retained by
the Company or any of its subsidiaries) to, immediately cease and terminate any
existing activities, discussions or negotiations, if any, with any parties
(other than Parent and Offeror, any affiliate or associate of Parent and Offeror
or any designees of Parent and Offeror) conducted heretofore with respect to any
acquisition or exchange of all or any material portion of the assets of, or more
than 20% of the equity interest in, the Company or any of its subsidiaries (by
direct purchase from the Company, tender or exchange offer or otherwise) or any
business combination, merger or similar transaction (including an exchange of
stock or assets) with or involving the Company or any subsidiary of the Company
(an "Acquisition Transaction"), other than the Offer and the Merger. Except as
otherwise set forth in this paragraph, the Company has also agreed that it shall
not, and shall use its best efforts to cause its nonstockholder affiliates and
the officers, directors and employees of the Company and its subsidiaries not
to, and shall instruct its stockholder affiliates and the representatives and
agents of the Company and its subsidiaries (including, without limitation, any
investment banker, attorney or accountant retained by the Company or any of its
subsidiaries) not to, directly or indirectly, knowingly encourage, solicit,
participate in or initiate discussions or negotiations with, or provide any
nonpublic information or data (other than the Company's standard public
information package) to, any corporation, partnership, person or other entity or
group (other than Parent and Offeror, any affiliate or associate of Parent and
Offeror or any designees of Parent and Offeror) with respect to any inquiries or
the making of any offer or proposal (including, without limitation, any offer or
proposal to the stockholders of the Company) concerning an Acquisition
Transaction (an "Acquisition Proposal" (it being understood that an Acquisition
Proposal that is conditioned upon the
20
<PAGE> 23
completion of due diligence shall be deemed to constitute a bona fide
Acquisition Proposal if such proposal otherwise meets the definition of
Acquisition Proposal)) or otherwise knowingly facilitate any effort or attempt
to make or implement an Acquisition Proposal; provided, however, that prior to
Offeror beneficially owning a majority of the then outstanding Shares, the
Company may furnish information and access, but only in response to a request
for information or access, to any person or entity making a bona fide written
Acquisition Proposal to the Board of Directors of the Company after the date of
the Merger Agreement which was not knowingly encouraged, solicited or initiated
by the Company or any of its affiliates or any director, employee,
representative or agent of the Company or any of its subsidiaries (including,
without limitation, any investment banker, attorney or accountant retained by
the Company or any of its subsidiaries) on or after the date of the Merger
Agreement and may participate in discussions and negotiate with such person or
entity concerning any such Acquisition Proposal and may authorize the Company to
enter into a binding written agreement concerning a Superior Proposal (as
defined below), if and only if, in any such case, (i) the Board of Directors
determines in good faith, (A) after consultation with outside counsel to the
Company to the effect that failing to provide such information or access or to
participate in such discussions or negotiations or so to authorize, as the case
may be, is reasonably likely to constitute a breach of the Board of Directors'
fiduciary duties under applicable law and (B) after consultation with the
financial advisors to the Company to such effect, that such Acquisition
Proposal, if accepted, is reasonably likely to be consummated, taking into
account all legal, financial and regulatory aspects of the proposal and the
person or entity making the proposal and would, if consummated, result in a
transaction more favorable to the Company's stockholders from a financial point
of view than the transaction contemplated by the Merger Agreement (any such more
favorable Acquisition Proposal as to which both of the determinations referred
to in subclauses (A) and (B) above have been made being referred to as a
"Superior Proposal"), and (ii) the Company receives from the person or entity
making such bona fide written Acquisition Proposal an executed confidentiality
agreement the terms of which are (without regard to the terms of such
Acquisition Proposal) (A) no less favorable to the Company, and (B) no less
restrictive to the person or entity making such bona fide written Acquisition
Proposal than those contained in the Confidentiality Agreement. Nothing in the
Merger Agreement shall prohibit the Board of Directors from, to the extent
applicable, complying with Rule 14e-2 or 14d-9 promulgated under the Exchange
Act with regard to an Acquisition Proposal. The Company has further agreed to
notify Parent within 48 hours if any such inquiries or proposals are received
by, any such information is requested from, or any such negotiations or
discussions are sought to be initiated or continued with the Company and shall
in such notice indicate the identity of the offeror and the material terms and
conditions of any such proposal and thereafter shall keep Parent reasonably
informed, on a current basis, of the status and material terms of such proposals
and the status of such negotiations or discussions, providing copies to Parent
of any Acquisition Proposals made in writing. The Company is required to provide
Parent with three business days advance notice of, in each and every case, its
intention to either enter into any agreement with or to provide any information
to any person or entity making any such inquiry or proposal. The Company has
also agreed not to release any third party from, or waive any provisions of, any
confidentiality or standstill agreement to which the Company is a party and will
use its best efforts to enforce any such agreements at the request of and on
behalf of Parent. The Company is required to inform the individuals or entities
referred to in the first sentence of this paragraph of the obligations
undertaken in this paragraph. The Company also is required to promptly request
each person or entity which has executed, within 12 months prior to the date of
the Merger Agreement, a confidentiality agreement in connection with its
consideration of acquiring the Company to return or destroy all confidential
information furnished to such person or entity by or on behalf of the Company.
Fees and Expenses. Pursuant to the Merger Agreement, the Surviving
Corporation shall pay all charges and expenses, including those of the exchange
agent for the Merger, in connection with the Merger, and Parent shall reimburse
the Surviving Corporation for such charges and expenses. The Merger Agreement
also provides that except as otherwise described below, whether or not the
Merger is consummated, all costs and expenses incurred in connection with the
Merger Agreement, the Stock Option Agreement, the Shareholders Agreement, the
Offer and the Merger and the other transactions contemplated by the Merger
Agreement, the Stock Option Agreement and the Shareholders Agreement shall be
paid by the party incurring such expense.
21
<PAGE> 24
The Merger Agreement provides that, under certain circumstances, the
Company shall pay to Parent a one-time fee equal to $2.0 million (the
"Termination Fee") and to reimburse Parent all of the charges and expenses
incurred by Parent or Offeror in connection with the Merger Agreement, the Stock
Option Agreement and the Shareholders Agreement and the transactions
contemplated by the Merger Agreement and the Stock Option Agreement and the
Shareholders Agreement, including, without limitation, fees and expenses of
accountants, attorneys and financial advisors, up to a maximum of $500,000 in
the aggregate. The Company is obligated to pay the Termination Fee under the
following circumstances: (i)(A) a bona fide Acquisition Proposal shall have been
made to the Company or any of its stockholders or any person shall have
announced an intention (whether or not conditional) to make an Acquisition
Proposal with respect to the Company, and on or following the date of the Merger
Agreement but prior to the date that the Offer is consummated and Parent owns a
majority of the outstanding Shares, such Acquisition Proposal, announcement or
intention is or becomes publicly known, and (B) on or following the date of the
Merger Agreement and prior to the time such Acquisition Proposal, announcement
or intention is or becomes publicly known, the occurrence of an event which
would have a material adverse effect on the ability of Parent and Offeror to
consummate the Merger shall not have become publicly known, and (C) on or
following the date on which such Acquisition Proposal, announcement or intention
is or becomes publicly known, the Merger Agreement is terminated by either
Parent or the Company because the Merger shall not have been consummated by
February 1, 2000 (subject to extension, in certain circumstances, to March 1,
2000), whether such date is before or after the date of approval by the
stockholders of the Company, and if terminated by Parent or Offeror, they shall
not collectively beneficially own a majority of the outstanding Shares on a
fully diluted basis, or (ii) the Merger Agreement is terminated (x) by the
Company because it has determined to enter into a binding written agreement
concerning a Superior Proposal and the Company notifies Parent in writing that
it intends to enter into such an agreement, attaching the most current version
of such agreement to such notice, and Parent does not make, within three
business days of receipt of the Company's written notification of its intention
to enter into such an agreement, a written offer that is at least as favorable,
from a financial point of view, to the stockholders of the Company as the
Superior Proposal or (y) by Parent if the Board of Directors of the Company
shall have failed to recommend, or shall have withdrawn or adversely modified
its approval or recommendation of, the Offer or the Merger or failed to
reconfirm its recommendation of the Offer or the Merger within five calendar
days after a written request by Parent to do so, or shall have resolved to do
any of the foregoing, or (z) because of the failure of the conditions to the
Offer described in paragraphs (e) and (f) of Section 14, provided, however, that
the Termination Fee shall not be payable to Parent in accordance with clause (i)
above unless and until (I) any person or entity (other than Parent) (an
"Acquiring Party") has within 9 months of such termination entered into a
definitive agreement to acquire, by purchase, merger, consolidation, sale,
assignment, lease, transfer or otherwise, in one transaction or any related
series of transactions, a majority of the voting power of the outstanding
securities of the Company or (II) a definitive agreement has been entered into
with respect to a merger, consolidation or similar business combination between
the Company and an Acquiring Party or an affiliate thereof as a result of which
the stockholders of the Company immediately prior to the transaction do not own
at least 50% of the surviving entity.
Pursuant to the Merger Agreement, any Termination Fee described above
required to be paid to Parent would be reduced (but not below zero) to the
extent necessary so that the sum of (1) the portion of any Termination Fee
actually paid to Parent, (2) the aggregate of all Cancellation Amounts (as
defined below) paid to Parent pursuant to the Stock Option Agreement and (3) the
proceeds actually received by Parent as the result of selling Shares issued to
Parent pursuant to the Stock Option Agreement to a third party which acquires
more than 50% of the Company's outstanding voting securities (other than the
Company or any of its affiliates) shall not exceed $4.4 million. Parent and the
Company have agreed that in no event shall (i) the sum of the portion of any
Termination Fee actually paid to Parent and the cash proceeds actually received
by Parent as the result of selling Shares issued to Parent pursuant to the Stock
Option Agreement to a third party which acquires more than 50% of the Company's
outstanding voting securities (other than the Company or any of its affiliates)
exceed $4.4 million, or (ii) the sum of the portion of any Termination Fees
actually paid to Parent, the aggregate Cancellation Amounts paid to Parent
pursuant to the Stock Option Agreement and the cash proceeds actually received
by Parent as the result of selling Shares issued to Parent pursuant to the
22
<PAGE> 25
Stock Option Agreement to a third party which acquires more than 50% of the
Company's outstanding voting securities (other than the Company or any of its
affiliates) exceed $4.4 million.
Other Agreements. The Merger Agreement provides that the Company and
Parent shall cooperate with each other and use (and shall cause their respective
subsidiaries to use) their respective commercially reasonable best efforts to
take or cause to be taken all actions, and do or cause to be done all things,
necessary, proper or advisable under the Merger Agreement, the Stock Option
Agreement, the Shareholders Agreement and applicable laws to consummate and make
effective the Merger and the other transactions contemplated by the Merger
Agreement, the Stock Option Agreement and the Shareholders Agreement as soon as
practicable, including preparing and filing as promptly as practicable all
documentation to effect all necessary applications, notices, petitions, filings
and other documents and to obtain as promptly as practicable all permits,
consents, approvals and authorizations necessary or advisable to be obtained
from any third party and/or any U.S. governmental or regulatory authority,
agency, commission, body or other governmental entity ("Governmental Entity") in
order to consummate the Offer and the Merger or any of the other transactions
contemplated by the Merger Agreement, the Stock Option Agreement and the
Shareholders Agreement.
Conditions to the Merger. The Merger Agreement provides that the
respective obligation of each party to effect the Merger is subject to the
satisfaction or waiver at or prior to the closing of the Merger of each of the
following conditions: (i) if the approval of the Merger Agreement and the Merger
by the holders of Shares is required by applicable law, the Merger Agreement
shall have been duly adopted by holders of a majority of the Shares outstanding;
(ii) any waiting period applicable to the consummation of the Merger under the
HSR Act shall have expired or been terminated; (iii) (A) no court or
Governmental Entity of competent jurisdiction shall have enacted, issued,
enforced or entered any statute, rule, regulation, judgment, decree, injunction
or other order (whether temporary, preliminary or permanent) that is in effect
and restrains, enjoins or otherwise prohibits consummation of the Offer or
Merger (collectively, an "Order"); provided however, that prior to invoking this
provision, each party shall use its commercially reasonable best efforts to have
any such Order lifted or withdrawn, and (B) no Governmental Entity shall have
instituted any proceeding seeking any such Order; (iv) Offeror shall have (A)
commenced the Offer and (B) purchased, pursuant to the terms and conditions of
such Offer, all Shares duly tendered and not withdrawn; provided, however, that
neither Parent nor Offeror shall be entitled to rely on the condition described
in clause (iv)(B) above if either of them shall have failed to purchase Shares
pursuant to the Offer in breach of their obligations under the Merger Agreement.
Termination. The Merger Agreement, notwithstanding approval thereof by the
stockholders of the Company, may be terminated at any time prior to the
Effective Time:
(a) by mutual written consent of the Company, Parent and Offeror;
(b) by Parent or the Company:
(i) if the Merger shall not have been consummated by February 1,
2000, whether such date is before or after the date of approval by the
stockholders of the Company; provided, however, that if a request for
additional information is received from the United States Federal Trade
Commission (the "FTC") or the Antitrust Division of the United States
Department of Justice pursuant to the HSR Act or additional information
is requested by a governmental authority pursuant to the antitrust,
competition, foreign investment, or similar laws or any foreign
countries or supranational commissions or boards that require pre-merger
notifications or filings with respect to the Merger, then such date
shall be extended to the 30th day following certification by Parent
and/or the Company, as applicable, that Parent and/or the Company, as
applicable, have substantially complied with such request, but in any
event not later than March 1, 2000; provided that the right to terminate
the Merger Agreement described in this clause (i) shall not be available
to any party that has breached in any material respect its obligations
under the Merger Agreement in any manner that shall have been the
proximate cause of, or resulted in, the failure to consummate the Merger
by the date referred to in this clause (i);
23
<PAGE> 26
(ii) if the Stockholders Meeting shall have been convened, held and
completed and the approval of the Company stockholders shall not have
been obtained thereat or at any adjournment or postponement thereof,
provided however, that Parent shall not be permitted to terminate the
Merger Agreement pursuant to the circumstances described in this clause
(ii) if Parent or Offeror shall not have voted all Shares then owned
beneficially or of record by them in favor of approval and adoption of
the Merger Agreement, the Merger and the transactions contemplated
hereby;
(iii) if any Order permanently restraining, enjoining or otherwise
prohibiting the Offer or the Merger shall become final and
non-appealable (whether before or after the approval of the Company
stockholders); provided, however, that the right to terminate the Merger
Agreement pursuant to the circumstances described in this clause (iii)
shall not be available to any party that fails to use commercially
reasonable best efforts to prevent such Order from being issued and to
use commercially reasonable best efforts to cause such Order to be
vacated, withdrawn or lifted; or
(iv) if the Offer terminates or expires on account of the failure
of any condition described in Section 14 without Offeror having
purchased any Shares thereunder.
(c) by the Company:
(i) if (a) the Company is not in material breach of any of its
covenants and agreements in the Merger Agreement, (b) the Board of
Directors of the Company authorizes the Company, prior to Parent
beneficially owning a majority of the Shares, and subject to complying
with the terms of the Merger Agreement, to enter into a binding written
agreement concerning a Superior Proposal and the Company notifies Parent
in writing that it intends to enter into such an agreement, attaching
the most current version of such agreement to such notice, and (c)
Parent does not make, within three business days of receipt of the
Company's written notification of its intention to enter into such an
agreement, a written offer that is at least as favorable, from a
financial point of view, to the stockholders of the Company as the
Superior Proposal; provided that the Company agreed (x) that it would
not enter into a binding agreement referred to in clause (b) until at
least the first calendar day following the third business day after it
has provided the written notice to Parent described therein, (y) to
notify Parent promptly if its intention to enter into a written
agreement referred to in such notice shall change at any time after
giving such notification and (z) that it will not terminate the Merger
Agreement or enter into a binding agreement referred to in clause (b) if
Parent has, within the period referred to in clause (x) of this
sentence, made a written offer that is at least as favorable to the
Company's stockholders from a financial point of view as the Superior
Proposal;
(ii) if, prior to consummation of the Offer and prior to Parent
beneficially owning a majority of the outstanding shares of Common
Stock, there has been a material breach by Parent or Offeror of any
representation, warranty, covenant or agreement of Parent or Offeror
contained in the Merger Agreement which has had, or is reasonably likely
to have, the effect of materially impairing the ability of Parent or
Offeror to consummate the Offer or the Merger (a "Terminating Parent
Breach"); provided, however, that, if such Terminating Parent Breach is
curable by Parent through the exercise of reasonable best efforts and
such cure is reasonably likely to be completed prior to the termination
date of the Merger Agreement described in (b)(i) above, then for so long
as Parent continues to exercise reasonable best efforts to cure such
Terminating Parent Breach, the Company may not terminate the Merger
Agreement under the circumstances described in this clause (ii); or
(iii) if Offeror shall have failed to commence the Offer within
five business days after the date of the Merger Agreement.
(d) by Parent, prior to the Parent and Offeror collectively
beneficially owning (excluding from the determination of beneficial
ownership shares of Common Stock issuable upon exercise of or subject to
the Stock Option Agreement and the Shareholders Agreement) a majority of
the outstanding shares on a
24
<PAGE> 27
fully diluted basis (excluding from the determination of outstanding shares
on a fully diluted basis, shares subject to the Stock Option Agreement):
(i) if the Board of Directors shall have failed to recommend, or
shall have withdrawn or adversely modified its approval or
recommendation of, the Offer or the Merger or failed to reconfirm its
recommendation of the Offer or the Merger within five calendar days
after a written request by Parent to do so, or shall have resolved to do
any of the foregoing; or
(ii) if there has been a material breach by the Company of any
representation, warranty, covenant or agreement of the Company contained
in the Merger Agreement which would give rise to the failure of the
condition to the Offer that (A) the representations and warranties of
the Company set forth in the Merger Agreement shall be true and correct
as of the date of the Merger Agreement and as of the consummation of the
Offer (except for those representations and warranties made as of a
specific date, which shall be true and correct as of such date), and
considered without regard to any qualification by, or references to,
"material," "in all material respects" or "Company Material Adverse
Effect," except for such failures of such representations and warranties
to be true and correct that individually or in the aggregate, do not
have and are not reasonably likely to have a Company Material Adverse
Effect (as defined in the Merger Agreement); or (B) the Company shall
have breached or failed to comply in any material respect with any of
its material obligations, covenants or agreements under the Merger
Agreement and any such breach or failure shall not have been
substantially cured by the Company within five business days after
Parent provides written notice to the Company of such breach or failure
(a "Terminating Company Breach"); provided, however, that, if such
Terminating Company Breach is curable by the Company through the
exercise of reasonable best efforts and such cure is reasonably likely
to be completed prior to the termination date of the Merger Agreement,
then for so long as the Company continues to exercise reasonable best
efforts, Parent may not terminate the Merger Agreement under the
circumstances described in this clause (ii).
Indemnification; Directors' and Officers' Insurance. The Merger Agreement
provides that from and after the earliest date on which Offeror owns at least a
majority of the outstanding Shares on a fully diluted basis, Parent will
indemnify, defend and hold harmless each individual and every person who is or
was a director or officer of the Company or any of its subsidiaries prior to the
Effective Time (the "Indemnified Parties"), against any costs or expenses
(including reasonable attorneys' fees), judgments, fines, losses, claims,
damages, liabilities and amounts paid in settlement incurred in connection with
any claim, action, suit, proceeding, inquiry or investigation, whether civil,
criminal, administrative or investigative, arising out of matters existing or
occurring at or prior to the Effective Time (including transactions contemplated
by the Merger Agreement), whether asserted or claimed prior to, at or after the
Effective Time (and Parent shall also advance expenses as incurred to the
fullest extent permitted under applicable law, provided the person to whom
expenses are advanced provides an undertaking to repay such advances if it is
ultimately determined that such person is not entitled to indemnification).
The Merger Agreement also provides that from and after the earliest date on
which Offeror owns at least a majority of the outstanding Shares on a fully
diluted basis, Parent will cause the Surviving Corporation to fulfill and honor
in all respects the obligations of the Company pursuant to each indemnification
agreement previously disclosed to Parent and any indemnification provision or
any exculpation provision set forth in the Company's certificate of
incorporation or bylaws in effect on the date of the Merger Agreement. In
addition, the certificate of incorporation and bylaws of the Surviving
Corporation shall contain the provisions with respect to indemnification and
exculpation from liability set forth in the Company's certificate of
incorporation and bylaws on the date of the Merger Agreement, and during the
period commencing on the earliest date in which Offeror purchases Shares
pursuant to the Offer and ending on the sixth anniversary of the Effective Time,
such provisions shall not be amended, repealed or otherwise modified in any
manner that would adversely affect the rights thereunder of any of the
Indemnified Parties.
Any Indemnified Party wishing to make a claim of indemnification under the
Merger Agreement, upon learning of any such claim, action, suit, proceeding,
inquiry or investigation, is required to promptly notify
25
<PAGE> 28
Parent thereof. In the event of any such claim, action, suit, proceeding,
inquiry or investigation (whether arising before or after the Effective Time),
(i) Parent or the Surviving Corporation shall have the right to assume the
defense thereof and Parent shall be liable to such Indemnified Parties for the
legal expenses of one counsel or any other expenses subsequently incurred by
such Indemnified Parties in connection with the defense thereof unless there is
a conflict of interest between the Indemnified Parties and Parent, in which
event Parent shall be liable to the Indemnified Parties for the fees and
expenses of each Indemnified Parties' counsel, (ii) the Indemnified Parties will
cooperate in the defense of any such matter and (iii) Parent shall not be liable
for any settlement effected without its prior written consent and no Indemnified
Party shall be liable for any settlement effected without its prior written
consent unless such settlement includes a complete unconditional release of all
claims against all Indemnified Parties; and provided, further, that Parent shall
not have any obligation hereunder to any Indemnified Party if and when a court
of competent jurisdiction shall ultimately determine, and such determination
shall have become final, that the indemnification of such Indemnified Party in
the manner contemplated hereby is prohibited by applicable law. Parent and the
Surviving Corporation jointly and severally have agreed to pay all expenses,
including attorneys' fees, that may be incurred by the Indemnified Parties in
enforcing the indemnity and other obligations described above.
The Merger Agreement also provides that prior to the Effective Time, the
Company may purchase insurance coverage extending for a period of six years
after the Effective Time the level and scope of the Company's directors' and
officers' liability insurance coverage in effect as of the date of the Merger
Agreement; provided that the aggregate annual premium payable for such insurance
shall not exceed 175% of the last annual premium paid for such coverage prior to
the date of the Merger Agreement. In addition, Parent has agreed that through
the sixth anniversary of the Effective Time, Parent shall maintain in effect,
for the benefit of the Indemnified Parties, such insurance coverage, and subject
to the limitations in the preceding sentence, shall pay the annual premium for
such insurance coverage. In the event the annual premium payable for such
insurance coverage exceeds 175% of the last annual premium paid by the Company
for such coverage, Parent shall be obligated to obtain and maintain in effect a
policy with the greatest amount of coverage available for a cost not exceeding
175% of such amount.
The Merger Agreement further provides that if the Surviving Corporation or
any of its successors or assigns (i) shall consolidate with or merge into any
other corporation or entity and shall not be the continuing or surviving
corporation or entity of such consolidation or merger or (ii) shall transfer all
or substantially all of its properties and assets to any individual, corporation
or other entity, then and in each such case, proper provisions shall be made so
that the successors and assigns of the Surviving Corporation shall assume all of
the obligations described above with respect to indemnification under the Merger
Agreement.
Certain Employee Matters. The Merger Agreement provides that during the
period commencing at the Effective Time and ending on the first anniversary
thereof, the employees will continue to be provided with benefits under employee
benefit plans (other than stock options or other plans involving the issuance of
securities of the Company or Parent) which in the aggregate are substantially
comparable to those currently provided by the Company to such employees. Parent
has agreed to cause each employee benefit plan of Parent in which employees are
eligible to participate to take into account for purposes of eligibility and
vesting thereunder the service of such employees with the Company as if such
service were with Parent, to the same extent that such service was credited
under a comparable plan of the Company and such service period would have been
credited to an employee of Parent participating in the relevant plan. Parent has
further agreed that for the first plan year ending after the Effective Time, any
pre-existing condition exclusion under any Parent benefit plan providing medical
or dental benefits shall be no more restrictive for any employee who,
immediately prior to commencing participation in such Parent benefit plan, was
participating in a Company benefit plan providing medical or dental benefits and
had satisfied any pre-existing condition provision under such Company benefit
plan. In addition, any expenses that were taken into account under a Company
benefit plan providing medical or dental benefits in which the employee
participated immediately prior to commencing participation in a Parent benefit
plan providing medical or dental benefits shall be taken into account to the
same extent under such Parent benefit plan, in accordance with the terms of such
Parent benefit plan, for purposes of satisfying applicable deductible,
coinsurance and maximum out-of-pocket provisions and life-time benefit limits.
Parent has further agreed that it will, and will cause the Surviving Corporation
to, honor in
26
<PAGE> 29
accordance with their terms (i) all employee benefit obligations to employees
accrued as of the Effective Time and (ii) all employee severance plans in
existence on the date of the Merger Agreement (and previously disclosed to
Parent) and all employment or severance agreements entered into prior to the
date of the Merger Agreement.
Amendment. Subject to the provisions of applicable law, at any time prior
to the Effective Time, the parties to the Merger Agreement may modify or amend
the Merger Agreement, by written agreement executed and delivered by duly
authorized officers of the respective parties.
Timing. The exact timing and details of the Merger will depend upon legal
requirements and a variety of other factors, including the number of Shares
acquired by Offeror pursuant to the Offer. Although Parent has agreed to cause
the Merger to be consummated on the terms contained in the Merger Agreement,
there can be no assurance as to the timing of the Merger.
Stock Option Agreement
The following is a summary of the material terms of the Stock Option
Agreement. This summary is not a complete description of the terms and
conditions thereof and is qualified in its entirety by reference to the full
text thereof, which is incorporated herein by reference and a copy of which has
been filed with the Commission as an exhibit to the Schedule 14D-1.
Concurrently with the execution and delivery of the Merger Agreement, the
Company entered into the Stock Option Agreement with Parent and Offeror.
Pursuant to the Stock Option Agreement, the Company has agreed, on the terms and
subject to the conditions thereof, to grant an option to purchase up to
1,931,050 Shares. Any reference to a majority of the issued and outstanding
Shares or Shares outstanding on a fully diluted basis, or similar references,
for purposes of this Offer to Purchase, as provided in the documents described
herein, exclude from the determination thereof any shares of Common Stock
issuable upon the exercise of the Stock Option Agreement and any reference to
beneficial ownership of Shares, or similar references, exclude from the
determination thereof any Shares issuable upon exercise of or subject to the
Shareholders Agreement or the Stock Option Agreement.
Grant of Purchase Option. Under the Stock Option Agreement, the Company
granted to Parent an irrevocable option (the "Option") to purchase up to
1,931,050 Shares at a cash purchase price equal to $8.50 per share (the
"Purchase Price"). The Option may be exercised by Parent, in whole or in part,
at any time, but only on one occasion, following (but not prior to) the
occurrence of the events set forth in any of clauses (i) or (ii) below, and
prior to the Option Termination Date (as defined below). The Option is subject
to appropriate adjustment in the event of any change in the number of issued and
outstanding shares of capital stock of the Company to maintain Parent's rights
under the Stock Option Agreement, including the right to purchase 19.9% of the
capital stock of the Company entitled to vote generally for election of
directors of the Company outstanding immediately prior to exercise.
Exercise of Option. The option may be exercised if:
(i) (A) a bona fide Acquisition Proposal shall have been made to the
Company or any of its stockholders or any person or entity shall have
announced an intention (whether or not conditional) to make an Acquisition
Proposal with respect to the Company, and on or following the date of the
Merger Agreement but prior to the date that the Offer is consummated and
Parent owns a majority of the outstanding shares of Common Stock, such
Acquisition Proposal, announcement or intention is or becomes publicly
known, and (B) on or following the date of the Merger Agreement but prior
to the time such Acquisition Proposal, announcement or intention is or
becomes publicly known, the occurrence of an event that would have a
material adverse effect on the ability of Parent or Offeror to consummate
the Merger shall not have become publicly known, and (C) on or following
the date on which such Acquisition Proposal, announcement or intention is
or becomes publicly known, the Merger Agreement is terminated by either
Parent or the Company because, subject to certain exceptions, the Merger
shall not have been consummated by February 1, 2000 (subject, in certain
circumstances, to extension to March 1, 2000), and if terminated by Parent
and Parent or the Offeror, Parent or the Offeror shall not collectively
27
<PAGE> 30
beneficially own a majority of the outstanding Shares on a fully diluted
basis, and the Termination Fee under the Merger Agreement has become
payable; or
(ii) the Merger Agreement is terminated (x) by the Company because it
has determined to enter into a binding written agreement concerning a
Superior Proposal and the Company notifies Parent in writing that it
intends to enter into such an agreement, attaching the most current version
of such agreement to such notice, and Parent does not make, within three
business days of receipt of the Company's written notification of its
intention to enter into such an agreement, a written offer that is at least
as favorable, from a financial point of view, to the stockholders of the
Company as the Superior Proposal or (y) by Parent if the Board of Directors
of the Company shall have failed to recommend, or shall have withdrawn or
adversely modified its approval or recommendation of, the Offer or the
Merger or failed to reconfirm its recommendation of the Offer or the Merger
within five calendar days after a written request by Parent to do so, or
shall have resolved to do any of the foregoing, or (z) because of the
failure of certain conditions to the Offer described in paragraphs (e) and
(f) of Section 14.
Under the Stock Option Agreement, if at any time the Option is then
exercisable and at or prior to such time the Termination Fee shall have become
payable, Parent may on one occasion elect, in lieu of exercising the Option to
purchase Shares, to send a written notice to the Company (a "Cash Exercise
Notice") specifying a date not later than 20 business days and not earlier than
10 business days following the date such notice is given on which date the
Company shall pay to Parent an amount in cash (the "Cancellation Amount") equal
to the Spread (as defined below) multiplied by all or such portion of the Shares
subject to the Option as Parent shall specify. As used in the Stock Option
Agreement, "Spread" means the excess, if any, over the Purchase Price of the
higher of (x) if applicable, the highest price per Share (including any
brokerage commissions, transfer taxes and soliciting dealers' fees) paid or
proposed to be paid by any person pursuant to any Acquisition Proposal occurring
after the date of the Stock Option Agreement and prior to the Option Termination
Date (the "Alternative Purchase Price") or (y) the average of the closing bid
and asked prices of the Shares on the NASDAQ/NMS or on such other national
securities exchange on which the Shares are then listed for the last five
trading days immediately prior to the date of the Cash Exercise Notice (the
"Closing Price"). If the Alternative Purchase Price includes any property other
than cash, the Alternative Purchase Price shall be the sum of (i) the fixed cash
amount, if any, included in the Alternative Purchase Price plus (ii) the fair
market value of such other property. If such other property consists of
securities with an existing public trading market, the average of the closing
prices (or the average of the closing bid and asked prices if closing prices are
unavailable) for such securities in their principal public trading market on the
five trading days ending five days prior to the date of the Cash Exercise Notice
shall be deemed to equal the fair market value of such property. If such other
property consists of something other than cash or securities with an existing
public trading market and, as of the payment date for the Spread, agreement on
the value of such other property has not been reached, the Alternative Purchase
Price shall be deemed to equal the Closing Price. Upon exercise of its right to
receive cash described in this paragraph, the obligations of the Company to
deliver Shares pursuant to the Option shall be terminated with respect to such
number of Shares for which Parent shall have elected to be paid the Spread.
Profit Limitation. The Stock Option Agreement provides that any
Cancellation Amount shall be reduced (but not below zero) to the extent
necessary so that the sum of (1) the portion of any Termination Fee actually
paid to Parent (such portion actually paid, the "Actual Termination Fee"), (2)
the aggregate of all Cancellation Amounts paid to Parent pursuant to the Stock
Option Agreement and (3) the cash proceeds actually received by Parent as the
result of selling Shares issued to Parent pursuant to the Stock Option Agreement
to a third party which acquires more than 50% of the Company's outstanding
voting securities (other than any such acquisitions by the Company or any of its
affiliates) shall not exceed $4.4 million. The Stock Option Agreement further
provides that in no event shall (i) the sum of the Actual Termination Fee and
the cash proceeds actually received by Parent as the result of selling Shares
issued to Parent pursuant to the Stock Option Agreement to a third party which
acquires more than 50% of the Company's outstanding voting securities (other
than the Company or any of its affiliates) exceed $4.4 million, or (ii) the sum
of the Actual Termination Fee, the aggregate Cancellation Amounts paid to Parent
pursuant to the Stock Option Agreement and the cash proceeds actually received
by Parent as the result of selling Shares issued to Parent
28
<PAGE> 31
pursuant to the Stock Option Agreement to a third party which acquires more than
50% of the Company's outstanding voting securities (other than any such
acquisitions by the Company or any of its affiliates) exceed $4.4 million.
Registration Rights. The Stock Option Agreement provides that, in the
event that the Parent shall desire to sell any of the Shares within two years
after the purchase of such Shares pursuant to the Option, and such sale
requires, in the opinion of counsel to Parent, which opinion shall be reasonably
satisfactory to the Company and its counsel, registration of such Shares under
the Securities Act, the Company will cooperate with Parent and any underwriters
(which underwriters must be reasonably satisfactory to the Company) in
registering such Shares for resale, including, without limitation, promptly
filing a registration statement which complies with the requirements of
applicable federal and state securities laws, and entering into an underwriting
agreement with such underwriters upon such terms and conditions as are
customarily contained in underwriting agreements with respect to secondary
distributions; provided that the Company shall not be required to have declared
effective more than two registration statements and shall be entitled to delay
the filing or effectiveness of any registration statement and may suspend the
use of any registration statement (and related prospectus) for one or more
periods of time not exceeding an aggregate of 60 days in any one-year period if
the offering would, in the judgment of the Board of Directors of the Company,
require premature disclosure of any material corporate development or material
transaction involving the Company or interfere with any previously planned
securities offering by the Company. The Stock Option Agreement also provides
that the Company shall bear the cost of the registration, including, but not
limited to, all registration and filing fees, printing expenses, and fees and
disbursements of counsel and accountants for the Company, except that Parent
shall pay the fees and disbursements of its counsel, and the underwriting fees
and selling commissions applicable to the Shares sold by Parent. The Stock
Option Agreement further provides that the Company shall indemnify and hold
harmless (i) Parent, its affiliates and its officers and directors and (ii) each
underwriter and each person who controls any underwriter within the meaning of
the Securities Act or the Exchange Act (collectively, the "Underwriters") ((i)
and (ii) being referred to as "Registration Indemnified Parties") against any
losses, claims, damages, liabilities or expenses, to which the Registration
Indemnified Parties may become subject, insofar as such losses, claims, damages,
liabilities (or actions in respect thereof) and expenses arise out of or are
based upon any untrue statement or alleged untrue statement of any material fact
contained or incorporated by reference in any registration statement filed
pursuant to the registration rights under the Stock Option Agreement, or arise
out of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading; provided, however, that the Company will not be liable
in any such case to the extent that any such loss, liability, claim, damage or
expense arises out of or is based upon (A) an untrue statement or alleged untrue
statement in or omission or alleged omission from any such documents in reliance
upon and in conformity with written information furnished to the Company by the
Registration Indemnified Parties expressly for use or incorporation by reference
therein, or (B) the fact that the person asserting any such loss, liability,
claim, damage or expense did not receive a copy of an amended preliminary
prospectus or the final prospectus (or the final prospectus as amended or
supplemented) at or prior to the written confirmation of the sale of the Shares
to such person because of the failure of Parent to so provide such amended
preliminary or final prospectus. In addition, Parent has agreed and the
Underwriters will be required to agree to indemnify and hold harmless the
Company, its affiliates and its officers and directors against any losses,
claims, damages, liabilities or expenses to which the Company, its affiliates
and its officers and directors may become subject, insofar as such losses,
claims, damages, liabilities (or actions in respect thereof) and expenses arise
out of or are based upon (i) any untrue statement of any material fact contained
or incorporated by reference in any registration statement filed pursuant to the
registration rights under the Stock Option Agreement, or arise out of or are
based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading, in each case to the extent, but only to the extent, that such untrue
statement or alleged untrue statement or omission or alleged omission was made
in reliance upon and in conformity with written information furnished to the
Company by the Indemnified Parties, as applicable, specifically for use or
incorporation by reference therein, or (ii) the fact that the person asserting
any such loss, liability, claim, damage or expense did not receive a copy of an
amended preliminary prospectus or the final prospectus (or the final prospectus
as amended or supplemented) at or prior to the written confirmation
29
<PAGE> 32
of the sale of the Shares to such person because of the failure of Parent to so
provide such amended preliminary or final prospectus.
Other Agreements. The Stock Option Agreement provides that after the
Option becomes exercisable, the Company will promptly file an application to
list the Shares on NASDAQ/NMS or on such other national securities exchange on
which the Shares are then listed and will use its reasonable best efforts to
obtain approval of such listing and to effect all necessary filings by the
Company under the HSR Act and any other necessary consents.
Conditions. The Stock Option Agreement provides that the Company's
obligation to deliver Shares upon exercise of the Option is subject to the
conditions that: (i) no preliminary or permanent injunction or other order
issued by any federal or state court of competent jurisdiction prohibiting the
delivery of the Shares shall be in effect; (ii) any applicable waiting periods
under the HSR Act shall have expired or been terminated; (iii) the
representations and warranties of Parent made in the Stock Option Agreement
shall be true and correct in all material respects as of the date of the closing
of the issuance of the Shares; and (iv) the existence of the circumstances
described in clause (i) and (ii) under Exercise of Options.
Termination. The Stock Option Agreement provides that the right to
exercise the Option shall terminate at (and the Option shall no longer be
exercisable after) the earliest of (i) the Effective Time, (ii) the nine month
anniversary of the earliest to occur of the events set forth in Exercise of
Options, and (iii) the fifteenth day following the termination of the Merger
Agreement if prior to such fifteenth day the events set forth in clause (i) or
(ii) of the Exercise of Options shall not have occurred (such earliest date the
"Option Termination Date"); provided that, if the Option cannot be exercised or
the Shares cannot be delivered to Parent upon such exercise because one or more
of the conditions set forth in clause (i) or (ii) in "Conditions" above have not
yet been satisfied, the Option Termination Date shall be extended until fifteen
days after such impediment to exercise or delivery has been removed.
Other. Because the rights and obligations of Parent and the Company under
the Stock Option Agreement are subject to compliance with the HSR Act, Parent
will include in its merger notifications to be filed with the Department of
Justice and Federal Trade Commission a description of its rights under the Stock
Option Agreement. See Section 15.
Shareholders Agreement
The following is a summary of the material terms of the Shareholders
Agreement. This summary is not a complete description of the terms and
conditions thereof and is qualified in its entirety by reference to the full
text thereof, which is incorporated herein by reference and a copy of which has
been filed with the Commission as an exhibit to the Schedule 14D-1.
Tender of Shares. Concurrently with the execution and delivery of the
Merger Agreement, and in order to induce Parent and Offeror to enter into the
Merger Agreement, the Major Stockholders who beneficially own in the aggregate,
as of July 30, 1999 approximately 34.1%, of the outstanding Shares including
3,188,057 shares of Common Stock and options representing the right to purchase
189,790 Shares (collectively, the "Optioned Securities") or have the right to
vote Shares or other securities (the "Voting Securities") have entered into a
Shareholders Agreement with Parent and Offeror. Pursuant to the Shareholders
Agreement, the Major Stockholders have agreed to tender the Optioned Securities
in the Offer and not to withdraw such Optioned Securities prior to the
expiration of the Offer. The obligation to sell any of such Optioned Securities
under the Shareholders Agreement, as described below, shall be satisfied, solely
with respect to the Shares so tendered, upon the purchase of such Shares by
Offeror pursuant to the Offer. In the event of any change in the Optioned
Securities by reason of stock dividends, split-up, recapitalizations,
combinations, exchanges or the like, the number of Optioned Securities subject
to the Shareholders Agreement will be appropriately adjusted.
Shareholder Option. Pursuant to the Shareholder Agreement, the Major
Stockholders have granted to Offeror an irrevocable option (the "Shareholder
Option") to purchase (i) all Optioned Securities at the Offer Price; and (ii)
any additional Optioned Securities acquired by the Major Stockholders during the
term of the Shareholders Agreement. The Shareholder Option may be exercised by
Offeror at any time after the date on
30
<PAGE> 33
which all waiting periods under the HSR Act applicable to the exercise of the
Shareholder Option have expired or been terminated, but only if:
(i) (A) a bona fide Acquisition Proposal shall have been made to the
Company or any of its stockholders or any person or entity shall have
announced an intention (whether or not conditional) to make an Acquisition
Proposal with respect to the Company, and on or following the date of the
Merger Agreement but prior to the date that the Offer is consummated and
Parent owns a majority of the outstanding shares of Common Stock, such
Acquisition Proposal, announcement or intention is or becomes publicly
known, and (B) on or following the date of the Merger Agreement but prior
to the time such Acquisition Proposal, announcement or intention is or
becomes publicly known, the occurrence of an event that would have a
material adverse effect on the ability of Parent or Offeror to consummate
the Merger shall not have become publicly known, and (C) on or following
the date on which such Acquisition Proposal, announcement or intention is
or becomes publicly known, the Merger Agreement is terminated by either
Parent or the Company because, subject to certain exceptions, the Merger
shall not have been consummated by February 1, 2000 (subject, in certain
circumstances, to extension to March 1, 2000), and if terminated by Parent
and Parent or the Offeror, Parent or the Offeror shall not collectively
beneficially own a majority of the outstanding Shares on a fully diluted
basis, and the Termination Fee under the Merger Agreement has become
payable; or
(ii) the Merger Agreement is terminated (x) by the Company because it
has determined to enter into a binding written agreement concerning a
Superior Proposal and the Company notifies Parent in writing that it
intends to enter into such an agreement, attaching the most current version
of such agreement to such notice, and Parent does not make, within three
business days of receipt of the Company's written notification of its
intention to enter into such an agreement, a written offer that is at least
as favorable, from a financial point of view, to the stockholders of the
Company as the Superior Proposal or (y) by Parent if the Board of Directors
of the Company shall have failed to recommend, or shall have withdrawn or
adversely modified its approval or recommendation of, the Offer or the
Merger or failed to reconfirm its recommendation of the Offer or the Merger
within five calendar days after a written request by Parent to do so, or
shall have resolved to do any of the foregoing, or (z) because of the
failure of certain conditions to the Offer described in paragraphs (e) and
(f) of Section 14.
Agreement to Vote and Irrevocable Proxy. The Major Stockholders have
further agreed to (a) vote all of their respective Voting Securities in favor of
the Merger; (b) not vote any Voting Securities in favor of any action or
agreement which would result in a breach in any material respect of any
covenant, representation or warranty or any other obligation of the Company
under the Merger Agreement; and (c) vote all Voting Securities of such Major
Stockholder against any action or agreement which would impede, interfere with
or attempt to discourage the Offer or the Merger, including, but not limited to:
(i) any Acquisition Proposal (other than the Offer and the Merger) involving the
Company or any of its subsidiaries; (ii) any change in the management or board
of directors of the Company, except as otherwise agreed to in writing by the
Offeror; (iii) any material change in the present capitalization or dividend
policy of the Company; or (iv) any other material change in the Company's
corporate structure or business. The Major Stockholders have also granted
Offeror or its designees an irrevocable proxy to vote their Shares for all
purposes whatsoever.
No Inconsistent Agreements; Non Solicitation. Pursuant to the Shareholders
Agreement, the Major Stockholders also agreed that while the agreement was in
effect they would not make any disposition of or enter into any voting
arrangement with respect to the subject securities or initiate or solicit or
enter into or endorse any Acquisition Proposal, or otherwise engage in any
action inconsistent with their performance of the Shareholders Agreement.
Representations and Warranties. The Shareholders Agreement contains
certain customary representations and warranties, including, without limitation,
representations by the Major Stockholders as to ownership of the Shares and
power and authority.
Termination. The Shareholder Option shall expire on the earliest of (1)
the Effective Time (as defined in the Merger Agreement), (2) the nine month
anniversary of the earliest to occur of the events set forth in clause (i) and
(ii) described under Shareholder Option, and (3) the fifteenth day following the
termination of
31
<PAGE> 34
the Merger Agreement if prior to such fifteenth day the events set forth in
clause (i) and (ii) described under Shareholder Option shall not have occurred
(such earliest date being referred to as the "Shareholder Option Expiration
Date"); provided that, if the Shareholder Option cannot be exercised or the
Optioned Securities cannot be delivered to Offeror upon such exercise because
(x) there shall be in effect a preliminary or permanent injunction or other
order issued by any federal or state court of competent jurisdiction prohibiting
delivery of the Optioned Securities or (y) any applicable waiting periods under
the HSR Act shall not have expired or been terminated, then the Shareholder
Option Expiration Date shall be extended until thirty days after such impediment
to exercise or delivery has been removed.
OTHER MATTERS.
Section 203 of the Delaware Law. Section 203 of the Delaware Law limits
the ability of a Delaware corporation to engage in business combinations with
"interested stockholders" (defined as any beneficial owner of 15% or more of the
outstanding voting stock of the corporation) unless, among other things, the
corporation's board of directors has given its prior approval to either the
business combination or the transaction which resulted in the stockholder's
becoming an "interested stockholder". On July 30, 1999, the Board of Directors
of the Company approved the Offer, the Merger and the Merger Agreement, the
Shareholders Agreement and the Stock Option Agreement for purposes of Section
203, and, therefore, Section 203 is inapplicable to the Offer, the Merger, the
Merger Agreement, the Shareholders Agreement and the Stock Option Agreement and
the transactions contemplated thereby. See Section 15.
Appraisal Rights. No appraisal rights are available to holders of Shares
in connection with the Offer, nor would they be available to holders of Shares
in connection with a "short-form" merger in accordance with Section 253 of the
Delaware Law. However, if the Merger is consummated, other than by a
"short-form" merger, holders of Shares will have certain rights under Section
262 of the Delaware Law to dissent and demand appraisal of, and payment in cash
for the fair value of, their Shares. Such rights, if the statutory procedures
are complied with, could lead to a judicial determination of the fair value
(excluding any element of value arising from accomplishment or expectation of
the Merger) required to be paid in cash to such dissenting holders for their
Shares. Any such judicial determination of the fair value of Shares could be
based upon considerations other than in addition to the Offer Price and the
market value of the Shares, including asset values and the investment value of
the Shares. The value so determined could be more or less than the Offer Price
or the Merger Consideration.
If any holder of Shares who demands appraisal under Section 262 of the
Delaware Law fails to perfect, or effectively withdraws or losses his right to
appraisal, as provided in the Delaware Law, the shares of such holder will be
converted into the Merger Consideration in accordance with the Merger Agreement.
A stockholder may withdraw his demand for appraisal by delivery to Parent of a
written withdrawal of his demand for appraisal and acceptance of the Merger.
Failure to follow the steps required by Section 262 of the Delaware Law for
perfecting appraisal rights may result in the loss of such rights.
Rule 13e-3: The Commission has adopted Rule 13e-3 under the Exchange Act
("Rule 13e-3"), which is applicable to certain "going private" transactions.
Rule 13e-3 requires, among other things, that certain financial information
concerning the company and certain information relating to the fairness of the
proposed transaction and the consideration offered to minority stockholders in
such transaction be filed with the Commission and disclosed to stockholders
prior to consummation of the transaction.
Parent believes that Rule 13e-3 will not be applicable to the Merger
because of the exemption afforded by Rule 13e-3(g)(1), among other reasons.
However, under certain circumstances, Rule 13e-3 could be applicable to the
Merger or other business combination in which Parent seeks to acquire the
remaining Shares it does not beneficially own following the purchase of Shares
pursuant to the Offer. For example, if the Merger as consummated is not
substantially similar to the Merger as described in this Offer to Purchase and
the Merger Agreement, Rule 13e-3 could apply. However, the terms and conditions
of the Merger are governed by the Merger Agreement, and any amendment to the
Merger Agreement must be approved by each party thereto. If Parent has exercised
its right to appoint directors to the Board of Directors following its purchase
of
32
<PAGE> 35
Shares pursuant to the Offer, any such amendment must be approved on behalf of
the Company by the directors of the Company, in the manner set forth above.
There can be no assurance that the Merger will take place, even though each
party has agreed in the Merger Agreement to use its best efforts to cause the
Merger to occur, because the Merger is subject to certain conditions, some of
which are beyond the control of either Parent or the Company. Since the Parent's
ultimate objective is to acquire ownership of all the Shares, if the Merger does
not take place, the Parent would consider the acquisition, whether directly or
through an affiliate of Shares through private or open market purchases, or
subsequent tender offers or a different type of merger or other combination of
the Company with the Offeror or an affiliate or subsidiary thereof, or by any
other permissible means deemed advisable by it. Except as described in the
section captioned "The Merger Agreement," any of these possible transactions
might be on terms the same as, or more or less favorable than, those of the
Offer or the Merger.
13. DIVIDENDS AND DISTRIBUTIONS.
Pursuant to the terms of the Merger Agreement, from and after the date of
the Merger Agreement until the Effective Time, unless Parent has consented in
writing thereto, the Company shall not, and shall not permit its subsidiaries
to, (a) issue, sell, pledge, dispose of or encumber any capital stock owned by
it in any of its subsidiaries; (b) split, combine or reclassify its outstanding
shares of capital stock; (c) declare, set aside or pay any dividend payable in
cash, stock or property in respect of any capital stock; (d) repurchase, redeem
or otherwise acquire, except in connection with the Company stock plans, or
permit any of its subsidiaries to purchase or otherwise acquire, any shares of
its capital stock or any securities convertible into or exchangeable or
exercisable for any shares of its capital stock; or (e) issue, sell, pledge,
dispose of or encumber any shares of, or securities convertible into or
exchangeable or exercisable for, or options, warrants, calls, commitments or
rights of any kind to acquire, any shares of its capital stock of any class or
any voting debt or any other property or assets (other than (A) the issuance of
Shares pursuant to options outstanding on the date of the Merger Agreement under
the Company stock plans and the issuance of Shares under the Company's Employee
Stock Purchase Plan and (B) the issuance of Shares upon conversion of
convertible preferred stock outstanding on the date of the Merger Agreement).
14. CERTAIN CONDITIONS TO THE OFFER.
Notwithstanding any other provision of the Offer, and subject to the terms
and conditions of the Merger Agreement, Offeror shall not be obligated to accept
for payment any Shares until all required regulatory approvals shall have been
obtained, made or satisfied including until the expiration or termination of any
waiting periods applicable under the HSR Act and Offeror shall not be required
to accept for payment or, subject to any applicable rules and regulations of the
Commission (including Rule 14e-l(c) under the Exchange Act) pay for, and may
delay the acceptance for payment of or payment for, any Shares tendered in the
Offer and (subject to the terms and conditions of the Merger Agreement,
including Section 1.1(b)) may amend, extend or terminate the Offer if, (i)
immediately prior to the scheduled Expiration Date of the Offer (as extended in
accordance with clauses (x), (y) or (z) of Section 1.1(b) of the Merger
Agreement) the Minimum Condition shall not have been satisfied or (ii) prior to
the expiration of the Offer, any of the following shall exist and be continuing:
(a) there shall be threatened or pending any action, litigation or
proceeding (hereinafter, an "Action") brought by any U.S. Governmental
Entity: (i) challenging the acquisition by Parent or Offeror of Shares or
seeking to restrain or prohibit the consummation of the Offer or the
Merger; (ii) seeking to prohibit or impose any material limitation on
Parent's, Offerors' or any of their respective affiliates' ownership or
operation of all or any material portion of the business or assets of the
Company and its subsidiaries taken as a whole or Parent and its
subsidiaries taken as a whole that, in each case described in this clause
(ii) individually or in the aggregate, is reasonably likely to have a
Material Adverse Effect (as defined in the Merger Agreement) on the Company
or Parent; or (iii) seeking to impose material limitations on the ability
of Parent or Offeror effectively to acquire or hold, or to exercise full
rights of ownership of, the Shares including the right to vote the Shares
purchased by them on an equal basis with all other Shares on all matters
properly presented to the stockholders of the Company;
33
<PAGE> 36
(b) any U.S. statute, rule, regulation, order or injunction shall be
enacted, promulgated, entered, enforced or deemed to or become applicable
to the Offer or the Merger (and in each case, remain in effect), or any
other action shall have been taken, by any court of competent jurisdiction
or other U.S. Governmental Entity, that has any of the consequences
described in clauses (i) through (iii) of paragraph (a) above;
(c) (i) the representations and warranties of the Company set forth in
the Merger Agreement shall be true and correct as of the date of the Merger
Agreement and as of the consummation of the Offer (except for those
representations and warranties made as of a specific date, which shall be
true and correct as of such date), and considered without regard to any
qualification by, or references to, "material," "in all material respects"
or "Company Material Adverse Effect," except for such failures of such
representations and warranties to be true and correct that individually or
in the aggregate, do not have and are not reasonably likely to have a
Company Material Adverse Effect; or (ii) the Company shall have breached or
failed to comply in any material respect with any of its material
obligations, covenants or agreements under the Merger Agreement and any
such breach or failure shall not have been substantially cured by the
Company within five business days after Parent provides written notice to
the Company of such breach or failure;
(d) the Merger Agreement shall have been terminated in accordance with
its terms;
(e) any corporation, entity, "group" or "person" (as defined in the
Exchange Act), other than Parent, Offeror or any of the shareholders that
are party to the Shareholders Agreement (so long as such shareholders do
not become beneficial owners of any additional Shares after the date of the
Merger Agreement and so long as such shareholders do not breach any of the
provisions of the Shareholders Agreement), shall have acquired beneficial
ownership of more than 20% of the outstanding Shares;
(f) the Board of Directors of the Company shall have modified or
amended its recommendation of the Offer in any manner adverse to Parent or
Offeror or shall have withdrawn its recommendation of the Offer or shall
have recommended acceptance of any Acquisition Proposal or shall have
failed to reconfirm its recommendation of the Offer within five calendar
days after a written request by Parent to do so, or shall have resolved to
do any of the foregoing; or
(g) there shall exist (i) any general suspension of, or limitation on
prices for, trading in securities on any national securities exchange or in
the over the counter market in the United States (other than shortening of
trading hours or any trading halt resulting from a specified increase or
decrease in a market index), (ii) a declaration of any banking moratorium
by federal or state authorities or any suspension of payments in respect of
banks or any limitation (whether or not mandatory) imposed by federal or
state authorities on the extension of credit by lending institutions in the
United States, or (iii) in the case of any of the foregoing existing at the
time of the commencement of the Offer, a material acceleration or worsening
thereof.
The conditions described in clauses (a) through (g) are for the sole
benefit of Parent and Offeror and may be asserted by Parent and Offeror
regardless of the circumstances giving rise to such conditions and may be waived
by Parent and Offeror in whole or in part at any time and from time to time, by
express and specific action to that effect, in their reasonable discretions. The
failure by Parent or Offeror at any time to exercise any of the foregoing rights
shall not be deemed a waiver of any such right, the waiver of any such right
with respect to particular facts and other circumstances shall not be deemed a
waiver with respect to any other facts and circumstances, and each such right
shall be deemed an ongoing right that may be asserted at any time and from time
to time.
Should the Offer be terminated pursuant to the foregoing provisions, all
tendered Shares shall be promptly returned by the Depositary to the tendering
stockholders.
15. CERTAIN REGULATORY AND LEGAL MATTERS.
Except as described in this Section 15, based on a review of publicly
available filings made by the Company with the Commission and other publicly
available information concerning the Company, as well as
34
<PAGE> 37
certain representations made to Parent and Offeror in the Merger Agreement by
the Company, neither Parent nor Offeror is aware of any license or regulatory
permit that appears to be material to the business of the Company and its
subsidiaries, taken as a whole, that might be adversely affected by the
Offeror's acquisition of Shares as contemplated herein or of any approval or
other action by any Governmental Entity that would be required for the
acquisition or ownership of Shares by Offeror as contemplated herein. Should any
such approval or other action be required, Parent and Offeror currently
contemplate that such approval or other action will be sought, except as
described below under "State Takeover Laws". While, except as otherwise
expressly described in this Section 15, Offeror does not presently intend to
delay the acceptance for payment of, or payment for, Shares tendered pursuant to
the Offer, pending the outcome of any such matter, there can be no assurance
that any such approval or other action, if needed, would be obtained or would be
obtained without substantial conditions or that failure to obtain any such
approval or other action might not result in consequences adverse to the
Company's business, or that certain parts of the Company's business might not
have to be disposed of if such approvals were not obtained or such other actions
were not taken or in order to obtain any such approval or other action. If
certain types of adverse action are taken with respect to the matters discussed
below (or if any governmental approval is not obtained), the Offeror could
decline to accept for payment or pay for any Shares tendered. See Section 14 for
certain conditions to the Offer.
State Takeover Laws. A number of states throughout the United States have
enacted takeover statutes that purport, in varying degrees, to be applicable to
attempts to acquire securities of corporations that are incorporated or have
assets, stockholders, executive offices or places of business in such states. In
Edgar v. MITE Corp., the Supreme Court of the United States held that the
Illinois Business Takeover Act, which involved state securities laws that made
the takeover of certain corporations more difficult, imposed a substantial
burden on interstate commerce and therefore was unconstitutional. In CTS Corp.
v. Dynamics Corp. of America, however, the Supreme Court of the United States
held that a state may, as a matter of corporate law and, in particular, those
laws concerning corporate governance, constitutionally disqualify a potential
acquiror from voting on the affairs of a target corporation without prior
approval of the remaining stockholders, provided that such laws were applicable
only under certain conditions.
The Company is incorporated under the laws of Delaware. Section 203 of the
Delaware Law prevents an "Interested Stockholder" (defined generally as a person
with 15% or more of the corporation's outstanding voting stock) from engaging in
a "Business Combination" (defined to include a variety of transactions,
including mergers) with a Delaware corporation for three years following the
date such person becomes an Interested Stockholder, unless (i) before such
person became an Interested Stockholder, the board of directors of the
corporation approved the transaction in which the Interested Stockholder became
an Interested Stockholder or approved the Business Combination, or (ii) upon
consummation of the transaction which resulted in the Interested Stockholder
becoming an Interested Stockholder, the Interested Stockholder owned at least
85% of the voting stock of the corporation outstanding at the time the
transaction commenced (excluding stock held by directors who are also officers
of the corporation and by certain employee stock ownership plans), or (iii)
following the transaction in which such person became an Interested Stockholder,
the Business Combination is approved by the board of directors of the
corporation and authorized at a meeting of stockholders by the affirmative vote
of the holders of two-thirds of the outstanding voting stock of the corporation
not owned by the Interested Stockholder. The Board of Directors has unanimously
approved the Merger Agreement and the transactions contemplated thereby,
including the Offer, the Merger, the Shareholders Agreement and the Stock Option
Agreement, for purposes of Section 203 of the Delaware Law, and the restrictions
of such Section 203 are, accordingly, not applicable to Parent, Offeror or their
affiliates or associates as a result of the consummation of the transactions
contemplated by this Offer to Purchase.
Neither Parent nor Offeror has currently complied with any state takeover
statute or regulation. Offeror reserves the right to challenge the applicability
or validity of any state law purportedly applicable to the Offer or the Merger
and nothing in this Offer to Purchase or any action taken in connection with the
Offer or the Merger is intended as a waiver of such right. If it is asserted
that any state takeover statute is applicable to the Offer or the Merger and an
appropriate court does not determine that it is inapplicable or invalid as
applied to the Offer or the Merger, Offeror might be required to file certain
information with, or to receive approvals from, the relevant state authorities,
and Offeror might be unable to accept for payment or pay for Shares
35
<PAGE> 38
tendered pursuant to the Offer or is delayed in consummating the Offer or the
Merger. In such case, Offeror may not be obliged to accept for payment or pay
for any Shares tendered pursuant to the Offer.
Antitrust. Under the HSR Act and the rules that have been promulgated
thereunder by the Federal Trade Commission ("FTC"), certain acquisition
transactions may not be consummated unless certain information has been
furnished to the Antitrust Division of the Department of Justice (the "Antitrust
Division") and the FTC and certain waiting period requirements have been
satisfied. The acquisition of Shares pursuant to the Offer is subject to these
requirements.
Parent expects to file a Notification and Report Form with respect to the
Offer under the HSR Act as soon as practicable following commencement of the
Offer. The waiting period under the HSR Act with respect to the Offer will
expire at 11:59 p.m., Washington, D.C. time, on the 15th day after the date such
form is filed, unless early termination of the waiting period is granted. In
addition, the Antitrust Division or the FTC may extend such waiting period by
requesting additional information or documentary material from Parent. If such a
request is made with respect to the Offer, the waiting period related to the
Offer will expire at 11:59 p.m., Washington, D.C. time, on the 10th day after
substantial compliance by Parent with such request. With respect to each
acquisition, the Antitrust Division or the FTC may issue only one request for
additional information. In practice, complying with a request for additional
information or material can take a significant amount of time. Expiration or
termination of applicable waiting periods under the HSR Act is a condition to
Offeror's obligation to accept for payment and pay for Shares tendered pursuant
to the Offer.
The FTC and the Antitrust Division frequently scrutinize the legality under
the antitrust laws of transactions such as Offeror's proposed acquisition of the
Company. At any time before or after Offeror's purchase of Shares pursuant to
the Offer, the Antitrust Division or the FTC could take such action under the
antitrust laws as it deems necessary or desirable in the public interest,
including seeking to enjoin the purchase of Shares pursuant to the Offer or the
consummation of the Merger or seeking the divestiture of Shares acquired by
Offeror or the divestiture of substantial assets of Parent or its subsidiaries,
or the Company or its subsidiaries. Private parties may also bring legal action
under the antitrust laws under certain circumstances. There can be no assurance
that a challenge to the Offer on antitrust grounds will not be made or, if such
a challenge is made, of the results thereof.
16. FEES AND EXPENSES.
The Parent has retained Morrow & Co., Inc. to act as the Information Agent
and Norwest Bank Minnesota, N.A. to serve as the Depositary in connection with
the Offer. The Information Agent and the Depositary each will receive reasonable
and customary compensation for their services, be reimbursed for certain
reasonable out-of-pocket expenses and be indemnified against certain liabilities
and expenses in connection therewith, including certain liabilities under the
federal securities laws.
Except as described herein, neither Parent nor Offeror will pay any fees or
commissions to any broker or dealer or other person in connection with the
solicitation of tenders of Shares pursuant to the Offer. Brokers, dealers, banks
and trust companies will be reimbursed by Offeror upon request for customary
mailing and handling expenses incurred by them in forwarding material to their
customers.
17. MISCELLANEOUS.
The Offer is not being made to (nor will tenders be accepted from or on
behalf of) holders of Shares in any jurisdiction in which the making of the
Offer or the acceptance thereof would not be in compliance with the laws of such
jurisdiction. Neither Parent nor Offeror is aware of any jurisdiction in which
the making of the Offer or the tender of Shares in connection therewith would
not be in compliance with the laws of such jurisdiction. If Parent or Offeror
becomes aware of any state law prohibiting the making of the Offer or the
acceptance of Shares pursuant thereto in such state, Offeror will make a good
faith effort to comply with any such state statute or seek to have such state
statute declared inapplicable to the Offer. If, after such good faith effort,
Offeror cannot comply with any such state statute, the Offer will not be made to
(nor will tenders be accepted from or on behalf of) the holders of Shares in
such jurisdiction. In any jurisdiction the securities, blue sky or other laws of
which require the Offer to be made by a licensed broker or dealer, the Offer
will be
36
<PAGE> 39
made on behalf of Offeror by one or more registered brokers or dealers licensed
under the laws of such jurisdiction.
NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
REPRESENTATION ON BEHALF OF PARENT OR OFFEROR NOT CONTAINED HEREIN OR IN THE
LETTER OF TRANSMITTAL AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION
MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED. NEITHER THE DELIVERY OF THIS
OFFER TO PURCHASE NOR ANY PURCHASE PURSUANT TO THE OFFER SHALL, UNDER ANY
CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE
AFFAIRS OF PARENT OR THE COMPANY SINCE THE DATE AS OF WHICH INFORMATION IS
FURNISHED OR THE DATE OF THIS OFFER TO PURCHASE.
Parent and Offeror have filed with the Commission the Schedule 14D-1
pursuant to Rule 14d-3 under the Exchange Act, furnishing certain additional
information with respect to the Offer. In addition, the Company has filed with
the Commission the Schedule 14D-9 pursuant to Rule 14d-9 under the Exchange Act,
setting forth its recommendation with respect to the Offer and the reasons for
such recommendation and furnishing certain additional related information. Such
schedules and any amendments thereto, including exhibits, should be available
for inspection and copies should be obtainable in the manner set forth in
Sections 8 and 9 (except that they will not be available at the regional offices
of the Commission).
MC SUBSIDIARY CORP.
August 6, 1999
37
<PAGE> 40
SCHEDULE I
DIRECTORS AND EXECUTIVE OFFICERS
OF PARENT AND OFFEROR
The names and ages of the directors and executive officers of Parent and of
Offeror, and their present principal occupations or employment and five-year
employment history, are set forth below. Unless otherwise indicated, each
individual is a citizen of the United States, his business address is One Merck
Drive, Whitehouse Station, New Jersey 08889-0100 and he has been employed by
Merck for the last five years.
PARENT
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT WITH
NAME AND AGE MERCK & CO., INC.; MATERIAL POSITIONS HELD DURING THE PAST FIVE YEARS
------------ ---------------------------------------------------------------------
<S> <C>
H. Brewster Atwater, Jr. (67)............. Director since 1998; Retired since 1996; Chairman of the Board and
Chief Executive Officer, General Mills, Inc. (consumer foods and
restaurants) for more than five years; Director, Darden Restaurants,
Inc., IDS Mutual Fund Group, Mayo Foundation, Public Radio
International and Walker Art Center; Member, The Business Council.
Sir Derek Birkin (69)..................... Director since 1992; Retired since 1997; Chairman of the Board, The
RTZ Corporation PLC (international mining company) for more than five
years; Director, Unilever PLC, Carlton Communications PLC and The
Merchants Trust PLC; Sir Derek is a British citizen.
Lawrence A. Bossidy (64).................. Director since 1992; Chairman of the Board and Chief Executive
Officer, AlliedSignal, Inc. (aerospace, automotive products and
engineered materials technology) for more than five years; Director,
Champion International Corporation and J.P. Morgan & Co.
Incorporated; Member, The Business Council and The Business
Roundtable.
William G. Bowen, Ph.D. (65).............. Director since 1986; President, The Andrew W. Mellon Foundation
(philanthropic foundation) for more than five years; Director,
American Express Company; Member, Board of Overseers, Teachers
Insurance and Annuity Association of America -- College Retirement
Equities Fund; Trustee, Denison University.
Johnnetta B. Cole, Ph.D. (62)............. Director since 1994; prior to that since September 1998 --
Presidential Distinguished Professor, Emory University; prior to that
from 1987 to June 1997 -- President, Spelman College; Director,
Coca-Cola Enterprises, The Home Depot, Inc. and Management and
Training Corporation; Trustee, Rockefeller Foundation and Gallaudet
University; Member, Council on Foreign Relations and National Council
of Negro Women; Fellow, American Anthropological Association.
Carolyne K. Davis, Ph.D. (67)............. Director since 1989; International Health Care Consultant for more
than five years; Director, Beckman Coulter, Inc., The Prudential
Insurance Company of America, Inc., Minimed Inc. and Beverly
Enterprises, Inc.; Trustee, University of Pennsylvania Health System;
Member, Institute of Medicine of the National Academy of Sciences.
</TABLE>
I-1
<PAGE> 41
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT WITH
NAME AND AGE MERCK & CO., INC.; MATERIAL POSITIONS HELD DURING THE PAST FIVE YEARS
------------ ---------------------------------------------------------------------
<S> <C>
Lloyd C. Elam, M.D. (70).................. Director since 1973; Professor of Psychiatry, Meharry Medical College
for more than five years; Director, Premark International Inc. and
Tupperware, Inc.; Trustee, Fisk University and The Alfred P. Sloan
Foundation.
Charles E. Exley, Jr. (69)................ Director since 1988; Retired (1991); prior to that from January 1988
to September 1991 -- Chairman of the Board and Chief Executive
Officer, NCR Corporation (business information processing systems);
Trustee, The Andrew W. Mellon Foundation; Member, The Business
Council and Board of Overseers, Columbia University Graduate School
of Business.
Carleton S. Fiorina (44).................. Director since 1999; President and Chief Executive Officer,
Hewlett-Packard Company since July 1999; prior to that Group
President, Global Services Provider Business, Lucent Technologies
Inc. (communications systems and technology) since October 1997;
prior to that from October 1996 to October 1997 -- President, Lucent
Technologies Consumer Products; prior to that from January 1996 to
October 1996 -- Executive Vice President, Corporate Operations,
Lucent Technologies Inc.; prior to that from January 1995 to January
1996 -- President, North America Region of the Network Systems Group,
AT&T; prior to that from July 1994 to January 1995 -- President,
Atlantic and Canada Region of the Network Systems Group, AT&T; prior
to July 1994 -- senior positions with AT&T; Director, Kellogg
Company.
Raymond Gilmartin (57).................... Director since 1994; Chairman of the Board since November 1994,
President and Chief Executive Officer since June 1994. From 1992 to
June 1994, Mr. Gilmartin was Chairman, President and Chief Executive
Officer of Becton Dickinson and Company.
William N. Kelley, M.D. (59).............. Director since 1992; Chief Executive Officer, University of
Pennsylvania Health System and Executive Vice President, Dean of the
School of Medicine and Robert G. Dunlop Professor of Medicine,
Biochemistry and Biophysics, University of Pennsylvania, for more
than five years; Director, Beckman Coulter, Inc., Greater
Philadelphia First and Philadelphia Orchestra Association; Trustee,
Emory University; Fellow, American Academy of Arts and Sciences;
Member, American Philosophical Society, Institute of Medicine of the
National Academy of Sciences, Board of Managers of Wistar Institute;
Chairman, Board of Governors of Leonard Davis Institute of Health
Economics; Master, American College of Physicians.
Edward M. Scolnick, M.D. (58)............. Director since 1997; Executive Vice President, Science and Technology
and President, Merck Research Laboratories for more than five years;
Member, National Academy of Sciences and its Institute of Medicine.
</TABLE>
I-2
<PAGE> 42
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT WITH
NAME AND AGE MERCK & CO., INC.; MATERIAL POSITIONS HELD DURING THE PAST FIVE YEARS
------------ ---------------------------------------------------------------------
<S> <C>
Samuel O. Thier, M.D. (61)................ Director since 1994; President since April 1997 and Chief Executive
Officer since July 1996, Partners HealthCare System, Inc.; prior to
that from May 1994 to April 1997 -- President, Massachusetts General
Hospital; prior to that from October 1991 to May 1994 -- President,
Brandeis University; Director, Fleet Financial Group; Member,
Institute of Medicine of the National Academy of Sciences; Fellow,
American Academy of Arts and Sciences; Trustee, Brandeis University,
Boston Museum of Science, Cornell University, The Commonwealth Fund
and WGBH Public Television; Master, American College of Physicians.
Dennis Weatherstone (68).................. Director since 1988; Retired (1995); Chairman of the Board, J.P.
Morgan & Co. Incorporated and Morgan Guaranty Trust Company of New
York (banking and other financial services) for more than five years;
Director, General Motors Corporation, L'Air Liquide and Institute for
International Economics; Independent Member of the Board of Banking
Supervision of the Financial Services Authority, London; President,
Royal College of Surgeons Foundation; Trustee, The Alfred P. Sloan
Foundation; Member, The Business Council. Mr. Weatherstone is also a
British citizen.
David W. Anstice (50)..................... President, Human Health-The Americas since January 1997 --
responsible for the Company's prescription drug business in the
United States, Canada and Latin America and medical and scientific
affairs; prior to that since September 1994 -- President, Human
Health-U.S./Canada -- responsible for the Company's prescription drug
business in the United States and Canada, worldwide coordination of
marketing policies and medical and scientific affairs; prior to that
since January 1994 -- President, Human Health Europe. Mr. Anstice is
an Australian citizen.
Paul R. Bell (53)......................... President, Human Health-Asia Pacific since April 1997 -- responsible
for the Company's prescription drug business in the Far East,
Australia, New Zealand and Japan; prior to that since March
1994 -- Vice President and Managing Director-Australia and New
Zealand.
Celia A. Colbert (42)..................... Vice President, Secretary and Assistant General Counsel since January
1997; prior to that since November 1993 -- Secretary and Assistant
General Counsel.
Linda M. Distlerath (45).................. Vice President, Public Affairs since January 1999 -- responsible for
public affairs and The Merck Company Foundation (a not-for-profit
charitable organization affiliated with the Company); prior to that
since October 1997 -- Executive Director, Public Policy and Merck
Research Laboratories (MRL) Public Affairs; prior to that since April
1995 -- Executive Director, MRL Public Affairs; prior to that since
October 1990 -- Senior Director, Science & Technology
Policy -- responsible for public policy strategies in support of the
Company's research and development programs.
</TABLE>
I-3
<PAGE> 43
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT WITH
NAME AND AGE MERCK & CO., INC.; MATERIAL POSITIONS HELD DURING THE PAST FIVE YEARS
------------ ---------------------------------------------------------------------
<S> <C>
Caroline Dorsa (39)....................... Vice President and Treasurer since February 1999 -- responsible for
the Company's treasury and tax functions; prior to that since January
1997 -- Vice President and Treasurer; prior to that since January
1994 -- Treasurer.
Kenneth C. Frazier (44)................... Vice President and Deputy General Counsel since January 1999; prior
to that since January 1997 -- Vice President, Public Affairs and
Assistant General Counsel -- responsible for public affairs,
corporate legal activities and The Merck Company Foundation (a
not-for-profit charitable organization affiliated with the Company);
prior to that since April 1994 -- Vice President, Public Affairs;
prior to that since May, 1992 -- Vice President, General Counsel and
Secretary, Astra/Merck Group (a joint venture affiliated with the
Company).
Richard C. Henriques Jr. (43)............. Vice President, Controller since February 1999 -- responsible for the
Corporate Controller's Group and providing financial support for U.S.
Human Health, Canada and Latin America (The Americas); prior to that
since January 1998 -- Vice President & Controller, The Americas;
prior to that since January 1997 -- Controller, The Americas; prior
to that since January 1994 -- Controller, North America
Pharmaceutical Care.
Bernard J. Kelley (57).................... President, Merck Manufacturing Division since December 1993.
Judy C. Lewent (50)....................... Senior Vice President and Chief Financial Officer since January
1997 -- responsible for financial and corporate development
functions, internal auditing and the Company's joint venture
relationships; prior to that since September 1994 -- Senior Vice
President and Chief Financial Officer -- responsible for financial
and public affairs functions, The Merck Company Foundation (a
not-for-profit charitable organization affiliated with the Company),
internal auditing and the Company's joint venture relationships;
prior to that since December 1993 -- Senior Vice President and Chief
Financial Officer (since January 1993) -- responsible for financial
and public affairs functions and The Merck Company Foundation.
Per G. H. Lofberg (51).................... President, Merck-Medco Managed Care, L.L.C., a wholly-owned
subsidiary of the Company since December 1995; prior to that since
January 1994 -- President, Merck-Medco Managed Care Division. Mr.
Lofberg is a Swedish citizen.
Adel Mahmoud (57)......................... President, Merck Vaccines since April 1999; prior to that since
October 1998 -- Executive Vice President, Merck Vaccines; prior to
that since 1987 -- John H. Hord Professor and Chairman, Department of
Medicine and Physician-in-Chief, Case Western Reserve University and
University Hospitals of Cleveland.
Mary M. McDonald (54)..................... Senior Vice President and General Counsel since January
1999 -- responsible for legal and public affairs functions and The
Merck Company Foundation (a not-for-profit charitable organization
affiliated with the Company); prior to that since January,
1993 -- Senior Vice President and General Counsel.
</TABLE>
I-4
<PAGE> 44
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT WITH
NAME AND AGE MERCK & CO., INC.; MATERIAL POSITIONS HELD DURING THE PAST FIVE YEARS
------------ ---------------------------------------------------------------------
<S> <C>
Roger M. Perlmutter (46).................. Executive Vice President, Worldwide Basic Research and Preclinical
Development, Merck Research Laboratories since July 1999; prior to
that since February 1999 -- Executive Vice President, Merck Research
Laboratories; prior to that since February 1997 -- Senior Vice
President, Merck Research Laboratories; prior to that since May
1989 -- Chairman, Department of Immunology, University of Washington.
Per Wold-Olsen (51)....................... President, Human Health-Europe, Middle East & Africa since January
1997 -- responsible for the Company's prescription drug business in
Europe, the Middle East and Africa and worldwide coordination of
marketing policies; prior to that since September, 1994 -- President,
Human Health-Europe -- responsible for the Company's European
prescription drug business; prior to that since January
1994 -- Senior Vice President, Worldwide Human Health Marketing. Mr.
Wold-Olson is a Norwegian citizen.
Wendy L. Yarno (45)....................... Vice President, Human Resources since June, 1999; prior to that since
January 1999 -- Vice President Worldwide Human Health Marketing;
prior to that since November 1997 -- Vice President, Women's Health
Care, Johnson & Johnson, Ortho-McNeil Pharmaceutical; prior to that
since January 1995 -- Vice President, Hypertension and Heart Failure
Therapeutic Business Group, U.S. Human Health, Merck & Co., Inc.;
prior to that senior positions with the U.S. Human Health division of
Merck.
</TABLE>
OFFEROR
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT WITH
NAME AND AGE MC SUBSIDIARY CORP.; MATERIAL POSITIONS HELD DURING THE PAST FIVE YEARS
- ------------ -----------------------------------------------------------------------
<S> <C>
George A. Dunston (30).................... Sole Director, Vice President and Assistant Secretary of the Offeror
since July 1999; Senior Attorney, Merck & Co., Inc. since 1998; prior
to that since June 1996 an associate of the New York law firm of
Brobeck, Pheleger & Harrison; prior to that since September 1994 an
associate of the New York law firm of Brown & Wood.
Judy C. Lewent (50)....................... President of the Offeror since July 1999. See description above.
Richard N. Kender (43).................... Vice President of the Offeror since July 1999. Vice President,
Financial Evaluation and Analysis and Business Development, Merck &
Co., Inc. since February 1999; prior to that since 1996 Vice President,
Corporate Development; prior to that since 1994 Executive Director,
Corporate Development.
Jon Filderman (41)........................ Vice President and Assistant Secretary of the Offeror since July 1999.
Assistant Counsel to Merck & Co., Inc. since 1995. Prior to 1995, an
associate of the New York law firm of Fried, Frank, Harris, Shriver &
Jacobson.
Celia A. Colbert (42)..................... Secretary of the Offeror since July 1999. See description above.
</TABLE>
I-5
<PAGE> 45
MANUALLY SIGNED FACSIMILE COPIES OF THE LETTER OF TRANSMITTAL WILL BE ACCEPTED.
THE LETTER OF TRANSMITTAL AND CERTIFICATES FOR SHARES AND ANY OTHER REQUIRED
DOCUMENTS SHOULD BE SENT OR DELIVERED BY EACH STOCKHOLDER OF THE COMPANY OR HIS
BROKER, DEALER, COMMERCIAL BANK, TRUST COMPANY OR OTHER NOMINEE TO THE
DEPOSITARY AT ONE OF THE ADDRESSES SET FORTH BELOW:
THE DEPOSITARY FOR THE OFFER IS:
NORWEST BANK MINNESOTA, N.A.
<TABLE>
<S> <C> <C>
BY MAIL: BY HAND IN NEW YORK: BY HAND/OVERNIGHT COURIER:
Norwest Bank Minnesota, N.A. The Depository Trust Company Norwest Bank Minnesota, N.A.
Shareowner Services Transfer Agent Drop Shareowner Services
Reorganization Department 55 Water Street -- 1st Floor 161 North Concord Exchange
P.O. Box 64858 New York, NY 10041-0099 South St. Paul, MN 55075
St. Paul, MN 55164-0858
FACSIMILE COPY NUMBER:
(651) 450-4163
</TABLE>
Any questions or requests for assistance or additional copies of the Offer to
Purchase and the Letter of Transmittal and Notice of Guaranteed Delivery may be
directed to the Information Agent at its telephone number and location listed
below. Stockholders may also contact their broker, dealer, commercial bank,
trust company or other nominee for assistance concerning the Offer.
THE INFORMATION AGENT FOR THE OFFER IS:
MORROW & CO., INC.
445 Park Avenue, 5th Floor
New York, New York 10022
Banks and Brokerage Firms Call:
(800) 662-5200
(212) 754-8000
Stockholders Please Call:
(800) 566-9061
<PAGE> 1
EXHIBIT (a)(2)
LETTER OF TRANSMITTAL
TO TENDER SHARES OF COMMON STOCK
(INCLUDING THE ASSOCIATED RIGHTS)
OF
SIBIA NEUROSCIENCES, INC.
PURSUANT TO THE OFFER TO PURCHASE
DATED AUGUST 6, 1999
BY
MC SUBSIDIARY CORP.,
A DIRECT WHOLLY-OWNED SUBSIDIARY OF
MERCK & CO., INC.
THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY
TIME, ON THURSDAY, SEPTEMBER 2, 1999, UNLESS THE OFFER IS EXTENDED.
The Depositary is:
NORWEST BANK MINNESOTA, N.A.
<TABLE>
<S> <C> <C>
By Mail: By Hand in New York: By Hand/Overnight Courier:
Norwest Bank Minnesota, N.A. The Depository Trust Company Norwest Bank Minnesota, N.A.
Shareowner Services Transfer Agent Drop Shareowner Services
Reorganization Department 55 Water Street - 1st Floor 161 North Concord Exchange
P.O. Box 64858 New York, NY 10041-0099 South St. Paul, MN 55075
St. Paul, MN 55164-0858
By Facsimile Transmission:
(651) 450-4163
To Confirm Receipt of Notice of Guaranteed Delivery:
(651) 450-4110
</TABLE>
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------------------------------
DESCRIPTION OF SHARES TENDERED
- -------------------------------------------------------------------------------------------------------------------------
NAME(S) AND ADDRESS(ES) OF REGISTERED HOLDER(S)
CERTIFICATE(S) ENCLOSED (PLEASE FILL IN, IF BLANK, EXACTLY AS NAME(S)
(ATTACH ADDITIONAL SIGNED LIST, IF NECESSARY) APPEAR(S) ON THE CERTIFICATE(S)
- -------------------------------------------------------------------------------------------------------------------------
TOTAL NUMBER
OF SHARES NUMBER
CERTIFICATE REPRESENTED BY OF SHARES
NUMBER(S)* CERTIFICATE(S)* TENDERED**
<C> <C> <C> <S>
- ------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------
Total Number of
Shares
- -------------------------------------------------------------------------------------------------------------------------
* Need not be completed by stockholders delivering Shares by book-entry transfer through the Depositary.
** Unless otherwise indicated, it will be assumed that all Shares represented by any certificates delivered to the
Depositary are being tendered. See Instruction 4.
[ ] CHECK HERE IF CERTIFICATES HAVE BEEN LOST OR MUTILATED. SEE INSTRUCTION 12.
- -------------------------------------------------------------------------------------------------------------------------
</TABLE>
<TABLE>
<S> <C> <C> <C> <C>
FOR OFFICE USE ONLY
DEBIT SHARES PARTIAL SBL/LT ALT PAYEE SPEC. DEL
APPROVED IMPUT AUDIT MAILED
</TABLE>
<PAGE> 2
------------------------------------------------------------
SPECIAL PAYMENT INSTRUCTIONS
(SEE INSTRUCTIONS 1, 5, 6 AND 7)
To be completed ONLY if the check for the purchase price of Shares
accepted for payment and/or Certificates for Shares not tendered or not
accepted for payment are to be issued in the name of someone other than
the undersigned.
Mail check and/or certificate(s) to:
Name
----------------------------------------------------
(PLEASE TYPE OR PRINT)
Address
---------------------------------------------------
------------------------------------------------------------
(INCLUDE A ZIP CODE)
------------------------------------------------------------
(RECIPIENT'S TAXPAYER IDENTIFICATION OR SOCIAL SECURITY
NUMBER)
(ALSO COMPLETE SUBSTITUTE FORM W-9 BELOW)
------------------------------------------------------------
------------------------------------------------------------
SPECIAL DELIVERY INSTRUCTIONS
(SEE INSTRUCTIONS 1, 5, 6 AND 7)
To be completed ONLY if the check for the purchase price of Shares
accepted for payment and/or Certificates for Shares not tendered or not
accepted for payment are to be mailed to someone other than the
undersigned or to the undersigned at an address other than that shown
above.
Mail check and/or certificate(s) to:
Name
-----------------------------------------------------
(PLEASE TYPE OR PRINT)
Address
---------------------------------------------------
------------------------------------------------------------
(INCLUDE A ZIP CODE)
------------------------------------------------------------
(RECIPIENT'S TAXPAYER IDENTIFICATION OR SOCIAL SECURITY
NUMBER)
(ALSO COMPLETE SUBSTITUTE FORM W-9 BELOW)
------------------------------------------------------------
2
<PAGE> 3
IMPORTANT:
STOCKHOLDER: SIGN HERE
(PLEASE COMPLETE SUBSTITUTE FORM W-9 BELOW)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SIGNATURE(S) OF STOCKHOLDER(S)
Dated:
- --------------------------- , 1999
(Must be signed by registered holder(s) exactly as name(s) appear(s) on
Certificate(s) or on a security position listing or by the person(s) authorized
to become registered holder(s) by Certificates and documents transmitted
herewith. If signature is by a trustee, executor, administrator, guardian,
attorney-in-fact, agent, officer of a corporation or other person acting in a
fiduciary or representative capacity, please set forth full title and see
Instruction 5).
Name(s):
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
(PLEASE TYPE OR PRINT)
Capacity (full title):
- --------------------------------------------------------------------------------
Address:
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
(INCLUDE A ZIP CODE)
Area Code and Telephone Number:
- --------------------------------------------------------------------------------
(HOME)
- --------------------------------------------------------------------------------
(BUSINESS)
Taxpayer Identification Number or Social Security Number:
- -------------------------------------------------------
(COMPLETE SUBSTITUTE FORM W-9 BELOW)
GUARANTEE OF SIGNATURE(S)
(SEE INSTRUCTIONS 1 AND 5)
FOR USE BY FINANCIAL INSTITUTIONS ONLY, PLACE MEDALLION GUARANTEE IN SPACE
BELOW.
Authorized Signature(s):
- --------------------------------------------------------------------------------
Name:
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
(PLEASE TYPE OR PRINT)
Title:
- --------------------------------------------------------------------------------
Name of Firm:
- --------------------------------------------------------------------------------
Address:
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
(INCLUDE A ZIP CODE)
Area Code and Telephone Number:
- --------------------------------------------------------------------------------
Dated:
- --------------------------- , 1999
3
<PAGE> 4
TO BE COMPLETED BY ALL TENDERING SHAREHOLDERS OF SECURITIES
(SEE INSTRUCTION 8)
<TABLE>
<S> <C> <C>
- ------------------------------------------------------------------------------------------------------------------------
PAYER'S NAME: NORWEST BANK MINNESOTA, N.A.
- ------------------------------------------------------------------------------------------------------------------------
SUBSTITUTE PART 1--PLEASE PROVIDE YOUR TIN IN THE BOX AT THE RIGHT
FORM W-9 AND CERTIFY BY SIGNING AND DATING BELOW. TIN: -----------------------
Social Security Number
or Taxpayer
Identification Number
-------------------------------------------------------------------------------------------
Department of the
Treasury, Internal PART 2-- FOR PAYEES EXEMPT FROM BACKUP WITHHOLDING
Revenue Service (See Instructions).
PAYOR'S REQUEST FOR -----------------------------------------------------------------------------------------
TAXPAYER IDENTIFICATION PART 3--CERTIFICATION--UNDER PENALTIES OF PERJURY, I CERTIFY THAT:
NUMBER ("TIN") AND
CERTIFICATION (1) The number shown on this form is my correct TIN (or I am waiting for a number
to be issued to me); and
(2) I am not subject to backup withholding because (a) I am exempt from backup
withholding, or (b) I have not been notified by the Internal Revenue Service ("IRS")
that I am subject to backup withholding as a result of a failure to report all interest
or dividends, or (c) the IRS has notified me that I am no longer subject to backup
withholding.
-----------------------------------------------------------------------------------------
SIGNATURE: ________________________________________ DATE: ________________
- ------------------------------------------------------------------------------------------------------------------------
</TABLE>
CERTIFICATION INSTRUCTIONS -- You must cross out item (2) above if you have been
notified by the IRS that you are subject to backup withholding because of
underreporting interest or dividends on your tax return. However, if after being
notified by the IRS that you were subject to backup withholding, you received
another notification from the IRS that you were no longer subject to backup
withholding, do not cross out item (2).
NOTE: FAILURE TO COMPLETE AND RETURN THIS SUBSTITUTE FORM W-9 MAY RESULT IN
BACKUP WITHHOLDING OF 31% OF ANY PAYMENTS MADE TO YOU PURSUANT TO THE
OFFER. PLEASE REVIEW THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER
IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9 FOR ADDITIONAL DETAILS.
YOU MUST COMPLETE THE FOLLOWING CERTIFICATE IF YOU WROTE "APPLIED FOR" IN PART 1
OF THE SUBSTITUTE FORM W-9.
<TABLE>
<S> <C>
- --------------------------------------------------------------------------------------------------
CERTIFICATE OF AWAITING TAXPAYER IDENTIFICATION NUMBER
I certify under penalties of perjury that a TIN has not been issued to me, and either (1) I have
mailed or delivered an application to receive a TIN to the appropriate IRS Center or Social
Security Administration Office or (2) I intend to mail or deliver an application in the near
future. I understand that if I do not provide a TIN by the time of payment to the payor, 31% of
all reportable payments pursuant to the Offer made to me will be withheld, but that such amounts
will be refunded to me if I then provide a TIN within 60 days.
Signature: ______________________________________________________ Date: ---------------------
- --------------------------------------------------------------------------------------------------
</TABLE>
NOTE: FAILURE TO COMPLETE AND RETURN THIS FORM MAY RESULT IN BACKUP WITHHOLDING
OF 31% OF ANY PAYMENTS MADE TO YOU PURSUANT TO THE OFFER. PLEASE REVIEW
THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION
NUMBER ON SUBSTITUTE FORM W-9 FOR INSTRUCTIONS.
4
<PAGE> 5
DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET
FORTH ABOVE OR TRANSMISSION OF INSTRUCTIONS VIA A FACSIMILE TRANSMISSION TO A
NUMBER OTHER THAN AS SET FORTH ABOVE WILL NOT CONSTITUTE A VALID DELIVERY TO THE
DEPOSITARY. YOU MUST SIGN THIS LETTER OF TRANSMITTAL IN THE APPROPRIATE SPACE
PROVIDED BELOW AND COMPLETE THE SUBSTITUTE FORM W-9 SET FORTH BELOW.
THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ
CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED.
This Letter of Transmittal is to be completed by stockholders of SIBIA
Neurosciences, Inc. if either certificates evidencing Shares ("Certificates")
are to be forwarded with this Letter of Transmittal or, unless an Agent's
Message (as defined in the Offer to Purchase) is utilized, if delivery of Shares
(as defined below) is to be made by book-entry transfer to an account maintained
by Norwest Bank Minnesota, N.A. at The Depository Trust Company (the "Book-Entry
Transfer Facility") pursuant to the procedures set forth in Section 3 of the
Offer to Purchase. DELIVERY OF DOCUMENTS TO A BOOK-ENTRY TRANSFER FACILITY DOES
NOT CONSTITUTE DELIVERY TO THE DEPOSITARY.
Stockholders whose Certificates are not immediately available or who cannot
deliver their Certificates and all other required documents to the Depositary
prior to the Expiration Date (as defined in Section 1 of the Offer to Purchase),
or who cannot complete the procedures for book-entry transfer on a timely basis,
must tender their Shares according to the guaranteed delivery procedures set
forth in Section 3 of the Offer to Purchase. See Instruction 2.
[ ] CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER
MADE TO AN ACCOUNT MAINTAINED BY THE DEPOSITARY WITH THE BOOK-ENTRY
TRANSFER FACILITY AND COMPLETE THE FOLLOWING (ONLY PARTICIPANTS IN THE
BOOK-ENTRY TRANSFER FACILITY MAY DELIVER SHARES BY BOOK-ENTRY TRANSFER):
Name of Tendering Institution:
Account Number:
Transaction Code Number:
[ ] CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED PURSUANT TO A NOTICE OF
GUARANTEED DELIVERY PREVIOUSLY SENT TO THE DEPOSITARY AND COMPLETE THE
FOLLOWING. PLEASE ENCLOSE A PHOTOCOPY OF SUCH NOTICE OF GUARANTEED
DELIVERY.
Name(s) of Registered Stockholder(s):
Window Ticket Number (if any):
Date of Execution of Notice of Guaranteed Delivery:
Name of Institution which Guaranteed Delivery:
NOTE: SIGNATURES MUST BE PROVIDED BELOW.
PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY.
5
<PAGE> 6
Ladies and Gentlemen:
The undersigned hereby tenders to MC Subsidiary Corp. ("Offeror"), a
Delaware corporation and a direct, wholly owned subsidiary of Merck & Co., Inc.,
a New Jersey corporation ("Parent"), the above-described shares of Common Stock,
par value $.001 per share (the "Common Stock"), including the associated
preferred stock purchase rights issued pursuant to the Rights Agreement, dated
March 17, 1997, and amended as of July 30, 1999, between the Company and
ChaseMellon Shareholder Services, L.L.C., as Rights Agent (the "Rights" and,
together with the Common Stock, the "Shares") of SIBIA Neurosciences, Inc., a
Delaware corporation (the "Company"), pursuant to Offeror's offer to purchase
all of the outstanding Shares at a purchase price of $8.50 per Share, net to the
seller in cash, without interest thereon, upon the terms and subject to the
conditions set forth in the Offer to Purchase, dated August 6, 1999 (the "Offer
to Purchase"), receipt of which is hereby acknowledged, and in this Letter of
Transmittal (which, as amended from time to time, together with the Offer to
Purchase collectively constitute the "Offer"). The Offer is being made pursuant
to an Agreement and Plan of Merger, dated as of July 30, 1999 (the "Merger
Agreement"), among Parent, Offeror and the Company. The undersigned understands
that Offeror reserves the right to transfer or assign, in whole or from time to
time in part, to one or more direct or indirect wholly owned subsidiaries of
Parent, the right to purchase all or any portion of the Shares tendered pursuant
to the Offer, but any such transfer or assignment will not relieve Offeror of
its obligations under the Offer or prejudice the rights of the tendering
stockholders to receive payment for Shares validly tendered and accepted for
payment pursuant to the Offer.
Subject to, and effective upon, acceptance for payment of, or payment for,
the Shares tendered herewith, the undersigned hereby sells, assigns and
transfers to, or upon the order of, Offeror all right, title and interest in and
to all the Shares that are being tendered hereby (and any and all other shares
or other securities issued or issuable in respect of such Shares on or after the
date of the Offer to Purchase) and appoints Norwest Bank Minnesota, N.A. (the
"Depositary") the true and lawful agent and attorney-in-fact of the undersigned
with respect to such Shares (and such other shares or securities), with full
power of substitution (such power of attorney being deemed to be an irrevocable
power coupled with an interest), to (a) deliver certificates for such Shares
(and such other shares or securities), or transfer ownership of such Shares (and
such other Shares or securities) on the account books maintained by the
Book-Entry Transfer Facility, together, in any such case, with all accompanying
evidences of transfer and authenticity, to or upon the order of the Offeror, (b)
present such Shares (and such other shares or securities) for transfer on the
books of the Company and (c) receive all benefits and otherwise exercise all
rights of beneficial ownership of such Shares (and such other shares or
securities), all in accordance with the terms and subject to the conditions of
the Offer.
The undersigned hereby irrevocably appoints each designee of Offeror as the
attorney-in-fact and proxy of the undersigned, each with full power of
substitution, to the full extent of the rights of the undersigned with respect
to the Shares tendered herewith and accepted for payment by Offeror prior to the
time of any vote or other action (and any and all other shares or other
securities issued or issuable in respect of such Shares on or after the date of
the Offer to Purchase). All such powers of attorney and proxies shall be
considered irrevocable and coupled with an interest. Such appointment will be
effective when, and only to the extent that, Offeror accepts such Shares for
payment. Upon such acceptance for payment, all prior powers of attorney and
proxies given by the stockholder with respect to such Shares (and such other
shares and securities) will, without further action, be revoked and no
subsequent powers of attorney and proxies may be given nor any subsequent
written consents executed (and, if given or executed, will not be deemed
effective). The designees of Offeror will, with respect to the Shares (and such
other shares and securities) for which such appointment is effective, be
empowered to exercise all voting and other rights of such stockholder as they in
their sole discretion may deem proper at any annual or special meeting of the
Company's stockholders, or any adjournment or postponement thereof by written
consent in lieu of any such meeting or otherwise. Offeror reserves the right to
require that, in order for Shares to be deemed validly tendered, immediately
upon Offeror's payment for such Shares, Offeror must be able to exercise full
voting and other rights with respect to such Shares (and such other shares and
securities), including voting at any meeting of stockholders then scheduled.
The undersigned hereby represents and warrants that the undersigned has
full power and authority to tender, sell, assign and transfer the Shares
tendered hereby (and any and all other shares or other securities issued or
issuable in respect of such Shares on or after the date of the Offer to
Purchase) and that when the same are accepted for payment by Offeror, Offeror
will acquire good and unencumbered title thereto, free and clear of all liens,
restrictions, charges and encumbrances and not subject to any adverse claim. The
undersigned, upon request, will execute and deliver any
6
<PAGE> 7
additional documents deemed by the Depositary or Offeror to be necessary or
desirable to complete the sale, assignment and transfer of the Shares tendered
hereby (and such other shares or securities).
All authority herein conferred or agreed to be conferred shall survive the
death or incapacity of the undersigned, and any obligation of the undersigned
hereunder shall be binding upon the heirs, personal representatives, successors
and assigns of the undersigned. Except as stated in the Offer, this tender is
irrevocable.
The undersigned understands that tenders of Shares pursuant to any one of
the procedures described in Section 3 of the Offer to Purchase and in the
instructions hereto will constitute a binding agreement between the undersigned
and Offeror upon the terms and subject to the conditions of the Offer.
The undersigned recognizes that, under certain circumstances set forth in
the Offer To Purchase, the Offeror may not be required to accept for payment any
of the Shares tendered hereby.
Unless otherwise indicated in this Letter of Transmittal under "Special
Payment Instructions," please issue the check for the purchase price and return
any Shares not tendered or not purchased in the name(s) of the undersigned.
Similarly, unless otherwise indicated under "Special Delivery Instructions,"
please mail the check for the purchase price and return any Certificates not
tendered or not purchased (and accompanying documents, as appropriate) to the
undersigned at the address shown below the undersigned's signature(s). In the
event that both "Special Payment Instructions" and "Special Delivery
Instructions" are completed, please issue the check for the purchase price and
return any Shares not tendered or not purchased in the name(s) of, and mail such
check and any certificates to, the person(s) so indicated. Unless otherwise
indicated under "Special Payment Instructions," in the case of book-entry
delivery of Shares, please credit the account maintained at the Book-Entry
Transfer Facility with respect to any Shares not accepted for payment. The
undersigned recognizes that Offeror has no obligation, pursuant to the "Special
Payment Instructions," to transfer any Shares from the name of the registered
holder(s) thereof if Offeror does not accept for payment any of the Shares so
tendered.
7
<PAGE> 8
INSTRUCTIONS
FORMING PART OF THE TERMS AND CONDITIONS OF THE OFFER
1. GUARANTEE OF SIGNATURES. Except as otherwise provided below,
signatures on Letters of Transmittal must be guaranteed by a member in good
standing of the Securities Transfer Agents Medallion Program, or by any other
firm which is a bank, broker, dealer, credit union or savings association (each
of the foregoing being referred to as an "Eligible Institution" and,
collectively, as "Eligible Institutions"), except in cases where Shares are
tendered (i) by a registered holder of Shares who has not completed either the
box labeled "Special Delivery Instructions" or the box labeled "Special Payment
Instructions" on the Letter of Transmittal or (ii) for the account of any
Eligible Institution. See Instruction 5. If the Certificates are registered in
the name of a person other than the signer of this Letter of Transmittal, or if
payment is to be made, or Certificates not accepted for payment or not tendered
are to be returned, to a person other than the registered holder, then the
Certificates must be endorsed or accompanied by duly executed stock powers, in
either case, signed exactly as the name of the registered holder appears on such
Certificates, with the signatures on such Certificates or stock powers
guaranteed by an Eligible Institution as provided herein. See Instruction 5.
2. REQUIREMENTS OF TENDER. This Letter of Transmittal is to be used if
either Certificates are to be forwarded herewith or, unless an Agent's Message
is utilized, if the delivery of Shares is to be made by book-entry transfer
pursuant to the procedures set forth in Section 3 of the Offer to Purchase.
Certificates for all physically delivered Shares, or a confirmation of a
book-entry transfer into the Depositary's account at one of the Book-Entry
Transfer Facilities of all Shares delivered electronically, as well as a
properly completed and duly executed Letter of Transmittal (or a manually signed
facsimile thereof) and any other documents required by this Letter of
Transmittal or an Agent's Message in the case of a book-entry delivery, must be
received by the Depositary at one of its addresses set forth on the front page
of this Letter of Transmittal by the Expiration Date. Stockholders who cannot
deliver their Shares and all other required documents to the Depositary by the
Expiration Date must tender their Shares pursuant to the guaranteed delivery
procedures set forth in Section 3 of the Offer to Purchase. Pursuant to such
procedures: (a) such tender must be made by or through an Eligible Institution;
(b) a properly completed and duly executed Notice of Guaranteed Delivery,
substantially in the form provided by Offeror, must be received by the
Depositary prior to the Expiration Date; and (c) the Certificates for all
tendered Shares, in proper form for transfer (or a Book-Entry Confirmation),
together with a properly completed and duly executed Letter of Transmittal (or a
manually signed facsimile thereof), and any required signature guarantees, or,
in the case of a book-entry transfer, an Agent's Message, and any other
documents required by this Letter of Transmittal must be received by the
Depositary within three trading days after the date of such Notice of Guaranteed
Delivery, all as provided in Section 3 of the Offer to Purchase. The term
"trading day" is any day on which the NASDAQ National Market is open for
business.
THE METHOD OF DELIVERY OF SHARES, THE LETTER OF TRANSMITTAL AND ALL OTHER
REQUIRED DOCUMENTS, INCLUDING DELIVERY THROUGH A BOOK-ENTRY TRANSFER FACILITY,
IS AT THE OPTION AND RISK OF THE TENDERING STOCKHOLDER. IF DELIVERY IS BY MAIL,
REGISTERED MAIL WITH RETURN RECEIPT REQUESTED, PROPERLY INSURED, IS RECOMMENDED.
No alternative, conditional or contingent tenders will be accepted, and no
fractional Shares will be purchased. By executing this Letter of Transmittal (or
a manually signed facsimile thereof), the tendering stockholder waives any right
to receive any notice of the acceptance for payment of the Shares.
3. INADEQUATE SPACE. If the space provided in this Letter of Transmittal
is inadequate, the information required under "Description of Shares Tendered"
should be listed on a separate schedule attached hereto.
4. PARTIAL TENDERS (NOT APPLICABLE TO STOCKHOLDERS WHO TENDER BY
BOOK-ENTRY TRANSFER). If fewer than all the Shares represented by any
Certificate delivered to the Depositary are to be tendered, fill in the number
of Shares which are to be tendered in the box entitled "Number of Shares
Tendered." In such case, a new Certificate for the remainder of the Shares
represented by the old Certificate(s) will be sent to the person(s) signing this
Letter of Transmittal unless otherwise provided in the appropriate box on this
Letter of Transmittal, as promptly as practicable after the Expiration Date. All
Shares represented by Certificate(s) delivered to the Depositary will be deemed
to have been tendered unless otherwise indicated.
5. SIGNATURES ON LETTER OF TRANSMITTAL; INSTRUMENTS OF TRANSFER AND
ENDORSEMENTS. If this Letter of Transmittal is signed by the registered
holder(s) of the Shares tendered hereby, the signature(s) must correspond with
the name(s) as written on the face of the Certificates without alteration,
enlargement or any change whatsoever.
8
<PAGE> 9
If any of the Shares tendered hereby are held of record by two or more
persons, all such persons must sign this Letter of Transmittal.
If any of the Shares tendered hereby are registered in different names on
different Certificates, it will be necessary to complete, sign and submit as
many separate Letters of Transmittal as there are different registrations of
Certificates.
If this Letter of Transmittal is signed by the registered holder(s) of the
Shares tendered hereby, no endorsements of Certificates or separate stock powers
are required unless payment of the purchase price is to be made, or Shares not
tendered or not purchased are to be returned, in the name of any person other
than the registered holder(s), in which case, the Certificate(s) for such Shares
tendered hereby must be endorsed, or accompanied by appropriate stock powers, in
either case, signed exactly as the name(s) of the registered holder(s)
appears(s) on the Certificate(s) for such Shares. Signatures on any such
Certificates or stock powers must be guaranteed by an Eligible Institution.
If this Letter of Transmittal is signed by a person other than the
registered holder(s) of the Shares tendered hereby, the Certificate must be
endorsed or accompanied by appropriate stock powers, in either case, signed
exactly as the name(s) of the registered holder(s) appear(s) on the Certificates
for such Shares. Signature(s) on any such Certificates or stock powers must be
guaranteed by an Eligible Institution.
If this Letter of Transmittal or any Certificate or stock power is signed
by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a
corporation or other person acting in a fiduciary or representative capacity,
such person should so indicate when signing, and proper evidence satisfactory to
the Offeror of the authority of such person so to act must be submitted.
6. STOCK TRANSFER TAXES. Except as set forth in this Instruction 6,
Offeror will pay any stock transfer taxes with respect to the sale and transfer
of any Shares to it or its order pursuant to the Offer. If, however, payment of
the purchase price is to be made to, or Shares not tendered or not purchased are
to be returned in the name of, any person other than the registered holder(s),
then the amount of any stock transfer taxes (whether imposed on the registered
holder(s), such other person or otherwise) payable on account of the transfer to
such person will be deducted from the purchase price unless satisfactory
evidence of the payment of such taxes, or exemption therefrom, is submitted.
EXCEPT AS PROVIDED IN THIS INSTRUCTION 6, IT WILL NOT BE NECESSARY FOR
TRANSFER TAX STAMPS TO BE AFFIXED TO THE CERTIFICATES LISTED IN THIS LETTER OF
TRANSMITTAL.
7. SPECIAL PAYMENT AND DELIVERY INSTRUCTIONS. If the check for the
purchase price of any Shares purchased is to be issued, or any Shares not
tendered or not purchased are to be returned, in the name of a person other than
the person(s) signing this Letter of Transmittal or if the check or any
Certificates not tendered or not purchased are to be mailed to someone other
than the person(s) signing this Letter of Transmittal or to the person(s)
signing this Letter of Transmittal at an address other than that shown above,
the appropriate boxes on this Letter of Transmittal should be completed.
8. SUBSTITUTE FORM W-9. Each tendering stockholder is required to provide
the Depositary with a correct Taxpayer Identification Number ("TIN") on
Substitute Form W-9, which is provided under "Important Tax Information" below
and to certify that the stockholder is not subject to backup withholding.
Failure to provide the information on the Substitute Form W-9 may subject the
tendering stockholder to a penalty and 31% federal income tax backup withholding
on the payment of the purchase price for the Shares. If the tendering
stockholder has not been issued a TIN and has applied for a TIN or intends to
apply for a TIN in the near future, the tendering stockholder should follow the
instructions set forth in Part 3 of the Substitute Form W-9 and sign and date
both the Substitute Form W-9 and the "Certificate of Awaiting Taxpayer
Identification Number." If the stockholder has indicated in Part 3 that a TIN
has been applied for and the Depositary is not provided with a TIN by the time
of payment, the Depositary will withhold 31% of all payments of the purchase
price, if any, made thereafter pursuant to the Offer. Such amounts, however,
will be refunded if a TIN is provided to the Depositary within 60 days.
9. FOREIGN HOLDERS. Foreign holders must submit a completed IRS Form W-8
to avoid 31% backup withholding. IRS Form W-8 may be obtained by contacting the
Depositary at one of the addresses on the face of this Letter of Transmittal.
10. REQUESTS FOR ASSISTANCE OR ADDITIONAL COPIES. Requests for assistance
or additional copies of the Offer to Purchase and this Letter of Transmittal may
be obtained from the Information Agent at the address or telephone number set
forth below.
9
<PAGE> 10
11. WAIVER OF CONDITIONS. The conditions of the Offer may be waived by
Offeror (subject to certain limitations in the Merger Agreement), in whole or in
part, at any time or from time to time, in Offeror's reasonable discretion.
12. LOST OR DESTROYED CERTIFICATES. If any Certificate(s) representing
Shares has been lost or destroyed, the holders should promptly notify the
Depositary, Norwest Bank Minnesota, N.A., at (800) 468-9716. The holders will
then be instructed as to the procedure to be followed in order to replace the
Certificate(s). This Letter of Transmittal and related documents cannot be
processed until the procedures for replacing lost or destroyed Certificates have
been followed.
IMPORTANT: THIS LETTER OF TRANSMITTAL OR A MANUALLY SIGNED FACSIMILE COPY
HEREOF (TOGETHER WITH CERTIFICATES OR CONFIRMATION OF BOOK-ENTRY TRANSFER AND
ALL OTHER REQUIRED DOCUMENTS) OR A NOTICE OF GUARANTEED DELIVERY MUST BE
RECEIVED BY THE DEPOSITARY PRIOR TO THE EXPIRATION DATE (AS DEFINED IN THE OFFER
TO PURCHASE).
10
<PAGE> 11
IMPORTANT TAX INFORMATION
Under federal income tax law, a stockholder whose tendered Shares are
accepted for payment is required to provide the Depositary (as payor) with such
stockholder's correct TIN on the Substitute Form W-9. If such stockholder is an
individual, the TIN is such stockholder's social security number. If the
Depositary is not provided with the correct TIN, the stockholder may be subject
to a $50 penalty imposed by the Internal Revenue Service. In addition, payments
that are made to such stockholder with respect to Shares purchased pursuant to
the Offer may be subject to backup withholding.
Certain stockholders (including, among others, all corporations and certain
foreign individuals) are not subject to these backup withholding and reporting
requirements and should indicate their status by writing "exempt" across the
face of, and by signing and dating, the substitute Form W-9. In order for a
foreign individual to qualify as an exempt recipient, that stockholder must
submit a statement, signed under penalties of perjury, attesting to that
individual's exempt status. Such statements may be obtained from the Depositary.
All exempt recipients (including foreign persons wishing to qualify as exempt
recipients) should see the enclosed Guidelines for Certification of Taxpayer
Identification Number on Substitute Form W-9 for additional instructions.
If backup withholding applies, the Depositary is required to withhold 31%
of any payments made to the stockholder. Backup withholding is not an additional
tax. Rather, the tax liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If backup withholding results in an
overpayment of taxes, a refund may be obtained from the IRS.
PURPOSE OF SUBSTITUTE FORM W-9
To prevent backup federal income tax withholding on payments that are made
to a stockholder with respect to Shares purchased pursuant to the Offer, the
stockholder is required to notify the Depositary of such stockholder's correct
TIN by completing the form certifying that the TIN provided on the Substitute
Form W-9 is correct.
WHAT NUMBER TO GIVE THE DEPOSITARY
The stockholder is required to give the Depositary the social security
number or employer identification number of the record owner of the Shares. If
the Shares are registered in more than one name or are not in the name of the
actual owner, consult the enclosed Guidelines for Certification of Taxpayer
Identification Number on Substitute Form W-9 for additional guidelines on which
number to report.
11
<PAGE> 12
MANUALLY SIGNED FACSIMILE COPIES OF THE LETTER OF TRANSMITTAL, PROPERLY
COMPLETED AND DULY EXECUTED, WILL BE ACCEPTED. THE LETTER OF TRANSMITTAL,
CERTIFICATES FOR SHARES AND ANY OTHER REQUIRED DOCUMENTS SHOULD BE SENT OR
DELIVERED BY EACH STOCKHOLDER OF THE COMPANY OR HIS BROKER, DEALER, COMMERCIAL
BANK, TRUST COMPANY OR OTHER NOMINEE TO THE DEPOSITARY AT ONE OF ITS ADDRESSES
SET FORTH ABOVE AND BELOW.
Questions and requests for assistance may be directed to the Information
Agent at the address and telephone numbers listed below. Additional copies of
the Offer to Purchase, the Letter of Transmittal and other tender offer
materials may be obtained from the Information Agent as set forth below, and
will be promptly furnished at the Offeror's expense. You may also contact your
broker, dealer, commercial bank, trust company or other nominee for assistance
concerning the Offer.
The Information Agent for the Offer is:
MORROW & CO., INC.
445 Park Avenue, 5th Floor
New York, New York 10022
Banks and Brokerage Firms Call:
(800) 662-5200
(212) 754-8000
Stockholders Please Call:
(800) 566-9061
<PAGE> 1
EXHIBIT (a)(3)
OFFER TO PURCHASE FOR CASH
ALL OUTSTANDING SHARES OF COMMON STOCK
(INCLUDING THE ASSOCIATED RIGHTS)
OF
SIBIA NEUROSCIENCES, INC.
AT
$8.50 NET PER SHARE
BY
MC SUBSIDIARY CORP.,
A DIRECT WHOLLY-OWNED SUBSIDIARY OF
MERCK & CO., INC.
THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT,
NEW YORK CITY TIME, ON THURSDAY, SEPTEMBER 2, 1999, UNLESS THE OFFER IS
EXTENDED.
To Brokers, Dealers, Commercial Banks, August 6, 1999
Trust Companies and Other Nominees:
We are writing to you in connection with the offer by MC Subsidiary Corp.,
a Delaware corporation (the "Offeror"), and a direct wholly owned subsidiary of
Merck & Co., Inc., a New Jersey corporation ("Parent") to purchase all
outstanding shares of Common Stock, par value $.001 per share (the "Common
Stock"), including the associated preferred stock purchase rights issued
pursuant to the Rights Agreement, dated March 17, 1997 and amended as of July
30, 1999, between the Company and ChaseMellon Shareholder Services, L.L.C., as
Rights Agent (the "Rights" and, together with the Common Stock, the "Shares") of
SIBIA Neurosciences, Inc., a Delaware corporation (the "Company"), at a purchase
price of $8.50 per Share, net to the seller in cash, without interest, upon the
terms and subject to the conditions set forth in the Offer to Purchase, dated
August 6, 1999 (the "Offer to Purchase") and in the related Letter of
Transmittal (which, together with any amendments or supplements thereto,
collectively constitute the "Offer") enclosed herewith. Offeror is a
corporation, newly formed by Parent in connection with the Offer and the
transactions contemplated thereby. The Offer is being made in connection with
the Agreement and Plan of Merger dated as of July 30, 1999, among Parent,
Offeror and the Company (the "Merger Agreement"). Holders of Shares whose
certificates for such Shares (the "Certificates") are not immediately available
or who cannot deliver their Certificates and all other required documents to
Norwest Bank Minnesota, N.A. (the "Depositary") or complete the procedures for
book-entry transfer prior to the Expiration Date (as defined in Section 1 of the
Offer to Purchase) must tender their Shares according to the guaranteed delivery
procedures set forth in Section 3 of the Offer to Purchase.
Please furnish copies of the enclosed materials to those of your clients
for whose accounts you hold Shares in your name or in the name of your nominee.
<PAGE> 2
Enclosed herewith for your information and forwarding to your clients are
copies of the following documents:
1. The Offer to Purchase, dated August 6, 1999.
2. The Letter of Transmittal to tender Shares for your use and for the
information of your clients. Facsimile copies of the Letter of Transmittal
may be used to tender Shares.
3. A letter to stockholders of the Company from Dr. William T. Comer,
President and Chief Executive Officer, together with a
Solicitation/Recommendation Statement on Schedule 14D-9 filed with the
Securities and Exchange Commission by the Company and mailed to the
stockholders of the Company.
4. The Notice of Guaranteed Delivery for Tender of Shares to be used
to accept the Offer if following the guaranteed delivery procedures set
forth in Section 3 of the Offer to Purchase.
5. A printed form of letter which may be sent to your clients for
whose accounts you hold Shares registered in your name, with space provided
for obtaining such clients' instructions with regard to the Offer.
6. Guidelines of the Internal Revenue Service for Certification of
Taxpayer Identification Number on Substitute Form W-9.
7. A return envelope addressed to Norwest Bank Minnesota, N.A. (the
"Depositary").
YOUR PROMPT ACTION IS REQUESTED. WE URGE YOU TO CONTACT YOUR CLIENTS AS
PROMPTLY AS POSSIBLE. PLEASE NOTE THAT THE OFFER AND WITHDRAWAL RIGHTS WILL
EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON THURSDAY, SEPTEMBER 2, 1999,
UNLESS THE OFFER IS EXTENDED.
Please note the following:
1. The tender price is $8.50 per Share, net to the seller in cash,
without interest.
2. The Offer is conditioned upon, among other things, there being
validly tendered and not withdrawn prior to the Expiration Date (as defined
in the Offer to Purchase) of the Offer that number of Shares which would
represent at least a majority of the outstanding Shares on a fully diluted
basis.
3. The Offer is being made for all of the outstanding Shares.
4. Tendering stockholders will not be obligated to pay brokerage fees
or commissions or, except as set forth in Instruction 6 of the Letter of
Transmittal, stock transfer taxes on the transfer of Shares pursuant to the
Offer. However, federal income tax backup withholding at a rate of 31% may
be required, unless an exemption is available or unless the required
taxpayer identification information is provided. See Important Tax
Information of the Letter of Transmittal.
5. The Board of Directors of the Company has unanimously approved the
Offer and the Merger (as defined in the Offer to Purchase) and determined
that the terms of the Offer and the Merger are fair to, and in the best
interests of, the stockholders of the Company, and recommends that the
stockholders of the Company accept the Offer and tender all of their Shares
pursuant thereto.
6. Notwithstanding any other provision of the Offer, payment for
Shares accepted for payment pursuant to the Offer will in all cases be made
only after timely receipt by the Depositary of (a) Certificates pursuant to
the procedures set forth in Section 3 of the Offer to Purchase or a timely
Book-Entry Confirmation (as defined in the Offer to Purchase) with respect
to such Shares, (b) a properly completed and duly executed Letter of
Transmittal (or a manually signed facsimile thereof) with any required
signature guarantees or an Agent's Message (as defined in the Offer to
Purchase) in connection with a book-entry delivery of Shares, and (c) any
other documents required by the Letter of Transmittal. Accordingly,
tendering stockholders may be paid at different times depending upon when
Certificates for Shares or Book-Entry Confirmations (as defined in the
Offer to Purchase) are actually received by the Depositary.
2
<PAGE> 3
In order to take advantage of the Offer, (i) a properly completed and duly
executed Letter of Transmittal (or a manually signed facsimile thereof) with any
required signature guarantees or an Agent's Message in connection with a
book-entry delivery of Shares, and any other documents required by the Letter of
Transmittal should be sent to the Depositary and (ii) Certificates representing
the tendered Shares or a timely Book-Entry Confirmation should be delivered to
the Depositary in accordance with the instructions set forth in the Letter of
Transmittal and the Offer to Purchase.
If holders of Shares wish to tender, but it is impracticable for them to
forward their Certificates or other required documents or complete the
procedures for book-entry transfer prior to the Expiration Date, a tender may be
effected by following the guaranteed delivery procedures specified in Section 3
of the Offer to Purchase.
None of Offeror or Parent, or any officer, director, stockholder, agent or
other representative of Offeror or Parent, will pay any fees or commissions to
any broker, dealer or other person (other than the Depositary and the
Information Agent as described in the Offer to Purchase) for soliciting tenders
of Shares pursuant to the Offer. Offeror will, however, upon request, reimburse
you for customary mailing and handling expenses incurred by you in forwarding
any of the enclosed materials to your clients. Offeror will pay or cause to be
paid any transfer taxes payable on the transfer of Shares to it, except as
otherwise provided in Instruction 6 of the Letter of Transmittal.
Any inquiries you may have with respect to the Offer should be addressed to
Morrow & Co., Inc., the Information Agent for the Offer, at its address and
telephone number set forth on the back cover of the Offer to Purchase.
Additional copies of the enclosed materials may be obtained from the
Information Agent or from brokers, dealers, commercial banks or trust companies.
Very truly yours,
MORROW & CO., INC.
NOTHING CONTAINED HEREIN OR IN THE ENCLOSED DOCUMENTS SHALL CONSTITUTE YOU
OR ANY OTHER PERSON AS THE AGENT OF PARENT, OFFEROR, PURCHASER, THE DEPOSITARY,
THE INFORMATION AGENT, OR ANY AFFILIATE OF ANY OF THEM, OR AUTHORIZE YOU OR ANY
OTHER PERSON TO MAKE ANY STATEMENT OR USE ANY DOCUMENT ON BEHALF OF ANY OF THEM
IN CONNECTION WITH THE OFFER OTHER THAN THE ENCLOSED DOCUMENTS AND THE
STATEMENTS CONTAINED THEREIN.
3
<PAGE> 1
EXHIBIT (a)(4)
OFFER TO PURCHASE FOR CASH
ALL OUTSTANDING SHARES OF COMMON STOCK
(INCLUDING THE ASSOCIATED RIGHTS)
OF
SIBIA NEUROSCIENCES, INC.
AT
$8.50 NET PER SHARE
BY
MC SUBSIDIARY CORP.,
A DIRECT WHOLLY-OWNED SUBSIDIARY OF
MERCK & CO., INC.
THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT,
NEW YORK CITY TIME, ON THURSDAY, SEPTEMBER 2, 1999,
UNLESS THE OFFER IS EXTENDED.
To Our Clients:
Enclosed for your consideration are the Offer to Purchase, dated August 6,
1999 (the "Offer to Purchase"), and the related Letter of Transmittal (which,
together with any amendments or supplements thereto, collectively constitute the
"Offer") relating to an offer by MC Subsidiary Corp., a Delaware corporation
("Offeror") and a direct wholly-owned subsidiary of Merck & Co., Inc., a New
Jersey corporation ("Parent"), to purchase all outstanding shares of Common
Stock, par value $.001 per share (the "Common Stock"), including the associated
preferred stock purchase rights issued pursuant to the Rights Agreement, dated
as of March 17, 1997 and amended as of July 30, 1999, between the Company and
ChaseMellon Shareholder Services, L.L.C., as Rights Agent (the "Rights" and,
together with the Common Stock, the "Shares"), of SIBIA Neurosciences, Inc., a
Delaware corporation (the "Company"), at a purchase price of $8.50 per Share,
net to the seller in cash, without interest, upon the terms and subject to the
conditions set forth in the Offer. The Offer is being made in connection with
the Agreement and Plan of Merger dated as of July 30, 1999, among Parent,
Offeror and the Company (the "Merger Agreement"). Offeror is a corporation,
newly formed by Parent in connection with the Offer and the transactions
contemplated thereby. This material is being forwarded to you as the beneficial
owner of Shares carried by us in your account but not registered in your name.
WE ARE (OR OUR NOMINEE IS) THE HOLDER OF RECORD OF SHARES HELD BY US FOR
YOUR ACCOUNT. A TENDER OF SUCH SHARES CAN BE MADE ONLY BY US AS THE HOLDER OF
RECORD AND PURSUANT TO YOUR INSTRUCTIONS. THE LETTER OF TRANSMITTAL IS FURNISHED
TO YOU FOR YOUR INFORMATION ONLY AND CANNOT BE USED BY YOU TO TENDER SHARES HELD
BY US FOR YOUR ACCOUNT.
Accordingly, we request instructions as to whether you wish to have us
tender any or all of the Shares held by us for your account pursuant to the
terms and conditions set forth in the Offer.
<PAGE> 2
Please note the following:
1. The tender price is $8.50 per Share, net to the seller in cash,
without interest.
2. The Offer is conditioned upon, among other things, there being
validly tendered and not withdrawn prior to the Expiration Date (as defined
in the Offer to Purchase) of the Offer that number of Shares which would
represent at least a majority of the outstanding Shares on a fully diluted
basis.
3. The Offer is being made for all of the outstanding Shares.
4. Tendering stockholders will not be obligated to pay brokerage fees
or commissions or, except as set forth in Instruction 6 of the Letter of
Transmittal, stock transfer taxes on the transfer of Shares pursuant to the
Offer. However, federal income tax backup withholding at a rate of 31% may
be required, unless an exemption is available or unless the required
taxpayer identification information is provided. See Important Tax
Information of the Letter of Transmittal.
5. The Board of Directors of the Company has unanimously approved the
Offer and the Merger (as defined in the Offer to Purchase) and determined
that the terms of the Offer and the Merger are fair to, and in the best
interests of, the stockholders of the Company, and recommends that the
stockholders of the Company accept the Offer and tender all of their Shares
pursuant thereto.
6. Notwithstanding any other provision of the Offer, payment for
Shares accepted for payment pursuant to the Offer will in all cases be made
only after timely receipt by the Depositary of (a) Certificates pursuant to
the procedures set forth in Section 3 of the Offer to Purchase or a timely
Book-Entry Confirmation (as defined in the Offer to Purchase) with respect
to such Shares, (b) a properly completed and duly executed Letter of
Transmittal (or a manually signed facsimile thereof) with any required
signature guarantees or an Agent's Message (as defined in the Offer to
Purchase) in connection with a book-entry delivery of Shares, and (c) any
other documents required by the Letter of Transmittal. Accordingly,
tendering stockholders may be paid at different times depending upon when
Certificates for Shares or Book-Entry Confirmations are actually received
by the Depositary.
THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK
CITY TIME, ON THURSDAY, SEPTEMBER 2, 1999, UNLESS THE OFFER IS EXTENDED.
If you wish to have us tender any or all of the Shares held by us for your
account, please so instruct us by completing, executing, detaching and returning
to us the instruction form set forth below. If you authorize the tender of your
Shares, all such Shares will be tendered unless otherwise indicated in such
instruction form. An envelope to return your instruction to us is enclosed.
PLEASE FORWARD YOUR INSTRUCTIONS TO US AS SOON AS POSSIBLE TO ALLOW US AMPLE
TIME TO TENDER YOUR SHARES ON YOUR BEHALF PRIOR TO THE EXPIRATION OF THE OFFER.
The Offer is not being made to, nor will tenders be accepted from or on
behalf of, holders of Shares residing in any jurisdiction in which the making of
the Offer or acceptance thereof would not be in compliance with the securities
laws of such jurisdiction. However, Offeror may, in its discretion, take such
action as it may deem necessary to make the Offer in any jurisdiction and extend
the Offer to holders of Shares in such jurisdiction.
In any jurisdiction where the securities, blue sky or other laws require
the Offer to be made by a licensed broker or dealer, the Offer will be deemed to
be made on behalf of Offeror by one or more registered brokers or dealers
licensed under the laws of such jurisdiction.
2
<PAGE> 3
INSTRUCTIONS WITH RESPECT TO THE OFFER TO PURCHASE
FOR CASH ALL OUTSTANDING SHARES OF COMMON STOCK
(INCLUDING THE ASSOCIATED RIGHTS)
OF
SIBIA NEUROSCIENCES, INC.
The undersigned acknowledge(s) receipt of your letter and the enclosed
Offer to Purchase, dated August 6, 1999 (the "Offer to Purchase"), and the
related Letter of Transmittal (which, together with any amendments or
supplements thereto, collectively constitute the "Offer") in connection with the
offer by MC Subsidiary Corp., a Delaware corporation ("Offeror") and a direct
wholly-owned subsidiary of Merck & Co., Inc., a New Jersey corporation
("Parent"), to purchase all outstanding shares of Common Stock, par value $.001
per share (the "Common Stock"), including the associated preferred stock
purchase rights issued pursuant to the Rights Agreement dated as of March 17,
1997 and amended as of July 30, 1999, between the Company and ChaseMellon
Shareholder Services, L.L.C., as Rights Agent (the "Rights" and, together with
the Common Stock, the "Shares"), of SIBIA Neurosciences, Inc., a Delaware
corporation (the "Company"), at a purchase price of $8.50 per Share, net to the
seller in cash, without interest, upon the terms and subject to the conditions
set forth in the Offer. Offeror has been formed by Parent in connection with the
Offer and the transactions contemplated thereby. The Offer is being made in
connection with the Agreement and Plan of Merger dated as of July 30, 1999,
among Parent, Offeror and the Company (the "Merger Agreement").
This will instruct you to tender to the Purchaser the number of Shares
indicated below (or if no number is indicated below, all Shares) which are held
by you for the account of the undersigned, upon the terms and subject to the
conditions set forth in the Offer.
<TABLE>
<S> <C>
Number of Shares to be Tendered:* SIGN HERE
-------------------------------------- -----------------------------------------------------
-----------------------------------------------------
SIGNATURE(S)
Account Number: ------------------------- -----------------------------------------------------
-----------------------------------------------------
(PRINT NAME(S))
-----------------------------------------------------
Date: -------------------------------, 1999 -----------------------------------------------------
(PRINT ADDRESS(ES))
-----------------------------------------------------
-----------------------------------------------------
(AREA CODE AND TELEPHONE NUMBER(S))
-----------------------------------------------------
(TAXPAYER IDENTIFICATION OR SOCIAL SECURITY
NUMBER(S))
</TABLE>
- ---------------
* Unless otherwise indicated, it will be assumed that all Shares held by us for
your account are to be tendered.
3
<PAGE> 1
EXHIBIT (a)(5)
NOTICE OF GUARANTEED DELIVERY
FOR TENDER OF SHARES OF COMMON STOCK
(INCLUDING THE ASSOCIATED RIGHTS)
OF
SIBIA NEUROSCIENCES, INC.
This form, or one substantially equivalent hereto, must be used to accept
the Offer (as defined below) if certificates for shares of Common Stock, par
value $.001 per share (the "Common Stock"), including the associated preferred
stock purchase rights issued pursuant to the Rights Agreement, dated March 17,
1997 and amended as of July 30, 1999, between the Company and ChaseMellon
Shareholder Services, L.L.C., as Rights Agent (the "Rights" and, together with
the Common Stock, the "Shares"), of SIBIA Neurosciences, Inc., a Delaware
corporation (the "Company"), are not immediately available or the procedure for
book-entry transfer cannot be completed on a timely basis or time will not
permit all required documents to reach the Depositary prior to the Expiration
Date (as defined in the Offer to Purchase). This Notice of Guaranteed Delivery
may be delivered by hand or facsimile transmission or mailed to the Depositary.
See Section 3 of the Offer to Purchase, dated August 6, 1999 (the "Offer to
Purchase").
The Depositary for the Offer is:
NORWEST BANK MINNESOTA, N.A.
<TABLE>
<S> <C> <C>
By Mail: By Hand in New York: By Hand/Overnight Courier:
Norwest Bank Minnesota, N.A The Depository Trust Company Norwest Bank Minnesota, N.A.
Shareowner Services Transfer Agent Drop Shareowner Services
Reorganization Department 55 Water Street - 1st Floor 161 North Concord Exchange
P.O. Box 64858 New York, NY 10041-0099 South St. Paul, MN 55075
St. Paul, MN 55164-0858
Facsimile Copy Number:
(651) 450-4163
For Confirmation Telephone:
(651) 450-4110
The Information Agent for the Offer is:
MORROW & CO., INC.
445 Park Avenue, 5th Floor
New York, New York 10022
Banks and Brokerage Firms Call:
(800) 662-5200
(212) 754-8000
Stockholders Please Call:
(800) 566-9061
</TABLE>
-------------------------
DELIVERY OF THIS NOTICE OF GUARANTEED DELIVERY TO AN ADDRESS, OR
TRANSMISSION OF INSTRUMENTS VIA FACSIMILE TRANSMISSION, OTHER THAN AS SET FORTH
ABOVE, DOES NOT CONSTITUTE A VALID DELIVERY.
This Notice of Guaranteed Delivery is not to be used to guarantee
signatures. If a signature on a Letter of Transmittal is required to be
guaranteed by an "Eligible Institution" under the instructions thereto, such
signature guarantee must appear in the applicable space provided in the
signature box on the Letter of Transmittal.
The Eligible Institution that completes this form must communicate the
guarantee to the Depositary and must deliver the Letter of Transmittal or an
Agent's Message (as defined in the Offer to Purchase) and certificates for
Shares to the Depositary within the time period shown herein. Failure to do so
could result in a financial loss to such Eligible Institution.
THE GUARANTEE ON THE REVERSE SIDE MUST BE COMPLETED.
<PAGE> 2
Ladies and Gentlemen:
The undersigned hereby tenders to MC Subsidiary Corp. ("Offeror"), a
Delaware corporation, and a direct wholly-owned subsidiary of Merck & Co., Inc.
("Parent"), a New Jersey corporation, upon the terms and subject to the
conditions set forth in the Offer to Purchase and in the related Letter of
Transmittal (which, together with any amendments or supplements thereto,
collectively constitute the "Offer"), receipt of each of which is hereby
acknowledged, the number of Shares indicated below, pursuant to the guaranteed
delivery procedure set forth in Section 3 of the Offer to Purchase. Offeror is a
corporation, newly formed by Parent in connection with the Offer and the
transactions contemplated thereby.
Number of Shares:
---------------------------------------------------------------
Certificate No(s). (if available):
----------------------------------------------
If Share(s) will be tendered by book-entry transfer, check the box.
[ ] The Depository Trust Company
Account Number:
-----------------------------------------------------------------
Date: Area Code and Telephone Number:
-------------------- -----------------------
Name(s) of Record Holder(s):
----------------------------------------------------
(Please Type or Print)
Signature(s):
-------------------------------------------------------------------
Address(es):
--------------------------------------------------------------------
(Include a Zip Code)
THE GUARANTEE SET FORTH BELOW MUST BE COMPLETED
GUARANTEE
(NOT TO BE USED FOR SIGNATURE GUARANTEE)
The undersigned, as Eligible Institution (as such term is defined in
Section 3 of the Offer to Purchase), hereby guarantees to deliver to the
Depositary the certificates representing the Shares tendered hereby, in proper
form for transfer, or a Book-Entry Confirmation (as defined in Section 3 of the
Offer to Purchase) with respect to transfer of such Shares into the Depositary's
account at Norwest Bank Minnesota, N.A., in each case, together with a properly
completed and duly executed Letter of Transmittal (or a manually signed
facsimile thereof) with any required signature guarantees or an Agent's Message
(as defined in the Offer to Purchase) in the case of a book-entry delivery of
Shares, and any other documents required by the Letter of Transmittal, all
within three Nasdaq National Market trading days after the date hereof.
Name of Firm:
----------------------------- ----------------------------------
(Authorized Signature)
Address: Name:
---------------------------------- -----------------------------
Title:
- ------------------------------------------ ----------------------------
(Include a Zip Code)
Area Code and Tel. No.: Date:
------------------- -----------------------------
DO NOT SEND CERTIFICATES FOR SHARES AND/OR RIGHTS WITH THIS NOTICE OF GUARANTEED
DELIVERY. CERTIFICATES SHOULD BE SENT TOGETHER WITH A LETTER OF TRANSMITTAL.
2
<PAGE> 1
EXHIBIT (a)(6)
GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION
NUMBER ON SUBSTITUTE FORM W-9
GUIDELINES FOR DETERMINING THE PROPER IDENTIFICATION NUMBER TO GIVE THE
PAYER.--Social Security numbers have nine digits separated by two hyphens: i.e.
000-00-0000. Employer identification numbers have nine digits separated by only
one hyphen: i.e. 00-0000000. The table below will help determine the number to
give the payer.
<TABLE>
<C> <S> <C>
- ------------------------------------------------------------
GIVE THE
FOR THIS TYPE OF ACCOUNT: SOCIAL SECURITY
NUMBER OF--
- ------------------------------------------------------------
1. An individual's account The individual
2. Two or more individuals (joint The actual owner of
account) the account or, if
combined funds, any
one of the
individuals(1)
3. Husband and wife (joint account) The actual owner of
the account or, if
joint funds, either
person(1)
4. Custodian account of a minor The minor(2)
(Uniform Gift to Minors Act)
5. Adult and minor (joint account) The adult or, if
the minor is the
only contributor,
the minor(1)
6. Account in the name of guardian or The ward, minor, or
committee for a designated ward, incompetent
minor, or incompetent person person(3)
7. a. The usual revocable savings The grantor-
trust account (grantor is also trustee(1)
trustee)
b. So-called trust account that is The actual owner(1)
not a legal or valid trust
under State law
8. Sole proprietorship account The Owner(4)
- ------------------------------------------------------------
- ------------------------------------------------------------
GIVE THE EMPLOYER
FOR THIS TYPE OF ACCOUNT: IDENTIFICATION
NUMBER OF--
- ------------------------------------------------------------
9. A valid trust, estate, or pension Legal entity (Do
trust not furnish the
identifying number
of the personal
representative or
trustee unless the
legal entity itself
is not designated
in the account
title.)(5)
10. Corporate account The corporation
11. Religious, charitable, or The organization
educational organization account
12. Partnership account held in the The partnership
name of the business
13. Association, club, or other tax- The organization
exempt organization
14. A broker or registered nominee The broker or
nominee
15. Account with the Department of The public entity
Agriculture in the name of a
public entity (such as a State or
local government, school district,
or prison) that receives
agricultural program payments
- ------------------------------------------------------------
</TABLE>
(1) List first and circle the name of the person whose number you furnish.
(2) Circle the minor's name and furnish the minor's social security number.
(3) Circle the ward's, minor's or incompetent person's name and furnish such
person's social security number.
(4) Show the name of the owner.
(5) List first and circle the name of the legal trust, estate, or pension trust.
NOTE: If no name is circled when there is more than one name, the number will be
considered to be that of the first name listed.
<PAGE> 2
GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION
NUMBER ON SUBSTITUTE FORM W-9
PAGE 2
OBTAINING A NUMBER
If you don't have a taxpayer identification number or you don't know your
number, obtain Form SS-5, Application for a Social Security Number Card, or Form
SS-4, Application for Employer Identification Number, at the local office of the
Social Security Administration or the Internal Revenue Service and apply for a
number.
PAYEES EXEMPT FROM BACKUP WITHHOLDING
Payees specifically exempted from backup withholding on ALL payments include the
following:
- A corporation.
- A financial institution.
- An organization exempt from tax under section 501(a), or an individual
retirement plan.
- The United States or any agency or instrumentality thereof.
- A State, the District of Columbia, a possession of the United States, or any
subdivision or instrumentality thereof.
- A foreign government, a political subdivision of a foreign government, or
any agency or instrumentality thereof.
- An international organization or any agency, or instrumentality thereof.
- A registered dealer in securities or commodities registered in the U.S. or a
possession of the U.S.
- A real estate investment trust.
- A common trust fund operated by a bank under section 584(a).
- An exempt charitable remainder trust, or a non-exempt trust described in
section 4947(a)(1).
- An entity registered at all times under the Investment Company Act of 1940.
- A foreign central bank of issue.
Payments of dividends and patronage dividends not generally subject to backup
withholding include the following:
- Payments to nonresident aliens subject to withholding under section 1441.
- Payments to partnerships not engaged in a trade or business in the U.S. and
which have at least one nonresident partner.
- Payments of patronage dividends where the amount received is not paid in
money.
- Payments made by certain foreign organizations.
- Payments made to a nominee.
Payments of interest not generally subject to backup withholding include the
following:
- Payments of interest on obligations issued by individuals. Note: You may be
subject to backup withholding if this interest is $600 or more and is paid
in the course of the payer's trade or business and you have not provided
your correct taxpayer identification number to the payer.
- Payments of tax-exempt interest (including exempt-interest dividends under
section 852).
- Payments described in section 6049(b)(5) to nonresident aliens.
- Payments on tax-free covenant bonds under section 1451.
- Payments made by certain foreign organizations.
- Payments made to a nominee.
Exempt payees described above should file Form W-9 to avoid possible erroneous
backup withholding. FILE THIS FORM WITH THE PAYER. FURNISH YOUR TAXPAYER
IDENTIFICATION NUMBER, WRITE "EXEMPT" ON THE FACE OF THE FORM, AND RETURN IT TO
THE PAYER. IF THE PAYMENTS ARE INTEREST, DIVIDENDS, OR PATRONAGE DIVIDENDS, ALSO
SIGN AND DATE THE FORM.
Certain payments other than interest, dividends, and patronage dividends, that
are not subject to information reporting are also not subject to backup
withholding. For details, see the regulations under sections 6041, 6041A(a),
6045, and 6050A.
PRIVACY ACT NOTICE.--Section 6109 requires most recipients of dividend,
interest, or other payments to give taxpayer identification numbers to payers
who must report the payments to IRS. IRS uses the numbers for identification
purposes. Payers must be given the numbers whether or not recipients are
required to file tax returns. Beginning January 1, 1993, payers must generally
withhold 31% of taxable interest, dividend, and certain other payments to a
payee who does not furnish a taxpayer identification number to a payer. Certain
penalties may also apply.
PENALTIES
(1) PENALTY FOR FAILURE TO FURNISH TAXPAYER IDENTIFICATION NUMBER.--If you fail
to furnish your taxpayer identification number to a payer, you are subject to a
penalty of $50 for each such failure unless your failure is due to reasonable
cause and not to willful neglect.
(2) FAILURE TO REPORT CERTAIN DIVIDEND AND INTEREST PAYMENTS.--If you fail to
include any portion of an includible payment for interest, dividends, or
patronage dividends in gross income, such failure will be treated as being due
to negligence and will be subject to a penalty of 5% on any portion of an
under-payment attributable to that failure unless there is clear and convincing
evidence to the contrary.
(3) CIVIL PENALTY FOR FALSE INFORMATION WITH RESPECT TO WITHHOLDING.--If you
make a false statement with no reasonable basis which results in no imposition
of backup withholding, you are subject to a penalty of $500.
(4) CRIMINAL PENALTY FOR FALSIFYING INFORMATION.--Falsifying certifications or
affirmations may subject you to criminal penalties including fines and/or
imprisonment.
FOR ADDITIONAL INFORMATION CONTACT YOUR TAX
CONSULTANT OR THE INTERNAL REVENUE SERVICE
<PAGE> 1
EXHIBIT (a)(7)
MERCK ACQUIRES SIBIA NEUROSCIENCES, INC., A CALIFORNIA-BASED
BIOTECHNOLOGY FIRM; ACQUISITION AUGMENTS MERCK'S DRUG DISCOVERY PROGRAM
WHITEHOUSE STATION, N.J. and LA JOLLA, Calif., Aug. 2 /PRNewswire/ --
Merck & Co., Inc., (NYSE: MRK), a research-driven pharmaceutical company, and
SIBIA Neurosciences, Inc., (Nasdaq: SIBI), a leading company in the biology and
chemistry of discovering drugs for central nervous system disorders, today
announced they have entered into a definitive agreement under which Merck will
acquire SIBIA for $8.50 per share in cash. Merck will commence a tender offer
for SIBIA shares by Aug. 6. The transaction will total approximately $87
million.
"Acquiring SIBIA will significantly enhance Merck's excellent basic
research capability in the field of central nervous system disorders," said
Bennett M. Shapiro, executive vice president of worldwide licensing and external
research, Merck Research Laboratories. "SIBIA researchers, who are among the
best in the biotechnology industry, have opened several avenues for potential
scientific discovery, and now we can further exploit them together."
William T. Comer, Ph.D., president, chief executive officer and director
of SIBIA, said: "By joining Merck, we will gain significant scientific,
technological and financial support to help exploit our broad drug discovery
platform and bring our basic research discoveries to the market. Merck has a
rich tradition of biomedical research, and we are proud to be joining it."
Richard N. Kender, Merck vice president of corporate development, said:
"In the search to discover and develop important medicines, Merck Research
Laboratories relies on its strong internal capability, and complements that with
external research collaborations. The acquisition of SIBIA strengthens our drug
discovery research capability."
"Merck already has a major CNS research facility in the United Kingdom
and it has been very successful," Dr. Shapiro said. "SIBIA augments our already
excellent CNS research and gives us a presence in the CNS research community in
the United States."
Upon closing of the agreement, SIBIA employees will become Merck
employees. Merck intends to keep SIBIA's existing facilities in La Jolla, Calif.
SIBIA stockholders owning approximately 33 percent of SIBIA's
outstanding shares have committed to support the transaction and have entered
into voting and option agreements, and SIBIA has granted Merck an option to
purchase other SIBIA shares under certain conditions. The acquisition is subject
to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and the
acquisition of a majority of SIBIA shares by Merck, as well as other customary
conditions. The two companies expect to complete the acquisition in September
1999.
Founded in 1981, SIBIA is engaged in the discovery and development of
novel small molecule therapeutics for the treatment of neurodegenerative,
neuropsychiatric and neurological disorders. The company, which went public in
1996, is a leader in the development of proprietary drug discovery platforms and
technologies.
1.
<PAGE> 2
Merck is a global, research-driven pharmaceutical company that
discovers, develops, manufactures and markets a broad range of human and animal
health products, directly and through its joint ventures, and provides
pharmaceutical benefit services through Merck-Medco Managed Care.
SIBIA was represented by the investment banking firm CIBC World Markets.
(For more information about the companies, visit http://www.sibia.com
and http://www.merck.com.)
2.
<PAGE> 1
EXHIBIT (a)(8)
FOR IMMEDIATE RELEASE
MERCK & CO. COMMENCES TENDER OFFER FOR SIBIA
NEUROSCIENCES, INC.
AT $8.50 PER SHARE
WHITEHOUSE STATION, NJ, August 6, 1999 -- Merck & Co., Inc. announced today
that a wholly owned subsidiary has commenced its previously announced tender
offer for shares of common stock of SIBIA Neurosciences, Inc. (NASDAQ: SIBI).
The tender offer, which is being made pursuant to an Agreement and Plan of
Merger dated as of July 30, 1999, is scheduled to expire at 12:00 midnight, New
York City time, on Thursday, September 2, 1999, unless extended. Following the
consummation of the tender offer, Merck intends to complete a merger to acquire
all of the remaining shares of SIBIA common stock that are not tendered in the
offer.
The Board of Directors of SIBIA has unanimously approved the tender offer, the
merger and the other transactions contemplated by the Agreement and Plan of
Merger, unanimously determined that the terms of the tender offer and merger
are fair to and in the best interests of SIBIA's stockholders, and unanimously
recommends that stockholders accept the offer and tender their shares pursuant
to the offer.
SIBIA stockholders owning approximately 33 percent of SIBIA's outstanding
shares have committed to support the transaction and have entered into voting
and option agreements, and SIBIA has granted Merck an option to purchase other
SIBIA shares under certain conditions. The acquisition is subject to clearance
under the Hart-Scott-Rodino Antitrust Improvements Act and the acquisition of a
majority of SIBIA shares by Merck, as well as other customary conditions.
Norwest Bank Minnesota, N.A. will act as depositary for the tender offer and
Morrow & Co., Inc. will act as information agent.
Merck is a global, research-driven pharmaceutical company that discovers,
develops, manufactures and markets a broad range of human and animal health
products, directly and through its joint ventures, and provides pharmaceutical
benefit services through Merck-Medco Managed Care.
<PAGE> 1
EXHIBIT (c)(1)
AGREEMENT AND PLAN OF MERGER
among
SIBIA NEUROSCIENCES, INC.,
MERCK & CO., INC.
and
MC SUBSIDIARY CORP.
Dated as of July 30, 1999
<PAGE> 2
Table of Contents
<TABLE>
<CAPTION>
Section Page
- ------- ----
<S> <C>
ARTICLE I The Tender Offer...................................................................................... 2
1.1. The Offer........................................................................................... 2
1.2. SEC Filings......................................................................................... 3
1.3. Company Action...................................................................................... 5
1.4 Composition of the Company Board..................................................................... 5
ARTICLE II The Merger; Closing; Effective Time.................................................................. 6
2.1. The Merger.......................................................................................... 6
2.2. Closing............................................................................................. 7
2.3. Effective Time...................................................................................... 7
ARTICLE III Certificate of Incorporation and Bylaws of the Surviving Corporation................................ 7
3.1. The Certificate of Incorporation.................................................................... 7
3.2. The Bylaws.......................................................................................... 8
ARTICLE IV Officers and Directors of the Surviving Corporation.................................................. 8
4.1. Directors........................................................................................... 8
4.2. Officers............................................................................................ 8
ARTICLE V Effect of the Merger on Capital Stock; Exchange of Certificates....................................... 8
5.1. Effect on Capital Stock............................................................................. 8
5.2. Surrender and Payment............................................................................... 9
5.3. Adjustment of Merger Consideration.................................................................. 12
5.4. Merger Without Meeting of Stockholders.............................................................. 12
5.5. Treatment of Convertible Preferred Stock............................................................ 12
ARTICLE VI Representations and Warranties....................................................................... 12
6.1. Representations and Warranties of the Company....................................................... 13
6.2. Representations and Warranties of Parent and Merger Sub............................................. 30
ARTICLE VII Covenants........................................................................................... 33
7.1. Company Interim Operations.......................................................................... 33
7.2. Acquisition Proposals............................................................................... 35
7.3. Company Stockholder Approval; Proxy Statement....................................................... 37
7.4. Approvals and Consents; Cooperation................................................................. 39
7.5. Filings; Other Actions; Notification................................................................ 40
7.6. Access.............................................................................................. 40
7.7. De-registration..................................................................................... 41
7.8. Publicity........................................................................................... 41
</TABLE>
-i-
<PAGE> 3
<TABLE>
<S> <C>
7.9. Benefits............................................................................................ 41
7.10. Expenses........................................................................................... 43
7.11. Indemnification; Directors' and Officers' Insurance................................................ 43
7.12. Other Actions by the Company and Parent............................................................ 45
7.13. Convertible Preferred Stock........................................................................ 46
ARTICLE VIII Conditions......................................................................................... 46
8.1. Conditions to Each Party's Obligation to Effect the Merger.......................................... 46
ARTICLE IX Termination.......................................................................................... 47
9.1. Termination by Mutual Consent....................................................................... 47
9.2. Termination by Either Parent or the Company......................................................... 47
9.3. Termination by the Company.......................................................................... 48
9.4. Termination by Parent............................................................................... 49
9.5. Effect of Termination and Abandonment............................................................... 49
ARTICLE X Miscellaneous and General............................................................................. 51
10.1. Survival........................................................................................... 52
10.2. Modification or Amendment.......................................................................... 52
10.3. Waiver of Conditions............................................................................... 52
10.4. Counterparts....................................................................................... 52
10.5. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL...................................................... 52
10.6. Notices............................................................................................ 53
10.7. Entire Agreement................................................................................... 54
10.8. No Third Party Beneficiaries....................................................................... 55
10.9. Obligations of Parent and of the Company........................................................... 55
10.10. Severability...................................................................................... 55
10.11. Specific Performance.............................................................................. 55
10.12. Interpretation.................................................................................... 56
10.13. Assignment........................................................................................ 56
10.14. Captions.......................................................................................... 56
</TABLE>
-ii-
<PAGE> 4
AGREEMENT AND PLAN OF MERGER (hereinafter called this
"Agreement"), dated as of July 30, 1999, among SIBIA Neurosciences, Inc., a
Delaware corporation (the "Company"), Merck & Co., Inc., a New Jersey
corporation ("Parent"), and MC Subsidiary Corp., a Delaware corporation and a
wholly owned subsidiary of Parent ("Merger Sub," the Company and Merger Sub
sometimes being hereinafter collectively referred to as the "Constituent
Corporations").
RECITALS
WHEREAS, the respective Boards of Directors of Parent, Merger
Sub and the Company have each approved the Offer (as defined herein) and the
Merger (as defined herein) and have determined that it is in the best interests
of their respective companies and stockholders for Parent to acquire the Company
upon the terms and subject to the conditions set forth herein;
WHEREAS, in order to complete such acquisition, the respective
Boards of Directors of Parent, Merger Sub and the Company have each approved the
merger of Merger Sub with and into the Company (the "Merger"), upon the terms
and subject to the conditions of this Agreement and in accordance with the
Delaware General Corporation Law (the "DGCL"), whereby each issued and
outstanding Share (as defined herein) not owned directly or indirectly by Parent
or the Company will be converted into the right to receive the highest price per
share in cash actually paid in the Offer;
WHEREAS, the Board of Directors of the Company has unanimously
approved this Agreement, the Offer and the Merger, has determined that the Offer
and the Merger are fair to and in the best interests of the Company's
stockholders and is recommending that the Company's stockholders accept the
Offer, tender their Shares thereunder and adopt this Agreement;
WHEREAS, contemporaneously with the execution and delivery of
this Agreement, the Company is entering into a stock option agreement with
Parent (the "Stock Option Agreement"), pursuant to which the Company has granted
to Parent an option to purchase Shares (as defined in Section 1.1(a)) under the
terms and conditions set forth in the Stock Option Agreement; and
WHEREAS, contemporaneously with the execution and delivery of
this Agreement, certain holders of Shares are entering into an agreement with
Parent (the "Shareholders Agreement") pursuant to which such holders have made
certain agreements with respect to the Shares held by them.
NOW, THEREFORE, in consideration of the premises, and of the
representations, warranties, covenants and agreements contained herein and in
the Stock Option Agreement, the parties hereto agree as follows:
-1-
<PAGE> 5
ARTICLE I
The Tender Offer
1.1. The Offer.
(a) Provided that this Agreement shall not have been
terminated in accordance with Article IX hereof and none of the events set forth
in Annex A hereto (the "Offer Conditions") shall be existing, within five
Business Days of the date hereof, Merger Sub will commence a tender offer (the
"Offer") for all of the outstanding shares of common stock, par value $0.001 per
share, of the Company (each a "Share" or, collectively, the "Shares") at a price
per Share of U.S. $8.50 net to the Seller in cash (such price, or any higher
price paid in the Offer, the "Price Per Share") upon the terms and conditions
set forth in this Agreement, including Annex A hereto.
(b) The obligation of Merger Sub to accept for payment,
purchase and pay for any Shares tendered pursuant to the Offer shall be subject
only to the satisfaction or waiver of the Offer Conditions, including the Offer
Condition that at least that number of Shares equivalent to a majority of the
total issued and outstanding Shares on a fully diluted basis on the date such
shares are purchased pursuant to the Offer shall have been validly tendered and
not withdrawn prior to the expiration of the Offer (the "Minimum Condition").
Merger Sub will not, without the prior written consent of the Company (such
consent to be authorized by the Company Board) (i) decrease the amount or change
the form of consideration payable in the Offer, (ii) decrease the number of
Shares sought in the Offer, (iii) impose additional conditions to the Offer,
(iv) change any Offer Condition or amend any other term of the Offer if any such
change or amendment would be adverse in any respect to the holders of Shares
(other than Parent or Merger Sub), (v) except as provided below, extend the
Offer if all of the Offer Conditions have been satisfied or (vi) amend or waive
the Minimum Condition. Subject to the terms and conditions hereof, the Offer
shall expire at midnight, New York City time, on the date that is twenty (20)
Business Days after the Offer is commenced (within the meaning of Rule 14d-2
under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (the
"Scheduled Expiration Date"); provided, however, that without the consent of the
Company Board, Merger Sub may (x) extend the Offer, if on the Scheduled
Expiration Date of the Offer any of the Offer Conditions shall not have been
satisfied or waived, for one (1) or more periods (none of which shall exceed ten
(10) Business Days) but in no event past 90 days from the date of this Agreement
unless the waiting period applicable to the transactions contemplated by this
Agreement under the HSR Act has not terminated or expired in which case not past
the date set forth in Section 9.2(i), (y) extend the Offer for such period as
may be required by any rule, regulation, interpretation or position of the
Securities and Exchange Commission ("SEC") or the staff thereof applicable to
the Offer or (z) extend the Offer for one (1) or more periods (each such period
to be for not more than three (3) Business Days and such extensions to be for an
-2-
<PAGE> 6
aggregate period of not more than ten (10) Business Days beyond the latest
expiration date that would otherwise be permitted under clause (x) or (y) of
this sentence) if on such expiration date the Offer Conditions shall have been
satisfied or waived but there shall not have been tendered that number of Shares
which would equal more than ninety percent (90%) of the issued and outstanding
Shares. Merger Sub agrees that if all of the Offer Conditions are not satisfied
on the Scheduled Expiration Date, then, provided that all such conditions are
and continue to be reasonably probable of being satisfied by the date that is 60
business days after the commencement of the Offer, Merger Sub shall extend the
Offer for one or more periods of not more than ten (10) Business Days each if
requested to do so by the Company; provided that Merger Sub shall not be
required to extend the Offer beyond 60 business days after commencement of the
Offer or, if earlier, the date of termination of this Agreement in accordance
with the terms hereof. On the terms of the Offer and subject to the satisfaction
or waiver of the Offer Conditions and the terms of this Agreement, Merger Sub
shall be obligated to purchase all Shares tendered and not validly withdrawn on
the earliest date that all of the Offer Conditions are first satisfied or waived
and shall pay for all Shares validly tendered and not withdrawn pursuant to the
Offer that Merger Sub becomes obligated to purchase pursuant to the Offer as
soon as practicable after the Scheduled Expiration Date of the Offer.
Notwithstanding any other provision of this Agreement, the Stock Option
Agreement or the Shareholders Agreement, any reference to a majority of the
total issued and outstanding shares or Shares, or shares or Shares outstanding
on a fully diluted basis, or similar references, shall, for purposes of such
agreements, exclude from the determination thereof any shares of Common Stock
issuable upon exercise of or subject to the Stock Option Agreement and any
reference to beneficial ownership of shares of Common Stock or similar
references shall, for purposes of such agreements, exclude from the
determination thereof any shares of Common Stock issuable upon exercise of or
subject to the Stock Option Agreement and/or the Shareholders Agreement.
1.2. SEC Filings.
(a) As soon as reasonably practicable after the execution of
this Agreement, but in any event no later than the date of commencement of the
Offer, Parent and Merger Sub shall file with the SEC a Tender Offer Statement on
Schedule 14D-l with respect to the Offer (as supplemented or amended from time
to time, the "Schedule 14D-l") to provide for the purchase of the issued and
outstanding Shares in accordance with the terms hereof. Parent and Merger Sub
agree, as to this Schedule 14D-l, the Offer to Purchase and related Letter of
Transmittal (which documents, as supplemented or amended from time to time,
together constitute the "Offer Documents") will comply as to form and content in
all material respects with the applicable provisions of the federal securities
laws. The Company and its counsel shall be given an opportunity to review and
comment upon the Offer Documents and any amendment or supplement thereto prior
to the filing thereof with the SEC and Parent and Merger Sub shall consider such
comments in good faith. Parent and Merger Sub agree to provide to the Company
and its
-3-
<PAGE> 7
counsel any comments which Parent, Merger Sub or their counsel may receive from
the Staff of the SEC promptly after receipt thereof, and any proposed responses
thereto, with respect to the Offer Documents and any amendment or supplement
thereto. Parent, Merger Sub and the Company agree to correct promptly any
information provided by any of them for use in the Offer Documents which shall
have become false or misleading in any material respect, and Parent and Merger
Sub further agree to take all steps necessary to cause the Schedule 14D-l as so
corrected to be filed with the SEC and to disseminate any revised Offer
Documents to the Company's stockholders, in each case as and to the extent
required by the applicable provisions of the federal securities laws.
(b) The Company Board shall recommend acceptance of the Offer
to its Stockholders in a Solicitation/Recommendation on Schedule 14D-9 (as
supplemented or amended from time to time, the "Schedule 14D-9"), provided,
however, that the Company Board may thereafter amend or withdraw its
recommendation if it has received an Acquisition Proposal which in accordance
with Section 7.2 is a Superior Proposal. The Company shall file the Schedule
14D-9 with the SEC upon commencement of the Offer which will comply as to form
and content in all material respects with the applicable provisions of the
federal securities laws. The Company will cooperate with Parent and Merger Sub
in mailing or otherwise disseminating the Schedule 14D-9 with the appropriate
Offer Documents to the stockholders of the Company. Parent and its counsel shall
be given an opportunity to review and comment upon the Schedule 14D-9 and any
amendment or supplement thereto prior to the filing thereof with the SEC, and
the Company shall consider any such comments in good faith. The Company agrees
to provide to Parent and Merger Sub and their counsel any comments which the
Company or its counsel may receive from the Staff of the SEC promptly after
receipt thereof, and any proposed responses thereto, with respect to the
Schedule 14D-9 and any amendment or supplement thereto. The Company, Parent and
Merger Sub agree to correct promptly any information provided by any of them for
use in the Schedule 14D-9 which shall have become false or misleading in any
material respect, and the Company further agrees to take all steps necessary to
cause such Schedule 14D-9 as so corrected to be filed with the SEC and
disseminated to the Company's stockholders, in each case as and to the extent
required by the applicable provisions of the federal securities laws. Parent,
Merger Sub and the Company each hereby agree to provide promptly such
information necessary to the preparation of the exhibits and schedules to the
Schedule 14D-9 and the Offer Documents which the respective party responsible
therefor shall reasonably request. The Company represents that CIBC World
Markets Corp. has delivered to the Company Board a written opinion, as of the
date hereof, that the consideration to be paid in the Offer and the Merger is
fair to the holders of the Shares from a financial point of view. The Company
hereby consents to the inclusion in the Offer Documents of the recommendations
and approvals referred to in this Section 1.2, unless the Company Board has
changed or withdrawn its recommendation after receipt of an Acquisition Proposal
that in accordance with Section 7.2 is a Superior Proposal.
-4-
<PAGE> 8
1.3. Company Action.
(a) In connection with the Offer, the Company shall promptly
furnish Merger Sub with such information (including a list of the record holders
of the Company Common Stock and their addresses, as well as mailing labels
containing the names and addresses of all record holders of Shares, any
non-objecting beneficial owner lists and lists of security positions of Shares
held in stock depositories in the Company's possession or control, in each case
as of a recent date), and shall thereafter render such assistance as Parent,
Merger Sub or their agents may reasonably request in communicating the Offer to
the record and beneficial holders of Shares. Subject to the requirements of
applicable law and except for such steps as are necessary to disseminate the
Offer Documents and any other documents necessary to consummate the Offer and
the Merger, Parent and Merger Sub shall (a) hold in confidence the information
contained in any of such labels and lists, (b) use such information only in
connection with the Offer and the Merger and (c) if this Agreement is
terminated, shall, upon request, deliver to the Company or destroy all copies of
such information then in their possession.
1.4 Composition of the Company Board.
(a) Promptly upon the acceptance for payment of, and payment
by Merger Sub in accordance with the Offer for, not less than that number of
Shares equal to the Minimum Condition, Merger Sub shall be entitled to designate
such number of members of the Company Board, rounded up to the next whole
number, equal to that number of directors which equals the product of the total
number of directors on the Company Board (giving effect to the directors elected
pursuant to this sentence) multiplied by the percentage that such number of
Shares owned in the aggregate by Merger Sub or Parent, upon such acceptance for
payment, bears to the number of Shares outstanding. Upon the written request of
Merger Sub, the Company shall, on the date of such request, (i) either increase
the size of the Company Board or use its reasonable efforts to secure the
resignations of such number of its incumbent directors as is necessary to enable
Parent's designees to be so elected to the Company Board and (ii) cause Parent's
designees to be so elected, in each case as may be necessary to comply with the
foregoing provisions of this Section 1.4(a).
(b) The Company's obligation to cause designees of Merger Sub
to be elected or appointed to the Company Board shall be subject to Section
14(f) of the Exchange Act and Rule 14f-l promulgated thereunder. The Company
shall promptly take all actions required pursuant to Section 14(f) and Rule
14f-l in order to fulfill its obligations under this Section 1.4, and shall
include in the Schedule 14D-9 such information with respect to Merger Sub and
its designees as is required under Section 14(f) and Rule 14f-l. Parent and
Merger Sub will supply to the Company in writing and be solely responsible for
any information with respect to any of them and their designees, officers,
directors and affiliates required by Section 14(f) and Rule 14f-l and applicable
-5-
<PAGE> 9
rules and regulations.
(c) After the time that Merger Sub's designees constitute at
least a majority of the Company Board and until the Effective Time, the Company
Board shall always have at least two members (the "Independent Directors") who
are neither officers of Parent nor designees, shareholders or affiliates of
Parent or Parent's affiliates. During such period, any (i) amendment or
termination of this Agreement, (ii) extension of time for the performance or
waiver of the obligations or other acts of Parent or Merger Sub or waiver of the
Company's rights hereunder or (iii) action by the Company with respect to this
Agreement and the transactions contemplated hereby which adversely affects the
interests of the stockholders of the Company, shall require the approval of a
majority of the Independent Directors in addition to any required approval
thereof by the full Company Board. Notwithstanding the foregoing, any amendment
or withdrawal by the Company's Board of its recommendation of the Merger
pursuant to Section 7.3(a) shall require only the approval of the Independent
Directors, and no other action on the part of the Company or any other director
of the Company shall be required to authorize or approve such matter. If the
number of Independent Directors shall be reduced below two for any reason
whatsoever, any remaining Independent Director shall be entitled to designate a
person to fill the vacancy, which designee shall not be a current or former
officer, affiliate of Parent or any of Parent's affiliates, or, if no
Independent Directors then remain, the other directors shall designate two
persons to fill such vacancies who shall not be current or former officers,
affiliates of Parent or any of Parent's affiliates, and such persons shall be
deemed to be Independent Directors for purposes of this Agreement. The Company
Board shall not delegate any matter set forth in this Section 1.4(c) to any
committee of the Company Board.
ARTICLE II
The Merger; Closing; Effective Time
2.1. The Merger. Upon the terms and subject to the conditions
set forth in this Agreement, at the Effective Time (as defined in Section 2.3)
Merger Sub shall be merged with and into the Company and the separate corporate
existence of Merger Sub shall thereupon cease. The Company shall be the
surviving corporation in the Merger (sometimes hereinafter referred to as the
"Surviving Corporation") and shall continue to be governed by the laws of the
State of Delaware, and the separate corporate existence of the Company with all
its rights, privileges, immunities, powers and franchises shall continue
unaffected by the Merger, except as set forth in Articles III and IV. The Merger
shall have the effects specified in the DGCL. Parent, as the sole stockholder of
Merger Sub, hereby approves the Merger and this Agreement.
2.2. Closing. The closing of the Merger (the "Closing") shall
take place (i) at the offices of Fried, Frank, Harris, Shriver & Jacobson, One
New York Plaza, New
-6-
<PAGE> 10
York, New York at 10:00 a.m. on the latest to occur of (A) the business day on
which the condition set forth in Section 8.1(a) shall be satisfied or waived in
accordance with this Agreement and (B) the first business day following the date
on which the last to be satisfied or waived of the other conditions set forth in
Article VIII (other than those conditions that by their nature are to be
satisfied at the Closing, but subject to the satisfaction or waiver of those
conditions) shall be satisfied or waived in accordance with this Agreement, or
(ii) at such other place and time and/or on such other date as the Company and
Parent may agree in writing (the "Closing Date").
2.3. Effective Time. As soon as practicable following the
Closing, the Company will cause a Certificate of Merger (the "Certificate of
Merger") to be executed, acknowledged and filed with the Secretary of State of
Delaware as provided in Section 251 of the DGCL. The Merger shall become
effective at the time when the Certificate of Merger has been duly filed with
the Secretary of State of the State of Delaware or, if agreed to by Parent and
the Company, such later time or date set forth in the Certificate of Merger (the
"Effective Time").
ARTICLE III
Certificate of Incorporation
and Bylaws of the Surviving Corporation
3.1. The Certificate of Incorporation. The certificate of
incorporation of Merger Sub as in effect immediately prior to the Effective Time
shall be the certificate of incorporation of the Surviving Corporation (the
"Charter"), except that Article FIRST of the Charter shall be amended to provide
that the name of the Surviving Corporation shall be the name of the Company.
3.2. The Bylaws. The bylaws of Merger Sub in effect
immediately prior to the Effective Time shall be the bylaws of the Surviving
Corporation (the "Bylaws"), until thereafter amended as provided therein or by
applicable law.
ARTICLE IV
Officers and Directors
of the Surviving Corporation
4.1. Directors. The directors of Merger Sub immediately prior
to the Effective Time shall, from and after the Effective Time, be the directors
of the Surviving Corporation until their successors have been duly elected or
appointed and qualified or until their earlier death, resignation or removal in
accordance with the Charter and Bylaws. Subject to the consummation of the Offer
and the purchase by Merger Sub of at
-7-
<PAGE> 11
least that number of shares equal to the Minimum Condition, prior to the
Effective Time, the Company shall take all actions necessary to obtain any
resignations of its directors necessary to give effect to the provisions of this
Section.
4.2. Officers. The officers of the Company immediately prior
to the Effective Time shall, from and after the Effective Time, be the officers
of the Surviving Corporation until their successors have been duly elected or
appointed and qualified or until their earlier death, resignation or removal in
accordance with the Charter and Bylaws.
ARTICLE V
Effect of the Merger on Capital Stock;
Exchange of Certificates
5.1. Effect on Capital Stock. At the Effective Time, as a
result of the Merger and without any action on the part of the Company, Parent,
Merger Sub or any holder of any capital stock of the Company:
(a) Merger Consideration. (i) Each Share issued and
outstanding immediately prior to the Effective Time (other than (A) Shares owned
by Parent or any direct or indirect Subsidiary of Parent (collectively, the
"Parent Companies"), (B) Dissenting Shares (as defined below), (C) or Shares
that are owned by the Company or any direct or indirect Subsidiary of the
Company (and in each case not held on behalf of third Parties) (collectively,
"Excluded Shares")) shall be converted into, and become exchangeable for the
right to receive the Price Per Share in cash (the "Merger Consideration").
(ii) At the Effective Time, all Shares shall no longer be
outstanding and shall be canceled and retired and shall cease to exist, and each
certificate (a "Certificate") formerly representing any of such Shares (other
than Excluded Shares) shall thereafter represent only the right to receive the
Merger Consideration.
(b) Cancellation of Excluded Shares. Each Excluded Share
issued and outstanding immediately prior to the Effective Time shall, by virtue
of the Merger and without any action on the part of the holder thereof, cease to
be outstanding, shall be canceled and retired without payment of any
consideration therefor and shall cease to exist.
(c) Merger Sub. As of and following the Effective Time, each
share of Common Stock, par value $.01 per share, of Merger Sub issued and
outstanding immediately prior to the Effective Time shall continue to remain
outstanding and shall constitute one share of common stock of the Surviving
Corporation.
-8-
<PAGE> 12
5.2. Surrender and Payment.
(a) Exchange Agent. Prior to the Effective Time, Parent shall
designate a bank or trust company reasonably acceptable to the Company to act as
agent for the holders of Shares in connection with the Merger (the "Exchange
Agent") to receive the Merger Consideration to which holders of Shares shall
become entitled pursuant to Section 5.1. Prior to the filing of the Certificate
of Merger with the Secretary of State of the State of Delaware, Parent or Merger
Sub shall deposit with the Exchange Agent cash in an aggregate amount equal to
the product of (i) the number of Shares outstanding (and not to be canceled
pursuant to Section 5.1(b)) immediately prior to the Effective Time, multiplied
by (ii) the Merger Consideration. The deposit made by Parent or Merger Sub
pursuant to the preceding sentence is hereinafter referred to as (the "Payment
Fund") . The Exchange Agent shall cause the Payment Fund to be (i) held for the
benefit of the holders of Shares and (ii) promptly applied to making the
payments provided for in Section 5.1(a). The Payment Fund shall not be used for
any purpose that is not provided for herein.
(b) Exchange Procedures. As soon as reasonably practicable
after the Effective Time, Parent shall cause the Exchange Agent to mail to each
holder of record of a certificate or certificates (the "Certificates") which
immediately prior to the Effective Time represented outstanding Shares, other
than shares to be canceled in accordance with Section 5.1(b), (i) a Letter of
Transmittal (which shall specify that delivery shall be effected, and risk of
loss and title to the Certificates shall pass, only upon delivery of the
Certificates to the Exchange Agent) and (ii) instructions for use in effecting
the surrender of the Certificates in exchange for the Merger Consideration. Upon
surrender of a Certificate for cancellation to the Exchange Agent, together with
such Letter of Transmittal, duly executed, and such other documents as may
reasonably be required by the Exchange Agent, the Exchange Agent shall pay the
holder of such Certificate the Merger Consideration in respect of such
Certificate, less any required withholding taxes, and the Certificate so
surrendered shall forthwith be canceled. If any portion of the Merger
Consideration is to be paid to a Person other than the registered holder of the
shares represented by the Certificate or Certificates surrendered in exchange
therefor, it shall be a condition to such payment that the Certificate or
Certificates so surrendered shall be properly endorsed or otherwise be in proper
form for transfer and that the Person requesting such payment shall pay to the
Exchange Agent any transfer or other taxes required as a result of such payment
to a Person other than the registered holder of such shares or establish to the
satisfaction of the Exchange Agent that such tax has been paid or is not
payable. Until surrendered as contemplated by this Section 5.2, each Certificate
-9-
<PAGE> 13
(other than Certificates representing Dissenting Shares (as defined below) or
Shares to be canceled pursuant to Section 5.1(b)) shall be deemed at any time
after the Effective Time to represent only the right to receive the Merger
Consideration upon such surrender.
(c) No Further Ownership Rights in Company Common Stock. All
Merger Consideration paid upon the surrender for exchange of Certificates in
accordance with the terms of this Article V shall be deemed to have been paid in
full satisfaction of all rights pertaining to the Shares theretofore represented
by such Certificates. There shall be no further registration of transfers on the
stock transfer books of the Surviving Corporation of the Shares which were
outstanding immediately prior to the Effective Time. If, after the Effective
Time, Certificates are presented to the Surviving Corporation or the Exchange
Agent for any reason, they shall be canceled and exchanged as provided in this
Article V, except as otherwise provided by law.
(d) Unclaimed Funds. Any portion of the Payment Fund made
available to the Exchange Agent pursuant to Section 5.2(a) that remains
unclaimed by holders of the Certificates for six months after the Effective Time
shall be delivered to the Surviving Corporation or a United States parent
thereof, upon demand, and any holders of Certificates who have not theretofore
complied with this Article V shall thereafter look only to Parent for payment of
their claim for Merger Consideration.
(e) No Liability. None of Parent, Merger Sub, the Company or
the Exchange Agent shall be liable to any Person in respect of any Merger
Consideration delivered to a public official pursuant to any applicable
abandoned property, escheat or similar law. If any Certificate has not been
surrendered prior to five years after the Effective Time (or immediately prior
to such earlier date on which Merger Consideration in respect of such
Certificate would otherwise escheat to or become the property of any public
official), any such shares, cash, dividends or distributions in respect of such
Certificate shall, to the extent permitted by applicable law, become the
property of the Surviving Corporation, free and clear of all claims or interest
of any person previously entitled thereto.
(f) Investment of Funds. The Payment Fund shall be invested by
the Exchange Agent in obligations of, or guaranteed by, the United States of
America, in commercial paper obligations rated A-l or P-l or better by Moody's
Investor Services or Standard & Poor's Corporation, respectively, in each case
with maturities not exceeding seven days. All earnings thereon shall inure to
the benefit of Parent or Merger Sub.
(g) Lost Certificates. In the event that any Certificate shall
have been lost, stolen or destroyed, upon the making of an affidavit of that
fact by the Person claiming such Certificate to be lost, stolen or destroyed
and, if required by Parent, the granting of an indemnity reasonably satisfactory
to Parent against any claim that may be made against it, the Surviving
Corporation or the Exchange Agent, with respect to such
-10-
<PAGE> 14
Certificate, the Exchange Agent will issue in exchange for such lost, stolen or
destroyed Certificate the Merger Consideration with respect to such Certificate,
to which such Person is entitled pursuant hereto.
(h) Dissenting Shares. Notwithstanding anything in this
Agreement to the contrary, Shares outstanding immediately prior to the Effective
Time and held by a holder who has not voted in favor of the Merger or consented
thereto in writing and who has demanded appraisal for such shares in accordance
with the DCCL (the "Dissenting Shares"), shall not be converted into a right to
receive the Merger Consideration, unless such holder fails to perfect or
withdraws or otherwise loses its right to appraisal. If after the Effective Time
such holder fails to perfect or withdraws or loses its right to appraisal, such
shares shall be treated as if they had been converted as of the Effective Time
into a right to receive the Merger Consideration. The Company shall give Parent
prompt notice of any demands received by the Company for appraisal of Shares,
and Parent shall have the right to participate in all negotiations and
proceedings with respect to such demands. The Company shall not, except with the
prior written consent of Parent, make any payment with respect to, or settle or
offer to settle, any such demands except as otherwise required under applicable
law.
5.3. Adjustment of Merger Consideration. In the event that,
subsequent to the date of this Agreement but prior to the Effective Time, the
outstanding Shares shall have been changed into a different number of shares or
a different class as a result of a stock split, reverse stock split, stock
dividend, subdivision, reclassification, split, combination, exchange,
recapitalization or other similar transaction, the Merger Consideration shall be
appropriately adjusted.
5.4. Merger Without Meeting of Stockholders. In the event that
Merger Sub, or any other direct or indirect subsidiary of Purchaser, shall
acquire at least 90 percent of the outstanding Shares, the parties hereto shall
take all necessary and appropriate action to cause the Merger to become
effective as soon as practicable after the expiration of the Offer without a
vote of stockholders of the Company, in accordance with Section 253 of the DGCL.
5.5. Treatment of Convertible Preferred Stock. The Convertible
Preferred Stock (as defined in Section 6.1(b)) shall be treated as set forth in
Section 7.13.
ARTICLE VI
Representations and Warranties
6.1. Representations and Warranties of the Company. The
Company hereby represents and warrants to Parent and Merger Sub, except as set
forth in the Company Reports (as defined in Section 6.1(e)) or in the Disclosure
Schedule delivered
-11-
<PAGE> 15
to Parent on the date of this Agreement (the "Company Disclosure Schedule"), as
follows:
(a) Organization, Good Standing and Qualification. Each of the
Company and its Subsidiaries is a corporation duly organized, validly existing
and in good standing (where such concept is recognized) under the laws of its
respective jurisdiction of organization and has all requisite corporate power
and authority to own and operate its properties and assets and to carry on its
business as presently conducted and is qualified to do business and is in good
standing as a foreign corporation in each jurisdiction (where such concept is
recognized) where the ownership or operation of its properties or conduct of its
business requires such qualification, except where the failure to be so
qualified or in such good standing, when taken together with all other such
failures, is not reasonably likely to have a Company Material Adverse Effect (as
defined below) or materially impair the ability of the Company, the Surviving
Corporation, Parent or any of their respective affiliates, following
consummation of the Offer or the Merger, to conduct any material business or
operations in any jurisdiction where they are now being conducted. The Company
has made available to Parent a complete and correct copy of the Company's and
its Subsidiaries' certificates of incorporation and bylaws (or documents of a
similar scope for corporations organized in jurisdictions outside the United
States), each as amended to date. The Company's and its Subsidiaries'
certificates of incorporation and bylaws (or similar documents) so made
available are in full force and effect.
As used in this Agreement, (i) "Subsidiary" means, with
respect to the Company, Parent or Merger Sub, as the case may be, any entity,
whether incorporated or unincorporated, of which at least a majority of the
securities or ownership interests having by their terms ordinary voting power to
elect a majority of the board of directors or other persons performing similar
functions is directly or indirectly owned or controlled by such party or by one
or more of its respective Subsidiaries or by such party and any one or more of
its respective Subsidiaries, and (ii) "Company Material Adverse Effect" means
any change in or effect on the business of the Company and its Subsidiaries that
is, or is reasonably likely to be, materially adverse to the business,
operations or assets (including intangible assets), liabilities (contingent or
otherwise), prospects, condition (financial or otherwise) of the Company and its
Subsidiaries, taken as a whole. In no event shall any of the following
constitute, or be taken into account in determining whether there has been or is
likely to be, a "Company Material Adverse Effect": (i) an adverse change in the
trading price of the Company's Common Stock between the date of this Agreement
and the Effective Time, in and of itself, (ii) any adverse conditions, events,
circumstances, changes or effects generally affecting the industry in which the
Company operates or arising from changes in general business or economic
conditions, (iii) any adverse conditions, events, circumstances, changes or
effects attributable to expenses (including without limitation legal, accounting
and financial consulting fees and expenses) incurred in connection with the
transactions contemplated by this Agreement,
-12-
<PAGE> 16
(iv) any conditions events, circumstances, changes or effects resulting from any
change in law or generally accepted accounting principles, which affect
generally entities such as the Company, or (v) any adverse conditions, events,
circumstances, changes or effects resulting from compliance by the Company with,
or the taking of any action required or contemplated by, the terms of this
Agreement or any other agreement entered into by the Company with Parent or
Merger Sub in connection with the transactions contemplated by this Agreement or
(vi) any event or condition referred to on Schedule 6.1(a).
(b) Capital Structure. The authorized capital stock of the
Company consists of 25,000,000 Shares, of which only 9,703,769 Shares were
outstanding as of the close of business on July 23, 1999, and 5,000,000 shares
of Preferred Stock, par value $0.001 per share (the "Preferred Shares"), of
which 150,000 shares have been designated Series A Junior Participating
Preferred Stock, none of which were outstanding as of the close of business on
July 23, 1999, one share has been designated as Series B Convertible Preferred
Stock, which share was outstanding as of the close of business on July 23, 1999.
All of the outstanding Shares have been duly authorized and are validly issued,
fully paid and nonassessable. Other than Shares reserved for issuance pursuant
to the Stock Option Agreement, the Company has no Shares or Preferred Shares
subject to issuance, except (i) 150,000 Preferred Shares, designated Series A
Junior Participating Preferred Stock, subject to issuance upon exercise of the
Rights (the "Rights") issued pursuant to the Rights Agreement, dated as of March
17, 1997 (the "Rights Agreement"), between the Company and ChaseMellon
Shareholder Services, L.L.C., as Rights Agent, (ii) one share of Series B
Convertible Preferred Stock, which was outstanding as of July 23, 1999, (iii)
2,513,141 shares reserved for issuance under the Company's 1996 Equity Incentive
Plan, as amended, of which options to acquire 1,057,205 shares are outstanding
as of July 23, 1999, (iv) 500,000 shares reserved for issuance under the
Company's Employee Stock Purchase Plan, of which 416,581 shares are available
for purchase as of July 23, 1999, (v) 235,000 shares reserved for issuance under
the Company's 1996 Non-Employee Directors' Stock Option Plan, of which options
to acquire 65,000 shares are outstanding as of July 23, 1999, (vi) 219,304
shares reserved for issuance under the Company's Amended and Restated 1992 Stock
Option and Restricted Stock Plan, of which options to acquire 219,304 shares are
outstanding as of July 23, 1999, (vii) 205,487 shares outstanding under the
Management Change of Control Plan and (viii) 1,410 shares outstanding under the
1981 Employee Stock Option Plan. The Company Disclosure Schedule sets forth a
correct and complete list of each outstanding option to purchase Shares under
the Stock Plans, as defined below (each a "Company Option"), as of July 23,
1999, including the holder, date of grant, exercise price and number of Shares
subject thereto. As of July 23, 1999, there are no shares of capital stock of
the Company authorized, issued or outstanding and except as set forth above,
there are no preemptive rights or any outstanding subscriptions, options,
warrants, rights, convertible securities or other agreements or commitments of
any character to which the Company is a party or may be bound relating to the
issued or unissued capital stock or other securities of the Company and the
Shares subject to the Stock Option Agreement
-13-
<PAGE> 17
shall not be subject to any preemptive rights. The Company does not have
outstanding any bonds, debentures, notes or other obligations the holders of
which have the right to vote (or convertible into or exercisable for securities
having the right to vote) with the stockholders of the Company on any matter
("Voting Debt"). Except for the Company's 1996 Equity Incentive Plan, 1996
Non-Employee Directors' Stock Option Plan, Employee Stock Purchase Plan, the
Amended and Restated 1992 Stock Option and Restricted Stock Plan and Management
Change of Control Plan and the 1981 Employee Stock Option Plan (such plans
collectively, the "Stock Plans"), at or after the Effective Time, neither the
Surviving Corporation nor Parent nor their respective affiliates will have any
obligation to issue, transfer or sell any shares or securities of the Surviving
Corporation, Parent or any of their respective affiliates pursuant to any
Compensation and Benefit Plan (as defined in Section 6.1(h)(i)) which
obligations were outstanding as of July 23, 1999. No Shares, Preferred Shares or
other securities of the Company, the Surviving Corporation, Parent or any of
their respective affiliates will be subject to issuance pursuant to the Rights
Agreement as a result of the Offer, the Merger or the other transactions
contemplated by this Agreement, the Stock Option Agreement and the Shareholders
Agreement and no Distribution Date or Shares Acquisition Date (as such terms are
defined in the Rights Agreement) shall have occurred as a result of the Offer,
the Merger or the other transactions contemplated by this Agreement, the Stock
Option Agreement or the Shareholders Agreement.
(c) Corporate Authority; Approval. (i) The Company has all
requisite corporate power and authority and has taken all corporate action
necessary in order to execute, deliver and perform its obligations under this
Agreement and the Stock Option Agreement and to consummate the Offer and,
subject only to obtaining the adoption of this Agreement by a majority of the
Shares outstanding as of the record date of the Company's stockholders meeting
(the "Company Requisite Vote"), the Merger. This Agreement and the Stock Option
Agreement are valid and binding agreements of the Company, enforceable against
the Company in accordance with their respective terms subject to (i) applicable
bankruptcy, insolvency, reorganization, fraudulent transfer, moratorium or
similar laws from time to time in effect affecting creditors' rights generally,
and (ii) general principles of equity including, without limitation, standards
of materiality, good faith, fair dealing and reasonableness, whether such
principles are considered in a proceeding of law or in equity.
(ii) The Company Board has, at a meeting duly called and held,
(A) unanimously approved this Agreement and the Stock Option Agreement, the
Offer and the Merger and the transactions contemplated hereby in accordance with
the DGCL, (B) determined that the Offer and the Merger are fair to and in the
best interests of the Company's stockholders, and (C) recommended that the
stockholders of the Company tender their shares of Company Common Stock into the
Offer and adopt this Agreement.
-14-
<PAGE> 18
(d) Governmental Filings; No Violations. (i) Other than any
filings and/or notices required (A) pursuant to Section 2.3, (B) under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act")
the Exchange Act and state securities or "blue sky" laws and (C) such filings or
consents, registrations, approvals, permits or authorizations as may be required
under the competition or antitrust laws of jurisdictions outside the United
States, no notices or other filings are required to be made with, nor are any
consents, registrations, approvals, permits or authorizations required to be
obtained by the Company from, any U.S. governmental or regulatory authority,
agency, commission, body or other governmental entity ("Governmental Entity"),
in connection with the execution and delivery of this Agreement and the Stock
Option Agreement by the Company and the consummation by the Company of the Offer
and the Merger and the other transactions contemplated hereby and thereby,
except those that the failure to make or obtain are not, individually or in the
aggregate, reasonably likely to have a Company Material Adverse Effect or
prevent, materially delay or materially impair the ability of the Company to
consummate the transactions contemplated by this Agreement and the Stock Option
Agreement.
(ii) Except as set forth in Schedule 6.1(d) (ii), the
execution, delivery and performance of this Agreement and the Stock Option
Agreement by the Company do not and will not, and the consummation by the
Company of the Offer and the Merger and the other transactions contemplated
hereby and thereby will not, constitute or result in (A) a breach or violation
of, or a default under, the certificate or bylaws of the Company or the
comparable governing instruments of any of its Subsidiaries, (B) a breach or
violation of, or a default under, the acceleration of any obligations or the
creation of a lien, pledge, security interest or other encumbrance on the assets
of the Company or any of its Subsidiaries (with or without notice, lapse of time
or both) pursuant to, any agreement, lease, contract, note, mortgage, indenture
or other obligation ("Contracts") binding upon the Company or any of its
Subsidiaries or any Law (as defined in Section 6.1(i)) or governmental or
non-governmental permit or license to which the Company or any of its
Subsidiaries is subject, or (C) any change in the rights or obligations of any
party under any of the Contracts, except, in the case of clause (B) or (C)
above, for any breach, violation, default, acceleration, creation or change
that, individually or in the aggregate, is not reasonably likely to have a
Company Material Adverse Effect or prevent, materially delay or materially
impair the ability of the Company to consummate the transactions contemplated by
this Agreement and the Stock Option Agreement. Schedule 6.1(d)(ii) sets forth a
correct and complete list of all consents and waivers which are or may be
required in connection with the consummation of the transactions contemplated by
this Agreement and the Stock Option Agreement (whether or not subject to the
exception set forth with respect to clause (B) or (C) above) under Contracts to
which the Company or any of its Subsidiaries is a party, other than any consent
or waiver (other than consents or waivers pursuant to Contracts relating to
indebtedness, securities or the guarantee thereof) the failure to obtain which
is not reasonably likely to have a Company Material Adverse Effect.
-15-
<PAGE> 19
(e) Company Reports; Financial Statements. The Company and, to
the extent applicable, each of its then or current Subsidiaries has made all
filings required to be made by it with the SEC since January 1, 1998
(collectively, including any such reports filed subsequent to the date hereof,
the "Company Reports"). The Company has made available to Parent each
registration statement, report, proxy statement or information statement filed
with the SEC by it since December 31, 1996, including, without limitation, (i)
the Company's Annual Report on Form 10-K for the year ended December 31, 1998,
(ii) the Company's Quarterly Report for the quarter ended March 31, 1999, as
amended, (iii) the Company's Proxy Statement filed on April 12, 1999, all in the
form (including exhibits, annexes and any amendments thereto) filed with the
SEC. Except as set forth in Schedule 6.1(e), as of their respective dates, the
Company Reports did not, and any Company Reports filed with the SEC prior to the
expiration of the Offer will not, contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements made therein, in light of the circumstances in which they
were made, not misleading. Each of the consolidated balance sheets included in
or incorporated by reference into the Company Reports (including the related
notes and schedules) presents fairly, or will present fairly, in all material
respects, the consolidated financial position of the Company and its
Subsidiaries as of its date and each of the consolidated statements of income
and of changes in financial position included in or incorporated by reference
into the Company Reports (including any related notes and schedules) presents
fairly, or will present fairly, in all material respects, the results of
operations, retained earnings and changes in financial position, as the case may
be, of the Company and its Subsidiaries for the periods set forth therein
(except as otherwise noted therein and subject, in the case of unaudited
statements, to notes and normal year-end audit adjustments that will not be
material in amount or effect), in each case in accordance with generally
accepted accounting principles ("GAAP") consistently applied during the periods
involved, except, in the case of unaudited financial statements, as permitted by
SEC Form 10-Q, and except as may be noted therein. Other than the Company
Reports specifically recited in clauses (i) through (v) of the first sentence of
this Section 6.1(e), the Company has not, on or prior to the date hereof, filed
any other definitive reports or statements with the SEC since the Audit Date (as
defined in Section 6.1(f)).
(f) Absence of Certain Changes. Except as disclosed in the
Company Reports filed prior to the date of this Agreement or in Schedule 6.1(f),
since December 31, 1998 (the "Audit Date") the Company and its Subsidiaries have
conducted their respective businesses in all material respects only in, and have
not engaged in any material transaction other than according to, the ordinary
and usual course of such businesses and there has not been (i) any change in the
financial condition, properties, business or results of operations of the
Company or any of its Subsidiaries or any occurrence or combination of
occurrences of which the Company has knowledge that, individually or in the
aggregate, has had or is reasonably likely to have a Company Material Adverse
Effect; (ii) any material damage, destruction or other casualty loss with
-16-
<PAGE> 20
respect to any material asset or property owned, leased or otherwise used by the
Company or any of its Subsidiaries, that has had or is reasonably likely to have
a Company Material Adverse Effect; (iii) any declaration, setting aside or
payment of any dividend or other distribution in respect of the capital stock of
the Company; or (iv) other than as set forth in Schedule 6.1(f), any material
change by the Company in accounting principles, practices or methods. Schedule
6.1(f) contains a document setting forth the name, title, salary and other
compensation of each employee of the Company as of July 23, 1999. Since the date
of such document, there has not been any increase in the compensation payable or
that could become payable by the Company or any of its Subsidiaries to officers
or key employees of the Company or its Subsidiaries, or any amendment of any of
the Stock Plans or compensation and Benefit Plans.
(g) Litigation and Liabilities. Except as disclosed in
Schedule 6.1(g) or as disclosed in the Company Reports filed prior to the date
of this Agreement, and except for matters which are not, individually or in the
aggregate, reasonably likely to have a Company Material Adverse Effect or
prevent or materially delay or materially impair the ability of the Company to
consummate the transactions contemplated by this Agreement, the Stock Option
Agreement and the License Agreement, there are no (i) civil, criminal,
administrative or regulatory actions, suits, claims, hearings, investigations or
proceedings pending or, to the knowledge of the Company, overtly threatened
against the Company or any of its Subsidiaries or (ii) material obligations or
liabilities, whether or not accrued, contingent or otherwise and whether or not
required to be disclosed, including those relating to matters involving any
Environmental Law (as defined in Section 6.1(k)).
(h) Employee Benefits.
(i) The Company Reports accurately describe in all
material respects all material incentive, bonus, deferred compensation, pension,
retirement, profit-sharing, thrift, savings, employee stock ownership, stock
bonus, stock purchase, restricted stock, stock option and other stock based
plans, all employment or severance agreements, plans, policies or arrangements,
other employee benefit plans and any applicable "change of control" or similar
provisions in any plan, agreement, policy or arrangement which covers current or
former employees of the Company and its Subsidiaries (the "Compensation and
Benefit Plans") or with respect to which the Company or any of its Subsidiaries
may have any liability. The Compensation and Benefit Plans and all other benefit
plans, agreements, policies or arrangements covering current or former employees
or directors of the Company and its Subsidiaries (the "Employees"), including,
but not limited to, "employee benefit plans" within the meaning of Section 3(3)
of the Employee Retirement Income Security Act of 1974, as amended ("ERISA"),
are listed in Schedule 6.1(h)(i). True and complete copies of all documents
embodying the Compensation and Benefit Plans, including written interpretations
thereof, and such other benefit plans, agreements, policies or arrangements,
including, but not limited to, any
-17-
<PAGE> 21
trust instruments and/or insurance contracts, if any, forming a part of any such
plans and agreements, and all amendments thereto have been provided or made
available to Parent.
(ii) The Compensation and Benefit Plans have been
administered in compliance with their terms and all applicable law, except where
the failure to administer in compliance would not have or be reasonably likely
to have a Company Material Adverse Effect. Each Plan which is an "employee
pension benefit plan" within the meaning of Section 3(2) of ERISA ("Pension
Plan") and which is intended to be qualified under Section 401(a) of the
Internal Revenue Code of 1986, as amended (the "Code") is so qualified, and has
received a favorable determination letter from the Internal Revenue Service, and
the Company is not aware of any circumstances likely to result in revocation of
any such favorable determination letter. There is no material pending or, to the
knowledge of the Company, threatened, litigation, audit or investigation
relating to any Compensation and Benefit Plan. Neither the Company nor any of
its Subsidiaries has engaged in a transaction with respect to any Compensation
and Benefit Plan that, assuming the taxable period of such transaction expired
as of the date hereof, could subject the Company or any of its Subsidiaries to a
tax or penalty imposed by either Section 4975 of the Code or Section 502(i) of
ERISA in an amount which would be material.
(iii) Neither the Company nor any of its Subsidiaries
has, nor has ever had, any obligation or liability with respect to an employee
benefit plan which is subject to Title IV of ERISA. There is no entity (other
than the Company or any of its Subsidiaries) which is or was considered one
employer with the Company or any of its Subsidiaries under Section 4001 of ERISA
or Section 414 of the Code (an "ERISA Affiliate"). No notice of a "reportable
event," within the meaning of Section 4043 of ERISA for which the 30-day
reporting requirement has not been waived, has been required to be filed for any
Compensation and Benefit Plan within the 12-month period ending on the date
hereof.
(iv) Except as set forth in Schedule 6.1(h)(iv), all
contributions required to be made under the terms of any Compensation and
Benefit Plan have been timely made or accrued on the Company's financial
statements.
(v) Neither the Company nor any of its Subsidiaries has
any obligations for retiree health and life benefits under any Compensation and
Benefit Plan, except as set forth on Schedule 6.1(h)(v). The Company or its
Subsidiaries may amend or terminate any Compensation and Benefit Plan at any
time without incurring any material liability thereunder.
(vi) Except as set forth on Schedule 6.1(h)(vi), the
consummation of the transactions contemplated by this Agreement will not (x)
entitle any Employees to severance pay, (y) accelerate the time of payment or
vesting or trigger any material
-18-
<PAGE> 22
payment or funding (through a grantor trust or otherwise) of compensation or
benefits under, materially increase the amount payable or trigger any other
material obligation pursuant to, any of the Compensation and Benefit Plans or
(z) result in payments under any of the Compensation and Benefit Plans which may
not be deductible under Section 162(m) or Section 280G of the Code.
(i) Compliance. Except as set forth in Schedule 6.1(i),
neither the Company nor any of its Subsidiaries is in default or violation of,
(i) any law, ordinance, rule, regulation, order, judgment, decree, arbitration
award, license or permit of any Governmental Entity (collectively, "Laws")
applicable to the Company or any of its Subsidiaries or by which its or any of
their respective properties are bound, or (ii) any Contract to which the Company
or any of its Subsidiaries is a party or by which the Company or any of its
Subsidiaries or its or any of their respective properties are bound or affected,
except for any such defaults or violations that, individually or in the
aggregate, are not reasonably likely to have a Company Material Adverse Effect,
or prevent or materially delay the transactions contemplated by this Agreement.
To the knowledge of the Company, no material change is required in the Company's
or any of its Subsidiaries' processes, properties or procedures in order to
comply in all material respects with any material Laws, and the Company has not
received any notice or overt communication of any material noncompliance with
any such material Laws that has not been cured.
(j) Antitakeover Statutes. The board of directors of the
Company has taken all necessary action to approve the transactions contemplated
by this Agreement, the Stock Option Agreement and the Shareholders Agreement
such that the restrictions under Section 203 of the DGCL shall not apply to such
transactions. No "fair price," "moratorium," "control share acquisition" or
other similar antitakeover statute or regulation (each, an "Antitakeover
Statute") is applicable to the Company, the Shares, the Offer, the Merger, this
Agreement, the Stock Option Agreement, the Shareholders Agreement or the other
transactions hereby or thereby.
(k) Environmental Matters. Except as disclosed in the Company
Reports filed with the Commission to the date of this Agreement or in Schedule
6.1(k) and except as would not have or be reasonably likely to have a Company
Material Adverse Effect, (i) the Company and its Subsidiaries have complied in
all material respects at all times with all applicable Environmental Laws; (ii)
to the knowledge of the Company, no property currently or formerly owned or
operated by the Company or any of its Subsidiaries (including soils,
groundwater, surface water, buildings or other structures) has been contaminated
with any Hazardous Substance; (iii) to the knowledge of the Company, neither the
Company nor any of its Subsidiaries is subject to any liability for Hazardous
Substance disposal or contamination on any third party property; (iv) to the
knowledge of the Company, neither the Company nor any of its Subsidiaries is
subject to liability for any release or threat of release of any Hazardous
Substance; (v)
-19-
<PAGE> 23
neither the Company nor any of its Subsidiaries has received any notice, demand,
letter, claim or request for information indicating that it may be in violation
of or subject to liability under any Environmental Law; (vi) neither the Company
nor any of its Subsidiaries is subject to any order, decree, injunction or other
arrangement with any Governmental Entity or any indemnity or other agreement
with any third party relating to liability under any Environmental Law; (vii) to
the knowledge or the Company, none of the properties of the Company or any of
its Subsidiaries contain any underground storage tanks, asbestos-containing
material, lead products, or polychlorinated biphenyls; (viii) to the knowledge
of the Company, there are no other circumstances or conditions involving the
Company or any of its Subsidiaries that could reasonably be expected to result
in any claims, liability, investigations, costs or restrictions on the
ownership, use, or transfer of any property in connection with any Environmental
Law; and (ix) the Company has delivered or made available to Parent copies of
all environmental reports, studies, assessments, sampling data and other
environmental information in its possession relating to the Company or any of
its Subsidiaries or any of their current or former properties or operations.
"Environmental Law" means any federal, state or local law,
regulation, order, decree, permit, authorization, common law or agency
requirement relating to (A) the protection, investigation or restoration of the
environment, health, safety, or natural resources, (B) the handling, use,
presence, disposal, release or threatened release of any Hazardous Substance or
(C) noise, odor, indoor air, employee exposure, wetlands, pollution,
contamination or any injury or threat of injury to persons or property relating
to any Hazardous Substance.
"Hazardous Substance" means any substance that is (A) listed,
classified or regulated pursuant to any Environmental Law; (B) any chemical,
petroleum product or by-product, asbestos-containing material, lead-containing
paint or plumbing, polychlorinated biphenyls, radioactive materials or radon,
pharmaceutical, biological and/or medical waste or materials; or (C) any other
substance which may be the subject of regulatory action by any Governmental
Authority in connection with any Environmental Law.
(l) Opinion of Financial Advisor. The Company's Board has
received the written opinion of CIBC World Markets Corp. to the effect that, as
of the date hereof, the consideration to be received by the holders of Shares
pursuant to the Offer and the Merger is fair to such holders from a financial
point of view.
(m) Taxation. The Company and each of its Subsidiaries, and
any consolidated, combined or unitary group for tax purposes of which the
Company or any of its Subsidiaries is or has been a member, has timely filed all
Tax Returns required to be filed by it in the manner provided by law except
where the failure to have so filed would not have or be reasonably likely to
have a Company Material Adverse Effect. All
-20-
<PAGE> 24
such Tax Returns are true, correct and complete in all material respects. The
Company and each of its Subsidiaries have timely paid all Taxes due or required
to be withheld from amounts owing to any employee, creditor or third party or
have provided adequate reserves in their financial statements for any Taxes that
have not been paid, whether or not shown as being due on any Tax Returns. Except
as has been disclosed to Parent in Schedule 6.1(m): (i) no material claim for
unpaid Taxes has become a lien or encumbrance of any kind against the property
of the Company or any of its Subsidiaries or is being asserted against the
Company or any of its Subsidiaries; (ii) no audit, examination, investigation or
other proceeding in respect of Taxes is pending being conducted, or to the
knowledge of the Company, threatened by a Tax authority; (iii) no material
issues have been raised by the relevant taxing authority in connection with any
examination of the Tax Returns filed by the Company and its Subsidiaries; (iv)
no extension or waiver of the statute of limitations on the assessment of any
Taxes has been granted by the Company or any of its Subsidiaries and is
currently in effect; (v) neither the Company nor any of its Subsidiaries is a
party to, is bound by, or has any obligation under, or potential liability with
regards to, any Tax sharing agreement, Tax indemnification agreement or similar
contract or arrangement; (vi) no power of attorney has been granted by or with
respect to the Company or any of its Subsidiaries with respect to any matter
relating to Taxes; (vii) neither the Company nor any of its Subsidiaries is a
party to any agreement, plan, contract or arrangement that would result,
separately or in the aggregate, in the payment of any "excess parachute
payments" within the meaning of Section 280G of the Code; (viii) neither the
Company nor any of its Subsidiaries has any deferred intercompany gain or loss
arising as a result of a deferred intercompany transaction within the meaning of
Treasury Regulation Section 1.1502-13 (or similar provision under state, local
or foreign law) or any excess loss accounts within the meaning of Treasury
Regulation Section 1.1502-19; (ix) the Company is not and has not been a United
States real property holding corporation (as defined in Section 897(c)(2) of the
Code) during the applicable period specified in Section 897(c)(1)(ii) of the
Code; (x) neither the Company nor any of its Subsidiaries has been the subject
to a Tax ruling that has continuing effect; and (xi) neither the Company nor any
of its Subsidiaries has agreed to include, or is required to include, in income
any adjustment under either Section 481(a) or 482 of the Code (or an analogous
provision of state, local or foreign law) by reason of a change in accounting
method or otherwise.
"Taxes" means any taxes of any kind, including but not limited
to those on or measured by or referred to as income, gross receipts, capital,
sales, use, ad valorem, franchise, profits, license, withholding, employment,
payroll, premium, value added, property or windfall profits taxes, environmental
transfer taxes, customs, duties or similar fees, assessments or charges of any
kind whatsoever, together with any interest and any penalties, additions to tax
or additional amounts imposed by any governmental authority, domestic or
foreign.
-21-
<PAGE> 25
"Tax Return" means any return, report or statement required to
be filed with any governmental authority with respect to Taxes.
(n) Certain Regulatory Matters. (i) Schedule 6.1(n) sets forth
a complete and accurate list for the last five years, of (a) all Warning Letters
(as defined below), Section 305 notices and similar letters or notices issued by
the Food and Drug Administration (the "FDA") or any other governmental entity,
domestic or foreign, that is concerned with the quality, identity, strength,
purity, safety, efficacy, marketing or manufacturing of the pharmaceutical
compounds or products tested or sold by the Company or its Subsidiaries (any
such governmental entity, a "Pharmaceutical Regulatory Agency") to the Company
or any of its Subsidiaries; (B) all United States product problem reporting
program complaints or reports, MedWatch form FDA-3500A, FDA-1639 or Form CIMOS I
filed by the Company or any of its Subsidiaries, which complaints or reports
pertain to any incident involving death or serious injury, and for which
incident there has been (I) a notice or follow-up inquiry to the Company or any
of its Subsidiaries by the FDA, (II) a litigation or arbitration claim or cause
of action commenced, or (III) a notice to any insurance carrier of the Company
or any of its Subsidiaries tendering the defense or giving any notice of a
possible or actual claim against the Company or such subsidiary; (C) all product
recalls conducted by or issued to the Company or any of its Subsidiaries and any
requests from the FDA or any other Pharmaceutical Regulatory Agency requesting
the Company or any of its Subsidiaries to cease to investigate, test or market
any compound or product; and (D) any civil penalty actions begun by the FDA or
any other Pharmaceutical Regulatory Agency against the Company or any of its
Subsidiaries and all consent decrees and all documents relating to the
negotiation of and compliance with such consent decree issued with respect to
the Company or any of its Subsidiaries. The Company has made available to Parent
copies of all documents referred to in Schedule 6.1(n) and any other written
communications between the Company or any of its Subsidiaries, on the one hand,
and the FDA or any other Pharmaceutical Regulatory Agency on the other hand that
describe matters that could have a material adverse effect on the projected
sales or revenues attributable to any compound, product or product line of the
Company or its Subsidiaries or discuss material issues concerning the quality,
identity, strength, purity, safety or efficacy of any such compound, product or
product line as well as copies of all complaints and other information required
to be maintained by the Company pursuant to the United States Federal Food, Drug
and Cosmetic Act and Comprehensive Drug Abuse Prevention and Control Act of 1970
and the corresponding laws of jurisdictions other than the United States. For
purposes of this subparagraph (i), "Warning Letter" means a letter characterized
by the FDA or any other Pharmaceutical Regulatory Agency as a warning letter, a
notice of adverse finding, observation of noncompliance or a similar letter or
report in which FDA or any other Pharmaceutical Regulatory Agency expresses the
opinion that violations of law, regulation or guideline have occurred.
-22-
<PAGE> 26
(ii) With such exceptions as will not have or be reasonably
likely to have a Company Material Adverse Effect and except as set forth in
Schedule 6.l(n), (A) the Company (or, if applicable, one of its Subsidiaries)
has obtained all consents, approvals, certifications, authorizations and permits
of, and has made all filings with, or notifications to, all Pharmaceutical
Regulatory Agencies pursuant to applicable requirements of all FDA regulations
and consent decrees, and all applicable state and foreign laws, and regulations
applicable to the Company or any of its Subsidiaries; (B) all representations
made by the Company or any of its Subsidiaries in connection with any such
consents, approvals, certifications, authorizations, permits, filings and
notifications were true and correct in all material respects at the time such
representations and warranties were made, and the Company's compounds and
products, and the compounds and products of its Subsidiaries, substantially
comply with, and perform in accordance with the specifications described in,
such representations; (C) the Company and its Subsidiaries and their respective
products and all of the facilities and entities which manufacture such compounds
and products, are in substantial compliance with all applicable FDA rules,
regulations and consent decrees, and all applicable state and foreign laws,
rules and regulations (including Good Manufacturing Practices) relating to
pharmaceutical manufacturers and distributors or otherwise applicable to the
Company's or its Subsidiaries' business; and (D) the Company has no reason to
believe that any of the consents, approvals, authorizations, registrations,
certifications, permits, filings or notifications that it or any of its
Subsidiaries has received or made to operate their respective businesses have
been or are being revoked or challenged.
(o) Intellectual Property.
(i) Set forth in Schedule 6.1(o)(i) is a complete list
of each of the following items (1) all patents and applications therefor,
registrations of trademarks (including service marks) and applications therefor,
and registrations of copyrights and applications therefor that are owned by the
Company or any of its Subsidiaries or licensed to the Company or any of its
Subsidiaries (collectively, the "Company Owned IP"), (2) all licenses,
agreements and contracts relating to the Company Intellectual Property (as
defined in Section 6.1(o) (ii) of this Agreement) pursuant to which the Company
or any of its Subsidiaries are entitled to use any Company Intellectual Property
owned by any third party (the "Third Party Licenses") and (3) all agreements
under which the Company or any of its Subsidiaries has granted any third party
the right to use any Company Intellectual Property, including the unexpired
material transfer agreements.
(ii) Except to the extent identified in Schedule
6.1(o)(ii) and except for any failures of this representation and warranty to be
true and accurate that have or would be reasonably likely to have a Company
Material Adverse Effect that arise from instances involving the infringement by
the Company or its Subsidiaries on the intellectual property rights of others or
the infringement by others on intellectual property rights of the Company or its
Subsidiaries of which, in either such case, the Company does
-23-
<PAGE> 27
not have any knowledge after due investigation, the Company, or its Subsidiaries
where expressly indicated, is the owner of, or is licensed to use, or otherwise
possesses legally enforceable rights in, all intellectual property, including,
without limitation, all patents and patent applications, supplementary
protection certificates and patent extensions, trademarks and trademark
applications, service mark and service mark registrations, logos, commercial
symbols, business name registrations, trade names, copyrights and copyright
registrations, computer software, mask works and mask work registration
applications, industrial designs and applications for registration of such
industrial designs, including, without limitation, any and all applications for
renewal, extensions, reexaminations and reissues of any of the foregoing
intellectual property rights where applicable, inventions, biological materials,
trade secrets, formulae, know-how, technical information, research data,
research raw data, laboratory notebooks, procedures, designs, proprietary
technology and information held or used in the business of the Company and its
Subsidiaries (hereinafter the "Company Intellectual Property").
(iii) Except to the extent identified in Schedule
6.1(o)(iii), the Company and its Subsidiaries are the sole legal and beneficial
owners of all the Company Intellectual Property (except for the Company
Intellectual Property that is the subject of any Third Party Licenses) and all
the Company Intellectual Property is valid and subsisting.
(iv) The Company has not entered into any agreements,
licenses or created any mortgages, liens, security interests, leases, pledges,
encumbrances, equities, claims, charges, options, restrictions, rights of first
refusal, title retention agreements or other exceptions to title which
materially affect the Company Intellectual Property or materially restrict the
use by the Company or any of its Subsidiaries of the Company Intellectual
Property, except as provided in agreements and instruments disclosed in Schedule
6.1(o)(i) and furnished or made available to Parent prior to the date of this
Agreement.
(v) Except as listed in Schedule 6.1(o)(v), to the
knowledge of the Company, the Company and its Subsidiaries are in compliance in
all material respects with the Third Party Licenses that are material to the
conduct of the business of the Company.
(vi) The Company and its Subsidiaries are not, and will
not be as a result of the execution, delivery or performance of this Agreement
or the Stock Option Agreement or the consummation of the Offer and the Merger or
the other transactions contemplated hereby or thereby in breach, violation or
default of any Third Party Licenses that are material to the conduct of the
business of the Company. Except as indicated in Schedule 6.1(o)(vi), the rights
of the Company or any of its Subsidiaries to the Company Intellectual Property
will not be affected by the execution, delivery or
-24-
<PAGE> 28
performance of this Agreement or the Stock Option Agreement or the consummation
of the Offer and the Merger or the other transactions contemplated hereby or
thereby.
(vii) The Company and its Subsidiaries have the right to
license to third parties the use of the Company Owned IP.
(viii) Except as listed in Schedule 6.1(o)(viii), all
registrations and filings relating to the Company Owned IP are in good standing.
All maintenance and renewal fees necessary to preserve the rights of the Company
in respect of the Company Owned IP have been made. Except as indicated in
Schedule 6.1(o)(viii), the registrations and filings relating to the Company
Owned IP are proceeding and there are no material facts of which the Company has
knowledge after due investigation which could significantly undermine those
registrations or filings or reduce to a significant extent the scope of
protection of any patents arising from such applications.
(ix) The manufacturing, marketing, distribution, sale
and use of compounds by the Company or its Subsidiaries, licensees or
sublicensees in the countries where the Company has conducted or proposes to
conduct such activities, to the knowledge of the Company after due
investigation, does not and would not infringe the patents, patent applications,
trademarks, trademark applications, service marks, service mark applications,
copyrights, copyright applications, and proprietary trade names, publication
rights, computer programs (including source code and object code), inventions,
know-how, trade secrets, technology, processes, confidential information and all
other intellectual property rights throughout the world (collectively,
"Intellectual Property Rights") of any third party.
(x) Except for the matters set forth in Schedule
6.1(o)(x), there are no allegations, claims or proceedings instituted or pending
which challenge the rights possessed by the Company or its Subsidiaries to use
the Company Intellectual Property or the validity or effectiveness of the
Company Intellectual Property, including without limitation any interferences,
oppositions, cancellations or other contested proceedings.
(xi) There are no outstanding claims or proceedings
instituted or pending by any third party challenging the ownership, priority,
scope or validity or effectiveness of any Company Intellectual Property.
(xii) To the knowledge of the Company, there are no
Intellectual Property Rights of any third party that have been or would be
infringed by the identification, manufacture, marketing, distribution and sale
and use of any products that have been identified for development by the
Company.
(xiii) To the knowledge of the Company, there are no
Intellectual Property Rights of any third party that would be infringed by the
continued practice of any technologies previously used or presently in use by
the Company.
-25-
<PAGE> 29
(xiv) To the knowledge of the Company, except for the
matters set forth in Schedule 6.1(o)(xiv) or as would not have or be reasonably
likely to have a Company Material Adverse Effect, there is no unauthorized use,
infringement or misappropriation of the Company Intellectual Property by any
third party, including any employee or former employee of the Company or any of
its Subsidiaries.
(xv) Except for the matters set forth in Schedule
6.1(o)(xv), the Company and its Subsidiaries have not granted any licenses,
immunities, options or other rights to the Company Intellectual Property which
could provide a third party with a defense to patent infringement proceedings,
whether domestic or foreign.
(xvi) Commercially reasonable measures have been taken
to maintain the confidentiality of the inventions, trade secrets, formulae,
know-how, technical information, research data, research raw data, laboratory
notebooks, procedures, designs, proprietary technology and information of the
Company and its Subsidiaries, and all other information the value of which to
the Company or any of its Subsidiaries is contingent upon maintenance of the
confidentiality thereof. Without limiting the generality of the foregoing, (1)
each employee of the Company and each consultant to the Company who has had
access to proprietary information with respect to the Company has entered into
an agreement suitable to vest ownership rights to any inventions, creations,
developments, and works in the Company and has entered into an agreement for
maintaining the confidential information of the Company and (2) each officer and
director of the Company has entered into an agreement to maintain the
confidential information of the Company, except for those individuals listed in
Schedule 6.1(o) (xvi) whose involvement in the business of the Company is
described with specificity therein.
(p) Product Registration Files. The product registration files
and dossiers of the Company and its Subsidiaries have been maintained in
accordance with reasonable industry standards. The Company and each of its
Subsidiaries has in its possession copies of all the material documentation
filed in connection with filings made by the Company or any of its Subsidiaries
for regulatory approval or registration of the compounds and products of the
Company or any of its Subsidiaries, as the case may be. To the knowledge of the
Company, the filings made by the Company and its Subsidiaries for regulatory
approval or registration of the products of the Company or any of its
Subsidiaries did not contain any untrue statement of a material fact or omit to
state any material fact necessary to make the statements therein not misleading.
(q) Year 2000 Compliance. Schedule 6.1(q) contains the
Company's Year 2000 plan, which indicates the actions to be taken pursuant to
such plan that have been completed as of the date of this Agreement and the
actions to be taken pursuant to such plan that have not been completed as of the
date of this Agreement and the aggregate expense expected to be incurred by the
Company in connection with the actions to be
-26-
<PAGE> 30
taken pursuant to such plan that have not been completed as of the date of this
Agreement.
(r) Labor Matters. Neither the Company nor any of its
Subsidiaries is a party to or otherwise bound by any collective bargaining
agreement, contract or other agreement or understanding with a labor union or
labor organization, nor is the Company or any of its Subsidiaries the subject of
any material proceeding asserting that the Company or any of its Subsidiaries
has committed an unfair labor practice or is seeking to compel it to bargain
with any labor union or labor organization nor is there pending or, to the
knowledge of the Company, threatened, any labor strike, walkout, work stoppage,
slow-down or lockout involving the Company or any of its Subsidiaries.
(s) Rights Agreement. The Company has irrevocably amended the
Rights Agreement to provide that neither Parent nor Merger Sub nor any of their
respective affiliates shall be deemed to be an Acquiring Person (as such term is
defined in the Rights Agreement), that neither a Distribution Date nor a Shares
Acquisition Date (as each such term is defined in the Rights Agreement) shall be
deemed to occur, and the Rights will not separate from the Shares, as a result
of the execution, delivery or performance of this Agreement, the Stock Option
Agreement or the Shareholders Agreement or the consummation of the Offer and the
Merger or the other transactions contemplated hereby or thereby, and that none
of the Company, Parent, Merger Sub, nor the Surviving Corporation, nor any of
their respective affiliates, shall have any obligations under the Rights
Agreement to any holder (or former holder) of Rights as of and following the
consummation of the Offer and/or the Effective Time.
(t) Brokers and Finders. Except as disclosed in Schedule
6.1(t), neither the Company nor any of its Subsidiaries, officers, directors or
employees has employed any broker or finder or incurred any liability for any
brokerage fees, commissions or finders' fees in connection with the Offer and
the Merger or the other transactions contemplated by this Agreement, the Stock
Option Agreement or the Shareholders Agreement, except that the Company has
employed CIBC World Markets Corp. as its financial advisor, the arrangements
with which have been disclosed to Parent prior to the date hereof.
(u) Supply Arrangements. As of the date of this Agreement, to
the Company's knowledge, there are no facts or circumstances that have
materially adversely affected or are reasonably likely to materially adversely
affect the continued supply (either for clinical purposes or in bulk) of the
active ingredients of the compounds of the Company and its Subsidiaries
currently used in clinical trials.
(v) Investigational Compounds. As of the date of this
Agreement, to the Company's knowledge, there are no facts or circumstances that
have materially adversely affected or that management of the Company has
determined are reasonably likely to
-27-
<PAGE> 31
materially adversely affect the commercialization of its compounds, other than
factors that are generally applicable to the development and commercialization
of pharmaceutical compounds that are not specific to the Company or such
compounds.
(w) Certain Agreements. (i) All contracts listed as an exhibit
to the Company's Annual Report on Form 10-K under the rules and regulations of
the SEC relating to the business of the Company and its Subsidiaries and (ii)
any other agreement within the meaning set forth in item 601(b)(10) of
Regulation S-K of Title 17, Part 229 of the Code of Federal Regulations (all of
which are listed on Schedule 6.1(w)) (the "Company Material Contracts") are
valid and in full force and effect, except to the extent they have previously
expired in accordance with their terms and other than as is not reasonably
likely to have, individually or in the aggregate, a Material Adverse Effect on
the Company. Neither the Company nor its Subsidiaries has violated any provision
of, or committed or failed to perform any act which, with or without notice,
lapse of time, or both, is reasonably likely to constitute a default under the
provisions of, any such Company Material Contract, and neither the Company nor
any of its Subsidiaries has received notice that any party to any Company
Material Contract intends to cancel, terminate or otherwise modify the terms of
any applicable Company Material Contract, except in each case, as is not
reasonably likely to have, individually or in the aggregate, a Material Adverse
Effect on the Company. To the knowledge of the Company, no counterparty to any
such Company Material Contract has violated any provision of, or committed or
failed to perform any act which, with or without notice, lapse of time, or both,
is reasonably likely to constitute a default or other breach under the
provisions of, such Company Material Contract, except for defaults or breaches
which are not reasonably likely, individually or in the aggregate, to have a
Material Adverse Effect on the Company. Neither the Company nor any of its
Subsidiaries is a party to, nor are any of their assets bound by, any agreement,
arrangement, commitment or understanding with any company engaged primarily in
the pharmaceutical business, other than as listed on Schedule 6.1(w).
(x) Schedule 14D-9; Offer Documents. Neither the Schedule
14D-9, any other document required to be filed by the Company with the SEC in
connection with the transactions contemplated hereby, nor any information
supplied by the Company for inclusion in the Offer Documents shall, at the
respective times the Schedule 14D-9, any such other filings by the Company, the
Offer Documents or any amendments or supplements thereto are filed with the SEC
or are first published, sent or given to stockholders of the Company, as the
case may be, contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make
the statements made therein, in light of the circumstances under which they are
made, not misleading. The Schedule 14D-9, any other document required to be
filed by the Company with the SEC in connection with the transactions
contemplated by this Agreement will, when filed by the Company with the SEC,
comply as to form in all material respects with the applicable provisions of the
Exchange Act and the rules and
-28-
<PAGE> 32
regulations thereunder. Notwithstanding the foregoing, the Company makes no
representation or warranty with respect to the statements made in any of the
foregoing documents based on and in conformity with information supplied by or
on behalf of Parent or Merger Sub in writing specifically for inclusion therein.
(y) Required Vote of Company Stockholders. Unless the Merger
may be consummated in accordance with Section 253 of the DGCL, the only vote of
the stockholders of the Company required to adopt this Agreement and the Stock
Option Agreement and to approve the Merger and the transactions contemplated
hereby and thereby, is the affirmative vote of the holders of a majority of the
outstanding shares of Common Stock (the "Company Requisite Vote").
6.2. Representations and Warranties of Parent and Merger Sub.
Parent and Merger Sub each hereby represent and warrant to the Company, except
as set forth in the Disclosure Schedule delivered to the Company on the date of
this Agreement (the "Parent Disclosure Schedule"), as follows:
(a) Capitalization of Merger Sub. The authorized capital stock
of Merger Sub consists of one thousand (1,000) shares of Common Stock, par value
$.01 per share, all of which are validly issued and outstanding. All of the
issued and outstanding capital stock of Merger Sub is, and upon the consummation
of the Offer and at the Effective Time will be, owned by Parent, and there are
(i) no other shares of capital stock or other voting securities of Merger Sub,
(ii) no securities of Merger Sub convertible into or exchangeable for shares of
capital stock or voting securities of Merger Sub and (iii) no options or other
rights to acquire from Merger Sub, and no obligations of Merger Sub to issue,
any capital stock, voting securities or securities convertible into or
exchangeable for capital stock or voting securities of Merger Sub. Merger Sub
has not conducted any business prior to the date hereof and has no, and prior to
the Effective Time will have no, assets, liabilities or obligations of any
nature other than those incident to its formation and pursuant to this
Agreement, the Offer and the Merger and the other transactions contemplated by
this Agreement.
(b) Organization, Good Standing and Qualification. Each of
Parent and its Subsidiaries is a corporation duly organized, validly existing
and in good standing (where such concept is recognized) under the laws of its
respective jurisdiction of organization and has all requisite corporate or
similar power and authority to own and operate its properties and assets and to
carry on its business as presently conducted and is qualified to do business and
is in good standing as a foreign corporation in each jurisdiction (where such
concept is recognized) where the ownership or operation of its properties or
conduct of its business requires such qualification, except where the failure to
be so qualified or in such good standing, when taken together with all other
such failures, is not reasonably likely to prevent, materially delay or
materially impair the ability of Parent and Merger Sub to consummate the
transactions contemplated by this
-29-
<PAGE> 33
Agreement, the Stock Option Agreement and the Shareholders Agreement. Parent has
made available to the Company a complete and correct copy of Parent's and Merger
Sub's certificate of incorporation and bylaws, as amended to the date hereof.
Parent's and Merger Sub's certificate of incorporation and bylaws so delivered
are in full force and effect.
(c) Corporate Authority. No vote of holders of capital stock
of Parent is necessary to approve this Agreement, the Offer and the Merger and
the other transactions contemplated hereby. Each of Parent and Merger Sub has
all requisite corporate power and authority and each has taken all corporate
action (including approval of the shareholders of Merger Sub) necessary in order
to execute, deliver and perform its obligations under this Agreement and to
consummate the Offer and the Merger. Parent has all requisite power and
authority and has taken all corporate action necessary in order to execute,
deliver and perform its obligations under the Stock Option Agreement. This
Agreement is a valid and binding agreement of Parent and Merger Sub, enforceable
against each of Parent and Merger Sub in accordance with its terms. The Stock
Option Agreement is a valid and binding agreements of Parent enforceable against
Parent in accordance with its respective terms.
(d) Governmental Filings; No Violations. (i) Other than any
filings and/or notices required (A) pursuant to Section 2.3, (B) under the HSR
Act and the Exchange Act and (C) such filings or consents, registrations,
approvals, permits or authorizations as may be required under the laws of the
competition or antitrust laws of jurisdictions outside the United States, no
notices or other filings are required to be made by Parent or Merger Sub with,
nor are any consents, registrations, approvals, permits or authorizations
required to be obtained by Parent or Merger Sub from, any Governmental Entity,
in connection with the execution and delivery of this Agreement by Parent and
Merger Sub or the execution and delivery of the Stock Option Agreement and the
License Agreement by Parent or the consummation by Parent and Merger Sub of the
Offer and the Merger and the other transactions contemplated hereby and by the
Stock Option Agreement, except those that the failure to make or obtain are not,
individually or in the aggregate, reasonably likely to prevent, materially delay
or materially impair the ability of Parent or Merger Sub to consummate the
transactions contemplated by this Agreement, the Stock Option Agreement and the
License Agreement.
(ii) The execution, delivery and performance of this
Agreement and the Stock Option Agreement, by Parent and Merger Sub, as the case
may be, do not and will not, and the consummation by Parent and Merger Sub of
the Offer and the Merger and the other transactions contemplated hereby and by
the Stock Option Agreement, will not, constitute or result in (A) a breach or
violation of, or a default under, the certificate or bylaws of Parent and Merger
Sub or the comparable governing instruments of any of its Subsidiaries, (B) a
breach or violation of, or a default under, the acceleration of or the creation
of a lien, pledge, security interest or other encumbrance on
-30-
<PAGE> 34
the assets of Parent or any of its Subsidiaries (with or without notice, lapse
of time or both) pursuant to, any Contracts binding upon Parent or any of its
Subsidiaries or any Law or governmental or non-governmental permit or license to
which Parent or any of its Subsidiaries is subject, or (C) any change in the
rights or obligations of any party under any of the Contracts, except, in the
case of clause (B) or (C) above, for breach, violation, default, acceleration,
creation or change that, individually or in the aggregate, is not reasonably
likely to prevent, materially delay or materially impair the ability of Parent
or Merger Sub to consummate the transactions contemplated by this Agreement.
(e) Litigation. Except as disclosed in the Parent Reports
filed prior to the date hereof, and except for matters which are not,
individually or in the aggregate, reasonably likely to prevent or materially
delay or materially impair the ability of Parent or Merger Sub to consummate the
transactions contemplated by this Agreement, the Stock Option Agreement and the
License Agreement, there are no civil, criminal, administrative or regulatory
actions, suits, claims, hearings, investigations or proceedings pending or, to
the knowledge of Parent, overtly threatened against Parent or any of its
Subsidiaries.
(f) Compliance. Neither Parent nor any of its Subsidiaries is
in default or violation of, (i) any Law applicable to Parent or any of its
Subsidiaries or by which its or any of their respective properties are bound, or
(ii) any Contract to which Parent or any or its Subsidiaries is a party or by
which Parent or any of its Subsidiaries or its or any of their respective
properties are bound or affected, except for any such defaults or violations
that, individually or in the aggregate, are not reasonably likely to prevent,
materially delay or materially impair the ability of Parent or Merger Sub to
consummate the transactions contemplated by this Agreement.
(g) Brokers and Finders. Neither Parent nor any of its
Subsidiaries, officers, directors or employees has employed any broker or finder
or incurred any liability for any brokerage fees, commissions or finders' fees
in connection with the Merger or the other transactions contemplated by this
Agreement, the Stock Option Agreement or the Shareholders Agreement.
(h) Financing. Parent will have the funds necessary to
consummate the Offer and the Merger on the terms contemplated by this Agreement
and will provide such funds to Merger Sub at or prior to the consummation of the
Offer and the Merger, as applicable.
(i) Offer Documents. The Offer Documents and any other
documents to be filed by Parent with the SEC or any other Government Entity in
connection with the Merger and the other transactions contemplated hereby will
(in the case of the Offer Documents and any such other documents filed with the
SEC under the Securities Act or the Exchange Act) comply as to form in all
material respects with applicable provisions
-31-
<PAGE> 35
of the Exchange Act and the Securities Act, respectively, and the rules and
regulations thereunder. None of the Offer Documents, any other documents
required to be filed by Parent with the SEC in connection with the transactions
contemplated hereby, nor any information supplied by Parent for inclusion in the
Schedule 14D-9 or in the information required to be distributed to the
stockholders of the Company pursuant to Section 14(f) of the Exchange Act and
Rule 14f-1 promulgated thereunder as is necessary to enable Parent's designees
to be elected to the Company's Board pursuant to Section 1.4 hereof shall, at
the respective times the Offer Documents or any amendments and supplements
thereto, any such other filings by Parent or Purchaser are filed with SEC or are
first published, sent or given to stockholders of the Company, as the case may
be, contain any untrue statement of a material fact, or omit to state any
material fact required to be stated therein or necessary in order to make the
statements made therein, in the light of the circumstances under which they are
made, not misleading. Notwithstanding the foregoing, neither Parent nor Merger
Sub makes any representation or warranty with respect to the statements made in
any of the foregoing documents based on and in conformity with information
supplied by or on behalf of the Company in writing specifically for inclusion
therein.
ARTICLE VII
Covenants
7.1. Company Interim Operations. Except as set forth in the
document entitled "Schedule 7.1" furnished to the Company by Parent prior to the
execution and delivery of this Agreement, the Company covenants and agrees as to
itself and its Subsidiaries that, after the date hereof and prior to the
Effective Time (unless Parent shall otherwise consent in writing (such consent
not to be unreasonably withheld or delayed) and except as otherwise expressly
contemplated by this Agreement and the Stock Option Agreement):
(a) the business of it and its Subsidiaries shall be
conducted, in all material respects, in the ordinary and usual course and, to
the extent consistent therewith, it and its Subsidiaries shall use their
respective commercially reasonable best efforts to preserve its business
organization substantially intact and substantially maintain its existing
relations and goodwill with customers, suppliers, distributors, creditors,
lessors, employees and business associates;
(b) it shall not (i) issue, sell, pledge, dispose of or
encumber any capital stock owned by it in any of its Subsidiaries; (ii) amend
its certificate or bylaws or amend, modify or terminate the Rights Agreement,
except as set forth in Section 6.1(s) hereof; (iii) split, combine or reclassify
its outstanding shares of capital stock; (iv) declare, set aside or pay any
dividend payable in cash, stock or property in respect of any capital stock, or
(v) repurchase, redeem or otherwise acquire, except in connection with the
-32-
<PAGE> 36
Stock Plans, or permit any of its Subsidiaries to purchase or otherwise acquire,
any shares of its capital stock or any securities convertible into or
exchangeable or exercisable for any shares of its capital stock;
(c) neither it nor any of its Subsidiaries shall (i) issue,
sell, pledge, dispose of or encumber any shares of, or securities convertible
into or exchangeable or exercisable for, or options, warrants, calls,
commitments or rights of any kind to acquire, any shares of its capital stock of
any class or any Voting Debt or any other property or assets (other than (A) the
issuance of Shares pursuant to options outstanding on the date of this Agreement
under the Stock Plans and the issuance of Shares under the Company's Employee
Stock Purchase Plan and (B) the issuance of Shares upon conversion of
Convertible Preferred Stock outstanding on the date of this Agreement); (ii)
transfer, lease, license, guarantee, sell, mortgage, pledge, dispose of or
encumber any other property or assets (including capital stock of any of its
Subsidiaries) or incur or modify any material indebtedness or other liability;
or (iii) make any commitments for, make or authorize any capital expenditures
or, by any means, make any acquisition of, or investment in, assets or stock of
any other Person or entity in each case, involving amounts in excess of $100,000
in the aggregate other than in the ordinary and usual course;
(d) Except as may be required by existing contractual
commitments or as required by applicable law, neither it nor any of its
Subsidiaries shall (i) enter into any new agreements or commitments for any
severance or termination pay to, or enter into employment or severance agreement
with, any of its directors, officers or employees, including adding new
participants to the Company's Management Change of Control Plan or (ii)
terminate, establish, adopt, enter into, make any new grants or awards under,
amend or otherwise modify, any Compensation and Benefit Plans or increase or
accelerate the salary, wage, bonus or other compensation of any employees,
officers or directors (except for increases in salaries, wages and cash bonuses
of nonexecutive employees made in the ordinary course of business consistent
with past practice) or pay or agree to pay any pension, retirement allowance or
other employee benefit not required by any existing Compensation and Benefit
Plan;
(e) neither it nor any of its Subsidiaries shall settle or
compromise any material claims or litigation or modify, amend or terminate any
of its material Contracts or waive, release or assign any material rights or
claims;
(f) neither it nor any of its Subsidiaries shall make any Tax
election or permit any insurance policy naming it as a beneficiary or
loss-payable payee to be canceled or terminated except in the ordinary and usual
course of business;
-33-
<PAGE> 37
(g) except as may be required as a result of a change in law
or in generally accepted accounting principles, neither it nor any of its
Subsidiaries shall change any of the accounting practices or principles used by
it;
(h) neither it nor any of its Subsidiaries shall adopt a plan
of complete or partial liquidation, dissolution, merger, consolidation,
restructuring, recapitalization, or other reorganization of the Company or any
of its subsidiaries not constituting an inactive Subsidiary (other than the
Merger);
(i) it shall not suffer or permit capital expenditures made or
incurred by the Company and its Subsidiaries for any period to exceed $100,000
except for expenses incurred in connection with the transactions contemplated by
this Agreement; and
(j) neither it nor any of its Subsidiaries will offer to, or
enter into an agreement to, do any of the foregoing.
7.2. Acquisition Proposals. The Company shall, and shall use
its best efforts to cause its nonstockholder affiliates and the officers,
directors and employees of the Company and its Subsidiaries to, and shall
instruct its stockholder affiliates and the representatives and agents of the
Company and its Subsidiaries (including, without limitation, any investment
banker, attorney or accountant retained by the Company or any of its
Subsidiaries) to, immediately cease and terminate any existing activities,
discussions or negotiations, if any, with any parties (other than Parent and
Merger Sub, any affiliate or associate of Parent and Merger Sub or any designees
of Parent and Merger Sub) conducted heretofore with respect to any acquisition
or exchange of all or any material portion of the assets of, or more than 20% of
the equity interest in, the Company or any of its Subsidiaries (by direct
purchase from the Company, tender or exchange offer or otherwise) or any
business combination, merger or similar transaction (including an exchange of
stock or assets) with or involving the Company or any Subsidiary of the Company
(an "Acquisition Transaction"), other than the Offer and the Merger. Except as
set forth in this Section 7.2, the Company shall not, and shall use its best
efforts to cause its nonstockholder affiliates and the officers, directors and
employees of the Company and its Subsidiaries not to, and shall instruct its
stockholder affiliates and the representatives and agents of the Company and its
Subsidiaries (including, without limitation, any investment banker, attorney or
accountant retained by the Company or any of its subsidiaries) not to, directly
or indirectly, knowingly encourage, solicit, participate in or initiate
discussions or negotiations with, or provide any nonpublic information or data
(other than the Company's standard public information package) to, any
corporation, partnership, person or other entity or group (other than Parent and
Merger Sub, any affiliate or associate of Parent and Merger Sub or any designees
of Parent and Merger Sub) with respect to any inquiries or the making of any
offer or proposal (including, without limitation, any offer or proposal to the
stockholders of the Company) concerning an Acquisition Transaction (an
"Acquisition Proposal" (it being understood that an
-34-
<PAGE> 38
Acquisition Proposal that is conditioned upon the completion of due diligence
shall be deemed to constitute a bona fide Acquisition Proposal if such proposal
otherwise meets the definition of Acquisition Proposal)) or otherwise knowingly
facilitate any effort or attempt to make or implement an Acquisition Proposal;
provided, however, that prior to the Merger Sub beneficially owning a majority
of the then outstanding Shares, the Company may furnish information and access,
but only in response to a request for information or access, to any person or
entity making a bona fide written Acquisition Proposal to the board of directors
of the Company after the date hereof which was not knowingly encouraged,
solicited or initiated by the Company or any of its affiliates or any director,
employee, representative or agent of the Company or any of its Subsidiaries
(including, without limitation, any investment banker, attorney or accountant
retained by the Company or any of its Subsidiaries) on or after the date hereof
and may participate in discussions and negotiate with such person or entity
concerning any such Acquisition Proposal and may authorize the Company to enter
into a binding written agreement concerning a Superior Proposal (as defined
below), if and only if, in any such case, (i) the board of directors of the
Company determines in good faith, (A) after consultation with outside counsel to
the Company to the effect that failing to provide such information or access or
to participate in such discussions or negotiations or so to authorize, as the
case may be, is reasonably likely to constitute a breach of such board's
fiduciary duties under applicable law, that failing to provide such information
or access or to participate in such discussions or negotiations or to so
authorize, as the case may be, is reasonably likely to constitute a breach of
such board's fiduciary duties under applicable law, and (B) after consultation
with the financial advisors to the Company to such effect, that such Acquisition
Proposal, if accepted, is reasonably likely to be consummated, taking into
account all legal, financial and regulatory aspects of the proposal and the
person or entity making the proposal and would, if consummated, result in a
transaction more favorable to the Company's stockholders from a financial point
of view than the transaction contemplated by this Agreement (any such more
favorable Acquisition Proposal as to which both of the determinations referred
to in subclauses (A) and (B) above have been made being referred to in this
Agreement as a "Superior Proposal"), and (ii) the Company receives from the
person or entity making such bona fide written Acquisition Proposal an executed
confidentiality agreement the terms of which are (without regard to the terms of
such Acquisition Proposal) (A) no less favorable to the Company, and (B) no less
restrictive to the person or entity making such bona fide written Acquisition
Proposal than those contained in the Confidentiality Agreement, dated as of June
21, 1999, referring to Parent as the "Recipient" (the "Company Confidentiality
Agreement"), between the Company and Parent. Nothing in this Agreement shall
prohibit the Board of Directors of the Company from, to the extent applicable,
complying with Rule 14e-2 or 14D-9 promulgated under the Exchange Act with
regard to an Acquisition Proposal. The Company will notify Parent within 48
hours if any such inquiries or proposals are received by, any such information
is requested from, or any such negotiations or discussions are sought to be
initiated or continued with the Company and shall in such
-35-
<PAGE> 39
notice indicate the identity of the offeror and the material terms and
conditions of any such proposal and thereafter shall keep Parent reasonably
informed, on a current basis, of the status and material terms of such proposals
and the status of such negotiations or discussions, providing copies to Parent
of any Acquisition Proposals made in writing. The Company shall provide Parent
with three business days advance notice of, in each and every case, its
intention to either enter into any agreement with or to provide any information
to any person or entity making any such inquiry or proposal. The Company agrees
not to release any third party from, or waive any provisions of, any
confidentiality or standstill agreement to which the Company is a party and will
use its best efforts to enforce any such agreements at the request of and on
behalf of Parent. The Company will inform the individuals or entities referred
to in the first sentence of this Section 7.2 of the obligations undertaken in
this Section 7.2. The Company also will promptly request each person or entity
which has executed, within 12 months prior to the date of this Agreement, a
confidentiality agreement in connection with its consideration of acquiring the
Company to return or destroy all confidential information heretofore furnished
to such person or entity by or on behalf of the Company.
7.3. Company Stockholder Approval; Proxy Statement
(a) If approval or action in respect of the Merger by the
stockholders of the Company is required by applicable law, the Company, acting
through the Company Board, shall (i) call as promptly as practicable following
consummation of the Offer, a meeting of its stockholders (the "Company
Stockholders Meeting") for the purpose of voting upon the Merger, (ii) hold the
Company Stockholders Meeting as soon as practicable following the purchase of
Shares pursuant to the Offer, and (iii) recommend to its stockholders the
approval of the Merger. Notwithstanding the foregoing, the Company Board may
withdraw, modify or amend any recommendation that the Stockholders approve the
merger if the Company has received an Acquisition Proposal which in accordance
with Section 7.2 is a Superior Proposal. The record date for the Company
Stockholders Meeting shall be a date subsequent to the date on which Parent or
Merger Sub becomes the a record holder of Shares purchased pursuant to the
Offer. At the Company Stockholders Meeting, Parent and Merger Sub shall cause
all shares then owned beneficially or of record by them to be voted in favor of
approval and adoption of this Agreement, the Merger and the transactions
contemplated hereby. Notwithstanding the foregoing, if Parent, Merger Sub or any
other subsidiary of Parent shall acquire at least 90% of the outstanding Shares
and outstanding Preferred Stock, the parties shall take all necessary and
appropriate action to cause the Merger to become effective as soon as
practicable after the expiration of the Offer without a stockholders meeting in
accordance with Section 253 of the DGCL.
(b) If required by applicable Law, the Company will, as soon
as practicable following the expiration of the Offer, prepare and file a
preliminary Proxy Statement (such proxy statement, and any amendments or
supplements thereto, the
-36-
<PAGE> 40
"Proxy Statement") or , if applicable, an information statement with the SEC
with respect to the Company Stockholders Meeting and will use its best efforts
to respond to any comments of the SEC or its staff and of any request by the SEC
or its staff for amendments or supplements to the Proxy Statement or for
additional information and will supply Parent with copies of all correspondence
between the Company or any of its representatives, on the one hand, and the SEC
or its staff, on the other hand, with respect to the Proxy Statement or the
Merger. Parent and Merger Sub shall furnish to the Company all information
regarding Parent, Merger Sub and their affiliates that may be required (pursuant
to the Exchange Act and other applicable Laws) to be set forth in the Proxy
Statement. The Company shall give Parent and its counsel the opportunity to
review the Proxy Statement prior to it being filed with the SEC and shall give
Parent and its counsel the opportunity to review all amendments and supplements
to the Proxy Statement and all responses to requests for additional information
and replies to comments prior to their being filed with, or sent to, the SEC.
Each of the Company and Parent agrees to use its best efforts, after
consultation with the other parties hereto, to respond promptly to all such
comments of and requests by the SEC. As promptly as practicable after the Proxy
Statement has been cleared by the SEC, the Company shall mail the Proxy
Statement to the stockholders of the Company. If at any time prior to the
approval of this Agreement by the Company's stockholders there shall occur any
event which should be set forth in an amendment or supplement to the Proxy
Statement, the Company will prepare and mail to its stockholders such an
amendment or supplement.
(c) The Company represents and warrants that the Proxy
Statement will comply in all material respects with the Exchange Act and, at the
respective times filed with the SEC and distributed to stockholders of the
Company, will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were
made, not misleading; provided that the Company makes no representation or
warranty as to any information included in the Proxy Statement that was provided
by Parent or Merger Sub. Parent represents and warrants that none of the
information supplied by Parent or Merger Sub for inclusion in the Proxy
Statement will, at the respective times filed with the SEC and distributed to
stockholders of the Company, contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading.
(d) Following the consummation of the Offer, the Company shall
use its best efforts to obtain the necessary approvals by its stockholders of
the Merger, this Agreement and the transactions contemplated hereby.
7.4. Approvals and Consents; Cooperation. The Company and
Parent shall cooperate with each other and use (and shall cause their respective
Subsidiaries to use) their respective commercially reasonable best efforts to
take or cause to be taken all
-37-
<PAGE> 41
actions, and do or cause to be done all things, necessary, proper or advisable
under this Agreement, the Stock Option Agreement, the Shareholders Agreement and
applicable Laws to consummate and make effective the Merger and the other
transactions contemplated by this Agreement, the Stock Option Agreement and the
Shareholders Agreement as soon as practicable, including preparing and filing as
promptly as practicable all documentation to effect all necessary applications,
notices, petitions, filings and other documents and to obtain as promptly as
practicable all permits, consents, approvals and authorizations necessary or
advisable to be obtained from any third party and/or any Governmental Entity in
order to consummate the Offer and the Merger or any of the other transactions
contemplated by this Agreement, the Stock Option Agreement and the Shareholders
Agreement. In particular, the Company and Parent each agree to use commercially
reasonable efforts to take, or cause to be taken, all appropriate action, and
do, or cause to be done, such things as may be necessary under federal or state
securities laws or the HSR Act applicable to or necessary for, and will file as
soon as reasonably practicable and, if appropriate, use commercially reasonable
efforts to have declared effective or approved, all documents and notifications
with the SEC and other governmental or regulatory bodies (including, without
limitation, the FDA) that they deem necessary or appropriate for, the
consummation of the Offer and the Merger or any of the other transactions
contemplated hereby and each party shall give the other information reasonably
requested by such other party pertaining to it and its subsidiaries and
affiliates to enable such other party to take such actions. Each of the Company,
Parent and Merger Sub agrees to use commercially reasonable efforts to contest
and resist any action, including legislative, administrative or judicial action,
and to have vacated, lifted, reversed or overturned any decree, judgment,
injunction or other order (whether temporary, preliminary or permanent) that is
in effect and that restricts, prevents or prohibits the consummation of the
Offer and the Merger or any of the other transactions contemplated by this
Agreement, including, without limitation, by pursuing available avenues of
administrative and judicial appeal. Each of the Company, Parent and Merger Sub
also agrees to use commercially reasonable efforts to take any and all actions
necessary to avoid or eliminate each and every impediment under any antitrust
law that may be asserted by any governmental antitrust authority or any other
party so as to enable the parties to close by the date specified in Section
9.2(i) the transactions contemplated hereby; provided, however, that nothing in
this Section 7.4 shall require, or be construed to require, Parent to proffer
to, or agree to, sell or hold separate and agree to sell, before or after the
Effective Time, any assets, businesses, or interest in any assets or businesses
of Parent, the Company or any of their respective affiliates (or to consent to
any sale, or agreement to sell, by the Company of any of its assets or
businesses) or to agree to any material changes or restriction in the operations
of any such assets or businesses; and provided, further, that nothing in this
Section 7.4 shall require, or be construed to require, a proffer or agreement
that would, in the good faith judgment of Parent, be reasonably likely to have a
material adverse effect on the benefits to Parent of the transactions
contemplated by this Agreement. Subject to applicable Laws relating to the
exchange of
-38-
<PAGE> 42
information, Parent and the Company shall have the right to review in advance,
and to the extent practicable each will consult the other on, all the
information relating to Parent or the Company, as the case may be, and any of
their respective Subsidiaries, that appear in any filing made with, or written
materials submitted to, any third party and/or any Governmental Entity in
connection with the Offer or the Merger and the other transactions contemplated
by this Agreement, the Stock Option Agreement and the Shareholders Agreement. In
exercising the foregoing right, each of the Company and Parent shall act
reasonably and as promptly as practicable.
7.5. Filings; Other Actions; Notification. (a) The Company and
Parent each shall, upon request by the other, furnish the other with all
information concerning itself, its subsidiaries, directors, officers and
stockholders and such other matters as may be reasonably necessary or advisable
in connection with the Proxy Statement or any other statement, filing, notice or
application made by or on behalf of Parent, the Company or any of their
respective subsidiaries to any Governmental Entity in connection with the Offer
or the Merger and the transactions contemplated by this Agreement, the Stock
Option Agreement and the Shareholders Agreement.
(b) The Company and Parent each shall keep the other apprised
of the status of matters relating to completion of the transactions contemplated
hereby, including promptly furnishing the other with copies of notice or other
communications received by Parent or the Company, as the case may be, or any of
their respective subsidiaries, from any third party or any Governmental Entity
with respect to the Offer or the Merger and the other transactions contemplated
by this Agreement, the Stock Option Agreement and the Shareholders Agreement.
The Company shall give prompt notice to Parent of any change that has resulted
in or is reasonably likely to result in a Company Material Adverse Effect and
Parent shall give the Company prompt notice of any event, fact, circumstance or
occurrence that would be reasonably likely to have an adverse effect on Parent's
or Merger Sub's ability to complete the Offer or the Merger or to comply with
their obligations contained in this Agreement or in the Stock Option Agreement.
7.6. Access. From the date hereof until the earlier of the
Effective Time or the termination of this Agreement, upon reasonable notice, the
Company shall afford to the officers, employees, accountants, counsel, financial
advisors and other representatives of Parent ("Parent Representatives")
reasonable access to all of its and its Subsidiaries properties, books,
contracts, commitments and records (including security position listings or
other information concerning beneficial and record owners of the Company's
securities) and its officers, management employees and representatives and,
during such period, the Company shall furnish promptly to Parent, consistent
with its legal obligations, all information concerning its business, properties
and personnel as the other party may reasonably request. Such information shall
be held in confidence to the
-39-
<PAGE> 43
extent required by, and in accordance with, the provisions of the Company
Confidentiality Agreement which shall remain in full force and effect.
7.7. De-registration. The Company shall use its best efforts
to cause the Shares to be de-registered from the NASDAQ National Market and
de-registered under the Exchange Act as soon as practicable following the
Effective Time.
7.8. Publicity. The initial press release relating to the
Offer and this Agreement shall be a joint press release, the content of which
shall be mutually agreed upon by the Company and Parent, and thereafter the
Company and Parent shall consult with each other prior to issuing any press
releases or otherwise making public statements with respect to the transactions
contemplated by this Agreement and the Stock Option Agreement and prior to
making any filings with any Governmental Entity with respect to the transactions
contemplated by this Agreement.
7.9. Benefits.
(a) Stock Options. (i) At the Effective Time, each outstanding
Company Option under the Stock Plans, whether vested or unvested, shall be
deemed to constitute an option to acquire (a "New Parent Option"), on the same
terms and conditions as were applicable under such Company Option, the number of
shares of Common Stock of Parent (rounded to the nearest whole number) equal to
the product of (A) the number of Shares issuable upon exercise of such Company
Option and (B) the Price Per Share divided by the average of the closing sales
prices of Common Stock of Parent on the New York Stock Exchange for the ten (10)
consecutive days immediately prior to and including the day preceding the
Effective Time, at an exercise price per share (rounded to the nearest whole
cent) equal to (x) the aggregate exercise price for the Shares otherwise
purchasable pursuant to such Company Option divided by (y) the aggregate number
of shares of Common Stock of Parent purchasable pursuant to the New Parent
Option (as calculated immediately above); provided, however, that in the case of
any Company Option to which Section 422 of the Code applies, the option price,
the number of shares purchasable pursuant to such option and the terms and
conditions of exercise of such option shall be determined in accordance with the
foregoing, subject to such adjustments as are necessary in order to satisfy the
requirements of Section 424(a) of the Code. At or prior to the Effective Time,
the Company shall take all necessary actions to permit the assumption of the
unexercised Company Options by Parent pursuant to this Section and shall take
all action necessary to cause the funds held in the Company's Employee Stock
Purchase Plan to be used to purchase outstanding Shares through open market
transactions so that such Shares will be converted into the right to receive
cash in the Merger; provided that thereafter the Company shall terminate the
Company's Employee Stock Purchase Plan.
-40-
<PAGE> 44
(ii) Effective at the Effective Time, Parent shall assume, as
a New Parent Option, each outstanding Company Option in accordance with this
Section and with the terms of the Stock Plan under which it was issued and the
stock option agreement by which it is evidenced. Not later than thirty calendar
days after the Closing Date, Parent shall file a registration statement under
the Securities Act of 1933 on Form S-8, or other appropriate form, covering
shares of Parent Common Stock subject to such New Parent Options.
(b) Employee Benefits. Parent agrees that during the period
commencing at the Effective Time and ending on the first anniversary thereof,
the Employees will continue to be provided with benefits under employee benefit
plans (other than stock options or other plans involving the issuance of
securities of the Company or Parent) which in the aggregate are substantially
comparable to those currently provided by the Company to such Employees. Parent
will cause each employee benefit plan of Parent in which Employees are eligible
to participate to take into account for purposes of eligibility and vesting
thereunder the service of such Employees with the Company as if such service
were with Parent, to the same extent that such service was credited under a
comparable plan of the Company and such service period would have been credited
to an employee of the Parent participating in the relevant plan. For the first
plan year ending after the Effective Time, any pre-existing condition exclusion
under any Purchase Benefit Plan providing medical or dental benefits shall be no
more restrictive for any Employee who, immediately prior to commencing
participation in such Purchaser Benefit Plan, was participating in a Company
Benefit Plan providing medical or dental benefits and had satisfied any
pre-existing condition provision under such Company Benefit Plan. Any expenses
that were taken into account under a Company Benefit Plan providing medical or
dental benefits in which the Employee participated immediately prior to
commencing participation in a Purchaser Benefit Plan providing medical or dental
benefits shall be taken into account to the same extent under such Purchaser
Benefit Plan, in accordance with the terms of such Purchaser Benefit Plan, for
purposes of satisfying applicable deductible, coinsurance and maximum
out-of-pocket provisions and life-time benefit limits. Parent will, and will
cause the Surviving Corporation to, honor in accordance with their terms (i) all
employee benefit obligations to Employees accrued as of the Effective Time and
(ii) to the extent set forth on Schedule 6.1(h)(i), all employee severance plans
in existence on the date hereof and all employment or severance agreements
entered into prior to the date hereof.
7.10. Expenses. The Surviving Corporation shall pay all
charges and expenses, including those of the Exchange Agent, in connection with
the transactions contemplated in Article V, and Parent shall reimburse the
Surviving Corporation for such charges and expenses. Except as otherwise
provided in Section 9.5(b), whether or not the Merger is consummated, all costs
and expenses incurred in connection with this Agreement, the Stock Option
Agreement, the Shareholders Agreement, the Offer and the Merger and the other
transactions contemplated by this Agreement, the Stock Option
-41-
<PAGE> 45
Agreement and the Shareholders Agreement shall be paid by the party incurring
such expense.
7.11. Indemnification; Directors' and Officers' Insurance. (a)
From and after the earliest date on which Merger Sub owns at least a majority of
the outstanding Shares on a fully diluted basis, Parent agrees that it will
indemnify, defend and hold harmless each individual and every person who is or
was a director or officer of the Company or any of its Subsidiaries prior to the
Effective Time (the "Indemnified Parties"), against any costs or expenses
(including reasonable attorneys' fees), judgments, fines, losses, claims,
damages, liabilities and amounts paid in settlement (collectively, "Costs")
incurred in connection with any claim, action, suit, proceeding, inquiry or
investigation, whether civil, criminal, administrative or investigative, arising
out of matters existing or occurring at or prior to the Effective Time
(including transactions contemplated by this Agreement), whether asserted or
claimed prior to, at or after the Effective Time (and Parent shall also advance
expenses as incurred to the fullest extent permitted under applicable law,
provided the Person to whom expenses are advanced provides an undertaking to
repay such advances if it is ultimately determined that such Person is not
entitled to indemnification).
(b) From and after the earliest date on which Merger Sub owns
at least a majority of the outstanding Shares on a fully diluted basis, Parent
will cause the Surviving Corporation to fulfill and honor in all respects the
obligations of the Company pursuant to each indemnification agreement listed in
Schedule 7.11(b) and any indemnification provision or any exculpation provision
set forth in the Company's certificate of incorporation or bylaws in effect on
the date hereof. The certificate of incorporation and bylaws of the Surviving
Corporation shall contain the provisions with respect to indemnification and
exculpation from liability set forth in the Company's certificate of
incorporation and bylaws on the date of this Agreement, and during the period
commencing on the earliest date in which Merger Sub purchases Shares pursuant to
the Offer and ending on the sixth anniversary of the Effective Time, such
provisions shall not be amended, repealed or otherwise modified in any manner
that would adversely affect the rights thereunder of any of the Indemnified
Parties.
(c) Any Indemnified Party wishing to claim indemnification
under paragraph (a) of this Section 7.11, upon learning of any such claim,
action, suit, proceeding, inquiry or investigation, shall promptly notify Parent
thereof. In the event of any such claim, action, suit, proceeding, inquiry or
investigation (whether arising before or after the Effective Time), (i) Parent
or the Surviving Corporation shall have the right to assume the defense thereof
and Parent shall be liable to such Indemnified Parties for the legal expenses of
one counsel or any other expenses subsequently incurred by such Indemnified
Parties in connection with the defense thereof unless there is a conflict of
interest between the Indemnified Parties and Parent, in which event Parent shall
be liable to the Indemnified Parties for the fees and expenses of each
Indemnified Parties' counsel,
-42-
<PAGE> 46
(ii) the Indemnified Parties will cooperate in the defense of any such matter
and (iii) Parent shall not be liable for any settlement effected without its
prior written consent and no Indemnified Party shall be liable for any
settlement effected without its prior written consent unless such settlement
includes a complete unconditional release of all claims against all Indemnified
Parties; and provided, further, that Parent shall not have any obligation
hereunder to any Indemnified Party if and when a court of competent jurisdiction
shall ultimately determine, and such determination shall have become final, that
the indemnification of such Indemnified Party in the manner contemplated hereby
is prohibited by applicable law. Parent and the Surviving Corporation jointly
and severally agree to pay all expenses, including attorneys' fees, that may be
incurred by the Indemnified Parties in enforcing the indemnity and other
obligations provided for in this Section 7.11.
(d) Notwithstanding any contrary provision of this Agreement,
prior to the Effective Time, the Company may purchase insurance coverage
extending for a period of six years after the Effective Time the level and scope
of the Company's directors' and officers' liability insurance coverage in effect
as of the date hereof; provided that the aggregate annual premium payable for
such insurance shall not exceed 175% of the last annual premium paid for such
coverage prior to the date hereof. Through the sixth anniversary of the
Effective Time, Parent shall maintain in effect, for the benefit of the
Indemnified Parties, such insurance coverage, and subject to the limitations in
the preceding sentence, shall pay the annual premium for such insurance
coverage. In the event the annual premium payable for such insurance coverage
exceeds 175% of the last annual premium paid by the Company for such coverage,
Parent shall be obligated to obtain and maintain in effect a policy with the
greatest amount of coverage available for a cost not exceeding 175% of such
amount.
(e) If the Surviving Corporation or any of its successors or
assigns (i) shall consolidate with or merge into any other corporation or entity
and shall not be the continuing or surviving corporation or entity of such
consolidation or merger or (ii) shall transfer all or substantially all of its
properties and assets to any individual, corporation or other entity, then and
in each such case, proper provisions shall be made so that the successors and
assigns of the Surviving Corporation shall assume all of the obligations set
forth in this Section.
(f) The provisions of this Section shall survive the earliest
date on which Merger Sub owns at least a majority of the outstanding Shares on a
fully diluted basis and the consummation of the Merger and the Effective Time,
are intended to be for the benefit of, and shall be enforceable by, each of the
Indemnified Parties as intended third party beneficiaries and their heirs and
estates and shall be binding on all successors and assigns of Parent and the
Surviving Corporation.
-43-
<PAGE> 47
7.12. Other Actions by the Company and Parent.
(a) Rights. Prior to the consummation of the Offer, the
Company Board shall take all necessary action to ensure that the representation
and warranty in Section 6.1(s) is accurate.
(b) Antitakeover Statutes. If any Antitakeover Statute is or
may become applicable to the Offer or the Merger or the other transactions
contemplated by this Agreement, the Stock Option Agreement, or the Shareholders
Agreement, each of Parent and the Company and its board of directors shall grant
such approvals and take such lawful actions as are necessary so that such
transactions may be consummated as promptly as practicable on the terms
contemplated by this Agreement, the Stock Option Agreement or the Shareholders
Agreement or by the Offer or the Merger and otherwise act to eliminate or
minimize the effects of such statute or regulation on such transactions.
7.13. Convertible Preferred Stock. Prior to the Effective
Time, the Company and Parent shall take all action necessary to provide that on
and after the Effective Time, the Convertible Preferred Stock will be
convertible only into the Merger Consideration.
ARTICLE VIII
Conditions
8.1. Conditions to Each Party's Obligation to Effect the
Merger. The respective obligation of each party to effect the Merger is subject
to the satisfaction or waiver at or prior to the Closing of each of the
following conditions:
(a) Stockholder Approval. If the approval of this Agreement
and the Merger by the holders of Shares is required by applicable law, this
Agreement shall have been duly adopted by holders of Shares constituting the
Company Requisite Vote.
(b) Regulatory Consents. Any waiting period applicable to the
consummation of the Merger under the HSR Act shall have expired or been
terminated.
(c) Litigation. (i) No court or Governmental Entity of
competent jurisdiction shall have enacted, issued, enforced or entered any
statute, rule, regulation, judgment, decree, injunction or other order (whether
temporary, preliminary or permanent) that is in effect and restrains, enjoins or
otherwise prohibits consummation of the Offer or Merger (collectively, an
"Order"); provided however, that prior to invoking this provision, each party
shall use its commercially reasonable best efforts to have any such Order lifted
or withdrawn, and (ii) no Governmental Entity shall have instituted any
proceeding seeking any such Order.
-44-
<PAGE> 48
(d) Completion of the Offer. Merger Sub shall have (i)
commenced the Offer pursuant to Section 1.1 hereof and (ii) purchased, pursuant
to the terms and conditions of such Offer, all shares of Company Common Stock
duly tendered and not withdrawn; provided, however, that neither Parent nor
Merger Sub shall be entitled to rely on the condition in clause (ii) above if
either of them shall have failed to purchase shares of Company Common Stock
pursuant to the Offer in breach of their obligations under this Agreement.
ARTICLE IX
Termination
9.1. Termination by Mutual Consent. This Agreement may be
terminated and the Merger may be abandoned at any time prior to the Effective
Time, whether before or after the approval by stockholders of the Company
referred to in Section 8.1(a), by mutual written consent of the Company, Parent
and Merger Sub, by action of their respective boards of directors.
9.2. Termination by Either Parent or the Company. This
Agreement may be terminated and the Merger may be abandoned at any time prior to
the Effective Time by action of Parent or the board of directors of the Company
if (i) the Merger shall not have been consummated by February 1, 2000, whether
such date is before or after the date of approval by the stockholders of the
Company referred to in Section 8.1(a); provided, however, that if a request for
additional information is received from the United States Federal Trade
Commission or the Antitrust Division of the United States Department of Justice
pursuant to the HSR Act or additional information is requested by a governmental
authority (a "Foreign Authority") pursuant to the antitrust, competition,
foreign investment, or similar laws or any foreign countries or supranational
commissions or boards that require pre-merger notifications or filings with
respect to the Merger (collectively, "Foreign Merger Laws"), then such date
shall be extended to the 30th day following certification by Parent and/or the
Company, as applicable, that Parent and/or the Company, as applicable, have
substantially complied with such request, but in any event not later than March
1, 2000, (ii) the Company Stockholders Meeting shall have been convened, held
and completed and the approval referred to in Section 8.1(a) shall not have been
obtained thereat or at any adjournment or postponement thereof, provided
however, that Parent shall not be permitted to terminate the Agreement pursuant
to this clause (ii) if Parent or Merger Sub shall not have voted all Shares then
owned beneficially or of record by them in favor of approval and adoption of
this Agreement, the Merger and the transactions contemplated hereby as required
by Section 7.3(a), (iii) any Order permanently restraining, enjoining or
otherwise prohibiting the Offer or the Merger shall become final and
non-appealable (whether before or after the approval referred to in
-45-
<PAGE> 49
Section 8.1(a)) or (iv) if the Offer terminates or expires on account of the
failure of any condition specified in Exhibit A without Merger Sub having
purchased any Shares thereunder; provided that the right to terminate this
Agreement pursuant to clause (i) above shall not be available to any party that
has breached in any material respect its obligations under this Agreement in any
manner that shall have been the proximate cause of, or resulted in, the failure
to consummate the Merger by the date referred to in clause (i) of this Section
9.2 and, provided, further, that the right to terminate this Agreement pursuant
to clause (iii) of this Section 9.2 shall not be available to any party that has
breached its covenant in Section 7.4 to use commercially reasonable best efforts
to prevent such Order from being issued and to use commercially reasonable best
efforts to cause such Order to be vacated, withdrawn or lifted.
9.3. Termination by the Company. This Agreement may be
terminated and the Merger may be abandoned at any time prior to the Effective
Time, whether before or after the approval by stockholders of the Company
referred to in Section 8.1(a), by action of the board of directors of the
Company:
(a) If (i) the Company is not in material breach of any of its
covenants or agreements in this Agreement, (ii) the board of directors of the
Company authorizes the Company, prior to Parent beneficially owning a majority
of the outstanding shares of Common Stock, and subject to complying with the
terms of this Agreement, to enter into a binding written agreement concerning a
Superior Proposal and the Company notifies Parent in writing that it intends to
enter into such an agreement, attaching the most current version of such
agreement to such notice, and (iii) Parent does not make, within three business
days of receipt of the Company's written notification of its intention to enter
into such an agreement, a written offer that is at least as favorable, from a
financial point of view, to the stockholders of the Company as the Superior
Proposal. The Company agrees (x) that it will not enter into a binding agreement
referred to in clause (ii) of the previous sentence until at least the first
calendar day following the third business day after it has provided the written
notice to Parent required thereby, (y) to notify Parent promptly if its
intention to enter into a written agreement referred to in such notice shall
change at any time after giving such notification and (z) that it will not
terminate this Agreement or enter into a binding agreement referred to in clause
(ii) of the previous sentence if Parent has, within the period referred to in
clause (x) of this sentence, made a written offer that is at least as favorable
to the Company's stockholders from a financial point of view as the Superior
Proposal; or
(b) If, prior to consummation of the Offer and prior to Parent
beneficially owning a majority of the outstanding shares of Common Stock, there
has been a material breach by Parent or Merger Sub of any representation,
warranty, covenant or agreement of Parent or Merger Sub contained in this
Agreement which has had, or is reasonably likely to have, the effect of
materially impairing the ability of Parent or Merger Sub to consummate the Offer
or the Merger (a "Terminating Parent Breach");
-46-
<PAGE> 50
provided, however, that, if such Terminating Parent Breach is curable by Parent
through the exercise of reasonable best efforts and such cure is reasonably
likely to be completed prior to the applicable date specified in Section 9.2(i),
then for so long as Parent continues to exercise reasonable best efforts to cure
such Terminating Parent Breach, the Company may not terminate this Agreement
under this Section 9.3(b); or
(c) If Merger Sub shall have failed to commence the Offer
within five Business Days after the date of this Agreement.
9.4. Termination by Parent. This Agreement may be terminated
and the Merger may be abandoned at any time prior to the Parent and Merger Sub,
collectively beneficially owning a majority of the outstanding shares on a fully
diluted basis (so long as the Company has complied with its obligations under
Section 1.4 of this Agreement) by action of the Parent:
(a) If the board of directors of the Company shall have failed
to recommend, or shall have withdrawn or adversely modified its approval or
recommendation of, the Offer or the Merger or failed to reconfirm its
recommendation of the Offer or the Merger within five calendar days after a
written request by Parent to do so, or shall have resolved to do any of the
foregoing; or
(b) There has been a material breach by the Company of any
representation, warranty, covenant or agreement of the Company contained in this
Agreement which would give rise to the failure of a condition set forth in
paragraph (c) of Exhibit A (a "Terminating Company Breach"); provided, however,
that, if such Terminating Company Breach is curable by the Company through the
exercise of reasonable best efforts and such cure is reasonably likely to be
completed prior to the applicable date specified in Section 9.2(i), then for so
long as the Company continues to exercise reasonable best efforts, Parent may
not terminate this Agreement under this Section 9.4(b).
9.5. Effect of Termination and Abandonment. (a) In the event
of termination of this Agreement and the abandonment of the Merger pursuant to
this Article IX, this Agreement (other than as set forth in Section 10.1) shall
become void and of no effect with no liability of any party hereto (or any of
its directors, officers, employees, agents, legal and financial advisors or
other representatives); provided, however, that except as otherwise provided
herein, no such termination shall relieve any party hereto of any liability or
damages resulting from any willful breach of this Agreement.
(b) In the event that (i)(A) a bona fide Acquisition Proposal
shall have been made to the Company or any of its stockholders or any Person
shall have announced an intention (whether or not conditional) to make an
Acquisition Proposal with respect to the Company, and on or following the date
of this Agreement but prior to the date that the
-47-
<PAGE> 51
Offer is consummated and Parent owns a majority of the outstanding shares of
Common Stock, such Acquisition Proposal, announcement or intention is or becomes
publicly known, and (B) on or following the date of this Agreement and prior to
the time such Acquisition Proposal, announcement or intention is or becomes
publicly known, the occurrence of an event which would have a material adverse
effect on the ability of Parent and Merger Sub to consummate the Merger shall
not have become publicly known, and (C) on or following the date on which such
Acquisition Proposal, announcement or intention is or becomes publicly known,
this Agreement is terminated by either Parent or the Company pursuant to Section
9.2(i) and if terminated by Parent or Merger Sub, Parent or Merger Sub shall not
collectively beneficially own a majority of the outstanding Shares on a fully
diluted basis, or (ii) this Agreement is terminated (x) by the Company pursuant
to Section 9.3(a) or (y) by Parent pursuant to Section 9.4(a), or (z) pursuant
to Section 9.2(iv) as a result of the failure of the Company to satisfy any one
of the conditions set forth in paragraphs (e) or (f) of Annex A, then, subject
to Section 9.5(c), the Company (p) shall promptly, but in no event later than
two Business Days after the date of such termination if terminated by Parent or
Merger Sub and simultaneously with such termination if terminated by Company
(except as otherwise provided in the proviso to this sentence), pay Parent a
termination fee of $2 million in cash payable by wire transfer of same day
funds, and (q) shall promptly, but in no event later than two Business Days
after being notified of such by Parent, pay all of the charges and expenses
incurred by Parent or Merger Sub in connection with this Agreement, the Stock
Option Agreement and the Shareholders Agreement and the transactions
contemplated by this Agreement and the Stock Option Agreement and the
Shareholders Agreement, including, without limitation, fees and expenses of
accountants, attorneys and financial advisors, up to a maximum of $500,000, in
the aggregate; provided, however, that no termination fee shall be payable to
Parent by reason of Section 9.5(b)(i) unless and until (I) any person or entity
(other than Parent) (an "Acquiring Party") has within 9 months of such
termination entered into a definitive agreement to be acquired, by purchase,
merger, consolidation, sale, assignment, lease, transfer or otherwise, in one
transaction or any related series of transactions, a majority of the voting
power of the outstanding securities of the Company or (II) a definitive
agreement has been entered into with respect to a merger, consolidation or
similar business combination between the Company and an Acquiring Party or an
affiliate thereof as a result of which the stockholders of the Company
immediately prior to the transaction do not own at least 50% of the surviving
entity. The Company acknowledges that the agreements contained in this Section
9.5(b) are an integral part of the transactions contemplated by this Agreement,
and that, without these agreements, Parent and Merger Sub would not enter into
this Agreement; accordingly, if the Company fails to promptly pay the amount due
pursuant to this Section 9.5(b), and, in order to obtain such payment, Parent or
Merger Sub commences a suit which results in a binding nonappealable judgment
rendered by a court of competent jurisdiction against the Company for the fee
set forth in this paragraph (b) the Company shall pay to Parent or Merger Sub
its costs and expenses (including
-48-
<PAGE> 52
attorneys' fees) in connection with such suit, together with interest on the
amount of the fee at the prime rate of Citibank, N.A. in effect on the date such
payment was required to be made.
(c) Parent agrees that the payment provided for in Section
9.5(b) shall be the sole and exclusive remedy of Parent upon termination of this
Agreement pursuant to Sections 9.3(a) or 9.4(a) and such remedy shall be limited
to the aggregate of the sums stipulated in such Section 9.5(b); provided,
however, that nothing herein shall relieve any party from liability for the
willful breach of any of its representations, warranties, covenants or
agreements set forth in this Agreement. In no event shall the Company be
required to pay to Parent more than one termination fee pursuant to Section
9.5(b)(p). Notwithstanding any other provision of this Agreement or the Stock
Option Agreement, any termination fee required to be paid to Parent pursuant to
Section 9.5(b)(p) shall be reduced (but not below zero) to the extent necessary
so that the sum of (1) the portion of any termination fee actually paid to
Parent pursuant to Section 9.5(b)(p), (2) the aggregate of all Cancellation
Amounts (as defined in the Stock Option Agreement) paid to Parent pursuant to
the Stock Option Agreement and (3) the proceeds actually received by Parent as
the result of selling Shares issued to Parent pursuant to the Stock Option
Agreement to a third party which acquires more than 50% of the Company's
outstanding voting securities (other than the Company or any of its affiliates)
shall not exceed $4.4 million. In no event shall (i) the sum of the portion of
any termination fee actually paid to Parent pursuant to Section 9.5(b)(p), and
the cash proceeds actually received by Parent as the result of selling Shares
issued to Parent pursuant to the Stock Option Agreement to a third party which
acquires more than 50% of the Company's outstanding voting securities (other
than the Company or any of its affiliates) exceed $4.4 million, or (ii) the sum
of the portion of any termination fees actually paid to Parent pursuant to
Section 9.5(b)(p), the aggregate Cancellation Amounts paid to parent pursuant to
the Stock Option Agreement and the cash proceeds actually received by parent as
the result of selling Shares issued to Parent pursuant to the Stock Option
Agreement to a third party which acquires more than 50% of the Company's
outstanding voting securities (other than the Company or any of its affiliates)
exceed $4.4 million.
ARTICLE X
Miscellaneous and General
10.1. Survival. This Article X and the agreements of the
Company, Parent and Merger Sub contained in Articles I, II, III, IV and V and
Sections 7.9 (Benefits), 7.10 (Expenses), and 7.11 (Indemnification; Directors'
and Officers' Insurance) shall survive the consummation of the Offer and the
Merger. This Article X and the agreements of the Company, Parent and Merger Sub
contained in Section 7.10 (Expenses), and Section 9.5 (Effect of Termination and
Abandonment) shall survive the termination of this Agreement. All other
agreements and covenants in this Agreement and all representations
-49-
<PAGE> 53
and warranties contained herein shall not survive the consummation of the Merger
or the termination of this Agreement other than the representations and
warranties set forth in Section 6.1(s) which shall survive termination of this
Agreement.
10.2. Modification or Amendment. Subject to the provisions of
applicable law, at any time prior to the Effective Time, the parties hereto may
modify or amend this Agreement, by written agreement executed and delivered by
duly authorized officers of the respective parties.
10.3. Waiver of Conditions. The conditions to each of the
parties' obligations to consummate the Merger are for the sole benefit of such
party and may be waived by such party in whole or in part to the extent
permitted by applicable law.
10.4. Counterparts. This Agreement may be executed in any
number of counterparts, each such counterpart being deemed to be an original
instrument, and all such counterparts shall together constitute the same
agreement.
10.5. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL. (a) THIS
AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE
INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAWS OF THE
STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICT OF LAW PRINCIPLES THEREOF. THE
PARTIES HEREBY IRREVOCABLY SUBMIT TO THE JURISDICTION OF THE COURTS OF THE STATE
OF DELAWARE AND THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED IN
THE COUNTY OF NEW CASTLE, DELAWARE SOLELY IN RESPECT OF THE INTERPRETATION AND
ENFORCEMENT OF THE PROVISIONS OF THIS AGREEMENT, THE STOCK OPTION AGREEMENT AND
THE SHAREHOLDERS AGREEMENT AND OF THE DOCUMENTS REFERRED TO IN THIS AGREEMENT,
THE STOCK OPTION AGREEMENT AND THE SHAREHOLDERS AGREEMENT, AND IN RESPECT OF THE
TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY, AND HEREBY WAIVE, AND AGREE NOT TO
ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR THE INTERPRETATION OR
ENFORCEMENT HEREOF OR OF ANY SUCH DOCUMENT, THAT IT IS NOT SUBJECT THERETO OR
THAT SUCH ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE
IN SAID COURTS OR THAT THE VENUE THEREOF MAY NOT BE APPROPRIATE OR THAT THIS
AGREEMENT, THE STOCK OPTION AGREEMENT OR THE SHAREHOLDERS AGREEMENT OR ANY SUCH
DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND THE PARTIES HERETO
IRREVOCABLY AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION OR PROCEEDING
SHALL BE HEARD AND DETERMINED IN SUCH A DELAWARE STATE OR FEDERAL COURT. THE
PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT
-50-
<PAGE> 54
JURISDICTION OVER THE PERSON OF SUCH PARTIES AND OVER THE SUBJECT MATTER OF SUCH
DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH ANY
SUCH ACTION OR PROCEEDING IN THE MANNER PROVIDED IN SECTION 10.6 OR IN SUCH
OTHER MANNER AS MAY BE PERMITTED BY LAW, SHALL BE VALID AND SUFFICIENT SERVICE
THEREOF.
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY
CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT, THE STOCK OPTION AGREEMENT OR
THE SHAREHOLDERS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT,
THE STOCK OPTION AGREEMENT OR THE SHAREHOLDERS AGREEMENT, OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I)
NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH SUCH PARTY
UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH SUCH
PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH SUCH PARTY HAS BEEN INDUCED
TO ENTER INTO THIS AGREEMENT OR THE STOCK OPTION AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.5.
-51-
<PAGE> 55
10.6. Notices. Any notice, request, instruction or other
document to be given hereunder by any party to the others shall be in writing
and delivered personally or sent by registered or certified mail, postage
prepaid, or by facsimile:
if to Parent or Merger Sub
Celia Colbert
Merck & Co., Inc.
One Merck Drive
P.O. Box 100 WS3AB-05
Whitehouse Station, N.J. 08889-0100
Fax: (908) 735-1246
with copies to:
Gary P. Cooperstein, Esq.
Fried, Frank, Harris, Shriver & Jacobson
One New York Plaza
New York, NY 10004
Fax: (212) 859-4000
if to the Company
Stephen F. Keane
SIBIA Neurosciences, Inc.
505 Coast Blvd. South
Suite 300
La Jolla, CA 92037
fax: (619) 459-1609
with copies to:
Frederick T. Muto, Esq.
Cooley Godward LLP
4365 Executive Drive
Suite 1100
San Diego, California 92121
fax: (858) 453-3555
or to such other persons or addresses as may be designated in writing by the
party to receive such notice as provided above.
10.7. Entire Agreement. This Agreement (including any exhibits
hereto), the Stock Option Agreement, the Company Confidentiality Agreement and
the Parent Confidentiality Agreement constitute the entire agreement, and
supersede all other prior
-52-
<PAGE> 56
agreements, understandings, representations and warranties both written and
oral, among the parties, with respect to the subject matter hereof.
10.8. No Third Party Beneficiaries. Except as provided in
Section 7.11 (Indemnification; Directors' and Officers' Insurance), this
Agreement is not intended to confer upon any Person other than the parties
hereto any rights or remedies hereunder.
10.9. Obligations of Parent and of the Company. Whenever this
Agreement requires a Subsidiary of Parent to take any action, such requirement
shall be deemed to include an undertaking on the part of Parent to cause such
Subsidiary to take such action. Whenever this Agreement requires a Subsidiary of
the Company to take any action, such requirement shall be deemed to include an
undertaking on the part of the Company to cause such Subsidiary to take such
action and, after the Effective Time, on the part of the Surviving Corporation
to cause such Subsidiary to take such action.
10.10. Severability. The provisions of this Agreement shall be
deemed severable and the invalidity or unenforceability of any provision shall
not affect the validity or enforceability of the other provisions hereof. If any
provision of this Agreement, or the application thereof to any Person or any
circumstance, is invalid or unenforceable, (a) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such
provision to other Persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application
thereof, in any other jurisdiction.
10.11. Specific Performance. The parties hereto each
acknowledge that, in view of the uniqueness of the subject matter hereof, the
parties hereto would not have an adequate remedy at law for money damages if
this Agreement were not performed in accordance with its terms, and therefore
agree that the parties hereto shall be entitled to specific enforcement of the
terms hereof in addition to any other remedy to which the parties hereto may be
entitled at law or in equity.
10.12. Interpretation. The table of contents and headings
herein are for convenience of reference only, do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the
provisions hereof. Where a reference in this Agreement is made to a Section,
Schedule or Exhibit, such reference shall be to a Section of or Schedule or
Exhibit to this Agreement unless otherwise indicated. Whenever the words
"include," "includes" or "including" are used in this Agreement, they shall be
deemed to be followed by the words "without limitation."
10.13. Assignment. This Agreement shall not be assignable by
operation of law or otherwise; provided, however, that Parent may designate, by
written notice to the
-53-
<PAGE> 57
Company, another wholly owned direct subsidiary of Parent to be a Constituent
Corporation in lieu of Merger Sub, in the event of which, all references herein
to Merger Sub shall be deemed references to such other subsidiary. Any purported
assignment made in contravention of this Agreement shall be null and void.
10.14. Captions. The Article, Section and Paragraph captions
herein are for convenience of reference only and do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the
provisions hereof.
-54-
<PAGE> 58
IN WITNESS WHEREOF, this Agreement has been duly executed and
delivered by duly authorized officers of the parties hereto as of the date
hereof.
SIBIA NEUROSCIENCES, INC.
By: /s/ William T. Comer
-----------------------
Name: William T. Comer
Title: President, Chief
Executive Officer
MERCK & CO., INC.
By: /s/ Judy C. Lewent
----------------------
Name: Judy C. Lewent
Title: Senior Vice President
and Chief Financial
Officer
MC SUBSIDIARY CORP.
By: /s/ Judy C. Lewent
----------------------
Name: Judy C. Lewent
Title: President
-55-
<PAGE> 59
ANNEX A
CONDITIONS TO THE OFFER
Notwithstanding any other provision of the Offer, and subject to the
terms and conditions of the Agreement, Merger Sub shall not be obligated to
accept for payment any shares of Company Common Stock until all Required
Regulatory Approvals shall have been obtained, made or satisfied including until
the expiration or termination of any waiting periods applicable under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act")
and Merger Sub shall not be required to accept for payment or, subject to any
applicable rules and regulations of the SEC (including Rule 14e-l(c) under the
Exchange Act) pay for, and may delay the acceptance for payment of or payment
for, any shares of Company Common Stock tendered in the Offer and (subject to
the terms and conditions of the Agreement, including Section 1.1(b)) may amend,
extend or terminate the Offer if, (i) immediately prior to the Schedule
Expiration Date (as extended in accordance with clauses (x), (y) or (z) of
Section 1.1(b) of the Agreement) the Minimum Condition shall not have been
satisfied or (ii) prior to the expiration of the Offer any of the following
shall exist and be continuing:
(a) there shall be threatened or pending any action,
litigation or proceeding (hereinafter, an "Action") brought by any U.S.
Governmental Entity: (i) challenging the acquisition by Parent or Merger Sub of
shares of Company Common Stock or seeking to restrain or prohibit the
consummation of the Offer or the Merger; (ii) seeking to prohibit or impose any
material limitation on Parent's, Merger Sub's or any of their respective
affiliates' ownership or operation of all or any material portion of the
business or assets of the Company and its Subsidiaries taken as a whole or
Parent and its Subsidiaries taken as a whole that, in each case referred to in
this clause (ii) individually or in the aggregate, is reasonably likely to have
a Material Adverse Effect on the Company or Parent; or (iii) seeking to impose
material limitations on the ability of Parent or Merger Sub effectively to
acquire or hold, or to exercise full rights of ownership of, the shares of
Company Common Stock including the right to vote the shares of Company Common
Stock purchased by them on an equal basis with all other shares of Company
Common Stock on all matters properly presented to the shareholders of the
Company; or
(b) any U.S. statute, rule, regulation, order or injunction
shall be enacted, promulgated, entered, enforced or deemed to or become
applicable to the Offer or the Merger (and in each case, remain in effect), or
any other action shall have been taken, by any court of competent jurisdiction
or other U.S. Governmental Entity, that has any of the consequences referred to
in clauses (i) through (iii) of paragraph (a) above; or
(c) (i) The representations and warranties of the Company set
forth in this Agreement shall be true and correct as of the date of the
Agreement and as of the consummation of the Offer (except for those
representations and warranties made as of a
-56-
<PAGE> 60
specific date, which shall be true and correct as of such date), and considered
without regard to any qualification by, or references to, "material," "in all
material respects" or "Company Material Adverse Effect," except for such
failures of such representations and warranties to be true and correct that
individually or in the aggregate, do not have and are not reasonably likely to
have a Company Material Adverse Effect; or (ii) the Company shall have breached
or failed to comply in any material respect with any of its material
obligations, covenants or agreements under the Agreement and any such breach or
failure shall not have been substantially cured by the Company within five
Business Days after Parent provides written notice to the Company of such breach
or failure; or
(d) the Agreement shall have been terminated in accordance
with its terms; or
(e) any corporation, entity, "group" or "person" (as defined
in the Exchange Act), other than Parent, Merger Sub or any of the shareholders
that are party to the Shareholders Agreement (so long as such shareholders do
not become beneficial owners of any additional Shares after the date hereof and
so long as such shareholders do not breach any of the provisions of the
Shareholders Agreement), shall have acquired beneficial ownership of more than
20% of the outstanding Shares; or
(f) the Company's Board shall have modified or amended its
recommendation of the Offer in any manner adverse to Parent or Merger Sub or
shall have withdrawn its recommendation of the Offer or shall have recommended
acceptance of any Acquisition Proposal or shall have failed to reconfirm its
recommendation of the Offer within five calendar days after a written request by
Parent to do so, or shall have resolved to do any of the foregoing; or
(g) there shall exist (i) any general suspension of, or
limitation on prices for, trading in securities on any national securities
exchange or in the over the counter market in the United States (other than
shortening of trading hours or any trading halt resulting from a specified
increase or decrease in a market index), (ii) a declaration of any banking
moratorium by federal or state authorities or any suspension of payments in
respect of banks or any limitation (whether or not mandatory) imposed by federal
or state authorities on the extension of credit by lending institutions in the
United States, or (iii) in the case of any of the foregoing existing at the time
of the commencement of the Offer, a material acceleration or worsening thereof.
The conditions set forth in clauses (a) through (g) are for
the sole benefit of Parent and Merger Sub and may be asserted by Parent and
Merger Sub regardless of the circumstances giving rise to such conditions and
may be waived by Parent and Merger Sub in whole or in part at any time and from
time to time, by express and specific action to that effect, in their reasonable
discretions. The failure by Parent or Merger Sub at any time to exercise any of
the foregoing rights shall not be deemed a waiver of any such right, the waiver
of any such
-57-
<PAGE> 61
right with respect to particular facts and other circumstances shall not be
deemed a waiver with respect to any other facts and circumstances, and each such
right shall be deemed an ongoing right that may be asserted at any time and from
time to time.
The capitalized terms used in this Annex A shall have the
meanings set forth in the Agreement to which it is annexed.
-58-
<PAGE> 1
EXHIBIT (c)(2)
SHAREHOLDERS AGREEMENT
SHAREHOLDERS AGREEMENT (this "Agreement") dated as of July 30, 1999
among the persons listed on Schedule 1 hereto (each, a "Holder" and,
collectively, the "Holders"), Merck & Co., Inc., a New Jersey corporation
("Parent"), and MC Subsidiary Corp., a Delaware corporation and a wholly owned
subsidiary of Parent (the "Merger Sub"). Parent, Merger Sub and SIBIA
Neurosciences, Inc., a Delaware corporation (the "Company"), propose to enter
into a Merger Agreement (the "Merger Agreement") on the date of this Agreement
providing for the making of a tender offer by Merger Sub (the "Offer") for
shares of Common Stock, par value $0.001 per share, of the Company (the "Company
Common Stock"), at a purchase price of $8.50 per share, and a subsequent merger
(the "Merger") between the Company and the Merger Sub.
Each Holder owns the number of shares of Company Common Stock (the
"Shares") or options to purchase Company Common Stock (the "Stock Options" and
collectively, with the Shares, the "Optioned Securities"), or has the right to
vote the number of Shares or other securities (the "Voting Securities"), listed
opposite the name of such Holder on Schedule 1. Parent and the Merger Sub have
required, as a condition to entering into the Merger Agreement, that the Holders
enter into this Agreement. The Holders believe that it is in the best interest
of the Company and its stockholders to induce Parent and the Merger Sub to enter
into the Merger Agreement and, therefore, the Holders are willing to enter into
this Agreement.
Accordingly, in consideration of the mutual covenants and agreements
set forth herein and in consideration of $1.00 and such other valuable
consideration the receipt of which is hereby acknowledged, the parties hereto
agree as follows:
1. The Option. Each Holder hereby grants the Merger Sub an irrevocable
option (the "Option") to purchase all of the Optioned Securities of such Holder
at the price of $8.50 per share (or such higher price as may be paid pursuant to
the Offer), payable in cash, without interest.
2. Exercise of the Option; Term. On the terms and subject to the
conditions of this Agreement, the Merger Sub may exercise the Option at any time
after the date on which all waiting periods under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to
the exercise of the Option have expired or been terminated by written notice to
each Holder specifying a date and time for the closing not later than thirty
(30) business days from the date of such notice (which date and time may be one
day after the delivery of such notice), but only if (i) (A) a bona fide
Acquisition Proposal (as defined in the Merger Agreement) shall have been made
to the Company or any of its stockholders or any person or entity shall have
announced an intention (whether or not conditional) to make an Acquisition
Proposal with respect to the
<PAGE> 2
Company, and on or following the date of the Merger Agreement but prior to the
date that the Offer is consummated and Parent owns a majority of the outstanding
shares of Common Stock, such Acquisition Proposal, announcement or intention is
or becomes publicly known, and (B) on or following the date of the Merger
Agreement but prior to the time such Acquisition Proposal, announcement or
intention is or becomes publicly known, the occurrence of an event that would
have a material adverse effect on the ability of Parent or Merger Sub to
consummate the Merger shall not have become publicly known, and (C) on or
following the date on which such Acquisition Proposal, announcement or intention
is or becomes publicly known, the Merger Agreement is terminated by either the
Company or the Parent pursuant to Section 9.2(i) of the Merger Agreement and if
terminated by Parent or Merger Sub, Parent or Merger Sub shall not collectively
beneficially own a majority of the outstanding shares of Common Stock on a fully
diluted basis, and a termination fee has become payable pursuant to Section
9.5(b) of the Merger Agreement or (ii) the Merger Agreement is terminated (x) by
the Company pursuant to Section 9.3(a) of the Merger Agreement, or (y) by the
Parent pursuant to Section 9.4(a) of the Merger Agreement, or (z) pursuant to
Section 9.2(iv) of the Merger Agreement as a result of the failure to satisfy
any one of the conditions set forth in paragraphs (e) or (f) of Annex A of the
Merger Agreement. As used in this Agreement, "person" shall have the meaning
specified in Sections 3(a)(9) and 13(d)(3) of the Exchange Act. Notwithstanding
any other provision of this Shareholders Agreement, the Merger Agreement or the
Stock Option Agreement, any reference to a majority of the total issued and
outstanding shares or Shares, or shares or Shares outstanding on a fully diluted
basis, or similar references, shall, for purposes of such agreements, exclude
from the determination thereof any shares of Common Stock issuable upon exercise
of or subject to the Stock Option Agreement and any reference to beneficial
ownership of shares of Common Stock or similar references shall, for purposes of
such agreements, exclude from the determination thereof any shares of Common
Stock issuable upon exercise of or subject to the Stock Option Agreement and/or
the Shareholders Agreement. The Option shall expire on the earliest of (1) the
Effective Time (as defined in the Merger Agreement), (2) the nine month
anniversary of the earliest to occur of the events set forth in any of clauses
(i) and (ii) of Section 9.5(b) of the Merger Agreement and (3) the fifteenth day
following the termination of the Merger Agreement if prior to such fifteenth day
the events set forth in any of clauses (i) or (ii) of Section 9.5(b) of the
Merger Agreement shall not have occurred (such earliest date being referred to
in this Agreement as the "Expiration Date"); provided that, if the Option cannot
be exercised or the Optioned Securities cannot be delivered to the Merger Sub
upon such exercise because (x) there shall be in effect a preliminary or
permanent injunction or other order issued by any federal or state court of
competent jurisdiction prohibiting delivery of the Optioned Securities or (y)
any applicable waiting periods under the HSR Act shall not have expired or been
terminated, then the Expiration Date shall be extended until thirty days after
such impediment to exercise or delivery has been removed.
3. Closing. At the closing:
-2-
<PAGE> 3
(a) against delivery of the Optioned Securities, free and
clear of all liens, claims, charges and encumbrances of any kind or
nature whatsoever, Parent shall cause the Merger Sub to make payment to
each Holder of the aggregate price for such Holder's Optioned
Securities by wire transfer of immediately available funds; and
(b) each Holder shall deliver to the Merger Sub a duly
executed certificate or certificates representing the number of
Optioned Securities purchased from such Holder, together with transfer
powers endorsed in blank relating to such certificates and, if
requested by the Merger Sub, an irrevocable proxy duly executed by such
Holder, authorizing such persons as the Merger Sub shall designate to
act for such Holder as his lawful agents, attorneys and proxies, with
full power of substitution, to vote in such manner as each such agent,
attorney and proxy or his substitute shall in his sole discretion deem
proper, and otherwise act with respect to the Optioned Securities at
any meeting (whether annual or special and whether or not an adjourned
meeting) of the Company's Holders or otherwise, and revoking any prior
proxies granted by such Holder with respect to the Holder's Optioned
Securities.
Notwithstanding any provision of this Agreement to the contrary, the
Holders shall validly tender their Shares pursuant to the Offer and shall not
withdraw such Shares prior to the expiration of the Offer, and their obligation
to sell any Optioned Securities shall be satisfied, solely with respect to the
Shares so tendered, upon the purchase of such Shares by the Merger Sub pursuant
to the Offer.
4. Covenants of the Holders.
(a) During the period from the date of this Agreement until
the Expiration Date, except in accordance with the provisions of this
Agreement, each Holder severally and not jointly agrees that he will
not:
(i) sell, sell short, transfer, pledge, hypothecate,
assign or otherwise dispose of, or enter into any contract,
option, hedging arrangement or other arrangement or
understanding with respect to the sale, transfer, pledge,
hypothecation, assignment or other disposition of, any
Optioned Securities or Voting Securities;
(ii) deposit any Optioned Securities or Voting
Securities into a voting trust, or grant any proxies or enter
into a voting agreement with respect to any Optioned
Securities or Voting Securities; or
-3-
<PAGE> 4
(iii) initiate, solicit or knowingly encourage,
directly or indirectly, any inquiries or the making or
implementation of any proposal that constitutes, or may
reasonably be expected to lead to, any Acquisition Proposal
(as defined in the Merger Agreement) or enter into discussions
or negotiate with any person or entity in furtherance of such
inquiries or to obtain a Acquisition Proposal, or agree to or
endorse any Acquisition Proposal; except that any Holder who
is a member of the board of directors of the Company may
conduct himself in the manner expressly permitted under
Section 7.2 of the Merger Agreement.
(b) Any additional shares of Company Common Stock, warrants,
options or other securities or rights exercisable for, exchangeable for
or convertible into shares of Company Common Stock (collectively,
"Equity Securities") acquired by any Holder will become subject to this
Agreement and shall, for all purposes of this Agreement, be considered
Optioned Securities or Voting Securities, as the case may be.
(c) Each Holder agrees not to engage in any action or omit to
take any action which would have the effect of preventing or disabling
such Holder from delivering his Optioned Securities to the Merger Sub
or otherwise performing his obligations under this Agreement. To the
extent that any Optioned Securities (other than Company Common Stock)
may not be assigned by such Holder to the Merger Sub without
exercising, exchanging or converting such Optioned Securities for or
into Company Common Stock, each Holder agrees to exercise, exchange or
convert such Optioned Securities for or into Company Common Stock prior
to the closing of the purchase of such Optioned Securities upon
exercise of the Option.
5. Representations and Warranties of each Holder. Each Holder severally
and not jointly represents and warrants to Parent and the Merger Sub as follows:
(a) (i) such Holder is the record or beneficial owner of the
Optioned Securities, or has the right to vote the Voting Securities,
listed opposite the name of such Holder on Schedule 1, (ii) such
Optioned Securities or Voting Securities are the only Equity Securities
owned of record or beneficially by such Holder or in which such Holder
has any interest or which such Holder has the right to vote, as the
case may be, and (iii) such Holder does not have any option or other
right to acquire any other Equity Securities;
(b) such Holder has the right, power and authority to execute
and deliver this Agreement and to perform his obligations hereunder;
the execution, delivery and performance of this Agreement by such
Holder will not require the consent of any other person and will not
constitute a violation of, conflict with or result in a default under
(i) any contract, understanding or arrangement to which such Holder
-4-
<PAGE> 5
is a party or by which such Holder is bound, (ii) any judgment, decree
or order applicable to such Holder, or (iii) any law, rule or
regulation of any governmental body applicable to such Holder; and this
Agreement constitutes a valid and binding agreement on the part of such
Holder, enforceable in accordance with its terms, subject to applicable
bankruptcy, insolvency, moratorium or other similar laws relating to
creditors' rights and general principles of equity;
(c) any Shares included in the Optioned Securities owned by
such Holder have been validly issued and are fully paid and
nonassessable and any shares of Company Common Stock issuable upon
exercise of the Stock Options or Warrants, when issued and upon payment
of the exercise price therefor, will be validly issued, fully paid and
nonassessable;
(d) except as set forth on Schedule 1, the Optioned Securities
owned by such Holder are now, and at all times during the term of this
Agreement will be, held by such Holder free and clear of all adverse
claims, liens, encumbrances and security interests, and none of the
Optioned Securities or Voting Securities are subject to any voting
trust or other agreement or arrangement (except as created by this
Agreement) with respect to the voting or disposition of the Optioned
Securities or Voting Securities; and there are no outstanding options,
warrants or rights to purchase or acquire, or agreements (except for
this Agreement) relating to, such Optioned Securities or Voting
Securities; and
(e) upon purchase of the Optioned Securities owned by such
Holder, the Merger Sub will obtain good and marketable title to such
Optioned Securities, free and clear of all adverse claims, liens,
encumbrances and security interests (except any created by the Merger
Sub).
6. Effect of Representations, Warranties and Covenants of Holders. The
representations, warranties and covenants of the Holders shall be several and
not joint. The liability of each individual Holder shall extend only to the
representations, warranties and covenants of such Holder and not to any
representation, warranty or covenant of any other Holder.
7. Representations and Warranties of Parent and the Merger Sub. Each of
Parent and the Merger Sub hereby represents and warrants to each Holder that: it
is a corporation duly formed under the laws of the states of their respective
incorporations; it has all requisite corporate power and authority to enter into
and perform all its obligations under this Agreement; the execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby
have been duly authorized by all necessary corporate action on its part; this
Agreement has been duly executed and delivered by it; and this Agreement
constitutes a valid and binding agreement on its part, enforceable in accordance
with its terms, subject to applicable bankruptcy insolvency,
-5-
<PAGE> 6
moratorium or other similar laws relating to creditors' rights and general
principles of equity.
8. Voting of Equity Securities. Each Holder hereby agrees that, during
the time this Agreement is in effect, at any meeting of the stockholders of the
Company, however called, and in any action by written consent of the
stockholders of the Company, he shall (a) vote all Voting Securities of such
Holder in favor of the Merger; (b) not vote any Voting Securities in favor of
any action or agreement which would result in a breach in any material respect
of any covenant, representation or warranty or any other obligation of the
Company under the Merger Agreement; and (c) vote all Voting Securities of such
Holder against any action or agreement which would impede, interfere with or
attempt to discourage the Offer or the Merger, including, but not limited to:
(i) any Acquisition Proposal (other than the Offer and the Merger) involving the
Company or any of its subsidiaries; (ii) any change in the management or board
of directors of the Company, except as otherwise agreed to in writing by the
Merger Sub; (iii) any material change in the present capitalization or dividend
policy of the Company; or (iv) any other material change in the Company's
corporate structure or business. Each Holder hereby irrevocably appoints
designees of MC Merger Sub, the attorneys, agents and proxies, with full power
of substitution, for the undersigned and in the name, place and stead of the
undersigned to vote in such manner as such attorneys, agents and proxies or
their substitutes shall in their sole discretion deem proper and otherwise act,
including the execution of written consents, with respect to all Voting
Securities of the Company which the undersigned is or may be entitled to vote at
any meeting of the Company held after the date hereof, whether annual or special
and whether or not an adjourned meeting, or in respect of which the undersigned
is or may be entitled to act by written consent. This proxy is coupled with an
interest and shall be irrevocable and binding on any successor in interest of
the undersigned. This proxy shall operate to revoke any prior proxy as to Voting
Securities heretofore granted by the Holder. Such proxy shall terminate upon the
termination of this Agreement.
9. Adjustments. In the event of any increase or decrease or other
change in the Optioned Securities by reason of stock dividends, split-up,
recapitalizations, combinations, exchanges of shares or the like, the number of
Optioned Securities and Voting Securities subject to this Agreement shall be
adjusted appropriately.
10. Governing Law. This Agreement shall be governed by and construed in
accordance with the law of the State of Delaware without regard to its rules of
conflict of laws.
11. Further Assurances. Each party hereto shall perform such further
acts and execute such further documents as may reasonably be required to carry
out the provisions of this Agreement.
-6-
<PAGE> 7
12. Legend. As soon as practicable after the execution of this
Agreement, the following legend shall be placed on the certificates representing
the Optioned Securities:
"The Securities represented by this certificate are subject to
certain transfer and other restrictions contained in an Shareholders
Agreement, dated as of July 30, 1999, among Merck & Co., Inc., MC
Subsidiary Corp. and certain stockholders of the Corporation."
13. Assignment. This Agreement may not be assigned by any party hereto,
except that the Merger Sub may assign its right to purchase the Optioned
Securities to one or more of its affiliates.
14. Remedies. The parties agree that legal remedies for breach of this
Agreement will be inadequate and that this Agreement may be enforced by Parent
and the Merger Sub by injunctive or other equitable relief.
15. Notices. All notices or other communications required or permitted
hereunder shall be in writing (except as otherwise provided herein) and shall be
deemed duly given if delivered in person, by confirmed facsimile transmission or
by overnight courier service, addressed as follows:
To Parent or the Merger Sub:
Celia Colbert
Merck & Co., Inc.
One Merck Drive
P.O. Box 100 W53AB-05
Whitehouse Station, NJ 08889
Fax: (908) 735-1246
With a copy to:
Fried, Frank, Harris, Shriver
& Jacobson
One New York Plaza
New York, New York 10004
Attention: Gary P. Cooperstein, Esq.
Facsimile: (212) 859-4000
-7-
<PAGE> 8
To each Holder:
The Salk Institute
10010 North Torrey Pines Road
La Jolla, CA 92037-1099
Attention: Delbert E. Glanz
Executive Vice President
Fax: 535-9663
With copies to:
The Salk Institute
10010 North Torrey Pines Road
La Jolla, CA 92037-1099
Attention: Douglas D. Busch
General Counsel
Fax: 450-0509
16. Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any rule of law or public
policy, all other conditions and provisions of this Agreement shall nevertheless
remain in full force and effect so long as the economic or legal substance of
the transactions contemplated hereby is not affected in any manner adverse to
any party. Upon such determination that any term or other provision is invalid,
illegal or incapable of being enforced, the parties hereto shall negotiate in
good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible in an acceptable manner to the end that the
transactions contemplated hereby are fulfilled to the extent possible.
17. Counterparts. This Agreement may be executed in counterparts, each
of which shall be deemed to be an original, but all of which together shall
constitute one and the same agreement.
18. Binding Effect; Benefits. This Agreement shall survive the death or
incapacity of any Holder and shall inure to the benefit of and shall be binding
upon the parties hereto and their respective heirs, legal representatives,
successors and permitted assigns. Nothing in this Agreement, expressed or
implied, is intended to or shall confer on any person other than the parties
hereto and their respective heirs, legal representatives and successors and
permitted assigns any rights, remedies, obligations or liabilities under or by
reason of this Agreement.
-8-
<PAGE> 9
IN WITNESS WHEREOF, the Holders, Parent and Merger Sub have entered
into this Agreement as of the date first written above.
MERCK & CO., INC.
By: /s/ Judy C. Lewent
________________________________
Name: Judy C. Lewent
Title: Senior Vice President and
Chief Financial Officer
MC SUBSIDIARY CORP.
By: /s/ Judy C. Lewent
_________________________________
Name: Judy C. Lewent
Title: President
HOLDERS:
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
By: /s/ Delbert E. Glanz
____________________________________
Name: Delbert E. Glanz
Title: Executive Vice President
By: /s/ Douglas D. Busch
_____________________________________
Name: Douglas D. Busch
Title: General Counsel, Assistant
Secretary
SKANDIGEN A.B.
By: /s/ Gunnar Ekdahl
_______________________________________
Name: Gunnar Ekdahl
Title: Director
/s/ William T. Comer
_________________________________________
William T. Comer
-9-
<PAGE> 10
SCHEDULE 1
<TABLE>
<CAPTION>
Name Shares Stock Options Voting Securities
- ---- ------ ------------- -----------------
<S> <C> <C> <C>
The Name Salk Institute for
Biological Studies 1,933,461 0 1,933,461
Skandigen AB 986,696 0 986,696
William T. Comer 267,900 189,790 267,900
</TABLE>
-10-
<PAGE> 1
EXHIBIT (c)(3)
STOCK OPTION AGREEMENT
STOCK OPTION AGREEMENT, dated as of July 30, 1999 (the
"Agreement"), among Merck & Co., Inc., a New Jersey corporation (the "Grantee"),
MC Subsidiary Corp., a Delaware corporation and a wholly owned subsidiary of the
Grantee ("Merger Sub"), and SIBIA Neurosciences, Inc., a Delaware corporation
(the "Grantor"). Capitalized terms used herein and not otherwise defined shall
have the meanings given to such terms in the Merger Agreement (as defined
below).
WHEREAS, the Grantee, Merger Sub, and the Grantor are entering
into an Agreement and Plan of Merger, dated as of the date hereof (the "Merger
Agreement"), which provides, among other things, for the merger of Merger Sub
with and into Grantor (the "Merger");
WHEREAS, the Grantee and Merger Sub have requested that the
Grantor grant to the Grantee an option to purchase up to 1,931,050 shares of
Common Stock, par value $0.001 per share, of the Grantor (the "Common Stock"),
on the terms and subject to the conditions hereof; and
WHEREAS, the Grantor is willing to grant the Grantee the
requested option.
NOW, THEREFORE, in consideration of the premises and the
mutual covenants and agreements set forth herein, the parties hereto agree as
follows:
1. The Option; Exercise; Adjustments; Payment of Spread. (a)
Contemporaneously herewith the Grantee, Merger Sub and the Grantor are entering
into the Merger Agreement. Subject to the other terms and conditions set forth
herein, the Grantor hereby grants to the Grantee an irrevocable option (the
"Option") to purchase up to 1,931,050 shares of Common Stock (the "Shares") at a
cash purchase price equal to $8.50 per share (the "Purchase Price"). The Option
may be exercised by the Grantee, in whole or in part, at any time, but only on
one occasion, following (but not prior to) the occurrence of the events set
forth in any of clauses (i), (ii) or (iii) of Section 2(d) hereof, and prior to
the Termination Date (as defined below).
(b) In the event the Grantee wishes to exercise the Option,
the Grantee shall send a written notice to the Grantor (the "Stock Exercise
Notice") specifying the total number of Shares it wishes to purchase and a date
(subject to the expiration or termination of any applicable waiting period under
the HSR Act (as defined below) ) not later than 10 business days and not earlier
than three business days following the date such notice is given for the closing
of such purchase. In the event of any change in the number of issued and
outstanding shares of capital stock of the Company (by reason of any stock
dividend, stock split, split -- up, recapitalization, merger, issuance of
capital stock upon exercise of warrants or options or any other event), the
number of Shares
<PAGE> 2
subject to this Option and the purchase price per Share shall be appropriately
adjusted to restore the Grantee to its rights hereunder, including its right to
purchase Shares representing 19.9% of the capital stock of the Grantor entitled
to vote generally for the election of the directors of the Grantor which is
issued and outstanding immediately prior to the exercise of the Option.
(c) If at any time the Option is then exercisable pursuant to
the terms of Section 1(a) hereof and at or prior to such time the termination
fee referred to in Section 9.5(b) of the Merger Agreement shall have become
payable, the Grantee may on one occasion elect, in lieu of exercising the Option
to purchase Shares provided in Section 1(a) hereof, to send a written notice to
the Grantor (a "Cash Exercise Notice") specifying a date not later than 20
business days and not earlier than 10 business days following the date such
notice is given on which date the Grantor shall pay to the Grantee an amount in
cash (the "Cancellation Amount") equal to the Spread (as defined below)
multiplied by all or such portion of the Shares subject to the Option as Grantee
shall specify. As used herein "Spread" shall mean the excess, if any, over the
Purchase Price of the higher of (x) if applicable, the highest price per share
of Common Stock (including any brokerage commissions, transfer taxes and
soliciting dealers' fees) paid or proposed to be paid by any person pursuant to
any Acquisition Proposal (as defined in the Merger Agreement) occurring after
the date of this Agreement and prior to the Termination Date (the "Alternative
Purchase Price") or (y) the average of the closing bid and asked prices of the
Common Stock on the NASDAQ National Market ("NASDAQ") or on such other national
securities exchange on which the shares of the Grantor's common stock are then
listed for the last five trading days immediately prior to the date of the Cash
Exercise Notice (the "Closing Price"). If the Alternative Purchase Price
includes any property other than cash, the Alternative Purchase Price shall be
the sum of (i) the fixed cash amount, if any, included in the Alternative
Purchase Price plus (ii) the fair market value of such other property. If such
other property consists of securities with an existing public trading market,
the average of the closing prices (or the average of the closing bid and asked
prices if closing prices are unavailable) for such securities in their principal
public trading market on the five trading days ending five days prior to the
date of the Cash Exercise Notice shall be deemed to equal the fair market value
of such property. If such other property consists of something other than cash
or securities with an existing public trading market and, as of the payment date
for the Spread, agreement on the value of such other property has not been
reached, the Alternative Purchase Price shall be deemed to equal the Closing
Price. Upon exercise of its right to receive cash pursuant to this Section 1(c),
the obligations of the Grantor to deliver Shares pursuant to Section 3 shall be
terminated with respect to such number of Shares for which the Grantee shall
have elected to be paid the Spread.
2. Conditions to Delivery of Shares. The Grantor's obligation
to deliver Shares upon exercise of the Option is subject only to the conditions
that:
2
<PAGE> 3
(a) No preliminary or permanent injunction or other order
issued by any federal or state court of competent jurisdiction prohibiting the
delivery of the Shares shall be in effect; and
(b) Any applicable waiting periods under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 (the "HSR Act") shall have expired or been
terminated; and
(c) the representations and warranties of the Grantee made in
Section 5 of this Agreement shall be true and correct in all material respects
as of the date of the closing of the issuance of the Shares; and
(d) (i) (A) a bona fide Acquisition Proposal (as defined in
the Merger Agreement) shall have been made to the Company or any of its
stockholders or any Person shall have announced an intention (whether or not
conditional) to make an Acquisition Proposal with respect to the Company, and on
or following the date of the Merger Agreement but prior to the date that the
Offer is consummated and Grantee owns a majority of the outstanding shares of
Common Stock, such Acquisition Proposal, announcement or intention is or becomes
publicly known, and (B) on or following the date of the Merger Agreement but
prior to the time such Acquisition Proposal, announcement or intention is or
becomes publicly known, the occurrence of an event that would have a material
adverse effect on the ability of Grantee or Merger Sub to consummate the Merger
shall not have become publicly known, and (C) on or following the date on which
such Acquisition Proposal, announcement or intention is or becomes publicly
known, the Merger Agreement is terminated by either the Grantee or the Grantor
pursuant to Section 9.2(i) of the Merger Agreement and if terminated by Grantee
or Merger Sub, Grantee or Merger Sub shall not collectively beneficially own a
majority of the outstanding shares of Common Stock on a fully diluted basis, and
a termination fee has become payable pursuant to Section 9.5(b) of the Merger
Agreement or (ii) the Merger Agreement is terminated (x) by the Grantor pursuant
to Section 9.3(a) of the Merger Agreement, or (y) by the Grantee pursuant to
Section 9.4(a) of the Merger Agreement, or (z) pursuant to Section 9.2(iv) of
the Merger Agreement as a result of the failure to satisfy any one of the
conditions set forth in paragraphs (e) or (f) of Annex A of the Merger
Agreement. As used in this Agreement, "person" shall have the meaning specified
in Sections 3(a)(9) and 13(d)(3) of the Exchange Act. Notwithstanding any other
provision of this Stock Option Agreement, the Merger Agreement or the
Shareholders Agreement, any reference to a majority of the total issued and
outstanding shares or Shares, or shares or Shares outstanding on a fully diluted
basis, or similar references, shall, for purposes of such agreements, exclude
from the determination thereof any shares of Common Stock issuable upon exercise
of or subject to this Stock Option Agreement and any reference to beneficial
ownership of shares of Common Stock or similar references shall, for purposes of
such agreements, exclude from the
3
<PAGE> 4
determination thereof any shares of Common Stock issuable upon exercise of or
subject to this Stock Option Agreement and/or the Shareholders Agreement.
3. The Closing. (a) Any closing hereunder shall take place on
the date specified by the Grantee in its Stock Exercise Notice or Cash Exercise
Notice or as specified in Section 1(d), as the case may be, at 10:00 A.M., local
time, at the offices of Fried, Frank, Harris, Shriver & Jacobson, One New York
Plaza, New York, New York, or, if the conditions set forth in Section 2(a), (b)
or (c) have not then been satisfied, on the second business day following the
satisfaction of such conditions, or at such other time and place as the parties
hereto may agree (the "Closing Date"). On the Closing Date, (i) in the event of
a closing pursuant to Section 1(b) hereof, the Grantor will deliver to the
Grantee a certificate or certificates, representing the Shares in the
denominations designated by the Grantee in its Stock Exercise Notice and the
Grantee will purchase such Shares from the Grantor at the price per Share equal
to the Purchase Price, or (ii) in the event of a closing pursuant to Section
1(c) hereof, the Grantor will deliver to the Grantee cash in an amount
determined pursuant to Section 1(c) hereof. Any payment made by the Grantee to
the Grantor, or by the Grantor to the Grantee, pursuant to this Agreement shall
be made by certified or official bank check or by wire transfer of federal funds
to a bank designated by the party receiving such funds.
(b) The Grantee agrees not to transfer or otherwise dispose of
the Option or the Shares, or any interest therein, except in compliance with the
Securities Act of 1933, as amended (the "Securities Act") and any applicable
state securities law. The Grantee further agrees that the certificates
representing the Shares shall bear an appropriate legend relating to the fact
that such Shares have not been registered under the Securities Act.
4. Representations and Warranties of the Grantor. The Grantor
represents and warrants to the Grantee that (a) the Grantor is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware and has the requisite corporate power and authority to enter
into and perform this Agreement; (b) the execution and delivery of this
Agreement by the Grantor and the consummation by it of the transactions
contemplated hereby have been duly authorized by the Board of Directors of the
Grantor and this Agreement has been duly executed and delivered by a duly
authorized officer of the Grantor and constitutes a valid and binding obligation
of the Grantor, enforceable against Grantor in accordance with its terms,
subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting
creditors' rights and to general equity principles; (c) the Grantor has taken
all necessary corporate action to authorize and reserve the Shares issuable upon
exercise of the Option and the Shares, when issued and delivered by the Grantor
upon exercise of the Option and paid for by the Grantee as contemplated hereby,
will be duly authorized, validly issued, fully paid and non-assessable and free
of preemptive rights; (d) except as otherwise required by the HSR Act
4
<PAGE> 5
or the rules and regulations of NASDAQ, the execution and delivery of this
Agreement by the Grantor and the consummation by it of the transactions
contemplated hereby do not require the consent, waiver, approval or
authorization of or any filing with any person or public authority and will not
violate, result in a breach of or the acceleration of any obligation under, or
constitute a default under, any provision of the Grantor's certificate of
incorporation or bylaws, or any indenture, mortgage, lien, lease, agreement,
contract, instrument, order, rule, regulation, judgment, ordinance, or decree,
or restriction by which the Grantor or any of its subsidiaries or any of their
respective properties or assets is bound; (e) no "fair price," "moratorium,"
"control share acquisition," "interested shareholder" or other form of
antitakeover statute or regulation (including but not limited to Section 203 of
the Delaware General Corporation Law) is or shall be applicable to the
acquisition of Shares pursuant to this Agreement; and (f) the Grantor has taken
all corporate action necessary so that any Shares acquired pursuant to this
Agreement shall not be counted for purposes of determining the number of shares
of Common Stock beneficially owned by the Grantee or any of its Affiliates or
Associates pursuant to the Rights Agreement (as defined in the Merger Agreement,
the terms "Affiliate" and "Associate" having the respective meanings ascribed to
them in the Rights Agreement).
5. Representations and Warranties of the Grantee. The Grantee
represents and warrants to the Grantor that (a) the Grantee is a corporation
duly organized, validly existing and in good standing under the laws of the
State of New Jersey and has the requisite corporate power and authority to enter
into and perform this Agreement, (b) the execution and delivery of this
Agreement by the Grantee and the consummation by it of the transactions
contemplated hereby have been duly authorized by all necessary corporate action
on the part of the Grantee and this Agreement has been duly executed and
delivered by a duly authorized officer of the Grantee and constitutes a valid
and binding obligation of the Grantee, enforceable in accordance with its terms,
subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting
creditors' rights and to general equity principles; and (c) the Grantee is
acquiring the Option and, if and when it exercises the Option, will be acquiring
the Shares issuable upon the exercise thereof for its own account and not with a
view to distribution or resale in any manner which would be in violation of the
Securities Act.
6. Listing of Shares; Filings; Governmental Consents. Subject
to applicable law and the rules and regulations of NASDAQ or such other national
securities exchange on which the shares of the Grantor's common stock are then
listed, after the Option becomes exercisable hereunder, the Grantor will
promptly file an application to list the Shares on NASDAQ or on such other
national securities exchange on which the shares of the Grantor's common stock
are then listed and will use its reasonable best efforts to obtain approval of
such listing and to effect all necessary filings by the Grantor under the HSR
Act; provided, however, that if the Grantor is unable to effect such listing on
NASDAQ by the Closing Date, the Grantor will nevertheless be obligated to
deliver
5
<PAGE> 6
the Shares upon the Closing Date. Each of the parties hereto will use its
reasonable best efforts to obtain consents of all third parties and governmental
authorities, if any, necessary to the consummation of the transactions
contemplated by this Agreement.
7. Registration Rights. (a) In the event that the Grantee
shall desire to sell any of the Shares within two years after the purchase of
such Shares pursuant to this Agreement, and such sale requires, in the opinion
of counsel to the Grantee, which opinion shall be reasonably satisfactory to the
Grantor and its counsel, registration of such Shares under the Securities Act,
the Grantor will cooperate with the Grantee and any underwriters (which
underwriters must be reasonably satisfactory to the Grantor) in registering such
Shares for resale, including, without limitation, promptly filing a registration
statement which complies with the requirements of applicable federal and state
securities laws, and entering into an underwriting agreement with such
underwriters upon such terms and conditions as are customarily contained in
underwriting agreements with respect to secondary distributions; provided that
the Grantor shall not be required to have declared effective more than two
registration statements hereunder and shall be entitled to delay the filing or
effectiveness of any registration statement and may suspend the use of any
registration statement (and related prospectus) for one or more periods of time
not exceeding an aggregate of 60 days in any one year period if the offering
would, in the judgment of the board of directors of the Grantor, require
premature disclosure of any material corporate development or material
transaction involving the Grantor or interfere with any previously planned
securities offering by the Grantor. In addition, upon receipt of notice of the
happening of any event as a result of which any registration statement,
prospectus or prospectus supplement, contains any untrue statements of material
fact or fails or omits to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under
which they are made, not misleading the Grantee shall forthwith discontinue the
disposition of any Shares under such registration statement, prospectus or
prospectus supplement until the Grantee receives from the Grantor copies (which
subject to the limitations on suspension set forth above shall promptly be made
available by the Grantor) of an amended or supplemented registration statement,
prospectus or supplement so that, as thereafter delivered to purchasers of such
Shares, such registration statement, prospectus or prospectus supplement shall
not contain any untrue statement of material fact or fail or omit to state any
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they are made, not
misleading.
(b) If the Shares are registered pursuant to the provisions of
this Section 7, the Grantor agrees (i) to furnish copies of the registration
statement and the prospectus relating to the Shares covered thereby in such
numbers as the Grantee may from time to time reasonably request and (ii) if any
event shall occur as a result of which it becomes necessary to amend or
supplement any registration statement or prospectus, to prepare and file under
the applicable securities laws such amendments and supplements as may
6
<PAGE> 7
be necessary to keep available for at least 45 days a prospectus covering the
Shares meeting the requirements of such securities laws, and to furnish the
Grantee such numbers of copies of the registration statement and prospectus as
amended or supplemented as may reasonably be requested. The Grantor shall bear
the cost of the registration, including, but not limited to, all registration
and filing fees, printing expenses, and fees and disbursements of counsel and
accountants for the Grantor, except that the Grantee shall pay the fees and
disbursements of its counsel, and the underwriting fees and selling commissions
applicable to the shares of Common Stock sold by the Grantee. The Grantor shall
indemnify and hold harmless (i) the Grantee, its affiliates and its officers and
directors and (ii) each underwriter and each person who controls any underwriter
within the meaning of the Securities Act or the Securities Exchange Act of 1934,
as amended (collectively, the "Underwriters") ((i) and (ii) being referred to as
"Indemnified Parties") against any losses, claims, damages, liabilities or
expenses, to which the Indemnified Parties may become subject, insofar as such
losses, claims, damages, liabilities (or actions in respect thereof) and
expenses arise out of or are based upon any untrue statement or alleged untrue
statement of any material fact contained or incorporated by reference in any
registration statement filed pursuant to this paragraph, or arise out of or are
based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading; provided, however, that the Grantor will not be liable in any such
case to the extent that any such loss, liability, claim, damage or expense
arises out of or is based upon (A) an untrue statement or alleged untrue
statement in or omission or alleged omission from any such documents in reliance
upon and in conformity with written information furnished to the Grantor by the
Indemnified Parties expressly for use or incorporation by reference therein, or
(B) the fact that the person asserting any such loss, liability, claim, damage
or expense did not receive a copy of an amended preliminary prospectus or the
final prospectus (or the final prospectus as amended or supplemented) at or
prior to the written confirmation of the sale of the Shares to such person
because of the failure of the Grantee to so provide such amended preliminary or
final prospectus.
(c) The Grantee and the Underwriters shall indemnify and hold
harmless the Grantor, its affiliates and its officers and directors against any
losses, claims, damages, liabilities or expenses to which the Grantor, its
affiliates and its officers and directors may become subject, insofar as such
losses, claims, damages, liabilities (or actions in respect thereof) and
expenses arise out of or are based upon (i) any untrue statement of any material
fact contained or incorporated by reference in any registration statement filed
pursuant to this paragraph, or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, in each case to the
extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in
conformity with written information furnished to the Grantor by the Indemnified
Parties, as applicable, specifically for use or incorporation by reference
therein, or (ii) the fact that the person asserting any such loss,
7
<PAGE> 8
liability, claim, damage or expense did not receive a copy of an amended
preliminary prospectus or the final prospectus (or the final prospectus as
amended or supplemented) at or prior to the written confirmation of the sale of
the Shares to such person because of the failure of the Grantee to so provide
such amended preliminary or final prospectus.
(d) Promptly after receipt by an indemnified party under
subsection (b) or (c) above of notice of the commencement of any action, such
indemnified party shall, if a claim in respect thereof is to be made against the
indemnifying party under such subsection, notify the indemnifying party in
writing of the commencement thereof; but the omission so to notify the
indemnifying party shall not relieve it from any liability which it may have to
any indemnified party otherwise than under such subsection. In case any such
action shall be brought against any indemnified party and it shall notify the
indemnifying party of the commencement thereof, the indemnifying party shall be
entitled to participate therein and, to the extent that it shall wish, jointly
with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel satisfactory to such indemnified party (who shall not,
except with the consent of the indemnified party, be counsel to the indemnifying
party), and, after notice from the indemnifying party to such indemnified party
of its election so to assume the defense thereof, the indemnifying party shall
not be liable to such indemnified party under such subsection for any legal
expenses of other counsel or any other expenses, in each case subsequently
incurred by such indemnified party, in connection with the defense thereof other
than reasonable costs of investigation. No indemnified party shall settle any
action or claim without the consent of the indemnifying party, which consent
shall not be unreasonably withheld or delayed.
8. Expenses. Each party hereto shall pay its own expenses
incurred in connection with this Agreement, except as otherwise specifically
provided herein.
9. Modification or Amendment. Subject to the provisions of
applicable law, the parties hereto may modify or amend this Agreement, by
written agreement executed and delivered by duly authorized officers of the
respective parties.
10. Counterparts. This Agreement may be executed in any number
of counterparts, each such counterpart being deemed to be an original
instrument, and all such counterparts shall together constitute the same
agreement.
11. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL. (a) THIS
AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE
INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAWS OF THE
STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICT OF LAW PRINCIPLES THEREOF. THE
PARTIES HEREBY IRREVOCABLY SUBMIT TO THE JURISDICTION OF THE COURTS OF THE STATE
OF DELAWARE AND THE FEDERAL COURTS OF THE UNITED
8
<PAGE> 9
STATES OF AMERICA LOCATED IN THE COUNTY OF NEW CASTLE, DELAWARE SOLELY IN
RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF THIS
AGREEMENT, THE MERGER AGREEMENT AND OF THE OTHER DOCUMENTS REFERRED TO IN THIS
AGREEMENT AND THE MERGER AGREEMENT, AND IN RESPECT OF THE TRANSACTIONS
CONTEMPLATED HEREBY AND THEREBY, AND HEREBY WAIVE, AND AGREE NOT TO ASSERT, AS A
DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR THE INTERPRETATION OR ENFORCEMENT
HEREOF OR OF ANY SUCH DOCUMENT, THAT IT IS NOT SUBJECT THERETO OR THAT SUCH
ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID
COURTS OR THAT THE VENUE THEREOF MAY NOT BE APPROPRIATE OR THAT THIS AGREEMENT,
THE MERGER AGREEMENT, OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH
COURTS, AND THE PARTIES HERETO IRREVOCABLY AGREE THAT ALL CLAIMS WITH RESPECT TO
SUCH ACTION OR PROCEEDING SHALL BE HEARD AND DETERMINED IN SUCH A DELAWARE STATE
OR FEDERAL COURT. THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT
JURISDICTION OVER THE PERSON OF SUCH PARTIES AND OVER THE SUBJECT MATTER OF SUCH
DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH ANY
SUCH ACTION OR PROCEEDING IN THE MANNER PROVIDED IN SECTION 12 OR IN SUCH OTHER
MANNER AS MAY BE PERMITTED BY LAW, SHALL BE VALID AND SUFFICIENT SERVICE
THEREOF.
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY
WHICH MAY ARISE UNDER THIS AGREEMENT OR THE SHAREHOLDER AGREEMENT IS LIKELY TO
INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY
IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THIS AGREEMENT, THE MERGER AGREEMENT, THE OTHER DOCUMENTS REFERRED
TO IN THIS AGREEMENT AND THE MERGER AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED
HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK
TO ENFORCE THE FOREGOING WAIVER, (II) EACH SUCH PARTY UNDERSTANDS AND HAS
CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH SUCH PARTY MAKES THIS
WAIVER VOLUNTARILY, AND (IV) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS
AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
SECTION 11.
9
<PAGE> 10
12. Notices. Any notice, request, instruction or other
document to be given hereunder by any party to the others shall be in writing
and delivered personally or sent by registered or certified mail, postage
prepaid, or by facsimile:
if to the Grantee:
Celia Colbert
Merck & Co., Inc.
One Merck Drive
P.O. Box 100 WS3AB-05
Whitehouse Station, NJ 08889
Fax: (908) 735-1246
with copies to:
Gary P. Cooperstein, Esq.
Fried, Frank, Harris, Shriver and Jacobson
One New York Plaza
New York, NY 10004
Fax: (212) 859-4000
if to the Grantor:
Stephen F. Keane
SIBIA Neurosciences, Inc.
505 Coast Blvd. South
Suite 300
La Jolla, CA 92037
Fax: (619) 459-1609
with copies to:
Frederick T. Muto, Esq.
Cooley Godward LLP
4365 Executive Drive
Suite 1100
San Diego, CA 92121
Fax: (858) 453-3555
10
<PAGE> 11
or to such other persons or addresses as may be designated in writing by the
party to receive such notice as provided above.
13. Entire Agreement. This Agreement (including any exhibits
and schedules hereto), the Merger Agreement and the other documents referred to
in this Agreement and the Merger Agreement, constitute the entire agreement, and
supersede all other prior agreements, understandings, representations and
warranties both written and oral, among the parties, with respect to the subject
matter hereof.
14. No Third Party Beneficiaries. This Agreement is not
intended to confer upon any person or entity other than the parties hereto any
rights or remedies hereunder.
15. Severability. The provisions of this Agreement shall be
deemed severable and the invalidity or unenforceability of any provision shall
not affect the validity or enforceability of the other provisions hereof. If any
provision of this Agreement, or the application thereof to any person or entity
or any circumstance, is invalid or unenforceable, (a) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such
provision to other persons or entities or circumstances shall not be affected by
such invalidity or unenforceability, nor shall such invalidity or
unenforceability affect the validity or enforceability of such provision, or the
application thereof, in any other jurisdiction.
16. Specific Performance. The parties hereto each acknowledge
that, in view of the uniqueness of the subject matter hereof, the parties hereto
would not have an adequate remedy at law for money damages if this Agreement
were not performed in accordance with its terms, and therefore agree that the
parties hereto shall be entitled to specific enforcement of the terms hereof in
addition to any other remedy to which the parties hereto may be entitled at law
or in equity.
17. Assignment. This Agreement shall not be assignable by
operation of law or otherwise; provided, however, that the Grantee may assign
its rights and obligations under this Agreement to any of its direct or indirect
wholly owned subsidiaries (including Merger Sub). Any purported assignment made
in contravention of this Agreement shall be null and void.
18. Captions. The Section captions herein are for convenience
of reference only and do not constitute part of this Agreement and shall not be
deemed to limit or otherwise affect any of the provisions hereof.
19. Termination. (a) The right to exercise the Option granted
pursuant to this Agreement shall terminate at (and the Option shall no longer be
exercisable after)
11
<PAGE> 12
the earliest of (i) the Effective Time (as defined in the Merger Agreement),
(ii) the nine month anniversary of the earliest to occur of the events set forth
in any of clauses (i), (ii) or (iii) of Section 2(d), and (iii) the fifteenth
day following the termination of the Merger Agreement if prior to such fifteenth
day the events set forth in any of clauses (i), (ii), or (iii) of Section 2(d)
shall not have occurred (such earliest date being referred to in this Agreement
as the "Termination Date"); provided that, if the Option cannot be exercised or
the Shares cannot be delivered to the Grantee upon such exercise because one or
more of the conditions set forth in Section 2(a) or (b) hereof have not yet been
satisfied, the Termination Date shall be extended until fifteen days after such
impediment to exercise or delivery has been removed.
(b) All representations and warranties contained in this
Agreement shall survive delivery of and payment for the Shares.
20. Profit Limitation. Notwithstanding any other provision of
this Agreement or the Merger Agreement, any Cancellation Amount shall be reduced
(but not below zero) to the extent necessary so that the sum of (1) the portion
of any termination fee actually paid to the Grantee pursuant to Section
9.5(b)(p) of the Merger Agreement (such portion actually paid, the "Termination
Fee"), (2) the aggregate of all Cancellation Amounts paid to Grantee pursuant to
this Agreement and (3) the cash proceeds actually received by the Grantee as the
result of selling Shares issued to Grantee pursuant to this Agreement to a third
party which acquires more than 50% of the Grantor's outstanding voting
securities (other than any such acquisitions by Grantor or any of its
affiliates) shall not exceed $4.4 million. In no event shall (i) the sum of the
Termination Fee and the cash proceeds actually received by the Grantee as the
result of selling Shares issued to Grantee pursuant to this Agreement to a third
party which acquires more than 50% of the Grantor's outstanding voting
securities (other than any such acquisitions by Grantor or any of its
affiliates) exceed $4.4 million, or (ii) the sum of the Termination Fee, the
aggregate Cancellation Amounts paid to Grantee pursuant to this Agreement and
the cash proceeds actually received by the Grantee as the result of selling
Shares issued to Grantee pursuant to this Agreement to a third party which
acquires more than 50% of the Grantor's outstanding voting securities (other
than any such acquisitions by Grantor or any of its affiliates) exceed $4.4
million.
12
<PAGE> 13
IN WITNESS WHEREOF, this Agreement has been duly executed and
delivered by duly authorized officers of the parties hereto as of the date
hereof.
SIBIA NEUROSCIENCES, INC.
By: /s/ William T. Comer
------------------------
Name: William T. Comer
Title: President, Chief Executive
Officer
MERCK & CO., INC.
By: /s/ Judy C. Lewent
-----------------------
Name: Judy C. Lewent
Title: Senior Vice President and
Chief Financial Officer
MC SUBSIDIARY CORP.
By: /s/ Judy C. Lewent
------------------------
Name: Judy C. Lewent
Title: President
13
<PAGE> 1
EXHIBIT (c)(4)
CONFIDENTIAL DISCLOSURE AGREEMENT
This Agreement (the "Agreement") is entered into as of this 23rd day of June
1999 by and between SIBIA Neurosciences, Inc., having a business address of 505
Coast Boulevard South, Suite 300, La Jolla, CA 92037 ("SIBIA") and Merck & Co.,
Inc., with an address of One Merck Drive, Whitehouse Station, NJ 08889-0100
("Recipient").
1. PROPOSED RELATIONSHIP. SIBIA wishes to assure the protection and
preservation of the confidential and/or proprietary nature of information to be
disclosed to Recipient in connection with a possible business relationship
between the parties (the "Proposed Relationship").
2. CONFIDENTIAL INFORMATION. Except as set forth in Paragraph 3, all
information disclosed by SIBIA to Recipient relating to the Proposed
Relationship is "Confidential Information" and shall include all information
relating to the existence and contents of this Agreement and SIBIA's
pharmaceutical business including patents, copyrights, patent or copyrights
applications, trade secrets, techniques, formulas, products, protocols, test
data, results, conclusions or reports relating to the Proposed Relationship or
studies conducted by SIBIA or authorized by SIBIA to be conducted, whether in
oral, written, graphic or electronic form. Recipient shall, upon the request of
SIBIA, return all Confidential Information and any copies of such to SIBIA.
Information disclosed orally shall be identified as confidential at the time of
disclosure, and summarized in writing promptly following such disclosure.
3. NONCONFIDENTIAL INFORMATION. Confidential Information shall not include
information which (i) at the time of disclosure is readily available in the
public domain, or thereafter becomes publicly available other than through a
breach of this Agreement; (ii) was already known to Recipient prior to its
disclosure by SIBIA as documented in Recipient's written records made prior to
such disclosure by SIBIA; (iii) is disclosed to Recipient by a third party who
has the right to disclose such information and does not restrict its
disclosure; (iv) is independently developed by an employee or agent of
Recipient without knowledge of SIBIA's Confidential Information; or (v) is
required by law to be disclosed by Recipient.
4. PERMITTED USE AND DISCLOSURE. Recipient may use Confidential Information
only for the purposes of evaluating or discussing the Proposed Relationship.
Recipient may disclose Confidential Information only to its directors,
officers, employees and agents (including, in the case of Merck, officers and
employees of Merck & Co., Inc.) who have a need to know in order to properly
evaluate the Proposed Relationship and who have been apprised of its
confidential and proprietary nature.
5. NONUSE AND NONDISCLOSURE. Recipient shall exercise at least the same
standard of care in safeguarding Confidential Information as Recipient
exercises in safeguarding its highest level of confidential or proprietary
information. Recipient shall not, for a period of five (5) years from the date
of this Agreement (i) disclose Confidential Information to any person who does
not have a need to know such information or to any third party, without SIBIA's
prior written consent; (ii) permit or engage in any use of Confidential
Information not authorized by this Agreement; or (iii) reproduce in any form
any Confidential Information, except as required to evaluate the Proposed
Relationship.
<PAGE> 2
Confidential Disclosure Act Page 2
6. NO LICENSE. This Agreement does not grant to Recipient any license to or
right in the Confidential Information. Nothing in this Agreement shall be
construed, by implication or otherwise, as an obligation to enter into any
further agreement concerning the Confidential Information, or as a grant of a
license to Recipient to use the Confidential Information other than for the
purposes set forth in this Agreement. If Recipient expresses an interest in
acquiring rights in the Confidential Information, the parties will explore the
possibility of working out a mutually satisfactory agreement for the commercial
use of said Confidential Information.
7. SPECIFIC PERFORMANCE. In the event of a material breach of this Agreement
by Recipient, Recipient agrees that SIBIA shall be entitled to seek specific
performance of Recipient's obligations under this Agreement, as well as for
such further relief as may be granted by a court of competent jurisdiction or
other body chosen by the parties to settle disputes.
8. NO AGENT RELATIONSHIP. Recipient is not an agent of SIBIA and Recipient
shall have no authority to act as an agent of SIBIA.
9. ENTIRE AGREEMENT. This Agreement contains the entire understandings
between the parties. Nothing contained in this Agreement shall be construed as
an obligation of either party to enter into further agreement or negotiations.
10. GOVERNING LAW. This Agreement shall be governed by the laws of the state
of California.
SIBIA NEUROSCIENCES, INC. MERCK & CO., INC.
By: /s/ STEPHEN F. KEANE By: /s/ RICHARD N. KENDER
------------------------------- -------------------------------
Name: Stephen F. Keane Name: Richard N. Kender
Title: VP Corporate Development Title: Vice President, FE&A
Business Development
Date: 6/23/99 Date: 6/21/99
------- --------
